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Abstract
Herpes simplex virus 1 (HSV-1) naturally infects dendritic cells but this prevents 
the cell from undergoing maturation. Removal of the virus host shutoff protein 
(vhs) has been shown to improve the ability of both human dendritic cells and 
mouse bone marrow dendritic cells to mature following virus infection. An HSV- 
1 vhs* backbone was further modified by deletion of the ICP47 gene and mutation 
of the VP 16 gene resulting in a vector that does not interfere at all with the ability 
of mouse dendritic cells to mature. This virus therefore, provided a good 
candidate for use as vector for antigen delivery in immunotherapy. A recombinant 
vhs*ICP47'VP16* virus expressing the full length influenza nucleoprotein (NP) 
was constructed and used to determine the ability of this virus to induce immune 
responses upon immunisation with virus alone or upon immunisation with 
infected DCs. Both cellular and humoral responses were investigated and a CD8+ 
CTL response to both the NP gene and to the virus was obtained after different 
immunisation regimes confirming the potential of the virus to be used for 
immunotherapy.
In the attempt to further improve the vector, mGMCSF was added to the viral 
constructs and viruses expressing both mGMCSF and NP or full length 
plasmodium yoelii sporozoite surface protein 2 (PySSP2) or circumsporozoite 
protein (PyCS) were constructed. The effect of co-expressing mGMCSF from the 
virus was investigated. A convincing CD8+ CTL response was obtained against 
- the antigen upon direct virus injection though co-expression of mGMCSF did not 
seem to confer a significant advantage.
Overall an HSV-1 vector has been developed and optimised for the infection of 
dendritic cells and then successfully used for induction of specific CTL and 
antibody response to full length NP, PySSP or PyCS.
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Chapter 1
Introduction
1.1 Malaria
1.1.1 Malaria epidemiology
Malaria is still one of the major cause of mortality and morbidity world-wide, 
accounting for 1-3 million deaths, mainly in children under the age of 5, with 300- 
500 million new cases each year (WHO 1999), mostly in sub-Saharan Africa. 
Malaria is caused by the Plasmodium parasite, which is transmitted by the bite of 
an infected female Anopheles mosquito. The four strains that can infect humans 
are plasmodium falciparum, vivax, malariae, and ovale, distributed differently 
across the endemic countries. P. falciparum is predominant in Africa where it 
accounts for 90% of infections and causes the most severe form of the disease. P. 
falciparum infection does not relapse but can cause chronic infections and be 
fatal. P. vivax is mainly found in Asia, South America, and Oceania, and while 
causing clinical malaria, is rarely fatal and in African populations is mainly 
restricted to individuals negative for the Duffy antigen. Finally P. malariae and 
ovale cause infrequent cases of mild malaria especially in Africa. P. ovale in 
particular may be found in mixed infections with other species.
The clinical symptoms of malaria usually include fever, anaemia, metabolic 
acidosis, impaired circulation, hypoxia and cerebral malaria. These are due to 
infected erythrocytes that bind to endothelial cells eventually leading to 
obstruction of microvasculature in tissues and organs.
1.1.2 The malaria life cycle
Malaria has a complicated, multistage life cycle that makes construction of a 
vaccine challenging. The bite of the infected Anopheles injects sporozoites into 
the bloodstream of the host. These quickly reach the liver (within 30min) and 
infect hepatocytes where they replicate forming exo-erythrocytic shizonts that 
contain as many as 30,000 merozoites, which are released by cell rupture. These 
merozoites released into the bloodstream have surface antigens that allow binding 
and infection of erythrocytes, initiating the asexual reproductive cycle responsible 
for the symptoms of clinical malaria. Within 48hr, the merozoites mature and 
replicate in the red blood cells forming schizonts that contain as many as 36 
merozoites each. Rupture of the erythrocytes releases new merozoites that in turn
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infect more red blood cells. Some merozoites develop into female or male 
gametocytes, which are then taken up by the mosquito in a subsequent blood 
meal. Inside the mosquito, the sexual replication cycle takes place by fusion of the 
gametocytes, developing into an oocyst in the mosquito gut. The sporozoites that 
are released by the oocyst then migrate to the salivary gland from where a new 
cycle begins (figure 1.1).
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Schematic representation of the stages of malaria life cycle with the 
type of immune response generated at each stage.
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1.1.3 Protective immune responses to malaria
The malaria parasite interacts with each arm of the immune system stimulating 
various responses and also modulating responses to avoid clearance. 
Understanding both of these areas is therefore important for the construction of an 
appropriate vaccine.
The presence of both intracellular and extracellular stages in malaria infection 
implies that stimulation of both cellular and humoral responses would be 
necessary for protection (figure 1.1). Natural exposure to malaria induces, in 
human hosts, short lived, strain specific immunity (McGregor, 1974). Therefore, 
continued exposure is required to maintain immunity. This immunity is both T 
cell and antibody mediated.
The type of response induced by malaria infection has mainly been investigated 
by analysis of naturally immune individuals, the responses induced in infected 
mice, or the serum of volunteers or mice that have been immunised with irradiated 
sporozoites. The two main stages of the malaria life cycle that have attracted 
attention in the development of vaccines are the pre-erythrocytic liver stage and 
the blood stage, involving distinct types of responses. Cellular immunity seems to 
be necessary for targeting the liver stage to stop infection by blocking the release 
of merozoites. An immune response against the blood stage of the parasite is 
equally important, aimed at blocking red blood cell invasion, inhibit parasite 
growth or interfere with cytoadherence of infected erythrocytes.
CD8+T cells:
Cytotoxic T cells and IFNy producing cells can induce elimination of intracellular 
parasites. Several lines of evidence have identified these as the major players in 
liver stage immunity.
Naturally immune individuals have CTLs specific for the pre-erythrocytic stage 
antigens (Aidoo et al., 1995, Hill et al., 1992) , and elimination of these cells can 
reverse the protective effect (Schofield et al., 1987, Weiss et al., 1988). Semi- 
immune individuals and children with malaria, on the other hand, only have low 
levels of CTL (Aidoo et al., 1995).
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The important role played by CD8+T cells in the immune response to malaria was 
shown initially by analysing the response induced by immunisation with irradiated 
sporozoites. Mice receiving irradiated P. yoelii or P. berghei sporozoites were 
protected against subsequent challenges with sporozoites, and CD8+T cells against 
the circumsporozoite surface protein (CS) (Rodrigues et al., 1991, Romero et al., 
1989, Weiss et al., 1992) and sporozoites surface protein 2 (SSP2) (Wizel et al.,
1995) were identified and shown to recognise and destroy intrahepatic parasites 
(Romero et al., 1989, Schofield et al., 1987). Similarly, volunteers receiving 
irradiated P .falciparum, could produce CS (Malik et al., 1991) and SSP2 (Wizel et 
al., 1995) specific CD8+T cells. Depletion experiments further confirmed the 
importance of these cells by abrogating the immunity induced by irradiated 
sporozoites (Schofield et al., 1987, Weiss et al., 1988).
Insights into the possible protective role of CD8+T cells also came from adoptive 
transfer of the cloned CS (Rodrigues et al., 1991, Romero et al., 1989, Weiss et 
al., 1992) and SSP2 (Khusmith et al., 1991) specific CD8+T cells into nai've mice. 
These protected mice against liver stage development upon sporozoite (but not 
infected erythrocyte) challenge. Similarly, mice receiving tumour cells expressing 
SSP2 showed CD8+T cell mediated protection against parasite challenge 
(Khusmith etal., 1991).
Interestingly, CD8+T cells require a ~24hr “induction” period to become fully 
active to eliminate infected hepatocytes. After this initial phase the T cells follow 
a very tight program of action, undergoing maximal expansion between 3-4 days 
from activation, followed by a dramatic reduction in cell number between days 4- 
7, and finally reaching stabilisation and production of memory T cells (Tsuji & 
Zavala, 2003). CD8+T cells mainly respond by releasing IFNy, and this cytokine 
in particular (also released by CD4+T cells) has been associated with the 
protective immunity to malaria, making it important also to investigate the role of 
CD4+T cells (Doolan & Hoffman, 2000, Moreno et al., 1991, Schofield et al., 
1987, Seguin et al., 1994).
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CD4+T cells:
In an anti-malaria immune response, CD4+T cells are as important as CD8+T cells 
in that their absence results in a more than 90% reduction in CD8+T cell activity 
as they are in fact required for the survival of the newly activated CD8+T cells 
(Carvalho et al., 2002).
CD4+T cells have been shown to be present and specific for both pre-erythrocytic 
and erythrocytic stage antigens (Aidoo et al., 1995, Good, 1988, Hill et al., 1992, 
Malik et al., 1991, Nardin & Nussenzweig, 1993). Thl responses are required 
both during initial infection to promote a cell-mediated CD8+T cell response at the 
liver stage, as well as during the blood stage. CD4 Th2 cells, on the other hand, 
seem to be necessary to control parasitaemia after the first cycle of infection, 
during the blood stage, to promote neutralising antibody responses (Molano et al., 
2000, Su & Stevenson, 2002).
In addition to their role as helper cells for CD8+T cells and antibodies, CD4+T 
cells have also been shown to act directly against the malaria liver stage. Transfer 
of CD4+ Thl or Th2 cell clones from mice immunised with irradiated sporozoites 
(Tsuji et al., 1990) or with various synthetic peptides representing different 
epitopes of PyCS (Renia et al., 1993, Takita-Sonoda et al., 1996), into naive mice 
could in fact confer protection in the first case, and inhibit liver stage parasitaemia 
in the second.
CD4+T cells may also play a role in the clearance of blood stage parasites, both 
CD4+T cell clones and polyclonal populations of T cells can adoptively transfer 
protection, apparently in the absence of antibodies (Brake et al., 1988); (Amante 
& Good, 1997). Nonetheless, in humans, better evidence exists for antibody- 
mediated immunity being the main effective response in blood stage infection 
(Good et al., 1998).
Finally, deficiency of CD4+T cells in mice, showed that under these 
circumstances, the immunity stimulated by the irradiated sporozoites is abrogated 
(Rodrigues et al., 1993), and the protective response induced by immunisation
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with PySSP2 (Wang et al., 1996) or PyHEP17 (Charoenvit et al., 1999) synthetic 
peptides is prevented.
y8T cells:
y5 T cells are activated by binding to a schizont-associated antigen (Pichyangkul 
et al., 1997) but also require exogenous cytokines (Elloso et al., 1994, Waterfall et 
al., 1998). They expand early in infection with P .falciparum (Hviid et al., 2001, 
Langhome et al., 1994) and P. vivax (Langhome et al., 1994), including primary 
infection, and produce large amounts of IFNy (Hensmann & Kwiatkowski, 2001, 
Hviid et al., 2001) before the activation of other antigen specific T cells 
(Choudhury et al., 2000). y8 T cells are involved in liver stage immunity (Schmieg 
et al., 2003), but are not essential for the resolution of infection (Stevenson & 
Riley, 2004). In the absence of y8T cells, mice immunised with irradiated 
sporozoites show a reduced protective immunity (Tsuji et al., 1994), an increased 
parasitaemia in the liver (McKenna et al., 2000), as well as a few days delay in the 
elimination of parasites (Langhome et al., 2002). Adoptive transfer of these cells 
from mice immunised with irradiated sporozoites into naive mice, results in 
reduced liver stage infection in the recipient mice after sporozoite challenge (Tsuji 
et al., 1994).
NK cells:
NK cells are mainly seen as effectors against the blood stage of the disease. They 
are not seen in all immune individuals, but appear to be the first cells to react 
upon in vitro exposure of human PBMCs to P. falciparum infected erythrocytes 
(Artavanis-Tsakonas & Riley, 2002).
Upon infection, NK cells release IFNy, an essential step for the development of 
protective immunity to malaria which is associated with the clearance of infection 
(De Souza et al., 1997, Mohan et al., 1997). Absence of NK cells induces a more 
rapid increase in blood parasitaemia and less efficient disease resolution following 
primary infection (Mohan et al., 1997). A failure of NK, and possibly y8T cells, to 
produce IFNy early on, results in lethal infection (De Souza et al., 1997, Mohan et 
al., 1997). Although IFNy is released from NK cells in an IL12 dependent way,
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both IL12 and IL18 are not sufficient for activation of NK cells as direct contact 
with the infected erythrocytes is also required (Artavanis-Tsakonas & Riley, 
2002).
Antibody responses:
Antibodies are the main response against the erythrocytic stage of malaria and are 
directed against the merozoite molecules required for invasion of erythrocytes or 
aimed at stimulating antibody-dependent cytotoxicity (Druilhe & Perignon, 1994, 
Good & Doolan, 1999).
Sera from people living in endemic areas contain antibodies against merozoite 
antigens that prevent red cell invasion (Bull & Marsh, 2002). Anti-MSPl 
(merozoite surface protein-1) antibodies in particular, found in the sera of immune 
individuals, can mediate inhibition of parasite infectivity in vitro (Egan et al., 
1999) and have been associated with resistance to clinical malaria (Egan et al.,
1996). In addition, immune individuals have high titres of antibodies against the 
erythrocyte membrane protein (PfEMPl) to inhibit binding to endothelial cells 
(Miller et al., 2002), and studies carried out in monkeys show that the level of 
protection correlates with the level of anti-PfEMPl antibodies (Baruch et al.,
2002). Purified immunoglobulins from naturally immune individuals transferred 
into partially immune children can clear the parasite in vivo, but not in vitro, and 
this has been suggested to rely on anti-PfEMPl antibodies (Mahanty et al., 2003, 
McGregor, 1964).
Immunisation with irradiated sporozoites can also induce a humoral response as 
well, targeted at the sporozoite surface proteins. These antibodies can effectively 
inhibit parasite infectivity in vitro (Nardin et al., 1982, Zavala et al., 1985), and 
passive transfer protected naive mice and macaques against viable sporozoite 
challenge (Charoenvit et al., 1991, Potocnjak et al., 1980). Nonetheless, pre- 
erythrocytic immunity is mainly a cellular response, whereas antibodies are most 
important at the erythrocytic stage.
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Macrophages:
Macrophages have the ability to phagocytose infected erythrocytes in the absence 
of appropriate antibodies (Doolan et al., 2003, Good & Doolan, 1999, Stevenson 
& Riley, 2004), or to act as effector cells mediating antibody-dependent cellular 
inhibition (Stevenson & Riley, 2004). Macrophages are activated by IFNy and 
TNFa released by other cells and function by producing anti-parasite molecules 
such as nitric oxide to eliminate infection.
Cytokines:
Malaria infection emerging from the liver is co-ordinated with release of IFNy, 
TNF, IL12 and IL8 to fight infection in the serum of infected individuals, or in 
vitro (Stevenson & Riley, 2004). IFNy is the main effector cytokine in malaria 
responses, stimulated by irradiated sporozoites and released by CD8+T, CD4+T, 
y5T and NK cells. IFNy can probably induce infected hepatocytes to release nitric 
oxide leading to the arrest of the parasite development (Doolan & Hoffman, 2000) 
although there is no in vivo evidence that malaria antigens are presented on the 
surface of hepatocytes (Krzych et al., 2000).
Although IFNy and TNFa are both associated with parasite clearance, they are 
also associated with severe malaria if their levels become toxic (Dodoo et al., 
2002, Harpaz et al., 1992, Kwiatkowski et al., 1990). TGFp and IL10 are 
immunoregulatory cytokines in infection in both mice (Li et al., 2003, Omer et al., 
2003) and humans (Dodoo et al., 2002, Kurtzhals et al., 1998) in that they balance 
the level of release of IFNy and TNFa.
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1.1.4 Immune evasion by plasmodium
Having such a complicated life cycle that includes numerous replication cycles at 
various locations in the host, is itself a mechanism for the parasite to avoid 
immune responses. In addition, the plasmodium has other immune evasion 
mechanisms that include frequent antigenic variation (Newbold, 1999, Plebanski 
et al., 2002), altered peptide ligand (APL) antagonism (Plebanski et al., 2002), and 
specific interactions with lymphocytes that result in inhibition of immune 
responses.
Antigenic variation:
Antigenic variation is a mechanism frequently used by parasites to escape
immune responses. Some key plasmodium antigens display antigenic variation
\ ■
and although there are some conserved peptides within the protein, it very 
difficult to include them in any vaccine. The plasmodium genome contains variant 
genes that have been grouped into “variant gene families”. For the P. falciparum 
var, rif Stevor are the three main families (Rasti et al., 2004). Each family 
includes the different copies of one gene scattered around the genome. PfEMPl 
encoded by the var family of roughly 60 genes, has been the most widely studied. 
PfEMPl is the main antigen responsible for adherence to endothelial cells, and 
would therefore be a strong candidate as a vaccine target. However, since a 
different gene is expressed in each generation, it is very difficult to generate a 
targeted immune response (Saul, 1999). The high degree of variability, rapid rate 
of variation and high copy number of these genes within each parasite therefore 
limits the effectiveness of stimulating an immune response against this protein.
Altered peptide ligands (APL):
The use of altered peptide ligands by the parasite consists of presenting variants of 
the immunogenic epitopes on the surface of the cell. Instead of activating the T 
cell these epitopes antagonise the T cell receptor preventing effector functions 
such as cytotoxicity, cytokine release and proliferation or priming memory T cells 
from naive precursors (Plebanski et al., 1999a, Plebanski et al., 1999b).
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The CS protein, towards which many vaccines are targeted, itself contains highly 
polymorphic T cell epitopes. Fourteen variants of the immunodominant CD4+T 
cell epitope have been identified (Good, 1988), and three out of the four known 
human CTL epitopes, are polymorphic (Aidoo et al., 1995).
Naturally occurring altered peptide ligands (APL) variants have been shown to 
inhibit proliferation and IFNy production from T cells, but the mechanism of 
action may vary depending on the variation. A CS APL has been shown to inhibit 
IFNy release by promoting the switch towards IL10 production which can happen 
either when the epitope is co-presented on the same cell as the immunostimulating 
epitope or on a separate antigen presenting cell (Plebanski et al., 1999a). A 
different APL for the same epitope was shown not to have any effect if expressed 
on a different cell suggesting that various mechanisms are involved (Plebanski et 
al., 1999a).
Inhibition of lymphocyte action:
Although it has been possible to study the protective immune responses to the 
liver stage of malaria by infecting mice with irradiated sporozoites, this does not 
reflect the natural immune response pattern. Humans or mice receiving infectious 
sporozoites show a very small number of T cells reactive to the liver stage, and 
increased levels of IL10. The parasite has therefore developed mechanisms to 
inhibit T cell activity.
Inhibition of CD8+T cells by malaria infection has been reported in both mice 
(Ocana-Morgner et al., 2003) and humans (Good & Doolan, 1999, Urban et al., 
1999). T cells are inhibited indirectly, by impairment of dendritic cell activity. 
Although it is the immune response to the liver stage that is low, DC activity is 
not inhibited by the sporozoites. Instead, studies in both humans (Ocana-Morgner 
et al., 2003, Urban et al., 1999, Urban & Roberts, 2003) and mice (Ocana- 
Morgner et al., 2003) using P. falciparum or yoelii infected erythrocytes, have 
shown that it is this interaction of erythrocytes with DCs that prevents cell 
maturation, thus activation of pre-erythrocytic T cells (Ocana-Morgner et al., 
2003).
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During the course of parasitaemia, infected erythrocytes interact with DCs 
possibly by binding to CD36 and CD51 on human PBMC (Urban et al., 2001). 
This interaction interferes with the Toll like receptor 4 (TLR4) activation 
mechanism, responsible for normal LPS induced cell maturation and for the 
secretion of IL12, also seen in macrophages, resulting in reduced TNFa and IL1 
secretion during malaria infection (Schwarzer et al., 1992). As a consequence of 
this interaction, dendritic cells are driven to secrete IL10 rather than IL12, 
previous liver stage CD8 responses induced by irradiated sporozoites are reduced, 
and new anti-liver CD8 responses are prevented. Interestingly, despite the known 
effect of IL10 on inhibiting Thl responses, the lack of T cell responses does not 
seem to be due to the presence of this cytokine but rather to the decreased level of 
IL12 or to other soluble molecules released by the cells (Ocana-Morgner et al.,
2003). Additionally, although it has recently been shown that even intact 
uninfected erythrocytes can specifically inhibit phagocytosis of infected red blood 
cells by peripheral blood monocytes (Struik et al., 2004), the reduced level of T 
cell stimulation does not seem to be due to problems in the internalisation of the 
antigen by the DCs either (Ocana-Morgner et al., 2003).
Following from these effects, because the DCs that are in circulation after an 
initial blood stage infection are prevented from undergoing maturation, they can 
persist for longer, thus ensuring long term inhibition of T cell responses, even in 
the presence of only small amounts of infected erythrocytes (Ocana-Morgner et 
al., 2003).
Despite the evidence to support this immune evasion mechanism, there is 
controversial evidence showing that interaction between P. yoelii (Luyendyk et 
al., 2002, Perry et al., 2004) or P. chabaudi (Seixas et al., 2001) infected 
erythrocytes and BMDC still allows upregulation of maturation markers on the 
surface of the DC followed by activation of CD8+T cells with release of TNFa, 
IL12, and IFNy (Seixas et al., 2001), though in the first case T cell proliferation 
and IL12 secretion were inhibited.
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1.1.5 Malaria vaccines
1.1.5.1 The ideal vaccine
A vaccine should aim to induce long term immunity, especially for malaria since 
naturally exposed individuals gain only short term immunity that requires constant 
re-exposure. The aim of a malaria vaccine is to induce both cellular and humoral 
immune responses to multiple antigens covering the various stages of infection. 
The immune response needs to be greater than the one observed in naturally 
immunised individuals, and non-strain specific.
Whether T cell or B cell immunity should be stimulated depends on the stage of 
the disease targeted (Figure 1.2). As soon as the sporozoites are injected, 
neutralising antibodies should be present to inhibit hepatocyte invasion, but once 
in the liver, cell mediated immunity involving CD4+T cells and CD8+ cytotoxic T 
lymphocytes as well as various cytokines are required to kill infected hepatocytes 
and inhibit intrahepatic parasite growth. A pre-erythrocytic vaccine would be 
useful in stopping the parasite from reaching the blood cells, but the disadvantage 
with this is that no natural immunity would actually be stimulated, which would 
be useful for travellers but less useful for populations living in endemic areas.
To target the erythrocytic stage, antibodies against the merozoites are appropriate 
to inhibit invasion of red blood cells, to enable antibody mediated elimination of 
infected erythrocytes as well as inhibiting adhesion of erythrocytes to host cells. 
Cytokine mediated elimination of infected erythrocytes would also be useful at 
this stage of infection. The major targets of neutralising immune responses are the 
merozoites or sporozoites receptors that mediate invasion of RBCs and 
hepatocytes (Miller et al., 2002). These are found on the cell surface, or in 
organelles (micronemes, and in rhoptries) present on the invasive end of 
sporozoites and merozoites, but since RBCs lack MHCI and MHCII, it is only 
after cell rupture at the ring stage that the parasite is exposed to antibodies. 
Immunity targeted at the blood stage antigens does not achieve complete parasite 
clearance (Hoffman et al., 1987). A vaccine targeting this stage would therefore 
need to inhibit cell invasion as well as parasite growth and replication, thus
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avoiding the actual symptoms of clinical malaria while stimulating the building of 
natural immunity. This would be ideal for endemic populations.
Finally, the sexual stage should be targeted by antibodies, these would block the 
sexual stage both in the human host and in the mosquito gut. Transmission 
blocking vaccines are not beneficial to the infected individual, but they might be 
found to be an essential part of malaria eradication programs.
Drawing from the previous information, it appears that the ideal vaccine should be 
multistage and multiantigen, able to stimulate high titres of antibodies against 
sporozoites, merozoites, and gametocytes, and cytotoxicity of T cells against 
infected hepatocytes.
1.1.5.2 Candidate antisens
The 23Mb P. falciparum genome (Gardner et al., 2002) encodes around 5300 
genes and although various methods have been suggested to try to identify the 
most appropriate genes that should be included in a multigene vaccine (Doolan et 
al., 2003), no definite conclusion has yet been reached. Vaccine construction has 
so far relied on the evidence accumulated from studies of the immune responses 
present in naturally immune individuals, populations living in endemic areas and 
immune responses seen in mice and humans following injection of sporozoites.
Pre-erythrocvtic stage antigens
Circumsporozoite protein (CS): This protein is the most abundant protein on the 
surface of sporozoite as well as in the intracellular hepatic stages of the parasite. 
Most vaccines have used CS as their target, mainly because naturally immune 
individuals have been found to have CTL against this protein (Sedegah et al., 
1992).
Sporozoites surface protein 2 (SSP2) or Thrombospondin related adhesive protein 
(TRAP): Together with CS, SSP2 is also very abundant on the surface of the 
sporozoites. Malaria immune subjects have been found to have cytotoxic T cells 
against this protein (Aidoo et al., 1995) and similarly, volunteers immunised with 
irradiated sporozoites have been shown to produce a CTL response to it (Wizel et
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al., 1995). Also, monoclonal antibodies to SSP2 were identified in mice 
immunised with P. yoelii (Rogers et al., 1992).
Liver stage antigen 1 and 3 (LSA1, LSA3): Both these proteins are expressed on 
the surface of infected hepatocytes. Naturally immune persons have been shown 
to have developed CTL responses to both of these antigens (Aidoo et al., 2000, 
Connelly et al., 1997, Doolan et al., 1997, Hill et al., 1992), and immunised 
volunteers are capable of developing the same type of response (Doolan et al.,
1997).
P. yoelii hepatocyte erythrocyte protein (PyHepl7): This protein is a homologue 
of the P. falciparum exported protein 1. PyHepl7 has been used for numerous 
studies in mice where it was shown to be a target of protective antibodies and T 
cells, and immunisation with DNA expressing this protein can induce CD8 
mediated (Doolan et al., 1996a) although, as for TRAP, no specific epitope has so 
far been identified.
Erythrocytic stage antigens
Merozoite surface protein J(MSP1): MSP1 the best characterised antigen 
involved in erythrocyte invasion. Expressed in all species of plasmodium, it is 
responsible for parasite entry into cells. Antibody against this protein have been 
associated with resistance to clinical malaria (Egan et al., 1996), and can inhibit 
erythrocyte invasion (Weiss et al., 1998) as well as preventing parasite growth in 
vitro (Egan et al., 1999).
Apical membrane antigen 1 (AMA1): AMA1 is present in all species of 
plasmodium, is initially found in the apical organelles but then expressed on the 
surface of the merozoite where is involved in cell invasion. Its sequence has been 
conserved during evolution. Antibodies against this protein have been found in 
populations exposed to malaria (Thomas et al., 1994), and these antibodies have 
been shown to inhibit merozoite invasion in vitro (Hodder et al., 2001).
P. falciparum erythrocyte membrane protein 1 (PfEMPl): PfEMPl allows 
adherence to endothelial cells but the problem is the very high level of 
polymorphism of this protein (Richie & Saul, 2002). PflEMP 1 has been speculated 
to be a target for antibody mediated immunity since sera from immune individuals 
have high titres of antibodies against PfEMPl (Miller et al., 2002).
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Sexual stage antigens
Plasmodium antigen 25 and 28 (Pfs25, Pfs28): Pfs25 and Pfs28 are two 
transmission blocking antigens, present on the surface of the zygote and mature 
ookinete and found in many plasmodium species (Duffy & Kaslow, 1997, 
Tachibana et al., 2001, Tsuboi et al., 1998). They play important roles in ookinete 
survival in the midgut, penetration of the epithelium and transformation of the 
ookinete into the oocyst (Tomas et al., 2001). Antibodies against Pfs25 and Pfs28 
can inhibit maturation of zygotes into ookinetes and of ookinetes into oocysts 
(Tsuboi et al., 1997) as well as blocking ookinete penetration of the mosquito 
midgut (Kaslow et al., 1994).
Using multiple antigens should allow for an additive effect of the immune 
response induced by each antigen independently, resulting in substantial 
immunity. Also, mixtures of antigens should allow immunity in genetically 
heterologous populations, and protect against more than one species of malaria, 
reducing the emergence of parasites that escape vaccine-induced immunity. 
Nonetheless, it is possible that using a mixture of antigens could cause 
interference between them, or even increase the possibility of local reactogenicity 
as the number of antigens in the vaccine increases.
The problems that have obstructed the development of a malaria vaccine so far 
include the polymorphism and the antigenic diversity in particular in blood stage 
antigens, although there are conserved regions within these. Also, the presence of 
cryptic epitopes within antigens has been problematical as well as the lack of 
appropriate in vitro correlates of protection, ie in vitro results have not always 
correlated with in vivo results and vice-versa. Finally, the lack of suitable animal 
models for testing the efficacy of vaccine candidate antigens is an extra 
complication, as well as the lack of correlation between stimulation of immune 
responses and protection (Chauhan & Bhardwaj, 2003).
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1.1.6 Immunotherapy of malaria
The two stages of malaria infections that have mainly been targeted for vaccine 
design so far are the sporozoite and the liver stage.
1.1.6.1 Attenuated organisms
The first successful attempt to induce protective immunity was achieved by 
immunisation with irradiated sporozoites (Hoffman et al., 2002) (Herrington et al., 
1991). This immunisation induces both cellular (Doolan et al., 1997, Wizel et al., 
1995) and humoral (Nardin et al., 1982, Zavala et al., 1985) immune responses 
targeted at the sporozoite surface proteins, and has been shown to confer 
protection in over 90% of volunteers (Hoffman et al., 2002) in a T lymphocyte 
IFNy dependent way (Hoffman et al., 1989). Although efficient, this is hardly a 
practical method, but the fact that the irradiated sporozoite vaccine was efficient 
indicated that it is advisable to use multiple antigens from the same stage of the 
disease, and has directed a lot of efforts to trying to develop a vaccine targeted at 
sporozoite stage immunity.
1.1.6.2 DNA vaccines
DNA vaccines consist of plasmids encoding the sequence of a protein or of 
multiple epitopes from a single or various proteins. These plasmids are then 
injected, often mixed with an adjuvant to enhance immunogenicity, and taken up 
by the local dendritic cells or muscle cells, where the protein is translated and 
peptides are presented.
DNA vaccines expressing only one protein, CS, can induce strong CD8+ IFNy 
dependent and antibody responses in mice (Sedegah et al., 1994) and humans 
(Wang et al., 1998b) and confer partial protection that can be further improved by 
coinjection of a plasmid expressing GMCSF (Sedegah et al., 2000). Studies have 
subsequently reported similar results with a multi-antigen immunisation using two 
plasmids expressing the PyCS and PyHepl7 both from the pre-erythrocytic stage 
(Doolan et al., 1996b), and then looking at a vaccine composed of 4 plasmids 
expressing proteins from the sporozoite (PfCS, PfSSP2) and from the liver stage 
(PfExpl, PfLSAl). The four antigen vaccine was found to stimulate CD8+ CTL
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responses to all proteins in both monkeys (Wang et al., 1998a) and humans 
(Doolan & Hoffman, 2001), encouraging the use of multi-antigen multi-stage 
vaccines, and proving that no competition is present between the different 
proteins. Finally, a DNA multistage-multigene vaccine programme is now aiming 
at investigating a mixture consisting of 5 plasmids encoding proteins from the 
sporozoite stage and 4 from the blood stage (Webster & Hill, 2003).
The efficiency of DNA immunisation has proved to only be partially protective, 
even upon expression of multiple antigens and from multiple stages, or even using 
additional plasmids expressing a GMCSF (Moorthy et al., 2004a). Moreover, 
DNA subunit vaccines require potent adjuvants that may result in adverse 
reactions in humans, suggesting that different methods of immunisation may be 
more efficient.
1.1.6.3 Peptide vaccines
Peptide vaccination mainly induces strong antibody responses and rather low 
cellular immunity in humans and animals, probably because the peptide is loaded 
directly onto the MHC molecule without undergoing the class I processing 
pathway. When co-immunised with a universal T helper cell epitope, or even as a 
long synthetic peptide in an oil based adjuvant, peptides are able to elicit specific 
CD4 and CD8 T cell responses (Lopez et al., 2001, Nardin et al., 2001, Nardin et 
al., 2000) and protect mice from sporozoite challenge in P. yoelii and P. berghei 
models.
Peptide vaccines based on a single antigen (CS or SSP2) conjugated to tetanus 
toxoid initially gave encouraging results in mice, and rabbits, though only resulted 
in partial protection in phase I and II clinical trials (Etlinger et al., 1988, 
Herrington et al., 1987, Nussenzweig & Nussenzweig, 1989, Sharma et al., 1996, 
Zavala et al., 1985). Following this, a vaccine containing multiple (T and B cell) 
epitopes from the CS repeat region was shown to elicit strong antibody responses 
both in mice, monkeys (Collins et al., 1997, Moreno et al., 1999) and humans 
(Lopez et al., 2001, Nardin et al., 2001, Nardin et al., 2000), but, similarly to 
DNA vaccines, single peptide antigen vaccines have never resulted in high levels 
of protection. This has focussed research on subunit vaccines using multiple
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antigen peptides (MAP). The Spf66 vaccine was the first construct expressing 
sequences from three erythrocytic stage antigens (Moreno & Patarroyo, 1989, 
Patarroyo et al., 1987), but this vaccine still failed to provide consistent 
protection. Poor performance of this vaccine in Africa in phase III clinical trials 
showing similar cases of symptomatic falciparum malaria or any index of malaria 
in immunised and control groups in follow up trials shifted the attention to other 
alternatives (Acosta et al., 1999, Alonso et al., 1994, D'Alessandro et al., 1995, 
Maitland et al., 2003, Nosten et al., 1996, Patarroyo et al., 1992).
1.1.6.4 Recombinant proteins
Recombinant protein vaccines consist of injection of protein expressed in another 
organism. As for DNA or peptide vaccines, often it is not the whole protein that is 
expressed but only the immunodominant region. The advantage of this technique 
is that the protein can easily be fused to another protein that is known to induce 
strong responses (often Hepatitis B virus core protein), and can thus act as an 
adjuvant.
Recombinant protein vaccines for malaria initially used a single MSP1 purified 
(Perrin et al., 1984) or recombinant (Herrera et al., 1990) fusion protein showing 
partial protection in monkeys and humans (Keitel et al., 1999). Then, the 
immunodominant domain was expressed resulting in protective immunity in 
monkeys when specific adjuvants were used (Kumar et al., 2000). Similarly, 
apical membrane antigen 1 (AMA1) (Collins et al., 1994) and serine repeat 
antigen (SERA) (Inselburg et al., 1993, Inselburg et al., 1991), both from the 
merozoite stage, could only partially protect monkeys from parasite challenge. 
Not even a mixture of blood stage antigens (MSP1, MSP2, RES A) could confer 
protection upon blood stage challenge in volunteers (Lawrence et al., 2000), 
though a reduction in parasite density could be seen in previously exposed 
individuals (Genton et al., 2002). Vaccines targeting the sexual stage have also 
shown immunogenicity in mice and rabbits injected with a fusion protein of Pfs25 
and Pfs28 (TBV25-28) (Gozar et al., 2001).
To date, the most successful vaccine has been the RTS,S/AS02. This is a 
recombinant protein formed by the fusion of hepatitis B surface antigen with most
32
the of CS antigen expressed in yeast where this fusion protein (RTS) binds the 
hepatitis B surface antigen (S). Two-three repetitive injections of this recombinant 
fusion protein mixed with the adjuvant AS02 have been shown to induce 
antibodies to the sporozoite stage. Unfortunately, although this vaccine can induce 
protection in 30-60% of volunteers in America upon sporozoite challenge (Kester 
et al., 2001, Stoute et al., 1997), and is not strain specific (Alloueche et al., 2003), 
a clinical trial carried out in the Gambia (Bojang et al., 2001) has proved the 
response to be short lived (Bojang et al., 2001).
Other recombinant protein vaccines are currently undergoing clinical trials. ICC- 
1132 is the latest recombinant vaccine, an improvement of the RTS/AS02, 
consisting of T and B-cell epitopes from the repeat region of CS protein and a 
universal T cell epitope from the C terminus of the protein, expressed in the 
highly immunogenic recombinant hepatitis B virus core protein. This, prepared in 
adjuvants that would be suitable for humans, has so far been successful in mice 
and monkeys showing T cells and antibody responses, and is currently in phase I 
clinical trials (Birkett et al., 2002). Also, a construct expressing epitopes from 
nine P. falciparum stage specific antigens (sporozoite, liver, erythrocyte, and 
sexual stage) and a universal T epitope from tetanus toxoid expressed in 
baculovirus and purified, is currently being studied in non-human primates (Shi et 
al., 2000, Shi et al., 1999).
1.1.6.5 Viral vectors
Using a viral vector has the advantage of not requiring adjuvants and allowing 
expression of the recombinant protein inside the infected cells, therefore 
providing an efficient delivery to MHCI and MHCII antigen-processing pathways 
via endogenous pathways
Immunisation of mice with attenuated adenovirus expressing PyCS has resulted in 
IFNy mediated protection response and decreased level of parasitaemia in the liver 
(Rodrigues et al., 2000, Rodrigues et al., 1998). An influenza virus vector 
expressing a CS epitope has also been tested but this was only shown to induce 
strong CTL responses (Li et al., 1993).
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The most extensively used virus in malaria research, is vaccinia virus. Modified 
vaccinia Ankara (MVA) (Gilbert et al., 1999), and the highly attenuated NYVAC 
strain expressing the full length P. berghei CS protein can induce both antibody 
and cellular responses and confer CD8+T dependent protection against sporozoite 
challenge (Lanar et al., 1996). However, such recombinant viruses have mainly 
been used in prime-boost regimes (see later).
The most successful viral malaria vaccine so far has been the multigene, 
multistage NYVAC-Pf7 vector. This virus expresses seven full length or nearly 
full length P. falciparum proteins from the different stages of infection, in 
particular: three from the pre-erythrocytic stage (CS, TRAP, LSA1), three from 
the erythrocytic stage (MSP1, AMA1, SERA) and one sexual stage antigen of 
(Tine et al., 1996). NYVAC-Pf7 can successfully induce both antibody and CTL 
responses in monkeys (Tine et al., 1996) and in humans (Ockenhouse et al.,
1998), resulting in one volunteer being completely protected and others showing 
clear signs of delayed infection upon sporozoite challenge.
1.1.6.6 Other vectors
CS has also been expressed as a full length gene in recombinant Salmonella 
typhimurium, successfully inducing protein specific CD8+ CTL protection against 
sporozoite challenge (Aggarwal et al., 1990, Sadoff et al., 1988). Moreover, 
TyVLP, consisting of a single protein species that can be produced in yeast, could 
induce protective CTL responses when expressing a string of 15 epitopes (Gilbert 
et al., 1997), although could not protect against challenge when expressing CS 
alone (Gilbert et al., 1999).
1.1.6.7 Prime-boost resimes
Single immunisation or repeated homologous administration of DNA, or 
recombinant virus does not produce the levels of CD8+T cells required for 
protection against malaria in murine models (Gilbert et al., 1999, Lanar et al., 
1996, Prieur et al., 2004, Pye et al., 1991, Schneider et al., 1998, Sedegah et al., 
1990). The overall immunogenicity of a virus is greater than a plasmid or a 
protein, however, when used alone or in homologous prime-boost regimens, much
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of the immunogenicity of these recombinant viruses is targeted at the vector 
components. Heterologous prime-boost vaccination, using different vectors to 
prime and to boost has therefore been identified as the best strategy to induce 
immune responses.
DNA, viral vectors, as well as TyVLP (Allsopp et al., 1996, Gilbert et al., 1999) 
have been tested for their ability to prime and to boost an immune response, but 
the sequence with which they are used determines the efficiency of the boost (Li 
et al., 1993, Sedegah et al., 1998). Viral vectors such as fowlpox 9 (FP9) can 
usually be used both for priming or boosting (Anderson et al., 2004, Moorthy & 
Hill, 2002). However, MVA is not efficient at priming (Li et al., 1993). DNA has 
been shown to be efficient only if given first (Gilbert et al., 1999, Schneider et al.,
1999).
DNA vaccination is a very effective priming tool, and a DNA priming-MVA 
boosting regime has proved very efficient, leading in some cases to complete 
protection (Schneider et al., 1998). In addition, non replicating adenoviruses 
(Bruna-Romero et al., 2001), or recombinant influenza virus expressing PyCS 
have also been tested as priming vectors, and when followed by a dose of a highly 
attenuated vaccinia virus expressing the same epitope or gene, were shown to 
induces a high degree of vaccine protection (Li et al., 1993, Rodrigues et al., 
1994).
DNA, recombinant MVA or FP9 have been constructed expressing ME-TRAP. 
This is a multiple epitope (ME) construct consisting of a string of B and T cell 
epitopes from the pre-erythrocytic antigens fused to the whole SSP2 (TRAP) 
antigen. Various prime-boosting regimes have been tried using DNA (Moorthy et 
al., 2003a) or FP9 (Moorthy et al., 2003b) as priming vectors showing safety in 
humans and the ability to stimulate immune responses in animals. This 
vaccination gave promising results, although vaccination with the RTS,S/AS02 
still seems to be more protective probably due to the presence of antibody 
responses as well as cellular responses (Kester et al., 2001). Current studies are 
therefore assessing the effect of using MVA expressing CS in a prime boost 
regime with the peptide RTS/AS02 vaccine.
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MVA has also been tested recently, together with DNA and FP9, as a boosting 
factor for another polyantigen vaccine (L3SEPTL) formed from six 
preerythrocytic antigens expressed either by DNA, MVA, or FP9 (Prieur et al., 
2004).
Similarly to MVA, NYVAC is also capable of boosting the immune response, and 
protection against QS in mice (Sedegah et al., 1998), and in rhesus macaque 
immunised with a vaccine expressing two pre-erythrocytic antigens and two blood 
stage antigens (Rogers et al., 2001). Finally, similarly to the other approaches, the 
effectiveness of boosting can be further improved by including expression of 
immunostimulatory cytokines as GMCSF (Sedegah et al., 2000).
Although there is still no vaccine against malaria, all these studies have helped in 
reaching the conclusion that the ideal vaccine should be able to stimulate a CTL 
response as well as antibody responses, and include multiple epitopes from one 
protein as well as multiple antigens. A multistage, multiantigen vaccine using full- 
length genes and delivered as heterologous prime boost regime including a viral 
dose appears to be ideal. Antigens to be included would be CS, TRAP, LSA1, 
MSP1, RES A, SERA, PfEMPl, Pf25 and Pf28 together with an 
immunostimulatory cytokine.
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1.2. Dendritic cells
All cells in the body are antigen presenting cells (APC) since they can present 
peptides from internal antigens on MHCI molecules. Dendritic cells (DCs), 
together with macrophages, are specialised antigen presenting cells in that they 
also express MHCII molecules on which they present peptides from antigens 
taken up from the environment. Additionally, dendritic cells are considered the 
best antigen presenting cells in that they are the only ones able to stimulate naive 
T cells (Steinman, 1991).
1.2.1 Dendritic cell development
Dendritic cells originate in the bone marrow and are found across the body in an 
immature form where they act as sentinels, monitoring the environment, waiting 
to encounter a foreign antigen that they can process and present to cells of the 
immune system.
Dendritic cells are scattered around the body and differ in phenotype and activity 
depending on their location. Two main lineages of DCs have been identified in 
both humans and in mice, these are myeloid, and lymphoid cells. A third group, 
the plasmacytoid DCs, has also been characterised but whether this represents a 
different lineage or derives from the lymphoid lineage is still not clear. Both 
lymphoid and myeloid cells originate from a haemopoietic stem cell in the bone 
marrow that can give rise to a common myeloid precursor (CMP), or a common 
lymphoid precursor (CLP) depending on the cytokine available. Granulocyte- 
monocyte-colony-stimulating-factor (GMCSF) is the main inducer for the 
development of myeloid cells whereas TNFa or IL7 seem to be the cytokines 
triggering lymphoid cell differentiation (Manz et al., 2001). These cytokines can 
also be used in vitro to obtain the desired lineage.
The immature precursors leave the bone marrow, enter the blood stream and 
migrate to sites of potential antigen entry where, according to the cytokines 
present in the tissue, they differentiate and become immature resident tissue cells. 
Despars et al (Despars & O'Neill, 2004) have described this process with a 
“niche” model relying on the presence of different cytokines. Each organ would
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contain various niches and different precursors within which the different DCs 
can develop. For instance, the CMP gives rise to Langerhans cells in the skin 
under the influence of TGFp, but will also develop into interstitial cells in the 
epidermis. Residing in an immature state, these DCs patrol for the possible 
presence of antigens. Lymphoid cells arise from the CLP in the presence of IL3 
whereas Flt3 seems to preferentially induce production of plasmacytoid DCs 
(Figure 1.2).
Cells derived from myeloid precursors develop into Langerhans, dermal, and 
interstitial cells, all present in peripheral tissue. Those derived from lymphoid 
precursors give rise mainly to cells that are present in primary and secondary 
lymphoid organs, often responsible for T cell negative selection or involved in 
downregulation of primary peripheral T cell responses. Plasmacytoid DC are 
found in spleen (Grouard et al., 1997), bone marrow, blood (Liu et al., 2001b) and 
thymus (Bendriss-Vermare et al., 2001) and seem to originate from both myeloid 
and lymphoid precursors (Ardavin, 2003). Follicular DC, despite their name, are 
not related to those that originate from the BM, they are present in the LN and 
retain immune complexes over a period of months in their native conformation 
and are important for memory.
In mice six DC populations have been defined (Shortman & Liu, 2002), all 
expressing CD llc on their surface but differing for other surface markers 
(Figurel.2). Myeloid cells can be distinguished from lymphoid cells in that only 
myeloid cells express C D llb whereas the presence of CD8a  on the surface 
denotes cells of the lymphoid lineage. The spleen contains both myeloid (CD80Q 
and lymphoid cells (CD8a +) but whereas lymphoid cells are all negative for CD4, 
myeloid cells are further divided into CD4+ and CD4’ cells. In addition to these 
three cell types found in the spleen, two more are present in the LN. One type of 
cells corresponds to migrated Langerhans cells, therefore myeloid, expressing 
CDllc, CDllb, not CD8a  nor CD4, but with additional expression of langerin 
and CD205. The second extra population found in the LN is believed to be the 
mature form of interstitial DCs, thus again myeloid cells C D llc+CD llb+CD8a* 
CD4‘, but expressing moderate levels of CD205 on their surface. Finally the sixth
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type of DC present in mice is the plasmacytoid cells characterised by the B220 
marker and negative for CDllb while expressing CD8a (CDllc+CDllbCD4' 
CD8a+B220+)
BM Haematopoietic stem cell
GMCSF 
IL4 /
CMP CLP
Flt3
M veloid Plasmacvtoid
CD1 lc+ CD1 lb+ CD1 lc+ CD8a+B220+ CDl lc+ CD8 a
/  X  i  I
CD4+ CD4' IFNa/p IL10
XjFp
Langerhans
CD205 CDIaCD205mt CDla+CD205high
IL12
Figure 1.2: DC subsets development in mice
Myeloid, plasmacytoid and lymphoid cells derive from two precursors 
that develop from a bone marrow (BM) haematopoietic precursor: 
common myeloid precursor (CMP) or common lymphoid precursor 
(CLP) and further differentiate into cells expressing different surface 
markers and secreting different cytokines. All six types of cells are found 
in mice lymph nodes.
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The types of human DCs have not been studied as extensively as those from mice, 
and the presence of a lymphoid lineage is still controversial. All human DCs are 
characterised by expression of CD34a. The myeloid precursor develops into 
monocytes that are found in the blood stream where they patrol the body and 
migrate to the site of infection when necessary. Alternatively, the CMP stimulated 
by TGFp can develop into Langerhans cells that reside in the skin where they 
inspect the surface for incoming pathogens. Lymphoid cells have not really been 
defined, but the plasmacytoid population probably arising from a lymphoid 
precursor has been clearly characterised.
In the tissue of residence, DCs have high phagocytic activity and can take up both 
self and foreign antigens. Antigen uptake induces the cell into an activated state in 
which they are capable of inducing tolerance or an immune response to the 
antigen. The activated DCs start travelling to the LN that they reach upon full 
maturation. There they present the antigen to T cells and either induce an immune 
response or tolerance.
Lymphoid and myeloid cells differ in their function. Lymphoid cells found mainly 
in lymphoid tissues are not as efficient as myeloid cells at phagocytosis although 
they are effective at presenting antigens taken up from dying cells (cross­
priming). They only produce limited amounts of IL12 (needed for autostimulation 
and to stimulate T lymphocytes) and are rather inclined to induce tolerance and 
Th2 type of responses inducing IL10 release from CD8 cells. Myeloid cells, on 
the other hand, though not efficient at cross-priming, are the most efficient at 
inducing immunity to pathogens by reacting with, and activating T cells (Hannum 
et al., 1994). Upon activation myeloid cells release large amounts of IL12 and 
IFNy, resulting in Thl type immune response that activates CD8+T cells. 
Plasmacytoid cells are considered the natural interferon producing cells, releasing 
type IIFN.
Most research using DCs uses human monocyte cells derived from blood 
monocytes cultures including GMCSF and IL4, or the corresponding myeloid
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cells amplified from mouse bone marrow with GMCSF since these are the cells 
which usually react to incoming pathogens.
1.2.2 Antigen uptake by dendritic cells
The immature DC found in the periphery at locations where antigens are likely to 
enter the body, are very efficient in capturing and processing antigens (Steinman 
& Swanson, 1995). Mature DCs, on the other hand, predominantly found in 
lymph nodes, where contact with other lymphocytes is possible, are poor at taking 
up antigens but very efficient at interacting with cells and initiating an immune 
response (Lanzavecchia & Sallusto, 2000). Antigen uptake triggers cell 
maturation resulting in immature DCs loosing the receptors required for the 
capture of antigen (Fey and Fc5 receptors) in favour of migration and T cell 
stimulatory functions (figure 1.3) (Lukas et al., 1996).
DCs continuously sample the antigenic content of their environment and can 
capture antigens via three different mechanisms. Particles and microbes can be 
phagocytosed (Banchereau & Steinman, 1998) which appears to be particularly 
efficient (Inaba et al., 1998). Alternatively, DCs can take up extracellular fluids 
and solutes by macropinocytosis, by the formation of a pinocytic vesicle (Sallusto 
et al., 1995, Steinman & Swanson, 1995). Finally, DCs can use adsorptive 
endocytosis that involves using C-type lectin receptors such as the macrophage 
mannose receptor (Sallusto et al., 1995) and DEC-205 (Jiang et al., 1995) as well 
as Fey and Fee receptors (Albert et al., 1998, Sallusto & Lanzavecchia, 1994) 
present on the cell surface. Although endocytosis appears to be downregulated 
after antigen uptake while the cell undergoes maturation, clathrin mediated uptake 
has been shown to still be possible even in mature cells (Mellman & Steinman, 
2001).
When they encounter local inflammatory mediators, such as TNFa or LPS, or 
when they take up an antigen, DCs become activated and undergo a series of 
physiological changes leading to terminal differentiation into potent professional 
APC (Banchereau & Steinman, 1998) coinciding with the ability to migrate to 
regional lymph nodes (Sallusto & Lanzavecchia, 1994).
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Figure 1.3: Life cycle of dendritic cell
The bone marrow precursor migrates to peripheral tissues where the 
immature DCs develop and upon encounter and uptake of antigen these 
mature upregulating surface markers and enter the lymphatics to reach the 
lymphoid tissues where the mature DC can interact and induce T cell 
activation via costimualtory molecules and released cytokines.
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42
1.2.3 DC Activation
DCs recognise bacteria, viruses and parasites via Toll like receptors (TLRs) 
(Janeway & Medzhitov, 2002, Medzhitov et al., 1997), a family of pattern 
recognition receptors present in and on the surface of antigen presenting cells. 
TLRs recognise specific ligands called pathogen-associated molecular patterns 
(PAMPs) present in pathogens (LPS, CpG ODN, dsRNA). TLR ligands can 
activate the DCs directly in-vivo. Alternatively, the presence of activated CD4+Th 
cells is required to induce CD40 activation of DC (Toes et al., 1999); (Bonifaz et 
al., 2002). Signalling from TLRs usually takes place through the MyD88 adaptor 
protein triggering a MAP kinase cascade leading to gene transcription (Kawai et 
al., 1999, Medzhitov, 2001). Alternatively, TLR ligands can also activate the DCs 
in a MyD88 independent mechanism (Akira et al., 2001, Medzhitov, 2001). DC 
activation is a reversible state that does not involve phenotypic changes but 
induces the cell to release pro-inflammatory cytokines for T cell activation.
The type of TLRs present on the surface of the cells varies depending on the DC 
subset, and different TLRs differ in their ligands and response they induce (table 
1.1). The type of response of the cell therefore depends on the stimulus and on the 
TLR activated, it is possible that different DC subsets determine Thl or Th2 
polarisation (Moser & Murphy, 2000).
TLR2 and TLR4 are present on myeloid DC, and can both bind LPS and 
purification of LPS or the use of synthetic lipid A revealed that TLR4 is the 
primary receptor involved in DC activation upon LPS stimulation (Hirschfeld et 
al., 2000). Binding of LPS to these receptors triggers IL12 release and minimal 
IL10 release, together with TNFa and IL6 (Thoma-Uszynski et al., 2000). 
Production of this set of cytokines polarises CD4 cells into a Thl type response, 
this is how microbial pathogens activate cell-mediated Thl immunity. On the 
other hand, plasmacytoid DC have TLR7 and TLR9 on their surface, the first 
binding to viruses and the latter to viral DNA. Binding to these receptors induces 
the cell to release IFNa and not IL12 therefore triggering an antiviral Th2 type 
response that does not involve IL12 (Jarrossay et al., 2001, Kadowaki et al., 2001, 
Krug et al., 2001).
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Toll Like Receptor Ligand Reference
TLR2 Components of gram -ve bacteria 
Mycobacteria
Yeast cell wall and gram +ve bacteria
(Jankovic et al., 
2001)
(Jankovic et al., 
2001)
(Aderem & 
Ulevitch, 2000)
TLR3 Double stranded DNA (Steinman & 
Pope, 2002)
TLR4 LPS
Gram-ve bacteria (except some components) 
Respiratory cyncytial virus
(Jankovic et al., 
2001)
(Jankovic et al., 
2001)
(Jankovic et al., 
2001)
TLR5 Bacterial flagellin from gram -ve and gram 
+ve bacteria
(Jankovic et al., 
2001)
TLR6 Yeast cell wall and gram +ve bacteria (Aderem & 
Ulevitch, 2000)
TLR7 Viruses
TLR9 Unmethylated CpG containing DNA (Jankovic et al., 
2001)
Table 1.1: TLR specificity.
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1.2.4 Antigen processing
Activation of DC by antigen uptake is followed by antigen presentation and cell 
maturation. Unlike activation, maturation is an irreversible state characterised by 
upregulation of antigen presenting molecules (MHCI and MHCII), and 
costimulatory markers (CD40, CD80, CD86), as well as by the secretion of 
cytokines from the DC (IL12, MIPla, IL1, IL6, IL10, TNFa) (Figure 1.3). These 
modifications allow for maximal T cell activation from the DC. Antigens are 
presented on the surface of DCs as peptides associated with MHCII or MHCI 
molecules, depending whether the antigen was taken up from the environment, or 
from the cytosol respectively.
1.2.4.1 MHCII anti sen presentation:
MHCII are formed in the rough endoplasmic reticule where the newly synthesised 
MHCII molecule associates with an invariant chain in the peptide binding cleft 
(figure 1.4). This complex is transported through the Golgi and from the trans- 
Golgi the invariant chain targets the MHCII to the late endosomes where it meets 
the internalised antigen. The antigen degradation process takes place in 
endosomes through a process of increasing acidic pH. In the late endosome, both 
the invariant chain and the antigen are degraded, this allows for the antigenic 
peptides to replace the invariant chain in the cleft of the MHCII.
The rate of production of MHCII molecules does not change during cell 
maturation, instead, in immature cells the large numbers of MHCII produced are 
sequestered intracellularly into lysosomes (Celia et al., 1997). The invariant chain 
that binds in the groove of newly formed MHCII molecules also contains a 
cytoplasmic domain with a lysosomal targeting signal. Degradation of the 
lysosomal targeting signal is only possible in mature cells where the activity of an 
anti-protease (cystatic C) is reduced in favour of a protease (catS) activity. This 
results in higher amount of MHCII avoiding the lysosomes and instead reaching 
the membrane (Pierre & Mellman, 1998). The vesicle that reaches the membrane 
contains both the MHCII-peptide complexes and CD86 molecules that remain 
close to the complex upon exposure, thus conferring an ideal field for T cell
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activation which remains stable for days (Celia et al., 1997, Mellman & Steinman, 
2001, Pierre et al., 1997).
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Figure 1.4: MHCII presentation pathway
Antigens are taken up from the environment and are internalised and 
processed into endosomes where they are then loaded onto MHCII 
molecules by replacing the invariant chain. The MHCII peptide is then 
delivered to the surface of the DC. MHCII molecules that are not 
loaded with antigen, as well as degraded invariant chain and peptides 
that are not presented are further degraded into lysosomes.
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1.2.4.2 M H C I antigen presentation:
Presentation of peptides on MHCI is needed to activate CD8+ CTL cells. Loading 
on the MHCI molecules usually takes place for antigens synthesised within the 
cell including those derived from infecting viruses that express the proteins inside 
the cell, or even proteins that have been taken up upon phagocytosis of dying cells 
(cross-presentation) (Albert et al., 1998). The endogenously synthesised proteins 
are cleaved by proteasomes, and the peptides transported by means of transporters 
for antigen presentation (TAP) into the rough ER. Here, the peptides are bound to 
the newly formed MHCI molecules that then leave via the Golgi to the surface of 
the cell (Pamer & Cresswell, 1998) (figure 1.5).
i
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Figure 1.5: MHCI presentation pathway
Cytoplasmic antigens are processed through a proteasome and transported 
into the ER by means TAP transported. In the ER the peptides are loaded 
onto MHCI molecules and then through the Golgi for presentation on cell 
surface.
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1.2.4.3 Cross presentation:
Cross presentation is the ability of DC to present in the context of MHCI, peptides 
from pathogen infected cells, and prime CTL responses against these intracellular 
microbial infections (Jung et al., 2002). Some endocytosed antigens derived from 
immune complexes, inactivated microbes, or antigens originally synthesised in 
other cells (cross-presentation) can gain access to the MHCI pathway (Bevan, 
1976, Heath & Carbone, 2001). The uptake depends on selective endocytic uptake 
receptors on the surface of the DCs and presentation is usually TAP transporter 
dependent (Huang et al., 1996, Regnault et al., 1999) relying on a specialised 
phagosome-to-cytosol pathway in BMDC (Kovacsovics-Bankowski & Rock, 
1995, Rodriguez et al., 1999). An endocytic vacuole is formed by FcyR that bind 
immune complexes and antibody coated tumour cells. Alternatively, the vacuole 
can form from the integrin and the phosphatidylserine receptor binding to dying 
cells, or even heat shock protein receptors binding their proteins. Antigens leave 
the vacuole probably by the action of a transporter and the ubiquitinilated proteins 
are then targeted to the proteasome for cleavage and subsequent TAP mediated 
transport to then undergo the normal MHCI loading pathway.
Necrotic cells release their toxic content, peptides and proteins in the surrounding 
environment causing inflammation. Apoptotic cells, on the other hand, die 
keeping all the substances and organelles confined within them. Because of their 
ability to induce inflammation, it was initially thought that only necrotic cells 
could stimulate DC activation and cross-presentation (Gallucci et al., 1999, Sauter 
et al., 2000). The phenomenon of cross-presentation implies that a peptide initially 
presented on MHCI is finally presented on MHCII of a DC. Again, necrotic cells 
were thought to be the only ones to stimulate this process since the released 
peptides could be taken up by the DCs and thus presented via the MHCII 
pathway. Recently it ahs been shown that DCs recognise apoptotic cells and these 
are taken up, thus resulting in DC activation and presentation on MHCII of 
antigens initially present on the MHCI of the dying cell.
The MHCI and MHCII complexes interact with the CD4 and CD8 respectively on 
Th and CTL cells. This and other connections formed between DC and T cell
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surface such as binding to TNF receptor family (eg. CD40) activate NF-kB 
transcriptional factors, resulting in release of inflammatory cytokines, 
upregulation of surface molecules, and activation of CD4+T, CD8+T or B cells.
1.2.5 DC maturation and migration
In addition to antigen presentation, the process of DC maturation also involves 
changes in the panel of surface costimulatory molecules and receptors to induce 
the cell to travel to the lymph node for interaction with T cells. Maturation and 
migration occur concomitantly, to allow the DC to reach the LN in a fully mature 
state.
DCs migrate in response to chemotactic stimuli. The CC receptor molecules 
(CCR) on the cell surface induce the cell to migrate towards sites with a high 
concentration of their ligand. During maturation the DCs loose CCR5 and CCR2 
that respond to inflammatory cytokines thus targeting the cell at the site of 
infection, in favour of expression of CCR7 that responds to chemokines expressed 
in the lymphatic vessel and lymphoid organs (Forster et al., 1999). Initially, the 
DC enters the lymphatics where the CCR7 ligand 6Ckine is produced. 
Subsequently, the cells are driven to the draining LN where MIP3p (another 
CCR7 ligand) is expressed (Sallusto & Lanzavecchia, 2000).
Activation of T cells in the LN is also dependent on chemokines. The fully mature 
DCs that reach the LN attract T cells by releasing chemokines. Thymus and 
activation regulated chemokine (TARC) (Lieberam & Forster, 1999) and 
macrophage derived chemokine (MDC) (Godiska et al., 1997) are both produced 
by the DCs, bind CCR4 in and CCR7 expressed by naive T cells, and are involved 
in attracting memory cells (Sallusto et al., 1999). DC-CK1 is also a CC 
chemokine produced in secondary lymphoid organs by DC. This chemoattracts 
CD4 and CD8 T cells and is involved in priming naive cells (Adema et al., 1997).
This ability of the DCs to travel is also exploited by viruses as a means of 
transport around the body to LN (Masurier et al., 1998).
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1.2.6 Dendritic cell stimulation of the immune system
1.2.6.1 Activation o fT  cells
Dendritic cells have the unique ability to prime naive T cells (Banchereau & 
Steinman, 1998). Mature DCs interact with ligands on the T cell (table 1.2). 
Following these interactions, both DCs and T cells release cytokines to maintain 
their activation state, and, depending on the type of pathogen that activated the 
DC (§ 1.2.1.3), these released cytokines polarise CD4+T cells into either Thl or 
Th2 (d'Ostiani et al., 2000). Viruses, intracellular pathogens and bacteria induce 
DCs to release IL12 that stimulates Thl differentiation whereas multicellular 
parasites stimulate Th2 differentiation.
Dendritic cell CD4+T cell
CD40 CD40L
CD80 CD28
CD86 CD28
ICAM 1 LFA1
DC-SIGN ICAM 3
LFA3 CD2
MHCII CD4/ T cell receptor
Table 1.2: Interactions that take place between a mature DC and a naive CD4+ cell
The CD40-CD40L interaction is the strongest stimulus. This prompts further 
upregulation of CD80 and CD86 on the DC, and induces release of cytokines 
some of which (eg. TNF and IL1) keep the DC in an active state (Celia et al., 
1996, Miga et al., 2001), and others (IL1, IL6, MIPla, IL12) that activate CD4+T 
cells, B cells or CD8+T cells. Most importantly, the CD40-CD40L interaction 
stimulates DCs to secrete high levels of IL12. IL12 is the mediator between innate 
(NK cells) and adaptive (T and B cells) immunity (Trinchieri, 1998). CD4Th cells 
that recognise MHCII and IL12 are activated into IFNy producing Thl cells (Koch 
et al., 1996). Mice that lack IL12, IL12p 1 receptor or the signal transducer and 
activator 4 (STAT4) have impaired IFNy release (Trinchieri, 1998). IL12 also 
directly activates NK cells to secrete IFNy. The IFNy released by Thl cells and 
NK cells in turn stimulates DCs to produce more IL12 (Snijders et al., 1998).
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Together IFNy and IL12 therefore maintain activation of the T cells and DC, and 
in some cases this stimulus has been shown to be enough to maintain T cell 
activation in an inversely proportional way to the presence of costimulatory 
molecules interaction (Jankovic et al., 2001). The importance of IL12 production 
can be seen from the fact that maintenance of T cell response in infection is due to 
constant presence of this cytokine (Yap et al., 2000), and that its receptor is 
expressed throughout the whole Thl cell life cycle (Trinchieri, 1998).
The IFNy produced by the polarised Thl cells increases the responsiveness of T 
cells to IL12 (Smeltz et al., 2002) and the number of naive cells developing into 
IFNy producers (Creusot et al., 2003). IFNy activates the anti-microbial activity of 
macrophages and together with IL12 promotes activation of CD8+CTLs. Thl cells 
also release IL2 that induces CD8+T cell to secrete IFNy that stimulates Thl 
differentiation by positive feedback (Mailliard et al., 2002) (figure 1.6). 
Additional cytokines which induce and maintain Thl responses include IL18, 
IL23 and type I interferons (Aliberti et al., 2000, Jankovic et al., 2001).
CD8 can also be activated by type I IFN independently of IL12 and, in the 
absence of IL12, these chemokines can, in human, directly polarise Thl responses 
(Jankovic et al., 2001). Overall, DCs usually activate CD8+T cells via IL12 
activation of CD4+Thl cells that secrete IFNy to act on the CD8+T cells (three- 
cells-system), but cytokines released by the activated DC (eg. IL12 ) may act 
directly on C8+T cells inducing their activation.
Polarisation of CD4+T cells into Th2 responses are particularly dependent on 
CD28 binding to CD86, this in fact stimulates STAT6 and GATA3 genes 
expression (Oki et al., 2000) leading to IL4, IL5, IL13 expression (Jankovic et al., 
2001) while downregulating IL12R. The main cytokine associated with Th2 
responses is IL4, but, although IL4 is needed, Th2 polarisation can happen also 
when IL4R and STAT6 are not involved (Jankovic et al., 2000). Th2 cells secrete 
IL4, IL5, IL9, IL10 and IL13, expressed in different combinations depending on 
the infecting pathogen (Jankovic et al., 2001) (Figure 1.6). Their main role is to 
stimulate growth and differentiation of mast cells and eosinophils and also to
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Figure 1.6 CD4 Th polarisation:
Depending on the stimulus received by the DC, this is stimulated to 
release IL12 and IL18 therefore polarising naive CD4+T cells into Thl 
cells that release IFNy. Alternatively, DCs are stimulated to release 
IL10 and by interaction with CD28 stimulate the naive CD4 to release 
IL4 that polarises the cell into Th2.
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induce production of IgE that mediate activation of these cells (Jankovic et al., 
2001) while inhibiting Thl polarisation by producing IL10. Cytotoxic T 
lymphocyte Ag 4 (CTLA4) is a ligand that acounterbalances Th2 responses, this 
in fact inhibits activation of the cells by binding to CD80 and CD86 (Jankovic et 
al., 2001).
Maintenance of Thl over Th2 activity is a balance between cytokines. IFNy 
secreted by Thl cells inhibits Th2 differentiation. Similarly, IL4 acts directly on 
Thl cells to inhibit their differentiation. Moreover, IFNy inhibits DC from 
secreting IL10 that has an inhibitory effect on IL12, whereas IL4 and IL10 inhibit 
IL12 secretion (Koch et al., 1996, Ria et al., 1998).
Nonetheless, the role of cytokines is not clear cut. IL 12 also stimulates B cells to 
produce IL6 and IL10 that are required for Th2 differentiation (Skok et al., 1999). 
Similarly, IL4 has also been shown to be able to promote release of bioactive 
IL12 from human and murine DC (Jankovic et al., 2001), and may act in 
conjunction with IL\2 to induce Thl responses (Biedermann et al., 2001).
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1.2.6.2 Activation o f B cells
DCs can induce B cell proliferation either directly (Dubois et al., 1997) or 
indirectly via stimulation of Th cell.
Indirect activation of B cells:
Induction of a B cell response via T cell activation requires interaction of both B 
and T cells on the same DC and production of IL6 by the DC. B cells express 
CD40 on their surface and this can interact with the CD40L on the surface of T 
cells. The IFNy released by Thl cells can then induce B cells to produce IgG2 
antibodies to mediate antibody dependent cellular cytotoxicity (ADCC). Th2, on 
the other hand, release IL4, IL5 and IL13 that induce B cells to produce IgE 
antibodies. These bind to antigen and to Fc receptors on the membranes of 
basophils, eosinophils and mast cells stimulating their degranulation that results in 
killing of the invading organism (Barton & Medzhitov, 2002) (Figure 1.7).
Direct activation of B cells:
Alternatively, DCs have been shown to be able to directly activate naive and 
memory B cells (Banchereau et al., 2000, Dubois et al., 1998, Kikuchi et al.,
2000). Naive B cells previously stimulated by CD40L can respond to soluble 
factors secreted by interstitial DC, mainly IL12 (Dubois et al., 1998, Dubois et al., 
1997). IL10 and TGFp for example can induce IgA secretion (Fayette et al., 
1997). In addition, DC can enhance differentiation of CD40 activated memory B 
cells by stimulating the IL6 dependent activation pathway of B cells. DCs can 
produce soluble IL6R (also called sgp80) that binds the IL6 released by the B cell 
forming a complex with high affinity to the consitutive transducing chain (Dubois 
et al., 1998).
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Figure 1.7 B cell activation
(a) B cell activation in Th dependent way involving different cytokines 
depending on the Th subtype
(b) Ability of DCs to activate directly B cells without requiring help by 
T cells
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1.2.6.3 Activation o f complement system
Immature DCs can activate the complement pathway by producing the Clq 
element that can bind apoptotic cells and trigger the complement cascade, but its 
production is downregulated upon DC maturation.
1.2.6.4 Induction o f tolerance
In addition to pathogenic antigens, DCs may also take up and present self­
antigens where they are required not to activate immune responses, but to silence 
them. Although T cell tolerisation usually takes place in the thymus where T cells 
that have high affinity for peptides are not allowed to mature and do not enter 
circulation, DCs presenting self-antigens can tolerise T cells in the periphery.
Immature DCs in-vivo, contrarily to those in-vitro, where high levels of MHC 
molecules on their surface (Inaba et al., 1998), and tolerance seems to be targeted 
at peptides presented on immature DCs that do not undergo maturation (Jonuleit 
et al., 2000). The tolerogenic DC presenting the peptides to T cells in the absence 
of maturation stimuli may induce^ T cells to proliferate but these become anergic 
to further stimulation (Moser, 2003). Alternatively, evidence seems to suggest that 
immature tolerogenic DCs may induce T cell tolerance to self components by 
stimulating regulatory T cells (Treg cells) that have a suppressive action 
(Dhodapkar et al., 2001, Jonuleit et al., 2000, Moser, 2003, Steinman et al., 2003). 
So far three types of Treg cells have been identified two of which can be induced 
in an IL10 and/or TGFp dependent way, and a third that arises spontaneously. 
This mechanism would promote memory of tolerance
In the construction of a vaccine vector the possibility of inducing tolerance over 
immunity needs to be taken into account, and possibly eliminated by ensuring a 
good level of maturation of the cells prior to injection.
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1.2.7 Dendritic cells as tools for immunotherapy
Because of their ability to take up exogenous antigens and present them to both 
CTL and B cells stimulating targeted responses, DCs are the ideal tool in the 
construction of an immunotherapeutic vaccine vector. Also, the possibility of 
obtaining large numbers of DCs in culture both from monocytes in the blood (for 
human cells) and from mouse bone marrow (for murine cells), allows testing for 
the efficiency of the vector by ex vivo loading of the DC, followed by re-injection, 
comparing it to direct immunisation. A major factor to consider in working 
towards an immunotherapeutic vector is to ensure correct maturation of the DC. 
This is both to avoid tolerance and to ensure maximal stimulation of T cells.
Advantages of using ex vivo loading include the possibility of monitoring the level 
of cell maturation, the efficiency of antigen uptake by DC and the dose of cell 
vaccination, together with the possibility of targeting the antigen-loaded DCs to 
specific locations, e.g. lymph node or tumour. On the other hand, direct in vivo 
vaccination is a more practical method with reduced manipulation, although 
specific targeting to the DCs can not be ensured but could still be achieved by 
cross presentation.
A problem with ex vivo antigen loading, is that cell reinjection may result in poor 
travelling of the DC to the LN. Less than 5% of the injected cells usually reach 
the draining node (De Vries et al., 2003), implying that specific stimuli such as 
immmunostimulatory cytokines that stimulate maturation and migration should be 
added to the vaccine. An alternative to override this problem is intranodal 
injection of antigen presenting cells, but although this is expected to increase T 
cell stimulation, it may well destroy the structure of the node, forcing the cells to 
migrate to the next one. Ideally a vaccine would be able to target and activate DCs 
directly in vivo, bypassing the in vitro manipulation, but appropriate activation 
stimuli to obtain correct cell maturation and avoid tolerance should be included 
(Bonifaz et al., 2002).
The DC targeted by the vector should therefore take up and present the antigen 
efficiently, as well as being stimulated and allowed to undergo maturation 
correctly. The stimuli induced by antigen uptake may be enough to activate the
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DC, alternatively, the cell may respond to exogenous cytokines (eg. TNF) 
released by neighbouring lymphocytes.
Numerous methods are available to achieve peptide presentation by the DCs, and 
all can be used for ex vivo or in vivo DC targeting although they vary in the 
strength of the response induced, efficiency of DC targeting and antigen 
processing, and on the level of safety.
1.2.8 Non viral antigen delivery to dendritic cells
1.2.8.1 Peptide loading
The successful use of irradiated viruses (Lidbury et al., 2000) or parasites (Malik 
et al., 1991) to induce an immune response in a host proved that de novo protein 
synthesis is not required to achieve peptide presentation by DC. A possibility is 
therefore to make the cell take up already processed short peptides corresponding 
to one epitope that can bind directly to the MHC molecules on the surface of the 
cell. Providing the DC with a synthetic peptide minimises problems due to 
inefficient protein processing or cell disruption by the antigen-carrying vector. In 
addition, this method allows an immune response to be specifically induced to the 
immunodominant peptide of an antigen as well as stimulating the most 
appropriate cell type (CD8+T, CD4+T, B cell) by using the identified epitope 
specific for it.
Adoptive transfer in mice of BMDCs pulsed with a peptide from lymphocytic 
choriomeningitic virus (LCMV) (Ludewig et al., 1998) or P. yoelii CS (Bruna- 
Romero & Rodriguez, 2001) showed that it is possible to induce a protective 
immune response using this method and focussing only on one epitope. Recently, 
Behboudi et al (Behboudi et al., 2004) have shown that similar results can also be 
obtained by using spleen CD8+ or CD8' DC. These cells pulsed with the P. 
berghei CS peptide can induce or boost an IFNy response to the peptide after i.v. 
immunisation.
Because of the very low level of safety concerns, this method has also been tested 
in non human primates where PBMC pulsed with ovalbumin could induce 
antibody responses in addition to CTL (Barratt-Boyes et al., 1998), and cancer
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studies have seen this method tested in humans as well. In a group of seven 
patients with advanced carcinoembryonic antigen (CEA)-expressing 
gastrointestinal malignancies four developed CTL responses following 
immunisation with PBMCs loaded with a CEA restricted peptide (Matsuda et al., 
2004). Similarly, three out of four patients with stage IV melanoma receiving 
PBMCs pulsed with a peptide from MAGE3, usually presented on HLA-A1, 
showed regression of tumour metastases and increased T cell responses 
(Godelaine et al., 2003).
A limitation of this loading technique is that only one epitope can be targeted. 
This has been overcome by loading DCs with a cocktail of epitopes from the same 
protein, allowing to target cells that facilitate and enhance the response (eg. 
CD4+Th) (Svane et al., 2004). Alternatively a mixture of peptides from different 
antigens can be used, resulting in a multiantigen vaccine. Combinations of malaria 
peptides have been administered to monkeys showing multiantigen long lasting B, 
CD4+Th and CD8+CTL responses (BenMohamed et al., 2004). Similarly, patients 
receiving PBMCs pulsed with a mixture of four melanoma antigen HLA restricted 
peptides resulted in five out of nine expressing a response to the antigens, and 
three out of these showing a response to two or more antigens (Palucka et al.,
2003).
A drawback of this approach remains the laborious effort required to find the 
immunodominant epitopes and the fact that the peptide-MHC complex formed 
from extracellular binding is not very stable and dissociates quite rapidly 
(Banchereau & Steinman, 1998). In addition, for synthetic peptides to be 
delivered directly in vivo, adjuvants are required that may often cause significant 
inflammatory reactions (Edelman et al., 2002). Recently, in vivo, delivery of 
peptides has been improved by using biodegradable poly-D,L-lactide-co-glycolide 
(PLGA) microspheres that allow release of antigen over a longer period of time, 
but this still does not provide an immunogenicity comparable to that of other 
loading methods (Rosas et al., 2001)
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1.2.8.2 DNA/RNA Loadinz:
DNA/RNA pulsing of DCs means that the DNA/RNA encoding for the gene of 
interest is directly delivered into the cell. This has the major advantage of 
allowing the cell to carry out expression and processing of the antigen peptides 
naturally. Advantages of using DNA loading include the inexpensive production 
and safety upon injection, as well as the option of using the full-length gene. The 
use of the entire gene provides additional advantages such as the availability of 
CD4, B cell, and also additional unknown epitopes. The other advantage of 
loading a DC directly with DNA is that the regulatory sequences can also be 
included and expressed, providing the signalling sequences for efficient peptide 
processing. Moreover the MHC-peptide complex formed from internal processing 
of the antigen is more stable than that formed from incubation of cells with 
peptides.
Bone marrow DCs can be transfected ex vivo, non-virally, by lipofectin, DNA- 
liposome complexes, calcium phosphate precipitation, or electroporation. Lately 
gene gun transfection has been shown to be the most efficient of these methods 
(Larregina et al., 2004), consisting of gold particles loaded with the DNA of 
interest that are shot directly into the cytosol of the cell. Cationic peptides are 
another option, these are positively charged peptides that condense the DNA to 
allow easier transfection (Irvine et al., 2000). Direct DNA loading of DCs in vivo 
is also possible. The plasmid expressing the specific antigen can be injected 
directly into the host, but the risk is that this will be taken up by other cells, 
resulting in cross presentation. Targeting of a DNA vaccine can be improved by 
including unmethylated CpG sequences, to target the DNA to TLR9-expressing 
cells (Klinman et al., 1997). Similarly, using other delivery techniques such as the 
gene gun (Sakai et al., 2003), or microparticles and nanoparticles (Yang et al., 
2004) efficiency of delivery to DCs can be improved.
DNA immunisation can induce both B and T cell responses (Leitner et al., 1997), 
and direct immunisation with naked DNA has proved able to stimulate CTL 
responses both in mice, monkeys and humans. Gene gun immunisation of a DNA 
vaccine expressing both the PbCS protein and IL12 into the liver or skin 
successfully stimulates Thl type responses (Yoshida et al., 2000). Antibody
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responses against malaria proteins have also been generated using this method 
(Belperron et al., 1999, Haddad et al., 1999, Sakai et al., 1999). In mice, 
intramuscular injection of naked DNA expressing PyCS resulted in 18 out of 28 
mice being protected against subsequent challenge (Sedegah et al., 1994), but in 
humans, while a response to the malaria PfCS protein could be induced (Le et al., 
2000) protection required very high doses of DNA (Wang et al., 1998b).
The success of vaccination relies on the successful transfection and activation of 
DC followed by initiation of T cell responses. It is difficult for a DNA vaccine to 
induce maturation whereas ex vivo transfected cells can be matured prior to 
injection. In vivo administration of naked DNA should therefore make use of 
adjuvants or carry signals/genes such as co-stimulatory molecules (eg. CD40L) 
that will induce DC maturation (Agadjanyan et al., 2003). The main problem with 
DNA transduction is the inefficiency of gene transfer (Arthur et al., 1997), 
possibly because of limited transfer to the cell nucleus (Luo & Saltzman, 2000). 
In addition, entering the nucleus may lead to integration of the DNA. Dendritic 
cells are therefore often also transduced with RNA. This has similar advantages to 
DNA but nuclear entry is not required and integration is avoided.
Similarly to DNA, RNA transfection can be achieved by electroporation giving 
similar levels of delivery as using poxviruses or adenoviruses (see later) (Van 
Tendeloo et al., 2001), and has the advantage that total RNA, for instance from 
cancerous cells, can be transfected into mouse BMDC (Jung et al., 2004). 
Electroporation into DC of the mRNA for the MAGE-A3 cancer antigen, showed 
that peptides are presented on both MHCI and MHCII (Bonehill et al., 2004). 
Also, mice immunised with DC transfected with total RNA from tumour cells can 
stimulate antitumour CTL responses and establish antitumour immunity (Liu et 
al., 2004). Similarly, human DCs transfected with RNA expressing carcino- 
embryonic antigen (CEA), have been shown to successfully induce CTL 
responses (Nair et al., 1998).
1.2.8.3 Bacteria loading:
The use of recombinant organisms that naturally target DCs is an improvement to 
DNA vaccination since full-length genes can be delivered to the cell for
63
endogenous processing onto MHCI. Bacteria can infect dendritic cells, resulting 
in antigens carried by the pathogen being expressed in the DC, and entering the 
MHCI pathway for presentation. This mechanism inducing CTL responses, makes 
bacteria an efficient vector for gene delivery to DC. Amongst others, attenuated 
strains of Salmonella typhimurium and Listeria monocytogenes have proved 
efficient in delivering DNA for tumour or viral antigens to DC, resulting in CTL 
responses and protective immunity (Cochlovius et al., 2002); (Weiskirch & 
Paterson, 1997).
Safety issues may arise using whole bacteria. Therefore their use has often 
focussed on bacterial toxins. These can enter the cytosol and traffic in a retrograde 
manner across the ER into the biosynthetic and secretory pathways. Fusion of a 
DNA antigen sequence to a bacteria toxin sequence allows for entry into the 
dendritic cell using the pathway usually used by the bacteria. Bacteria and anthrax 
toxins can enter directly through the endosomal membrane whereas the Bordatella 
pertussis enters via the plasma membrane (Moron et al., 2004). This then allows 
expression of the antigen within the DC so that it will undergo MHCI 
presentation. Adenylate cyclase (CyaA) derived from B. pertussis efficiently 
binds to the surface of DCs and can therefore specifically target these cells for the 
delivery of genetic material. CyaA coupled to viral or tumour epitopes has been 
shown to induce protective or therapeutic responses (El Azami El Idrissi et al., 
2002, Fayolle et al., 1999).
1.2.8.4 Virus Like Particle (VLP) Loading:
Virus like particles are formed by viral structural proteins that retain the virus 
external capsids but not the whole genome. Proteins on the surface of a virus are 
usually responsible for the entry into cells, therefore VLPs maintain this ability to 
enter cells and release the antigenic material that they contain while not 
undergoing replication. VLP have the advantage that they are able to stimulate 
DC maturation with the production of costimulatory signals to ensure the 
generation of efficient immune responses. They are, therefore, natural adjuvants, 
and induce a long lasting immune response (Sedlik et al., 1997).
64
VLP can be formed based on a number of viruses. One of the most widely used 
VLP is Hepatitis B virus small envelope protein (HBsAg), although 
papillomavirus (Chackerian et al., 2004) and parvovirus (Moron et al., 2003) 
VLPs have also proved efficient. Chimeric VLPs can carry foreign peptides and 
induce B and T cell responses following DC internalisation by micropinocytosis. 
HbsAg relies on endosomal processing in DCs. The antigen is processed inside 
the endocytic vesicle without reaching the cytoplasm, therefore binding to pre­
existing MHCI molecules. Other VLPs may be TAP independent (Ruedl et al.,
2002) or TAP dependent (eg. parvoviruses) (Moron et al., 2003).
Ty-virus like particles (Ty-VLP) consist of a single protein species that can be 
produced in yeast. They have been used for malaria immunotherapy expressing a 
string of 15 CTL epitopes from p. berghei resulting in non-protective responses 
following a single immunisation, though suggesting efficient targeting of DC 
(Gilbert et al., 1997). Similarly, clinical trials using Ty-VLP carrying part of the 
HIV 1 Gag gene (p24-VLP) gave disappointing results (Lindenburg et al., 2002). 
Although not strong enough to induce protective responses, Ty-VLPs have been 
found to act as good priming agents for subsequent viral boost (Gilbert et al., 
2002, Oliveira-Ferreira et al., 2000).
1.2.9 Viral vectors for immunotherapy:
Viruses are ideal for the delivery of genetic material to cells since they have 
evolved to gain access to cells and to use the cell machinery to facilitate their own 
replication. This is therefore probably the most efficient way of introducing 
exogenous DNA directly into the nucleus of DCs allowing natural processing and 
presentation of the peptides, resulting more efficient than other techniques 
(Larregina et al., 2004). Similarly to other DNA loading methods, expression of 
large amounts of DNA is possible, and superior antigen processing with more 
sustained presentation is seen compared to peptide uptake (Brossart et al., 1998, 
Germain & Margulies, 1993). In addition, viruses are usually relatively easy to 
propagate and to grow at high titres.
An advantage unique to viruses, in particular retroviruses and lentiviruses, is that 
pseudotyping of the envelope can overcome the limitation of a virus not naturally
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infecting DC. Alternatively, molecules (eg. CD40L) that will target the vims 
directly to the DC can be expressed on the coat of the vims. When using the virus 
for direct in vivo injection, specificity of infection is particularly important since 
the gene might be expressed in non-target cells. However, even here infected cells 
may be taken up for cross-presentation. Using ex vivo transduced DCs is in this 
case, therefore, an advantage.
A concern when using viral vectors, is safety and toxicity of the vims. The 
challenge in viral vector therapy is to maintain the efficiency of infection while 
minimising toxicity. Ideally the vector should induce an immune response only 
against the recombinant gene. Vims replication in DCs depends on the vims, and 
in some cases on the maturation state of the cell (Kaiserlian & Dubois, 2001). 
Lentivimses and rAAV are only minimally immunogenic in humans, therefore 
have good potentials as vectors for gene delivery.
An important point that needs to be addressed when using viruses to deliver 
antigens to DCs, is the effect that infection might have on cell functions. HSV-1 
and vaccinia vims, for example, when infecting immature DCs prevent the cell 
from undergoing subsequent maturation. Influenza or measles vims, on the other 
hand, allow DC maturation. The ability of the cell to mature and present antigens 
may be impaired as a result of genes expressed by the virus as an immune evasion 
mechanism. Deletion of such genes is therefore necessary to ensure efficient gene 
delivery and expression. Toxicity may also be avoided by ensuring efficient 
expression such that a lower dose of vims is required. At the same time, viral 
pathogenicity may act as a form of adjuvant.
Injection of a virus will stimulate an immune response even if highly attenuated. It 
is important to keep this response to the minimum to avoid destruction of the 
vector prior to stimulation of an immune response. Similar problems may arise 
from previous exposure of the host to the virus. Ex vivo transduction of DCs can 
again ensure that the vims has entered the cells rather than being eliminated by 
immune responses before reaching them in vivo (Brossart et al., 1997).
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Finally, an advantage of using viruses is that, depending on the virus, it is possible 
to incorporate relatively large amounts of exogenous DNA (Table 1.3). The 
deletion of toxic and non-essential genes helps in further increasing the amount of 
foreign DNA that can be incorporated. There are five main groups of viruses that 
have been considered for gene therapy: adenoviruses, adenoassociated viruses, 
retroviruses, lentiviruses and herpesviruses. Contrarily to transduction with naked 
DNA that is extrachromosomal, viruses can be further subdivided into 
extrachromosomal DNA viruses that persist in the infected cells as an episome 
(adenoviruses, adeno associated virus, herpesviruses), or integrating viruses 
(retroviruses) which may cause a further problem with insertional mutagenesis.
Viral vector Insert size Advantage Disadvantage
Adenovirus 8Kb Broad target population Immunogenicity
Adenoassociated 4Kb Non immunogenic Small insert size
Lentivirus 8Kb Long term expression Insertional mutation
Retrovirus 8Kb Long term expression Only dividing cells 
Insertional mutation
Herpes simplex virus 1 30-40Kb Large inset size Very immunogenic
Table 1.3 Main characteristics of five principally used viral vectors
1.2.9.1 Adenovirus:
Adenoviruses are double stranded DNA viruses with the ability to infect both 
dividing and non-dividing cells. Adenoviruses preferentially infect immature DCs 
(Zhong et al., 1999), with the advantage of not interfering with cell maturation 
(Dietz et al., 2001), although at high MOI DC viability is reduced (Rea et al., 
1999, Rouard et al., 2000), and that the transferred genetic material is 
epichromosomal (Ehrhardt et al., 2003).
Adenoviruses allow delivery of only up to ~8Kb of exogenous DNA depending 
on the number of deleted genes. However, the main problem with adenovirus 
vectors relates to their immunogenicity. Expression of the adenoviral early genes 
in DCs arrests the cell cycle of the stimulated T cells (Tuettenberg et al., 2004). 
Replication incompetent adenoviruses deficient in immediate early genes (El and 
E3) have therefore been used, but these still present with the possibility of 
reforming replication competent viruses. Further attenuated adenoviral vectors 
have been engineered leading to a “gutless” version that has all viral coding
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sequences removed and relies on a helper virus for replication. These viruses 
allow for long term expression, insertion of up to 37Kb of exogenous DNA and 
preparation of high titre stocks (Zou et al., 2000). The possibility of growing high 
titre stocks is important for this type of virus since high titres are needed to 
achieve good levels of transduction in DCs (Linette et al., 2000, Rea et al., 1999, 
Zhong et al., 1999).
Of the 51 different serotypes, serotypes 2 (Ad2) and 5 (Ad5) have mainly been 
studied, initially used to target the respiratory epithelium in cystic fibrosis studies 
(Kovesdi et al., 1997). These have then been further developed as gene delivery 
vectors to target other tissues and cells, including DC. Infection occurs by initial 
binding of the a capsid protein to the coxsackievirus and adenovirus receptor 
(CAR) on the cell surface (Bergelson et al., 1997, Tillman et al., 1999). Further 
interactions of proteins with integrins on the host cell surface result in virus 
internalisation (Barnett et al., 2002, Mathias et al., 1994, Wickham et al., 1993). 
Targeting can be improved by addition of a cell binding motif or CD40L in the 
capsid, and this has been shown to increase infectivity of DC and recombinant 
gene expression (Stockwin et al., 2002, Tillman et al., 1999, Worgall et al., 2004, 
Zhang et al., 2003).
Genetically modified adenoviruses can induce both cellular and humoral 
immunity. This virus has been used in vaccine studies including cancer, viral and 
parasitic infections. Mice immunised with dendritic cells infected with adenovirus 
expressing the MARTI antigen could stimulate CTL responses and confer partial 
protection (Broder et al., 2003), and studies using the thyroid peroxidase gene 
additionally showed stimulation of antibody responses following injection with 
infected DCs or neat adenovirus (Guo et al., 2003). Similarly, in malaria research, 
an adenovirus expressing PyCS could successfully stimulate CD8+ and CD4+T 
cells upon virus injection implying that DCs are targeted and can present the 
recombinant antigen to induce protection (Rodrigues et al., 1997, Rodrigues et al., 
1998). Non-human primates have also received DC transduced with recombinant 
virus expressing the Gag antigen of SIV, and successfully developed CD8+T cell 
responses following skin or lymph node injection (Brown et al., 2003)..
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1.2.9.2 Adeno-associated virus (AA V):
AAV is a non-pathogenic single stranded DNA parvovirus with a genome less 
than 5Kb long that can accomodate 4Kb of exogenous DNA. AAV needs a helper 
virus to replicate (Muzyczka, 1992). Wild type AAV specifically integrates on 
chromosome 19, although vector viruses integrate non-specifically. AAV only 
expresses two sets of proteins: replication proteins (rep) and capsid proteins (cap). 
The rep proteins are toxic due to downregulation of several cellular promoters. 
Most of the AAV regulatory elements (packaging, integration) are included in the 
inverted terminal repeats (ITRs) making it possible to delete both rep and cap 
proteins, replacing these with the genes to be delivered, and exploit the ITRs for 
replication, integration and packaging.
AAV is capable of infecting numerous human cell types both in vitro and in vivo, 
giving long term gene expression without requiring cell division. This makes 
AAV a safe vector to target various organs (Ponnazhagan et al., 2001). In 
particular, AAV can infect both murine and human dendritic cells that remain 
unaffected in their ability to undergo maturation (Liu et al., 2000b, Ponnazhagan 
et al., 2001, Zhang et al., 2000).
AAV was initially identified as a possible vector to deliver and express genes for 
muscular dystrophy inducing strong cellular and humoral immune responses 
(Cordier et al., 2001). In vitro, rAAV has been shown to deliver viral (Chiriva- 
Intemati et al., 2002, Sun et al., 2002) and tumour (Chiriva-Intemati et al., 2003) 
antigens to human dendritic cells with stimulation of both CD4+ and CD8+ T cell 
responses. Similarly, in vivo, injection of recombinant AAV expressing HSV-2 
glycoprotein B and D could stimulate both humoral and cellular responses 
(Manning et al., 1997), as did transfer of BMDC infected with a LacZ 
recombinant AAV leads to same type of responses (Zhang et al., 2000).
Although AAV is non-pathogenic, making it a safe option for use in humans, 
more than 80% of the population has antibodies against at least one AAV 
serotype, reducing its efficiency as a vector in these people (Peden et al., 2004).
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1.2.9.3 Retrovirus:
Retroviruses are enveloped ssRNA viruses that infect cells by binding to specific 
receptors on the cell surface. Their disadvantage of being poor at infecting non 
dividing cells can easily be overcome by pseudotyping. Vesicular stomatitis virus 
protein, for example allows for efficient transduction in the majority of dividing 
cells.
Following infection of a cell with a retrovirus, the incoming RNA is reverse- 
transcribed and randomly integrated into the host genome. This is an advantage as 
it allows the long term presence of the recombinant gene, though not ensuring 
stable expression, although insertional mutagenesis is also possible.
Moloney murine leukaemia virus (MMLV) is a typical retrovirus, containing the 
three genes identifying retroviruses: gag (structural protein), env (envelope 
protein) and pol (for nucleic acids metabolism). Additionally, the LTRs contain 
signals for reverse transcription, integration and transcription. Retrovirus based 
vectors can be constructed by transfecting vector plasmids that contain the gene of 
interest (up to 8Kb) flanked by the LTRs and m-elements into packaging cells 
that provide, in trans, the other proteins.
Although retroviral vectors are inefficient at infecting non dividing cells, dividing 
DC progenitors have been shown to be transfected by these viruses and retain 
their ability to differentiate into DCs capable of inducing T cell activation (Bello- 
Femandez et al., 1997, Grignani et al., 1998, Szabolcs et al., 1997). Using 
dividing progenitor cells, retroviruses have therefore been proved efficient in 
stimulating responses to tumour associated antigens (HER2) (zum Buschenfelde 
et al., 2001), parasite infection (PySSP2) (Hetttihewa, 2003), as well as responses 
against bacteria (Lysteria monocytogenes) (Nakamura et al., 2003) or viral 
antigens ( HbcAg) (Ding et al., 2003).
Despite the safety concerns of using retroviruses, CD34+ cells transfected with a 
Murine Leukaemia virus (MLV) based vector have been tested in clinical trials for
70
human X-linked severe combined immunodeficiency resulting so far already in 
three cases of adverse reaction (Buckley, 2002, Cavazzana-Calvo et al., 2000).
1.2.9.4 Lentivirus:
Lentiviruses are retroviruses that, in addition to gag, env and pol, express 
accessory proteins that contain nuclear localisation factors, allowing for 
transduction of non-dividing cells (Emerman, 1996, Lewis & Emerman, 1994). 
Both blood derived human DC or mouse bone marrow derived DC, which are 
preferentially immature, can be transduced (Gruber et al., 2000, Negre et al.,
2000). However, it appears that transduction of dividing human CD34+ progenitor 
cells is the most efficient (Salmon et al., 2001). In addition, maturation is not 
affected but rather stimulated by the presence of the virus (Esslinger et al., 2002, 
Gruber et al., 2000).
Lentivirus derived vectors are mainly based on human (HIV) or simian (SIV) 
immunodeficiency virus. They can be easily attenuated by deletion of genes, and 
can deliver up to ~8Kb of foreign DNA. As retroviruses, they integrate their 
provirus in certain non-dividing cells allowing long term persistence in DCs 
(Lewis & Emerman, 1994). High titre stocks of lentiviral vectors can relatively 
easily be produced, and an advantage of lentivectors is that pre-existing immunity 
in the host is relatively rare. In addition, immunogenicity of these viruses is low 
even though they are able to induce stronger immune responses to the delivered 
antigen than are andenovirus transduced cells (Esslinger et al., 2002).
Safety reasons require that lentiviral vectors are highly attenuated. Highly 
attenuated HIV-1 based vectors expressing the Flu peptide could efficiently 
transduce immature DCs of which 40% retained their ability to express the gene 
and the ability to activate T cells following maturation (Dyall et al., 2001). Also, 
highly attenuated SIV-based vector can efficiently transduce both terminally 
differentiated and monocyte-derived human DCs, suggesting that vectors based on 
lentiviruses from other species than humans could be used to reduce safety 
concerns (Mangeot et al., 2000).
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To avoid formation of infectious particles, recombinant lentiviruses are packaged 
in permanent, inducible packaging cell lines that express gag, pol, rev and the 
VSV-G envelope gene. The gene of interest is then introduced by repeated 
transduction by lentiviral particles prepared by transient transfection.
DCs transduced with lentivectors can stimulate immune responses against viruses, 
or melanoma (Metharom et al., 2001) upon injection of mice, and this response 
appears to be stronger than obtained with peptide pulsed (Esslinger et al., 2002, 
Zarei et al., 2004), or adenovirus transduced DCs (Esslinger et al., 2002). 
Moreover, efficiency of cell maturation and T cell responses have been further 
improved by including the expression of CD40L (Koya et al., 2003).
1.2.9.5 Vaccinia virus:
Vaccinia virus is a double stranded DNA viruses that remain extrachromosomal. 
Vaccinia virus has the advantage of allowing the delivery of multiple genes (up to 
25Kb can be delivered) (Carroll & Moss, 1997). Vaccinia virus does not replicate 
within DCs, making it a safe vector (Jenne et al., 2000). The two highly attenuated 
strains of vaccinia virus which are most commonly used are NYVAC (NewYork 
vaccinia strain), and the MVA (Modified Vaccinia Ankara). These transduce DCs 
even at low MOIs (up to 60% at MOI 2.5) (Drillien et al., 2000, Sutter & Moss, 
1992), and induce maturation upon infection (Bonini et al., 2001, Engelmayer et 
al., 1999); (Drillien et al., 2004). Both immature and mature DC can be 
transduced by endocytosis (Drillien et al., 2000). However, wild type virus does 
not induce DC maturation (Jenne et al., 2000). Infection, instead, results in a 
decrease in CD83 and CD80 expression on the cell surface paralleled by 
inhibition of maturation of immature cells and decreased ability to stimulate T cell 
responses from mature cells (Drillien et al., 2000, Engelmayer et al., 1999, Jenne 
et al., 2000).
Recombinant vaccinia viruses have proved relatively safe and effective. 
Following a DNA or an adenovirus priming dose, an MVA boost confers 
increased and protective CD8+, CD4+ and antibody responses to the malaria CS 
protein in mice (Bruna-Romero et al., 2001); (Gilbert et al., 2002). Similarly 
MVA has been applied to cancer therapy showing a response against MUC1 or
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tyrosinase after a single immunisation (Drexler et al., 1999, Trevor et al., 2001), 
and is now being developed as a vaccine for HIV (Nkolola et al., 2004), human 
cytomegalovirus (Wang et al., 2004), and also HSV-2 (Meseda et al., 2002). 
Norbury et al have shown the presence of infected DCs in the draining LN 
following virus infection thus supporting the use of this virus for direct injection 
(Norbury et al., 2002)
Human clinical trials have taken place targeting DCs in vivo for malaria therapy 
following DNA priming showing strong CD4+ and CD8+ responses (McConkey et 
al., 2003, Moorthy et al., 2003b). MVA can provide both a good initial stimulus 
and boosting dose, a boosting regime composed of two different poxviruses can 
lead to strong CTL responses in humans (Moorthy et al., 2004b), including when 
using multiple antigens (Prieur et al., 2004).
The delivery of multiple genes, has proved efficient in non-human primates, 
where DNA and virus expressing the malaria CS, SSP2, AMA1, and MSP1 
antigens resulted in protection of 2 out of 11 monkeys, and 7 were able to resolve 
parasitaemia spontaneously (Rogers et al., 2002).
1.2.9.6 Influenza virus:
Influenza virus is a negative stranded RNA virus that has the advantage of safety 
from the point of view of integration into the genome of the host cells. Mature 
human monocyte derived DCs can be transduced very efficiently resulting in 
more than 90% of cells containing the virus at MOI1, as shown by expression of 
the tumour associated antigen MAGE3 (Strobel et al., 2000). The infected cells 
retain their ability to mature, do not undergo apoptosis and can generate strong 
antiviral CD8+T cell responses but only at low MOI even if the virus used is 
inactivated (Bender et al., 1998). In addition, DCs have also been shown to cross­
present on MHCI viral proteins from other cells infected with influenza virus 
(Albert et al., 1998).
The possibility of using influenza virus for the induction of immune responses 
was first shown by Li et al using a recombinant virus expressing an epitope of the 
PyCS protein to stimulate T cell responses to plasmodium (Li et al., 1993).
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Dendritic cells infected with attenuated influenza virus have now been shown to 
induce CTL responses also to tumour genes (Strobel et al., 2000) and proto­
oncogenes (Efferson et al., 2003).
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1.3 Herpes Simplex Virus 1 (HSV-1)
1.3.1 Pathology ofHSV-1
Infection with herpes simplex virus 1 (HSV-1) affects over 80% of the population. 
HSV-1 infects both dividing (eg. epithelial) and non-dividing (eg. neurons) cells. 
HSV-1 enters the body by infection of epithelial cells of the skin or mucosal 
membrane, where it replicates at the site of infection. Progeny particles spread to 
axons of sensory neurones that innervate the primary site of infection and are 
carried by retrograde axonal transport to neuronal cell bodies where the virus 
enters latency. Upon occasional reactivation, due to stress, exposure to UV 
irradiation, tissue damage, or immunosuppression, HSV-1 travels down the 
neurones and infects the innervating skin mucosa causing the common cold sore.
Although the clinical signs of HSV-1 reactivation are usually mild (cold sore 
being the most common), in new-born and immunocompromised individuals this 
infection can lead to fatal encephalitis. Herpetic interstitial keratitis is another 
pathology that may follow HSV-1 infection, probably caused by tissue damage 
incurring form a disregulated inflammatory response (Streilein et al., 1997).
1.3.2 Structure of the HSV-1 virion
HSV-1 is a member of the Herpesviridae family, composed of eight members: 
Herpes simplex virus 1 and 2 (HSV-1, HSV-2), cytomegalovirus (CMV), Epstein- 
Barr virus (EBV), varicella zoster virus (VZV), and human herpesvirus 6, 7, 8 
(HHV). Within this family, HSV-1 is a member of the alphaviruses group. These 
are the neurotropic subfamily of herpesviruses. HSV-1 has a double stranded 
152Kb DNA genome encoding ~84 proteins, and is the herpesvirus that has 
mainly been used as gene delivery vector. All herpesviruses have a common 
genome structure, and some genes that are essential for replication are common 
between all the members of the family. The genome is organised so that a unique 
long (UL) and unique short (US) region, are flanked by two pairs of inverted 
terminal repeats (b/TRL-b’/TRL and c/TRS-c’TRS). Finally, both ends of the 
genome contain a short sequence (a) which may be repeated several times 
containing essential packaging signals (figurel.8).
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The viral genome is enclosed in an icosahedral nucleocapsid separated from the 
lipid bilayer envelope by a layer of proteins called the tegument, involved in 
facilitating the early stages of infection and initiation of viral transcription by 
carrying proteins necessary for these processes. Two of these proteins are virion 
protein 16 (VP 16) that contributes to the activation of immediate early genes, and 
the virion host shutoff protein (vhs) that favours viral replication by interfering 
with host protein synthesis (Fink & Glorioso, 1997). The envelope contains 
eleven glycoproteins (gB-gM) that mediate viral attachment and entry into the cell 
through fusion of the envelope with the cellular membrane, and it has recently 
been suggested that the cytoplasmic tails of glycoproteins in the envelope act to 
anchor the virion envelope onto the tegument (Farnsworth et al., 2003, Gross et 
al., 2003).
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Figure 1.8 HSV-1 structure
(a): Schematic representation of HSV-1 virion structure consisting of 
double stranded DNA genome enclosed in a capsid and tegument 
surrounded by an envelope.
(b) Schematic representation of the organisation of HSV-1 genome 
consisting of unique long (UL) and unique short (US) regions flanked by 
the terminal long and short repeats (TRL, and TRS) and internal long and 
short repeats (IRL, and IRS). The position of some most relevant genes is 
indicated.
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1.3.3 Life cycle of HSV-1
HSV-1 enters a cell by interaction of glycoproteins on the viral envelope with 
receptors on the cell surface leading to membrane fusion. The fundamental viral 
glycoproteins for this process are gB, gH, and gL, and the cellular receptors 
involved are a herpesvirus entry mediator (HVEM) receptor, and nectin receptors 
1 and 2. HVEM is a member of the TNFR family, found on epithelial cells, 
fibroblasts, leukocytes, and lymphocytes, including DC. Because of its presence 
on the surface of intact epithelium, it is believed to be associated with the 
incoming virus. Nectin receptors 1 and 2, on the other hand, are members of the 
immunoglobulin family, expressed on epithelial cells, fibroblasts, and neurones 
(Haarr et al., 2001, Mata et al., 2001). They are thought to be more associated 
with spreading of the virus within the epithelium and in neurones (Haarr et al.,
2001). Initially, gB and gC interact with binding receptors in a reversible manner. 
This gathers viral particles on the cell surface (Shukla et al., 2000). Subsequently, 
gD binds to entry receptors forming permanent bonds leading to membrane fusion 
possibly by undergoing conformational changes that allow it to interact with gB or 
with the gH-gL complex that might then trigger fusogenic activity. Alternatively, 
gD may not be part of this process making binding of gB and/or gH-gL to 
receptors directly trigger membrane fusion (Spear & Longnecker, 2003).
Following envelope fusion, the tegument and nucleocapsid are released into the 
cell together with the already formed tegument proteins (principally VP 16 and 
vhs) needed for immediate use in replication. Depending on the cell-type infected, 
the virus can either undergo lytic replication leading to cell death and virus 
release, or enter latency, a state in which the virus undertakes only minimal gene 
expression, and can persist for the lifetime of the host with occasional 
reactivation.
1.3.3.1 Lytic replication cycle:
Upon initial viral entry, and also after reactivation, the virus can replicate in 
epithelial cells. Entry of HSV1 into the cells correlates with a shutoff of cellular 
protein synthesis in favour of viral replication that takes place in a cascade like 
fashion. Replication starts with expression of immediate early (IE) a  genes that
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have regulatory functions and are responsible for activation of early (E) p genes 
involved in DNA synthesis, that in turn initiate late (L) y genes expression, these 
further divided into yl and y2 mainly coding for virion components (figure 1.9). 
y2 genes promoters have a TATA box but lack regulatory elements making their 
expression, unlike yl genes, dependent upon DNA replication (Rajcani et al.,
2004).
The VP 16 and vhs proteins incoming from the tegument are the two first and key 
proteins to act in favour of viral transcription. The tegument protein VP 16 triggers 
the replication cascade. VP 16 is one of the at least 15 tegument proteins that serve 
multiple functions at different steps during viral replication. VP 16 is a 65kDa 
protein encoded by UL48 and initially it functions as a transactivator of IE genes 
although also functioning as a modulator of the UL41 gene product vhs later in 
the cycle (Lam et al., 1996), and also being required for proper viral assembly and 
egress (Mossman et al., 2000b). VP 16 initiates viral transcription by inducing 
formation of the activation complex on the a  gene promoters that encode for the 
five immediate early infected cell polypeptides (ICP): ICP0, ICP4, ICP22, ICP27, 
ICP47.
The C terminal of VP 16 corresponds to the transactivator domain and binds to the 
TAATGARAT sequence present in all promoters of IE genes (Preston et al., 
1988). Because VP 16 only binds weakly to DNA the cellular Octl transcription 
factor initially binds to the promoter while the host cell factor (HCF) acts as 
mediator by binding to VP 16 and targeting it to the DNA-bound Octl for stable 
interaction with DNA (Herr & Cleary, 1995). This multicomponent protein-DNA 
binding transcription regulatory complex, called the VP16-induced complex 
(VIC), initiates transcription of the IE genes that subsequently engage in a self- 
sustaining cascade (Figure 1.9). In non permissive cells it is possible that the 
VP 16 complex is possibly prevented from binding to the promoters of the IE 
genes (Latchman, 1999).
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Figure 1.9: HSV-1 lytic cascade
Representation of HSV-1 gene expression during productive infection. 
VP 16 triggers the lytic cascade allowing expression of immediate early 
(IE, a) genes that activate early (E, P) genes that in turn activate late (L, 
y) genes. ICP4, ICP27 and ICP22 act both on E and L genes. ICP4 and 
ICP27 also downregulate IE genes expression (red arrows)
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Of the five immediate early genes ICP4 and ICP27 are essential for viral 
replication (DeLuca et al., 1985, Sacks et al., 1985) whereas deletion of ICPO and 
ICP22 significantly reduces viral growth especially at low MOI (Cai & Schaffer, 
1992, Chen & Silverstein, 1992, Sears et al., 1985).
Following their synthesis in the cytoplasm, ICP4 and ICP27 migrate into the 
nucleus where they form a complex with cellular nuclear structures known as 
ND10 that are found associated with the parental viral genome. Formation of this 
new complex with ICP4 and ICP27 is ICPO dependent at low MOI (Everett et al., 
1997, Everett et al., 1998), but not at high MOI (Everett et al., 2004). The 
complex targets the premyelocytic leukaemia (PML) component of ND10 for 
destruction in proteasomes and later develops into replication compartments for 
the expression of early genes (Everett et al., 2004).
ICPO is then responsible for activation of a few p genes, but its main role is to 
maintain expression of a  genes, acting more as an enhancer to ICP4, specifically 
efficient at activating p genes (Everett, 1984, Everett, 1987). ICP4 is an important 
regulator able to transactivate p and y genes expression as well as being able to 
downregulate a  genes. When phosphorylated, ICP4 binds the promoters with 
transcription activation complex and cellular factors to stimulate p gene 
expression, but in its non-phosphorylated form ICP4 downregulates ICPO and its 
own expression (Roberts et al., 1988). Furthermore, in conjunction with the action 
of ICPO it can also downregulate latency promoters (Batchelor & O'Hare, 1990, 
Goins et al., 1994). Finally, ICP4 can inhibit expression of p and y genes before 
the onset of viral replication. Elimination of ICP4 (essential) results in dramatic 
decrease in replication, but the virus still induces toxicity in the infected cells 
despite only four immediate early genes and ICP6 (large subunit of ribonucleotide 
reductase) and ORF P are produced (DeLuca et al., 1985, Yeh & Schaffer, 1993).
LCP27 is the other gene necessary for the generation of infectious viral progeny 
(Sacks et al., 1985). ICP27 facilitates DNA replication by enhancing expression of 
viral factors required for DNA synthesis and interacting with ICP4 (Uprichard & 
Knipe, 1996). Similarly to ICP4, ICP27 stimulates E and L genes (Samaniego et
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al., 1995) while also downregulating IE and E genes (McCarthy et al., 1989, Rice 
& Knipe, 1990, Sacks et al., 1985). ICP27 in addition acts at the protein level. It 
collaborates with vhs in the decrease of the amount of mRNA in the cell 
(Hardwicke & Sandri-Goldin, 1994, Song et al., 2001), and can modulate pre- 
mRNA polyadenylation efficiency (McGregor et al., 1996, McLauchlan et al., 
1992). ICP27 also binds and stabilises the 3’ end of the mRNA (Brown et al., 
1995), inhibits cell protein synthesis by sequestering snRNPs (Hardwicke & 
Sandri-Goldin, 1994, Hardy & Sandri-Goldin, 1994) and inhibits pre-mRNA viral 
splicing as well as allowing retention in the nucleus of transcripts still containing 
introns (Hardy & Sandri-Goldin, 1994); (Phelan et al., 1996). By inhibiting 
splicing of mRNA (McCarthy et al., 1989, Sacks et al., 1985) ICP27 establishes a 
method of stopping only translation of cellular genes, as only very few viral genes 
contain introns.
ICP22 is a cytotoxic protein that activates p and y genes by a phosphorylation 
mechanism including cellular RNA polymerase II (Rice et al., 1995). Deletion of 
ICP22 results in delayed early genes transcription and reduced late genes 
activation (Sears et al., 1985).
Finally, ICP47 is responsible for blocking peptide presentation on MHCI 
molecules by interfering with the activity of the protein transporter associated 
with antigen processing (TAP) by binding to the substrate binding site (Jugovic et 
al., 1998, Neumann et al., 1997). Deletion of ICP47 does not impair viral growth 
(Mavromara-Nazos et al., 1986).
Vhs is mainly responsible for the destabilisation of cellular mRNA and inhibition 
of host protein synthesis following infection (Fenwick & McMenamin, 1984, 
Kwong & Frenkel, 1987). Vhs is found in all alphaherpesviruses sequenced so far, 
synthesised as a y gene, but acting as an a  gene. It has a sequence very similar to 
that of cellular nucleases involved in DNA replication and repair. In fact, 
mutations that disrupt the catalytic activity of its homologues also disrupt the 
activity of vhs (Doherty et al., 1996, Everly et al., 2002, Everly & Read, 1997).
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Vhs mainly acts with ICP27 to decrease the amount of mRNA in the cytoplasm 
without allowing de-novo synthesis. It is not clear whether vhs is an RNAse or if 
it is part of a complex, but it acts as an mRNA specific RNAse both increasing the 
rate of mRNA degradation in the cytoplasm and by stopping cell protein synthesis 
(Kwong & Frenkel, 1987, Strom & Frenkel, 1987). Vhs disrupts pre-existing 
polyribosomes (Laurent et al., 1998), and helps ICP27 in inhibiting pre-mRNA 
splicing (Hardy & Sandri-Goldin, 1994) and repressing primary transcription 
(Long et al., 1999, Rice et al., 1995, Spencer et al., 1997).
Both cellular and viral cytoplasmic mRNAs are degraded, and both 5 ’ and 3 ’ ends 
of the mRNA are targeted (Elgadi et al., 1999, Karr & Read, 1999, Kwong & 
Frenkel, 1987, Oroskar & Read, 1987, Oroskar & Read, 1989). Initial studies 
looking at HSV TK suggested that vhs targets the 5’ sites of initiation of 
translation since this was degraded before the 3’ end (Karr & Read, 1999), and in 
addition, vhs has been shown to bind directly to cellular translation initiation 
factors like eIF4H (Feng et al., 2001). However, recently vhs has been suggested 
to be targeted at 3’ end AU-rich elements (ARE) that promote deadenylation and 
decapping in uninfected cells, followed by 3’-5’ degradation (Esclatine et al., 
2004a; Gao et al., 2001, Lai et al., 2003; Taddeo et al., 2003). Upon infection 
some mRNAs are induced and not degraded, amongst these are mRNAs encoding 
for ARE-targeted proteins (ex TTP, TIA1 and TIAR) all of which involved in 
degradation of ARE containing mRNAs (Esclatine et al., 2004b). Infection with 
vhs- virus result in lower amounts of TTP in the cytoplasm so, although vhs 
possibly does not upregulate TTP expression, in infected cells the degradation of 
ARE containing RNA is vhs dependent. TTP interacts with vhs to initiate 3’ 
degradation with a similar mechanism to the one that takes place on ARE 
containing RNAs in non infected cells (Esclatine et al., 2004a, Taddeo et al.,
2003).
Vhs mutated viruses only undergo a 5-10 fold reduction of replication in culture 
(Read & Frenkel, 1983, Read et al., 1993, Smibert & Smiley, 1990) although in 
vivo replication is severely impaired , probably due to the role of vhs in immune 
evasion (discussed in 1.3.4.2) (Leib et al., 1999, Strelow et al., 1997, Strelow & 
Leib, 1995). In neurones, vhs deficient viruses show a significant reduction in
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growth (Smith et al., 2002, Strelow & Leib, 1996), and vhs has been shown to 
degrade mRNA in these cells but requires much higher MOI. Susceptibility to vhs 
may therefore be reduced by nerve growth factor differentiation (Strand et al.,
2004).
VP 16 interacts with the lytic cycle not only by initiating it but also by supporting 
it later in infection by binding and inhibiting vhs activity to promote viral protein 
synthesis (Lam et al., 1996, Smibert et al., 1994; Knez et al., 2003).
1.3.3.2 Latent cycle:
Alternatively to the lytic cycle, the newly released particles can infect nearby 
sensory neurones present at the site of infection. The nucleocapsid is then 
transported in a retrograde manner to the cell body in the ganglia and enters the 
nucleus. Neurones may become productively infected and spread the virus across 
synapses resulting in death of the cell. Alternatively, HSV-1 can persist for a 
lifetime in the latent form as a stable episome (Gilden et al., 2001, Hemmi et al., 
2002). Latency is usually established in trigeminal ganglia or sacral dorsal root 
ganglia but also in the CNS (Baringer & Pisani, 1994, Itzhaki et al., 1997, Liedtke 
et al., 1993).
During latency the genome is maintained in an episomal state and most of the 
genes are silenced except for one part of the long repeat that generates latency 
associated transcripts (LAT) (Stevens et al., 1987). The main ~8.5Kb LAT 
transcript is transcribed from the LAP1 promoter (Stevens et al., 1987) and then 
spliced into a 2Kb fragment (Farrell et al., 1991, Krummenacher et al., 1997). 
This is the most abundant form of LAT, present as an intron not capped or 
polyadenylated in a lariat structure (Coffin et al., 1998a, Farrell et al., 1991, 
Rodahl & Haarr, 1997, Wu et al., 1996, Zabolotny et al., 1997). In neurones, the 
2Kb structure can be further spliced into ~1.5Kb fragment (Garber et al., 1997, 
Mador et al., 1998, Spivack et al., 1991).
It has not been possible so far to determine the exact function of the LAT 
transcripts but studies have shown this transcript to play a role in spontaneous 
reactivation (Leib et al., 1989, Pemg et al., 1996). Also, studies using LAT
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mutants have demonstrated that the absence of these transcripts seems to induce 
more apoptosis in trigeminal ganglia of both mice and rabbit upon switch from 
acute to latent infection (Ahmed et al., 2002; Pemg et al., 2000).
Interestingly, latency seems to be maintained also by a coordinated immune 
response relying on CD8+T cells releasing IFNy that prevents reactivation from 
sensory neurones (Liu et al., 2001a). In neurones, the latest model proposed is that 
after primary infection and a brief period of viral replication, macrophages and 
y8T cells initiate an infiltrate of CD4+T, CD8+T cells and macrophages that 
remain for the life time of infection. CD8+T cells position themselves in close 
contact with the neurone cell body whereas CD4+T cells localise to the axonal 
areas. The position of the CD8+T cells allows them to monitor for antigen 
presentation (gB in particular) on MHCI from the neurone in which case the 
CD8+T cell produces IFNy or later in reactivation lytic granules that force the 
genome to remain in the latent state (Liu et al., 2001a).
Nevertheless, occasional reactivation of the latent virus is possible under 
conditions of stress or immunosuppression. In this case the CD8+T cell function is 
compromised and reactivation is induced with formation of nucleocapsid and 
glycoproteins for virion assembly (Khanna et al., 2004). These travel to the 
mucosal membrane where they can lytically infect the epithelial cells in the 
proximity of the infected neurones (secondary infection). Reactivation is not well 
understood yet mainly because of the difficulties in studying this process ex vivo, 
but it appears to happen in only very few neurones (Sawtell & Thompson, 2004).
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1.3.4 HSV 1 as a gene delivery vector
HSV-1 can infect a wide range of cells including non dividing cells, cardiac cells 
(Coffin et al., 1996), dendritic cells and haematopoietic cells (Coffin et al., 1998b) 
as well as T and B cells from a culture of PBMCs (Papageorgiou et al., 2002), 
thus potentially allowing gene delivery for a wide range of applications including 
immunotherapy. Despite the large genome, many genes including toxic and 
replication-associated genes can be deleted without significantly affecting the rate 
of viral growth, enabling the introduction of up to 30Kb of exogenous DNA. Thus 
multiple full-length genes can be inserted. Genes encoding anti-inflammatory 
molecules or cytokines can also be included in addition to the immunogen, to 
favour or shift the immune response in a particular direction (Thl vhs Th2). In 
addition, HSV1 has the advantage of having a relatively stable genome (Sarisky et 
al., 2000), and large stocks of high purity virus can relatively easily be grown. 
Moreover, life long latent infections can be established such that long term gene 
expression is possible. The fact that HSV-1 persists as an episome in the nucleus 
avoiding insertional mutagenesis is another advantage.
To be used as human gene therapy vector, the cytotoxicity of HSV-1 needs to be 
minimised. HSV-1 has been modified in numerous ways for use as a vaccine 
vector. This ranges from the simple inactivation or deletion of genes, to the use of 
replication incompetent viruses, the construction of HSV-1 based amplicons, and 
disabled infectious single cycle (DISC) viruses (Ali et al., 2002, Palmer et al., 
2000, Willis et al., 2001). DISC are variants whose genomes do not contain the 
gene encoding the gH protein essential for infection thus allowing only a single 
cycle of infection of the virus.
Non-replicative HSV-1 can be obtained by deleting immediate early genes so as 
to block the viral gene expression cascade. Deletion of the essential ICP27 and 
ICP4 genes still allows the virus to replicate in vitro in complementing cell lines, 
while undergoing abortive replication in vivo. For complete ablation of 
cytotoxicity all IE genes should be deleted, requiring them to be provided in trans 
for virus growth. Unfortunately, the level of attenuation of the virus is inversely 
proportional to its ability to grow in vitro, making fully disabled viruses ideal for 
use in humans from a safety aspect, but impractical to produce (Ozuer et al.,
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2002). Deletion of the VP 16 gene would prevent the triggering of the lytic 
cascade avoiding having to delete all the IE genes. Unfortunately, although the 
activation domain of VP 16 can be deleted (Smiley & Duncan, 1997), and 
efficiency of replication in vitro compensated for by the addition of HMBA or by 
infecting at high MOI (Yang et al., 2002), the VP 16 coding gene can not be fully 
deleted, as VP 16 is required for proper viral assembly and egress (Mossman et al., 
2000b). Deletion of the whole gene prevents accumulation of enveloped 
cytoplasmic capsids although perinuclear enveloped virions can form but with 
altered morphology (Mossman et al., 2000b). Mutation at the C terminal 
activation domain of VP 16 reduces or abolishes the transactivating function of the 
protein without affecting the structural integrity of the virus (Ace et al., 1989, 
Smiley & Duncan, 1997).
Safety may be further improved by deleting genes that are not essential for virus 
replication but are toxic, such as ICP22, or ICP34.5 (the major neurovirulence 
factor) (Chou et al., 1990), that can be deleted without significantly affecting the 
efficiency of virus production.
The choice of promoters is also important when using an HSV based vector since 
many have been found to be transcriptionally silenced at the onset of latency 
unless LAT promoters (which usually drive the expression of the only latency 
associate transcripts) which are the only HSV RNA transcripts produced in 
latency) are used to ensure long-term expression during latency (Lachmann & 
Efstathiou, 1997, Lokensgard et al., 1997). Additionally, in neurones, the LAP1 
and LAP2 promoter regions also allow long term expression from exogenous 
neighbouring promoters (Lewis & Emerman, 1994, Lilley et al., 2001, Palmer et 
al., 2000).
HSV 1 vectors have mainly seen application for gene delivery to the nervous 
system (CNS) (Lilley et al., 2001, Palmer et al., 2000, Perez et al., 2004), or in 
cancer therapy delivering cytokines (Liu et al., 2003; Sundaresan et al., 2000). 
However, HSV-1 also holds good potentials as an immunotherapy vector 
targeting DCs (Coffin et al., 1998, Samady et al., 2003; Willis et al., 2001). HSV- 
1 in an immune context has so far been used to stimulate response, against the
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virus itself (Mueller et al., 2002), against bacterial (Lauterbach et al., 2004), and 
viral infections (Murphy et al., 2000), or in cancer therapy (Liu et al., 2003).
1.3.4.1 Gene delivery to the CNS:
Because of its ability to naturally infect neurones, HSV1 seems an ideal gene 
delivery vector for the nervous system. Since more widely used promoters like 
CMV are silenced during latency, long term expression requires the use of LAT 
promoters (Lachmann & Efstathiou, 1997, Palmer et al., 2000).
Both replication competent (ICP34.5' and inactivated VP 16) and replication 
incompetent HSV vectors (ICP27', and ICP4') delivered via the sciatic nerve or 
footpad injection into mice have been shown to be transported and to express 
genes in the long-term in the dorsal root ganglia (DRG) (Palmer et al., 2000). 
Also, replication incompetent vectors have been shown to express marker genes in 
the central nervous system following injection into the brain or in the spinal cord 
of rats (Lilley et al., 2001). Finally, Perez et al (Perez et al., 2004) have recently 
shown that peripheral administration of attenuated vectors can efficiently mediate 
transport of genes to motomeurones of adult mice and rats, and long term 
expression can be achieved when using replication incompetent viruses.
1.3.4.2 Gene delivery for cancer therapy:
HSV-1 can be used as an oncolytic vector, with the ability to infect numerous 
cancerous cell lines in vitro (Liu et al., 2003) and replicate selectively in them. 
Relying on this mechanism, viruses deleted for the ICP34.5 gene could clear 
cancer cells both in vitro, in mice (Kesari et al., 1995, Randazzo et al., 1997), and 
subsequently in Phase I clinical trials (MacKie et al., 2001). Similarly, a virus 
deleted for ICP34.5 and ICP6 could treat malignant glioma in mice (Sundaresan et 
al., 2000), non human primates (Hunter et al., 1999), and has been tested in 
patients administered by intratumoral injection (Markert et al., 2000). Because of 
the ability of this virus to infect cancer cells but not bone marrow progenitor cells, 
it has also been used to “purge” cancerous cells from bone marrow cells ex vivo, 
although this has not yet been tested in patients (Wu et al., 2001).
Following these results, a vector based on a clinical strain of HSV 1, has shown 
further improvement by deletion of the ICP47 gene in addition to ICP34.5, and 
also by including expression of GMCSF (Liu et al., 2003). So far this improved 
vector has demonstrated efficiency in vitro, and in mice where virus injection 
could clear the tumour and also protect against subsequent challenge (Liu et al.,
2003), and is currently undergoing clinical trials.
1.3.5 HSV-1 for immunotherapy
1.3.5.1 Anti-HSVl immune responses
In the development of a viral vector for immunotherapy, although a low level of 
protective immune response to the virus is potentially beneficial also to act as an 
adjuvant, a concern is that the antivector immune responses, either primary or pre­
existing, might prevent efficient stimulation of the targeted response against the 
recombinant antigen. HSV can be modified to minimise toxicity therefore 
allowing the virus to persist for the expression of exogenous genes. However, 
viruses deleted for the immediate early genes are still immunogenic in vaccination 
studies in animals (Da Costa et al., 1999b). In addition, given the high proportion 
of already infected individuals, recall responses may cause a problem. This has, 
however, been addressed in studies in mice that have demonstrated that previous 
exposure to the virus does not appear to impede the establishment of a durable 
immune response from the incoming vaccine virus (Brockman & Knipe, 2002, 
Chahlavi et al., 1999), although in some cases recombinant gene expression has 
been shown to be reduced.(Herrlinger et al., 1998).
Both antibodies, complement (Verschoor et al., 2003), NK (Pereira et al., 2001), 
and NK cells (Grubor-Bauk et al., 2003) have been shown to be involved in the 
control of HSV infections in vivo in a Thl type response (Brenner et al., 1994, 
Carr et al., 2001). HSV-1 infection results in an initial antiviral innate response 
followed by adaptive and acquired responses. The initial innate immunity 
mediates lysis of virally infected cells as well as providing a link to effective 
adaptive immunity (Wakimoto et al., 2003). When lesions occur there is an initial 
infiltration of NK and CD4+T cells and following CD4+T cell proliferative 
activity, CD8+T cells clear the infection (Koelle et al., 1998b)..
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Complement plays a major role in fighting HSV-1 infection. Depletion of 
complement from serum can reverse the antiviral activity of the serum (Ikeda et 
al., 2000). The complement cascade involves a series of proteins that are activated 
by proteolytic cleavage leading to the formation of a membrane attack complex 
(MAC). This can lyse microorganisms and infected cells. These proteins can also 
recruit and allow opsonization by macrophages. The complement cascade can be 
initiated by two different signals. The classical pathway is initiated by an IgM 
molecule that recognises an antigen, or several IgG molecules binding to an 
antigen. The “alternative” pathway or the “lectin” pathway is triggered by 
mannose-binding proteins that bind sugar moieties present on the virus surface.
Antibodies binding to virus or virus infected cells have been shown to inhibit 
further HSV-1 infection by neutralisation and cell lysis via antibody-dependent 
cellular cytotoxicity (Dubin et al., 1992), opsonisation, and classical pathway of 
complement activation (Da Costa et al., 1999a). Both humans and mice that have 
been immunised or infected with HSV1 develop high titres of circulating 
antibodies, primarily IgG (Brenner et al., 1994, Carr et al., 2001, Peek et al.,
2002). Naturally infected individuals usually develop antibodies against the viral 
envelope-bound glycoproteins, in particular gB, gC, gD, and over 90% of human 
adults possess circulating antibodies against this virus (Corey & Spear, 1986). 
Because these can bind viral particles, they have the potential to inhibit viral 
adhesion and entry, and to induce antibody-dependent cell mediated cytotoxicity. 
Interestingly, antibody immunity does not correlate with virus neutralisation in 
vitro, but correlates with the immune cytolysis in the presence of complement 
(Bystricka et al., 1997).
The humoral response to HSV is dependent on an intact classical complement 
pathway. Its effect is mediated via complement receptors CD21/CD35 (Da Costa 
et al., 1999a), and the C3 and C4 complement components produced by bone 
marrow derived myeloid cells. These C3 and C4 factors are critical and sufficient 
to induce B cell responses to inert proteins or infectious virus in response to a 
peripheral infection, implying that serum complement is probably not enough 
(Fischer et al., 1998, Gadjeva et al., 2002, Verschoor et al., 2003).
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Whereas antibodies are expected to prevent the spreading of the virus, cellular 
responses are triggered to resolve peripheral lesions (Mikloska et al., 1999). 
Strong CD4 responses are present in HSV infected individuals, which seem to be 
the predominant cells secreting IFNy in response to HSV (Asanuma et al., 2000), 
and depletion of CD4+T cells in mice result in increased susceptibility to 
challenge (Manickan & Rouse, 1995). In mice, immunisation with CD4 epitopes 
from gD can induce protective immune response to ocular challenge with HSV-1 
(BenMohamed et al., 2003), and in humans, CD4 responses have been found 
targeted at proteins from the various stages of lytic infection, as well as targeted at 
the envelope, tegument and capsid proteins, and against intracellular proteins such 
as ICP8 (Koelle & Corey, 2003). In addition, numerous CD4 epitopes on VP 16 
and VP22 have been identified (Koelle et al., 1998a, Koelle et al., 2000, Kwok et 
al., 2001).
CD8+T cells follow the infiltration of CD4+T cells in the lesions (Cunningham et 
al., 1985), and infiltration of CD8T cells, but not that of CD4 or NK cells, 
correlates with clearance of infection (Kurtzhals et al., 1998, Watanabe et al., 
1994). CD8+T cells can clear infection from peripheral nerve endings as well as 
from the skin (van Lint et al., 2004), and may also play a role against intraocular 
infection (Watanabe et al., 1994).
Depletion of CD8+T cells in Balb/c initially failed to completely clear the virus 
from sensory ganglia, associating clearance of the lytic infection in the ganglia 
with CD8+T cells (Simmons & Tscharke, 1992, Speck & Simmons, 1998). This 
response does not involve killing of neurones, instead, replication is terminated in 
a cytokine, IFNy dependent way (Liu et al., 2001a, Liu et al., 2000a, Martz & 
Gamble, 1992, Pereira et al., 2000, Speck & Simmons, 1998).
The IFNy released seems to inhibit ICPO production during the lytic cycle by 
decreasing the amount of cdk2 and cdk4 available (required for viral reactivation, 
replication and for post-translational modifications to activate ICPO). In addition, 
IFNy strongly upregulates expression of the various components of the ND10 
body to prevent transcription (Khanna et al., 2004)
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Both humans and mice HSV-1 infections result in increased NK cell activity 
(Fitzgerald et al., 1985, Habu et al., 1984). These cells are the first line of 
protection against viral infections and can kill malignant and virus infected cells 
without antigen presensitisation. Their main function is to release IFNy and they 
have also been shown to also be important in controlling reactivation of the virus 
(Biron, 1997, Bukowski et al., 1983). In their absence, individuals are highly 
susceptible to progressive HSV infections (Biron et al., 1989). y5T cells are also 
activated upon HSV-1 infection with the role of producing IFNy for macrophage 
stimulation that help in restricting the growth of HSV-1 (Cheng et al., 2000). 
Finally depletion studies in mice have shown that neutrophils also contribute to 
limiting the spread of viral infection in the eye, trigeminal ganglia and brain 
(Tumpey et al., 1996), providing initial clearance of the virus and also helping in 
CD4+T cell function (Thomas et al., 1997).
There is a persistant high level of cytokines during latency, implying that 
cytokines play an important role in the maintenance of latent infection to prevent 
reactivation. Type I IFNs have the most powerful antiviral property. These can 
render cells relatively non-permissive for productive infection (Leib et al., 1999). 
Looking at the effect of infection in mice deficient for IFNa/p signalling 
pathways, it emerged that these cytokines limit HSV-1 infection and spread 
(Hendricks et al., 1991, Leib, 2002, Leib et al., 1999), whereas in vitro 
experiments showed interference of IFNa/p with IE gene expression, (Mittnacht 
et al., 1988, Oberman & Panet, 1988) presumably by interacting with the VP 16 
initiation complex (De Stasio & Taylor, 1990).
Type I IFN initiates innate and specific immune responses (Riffault et al., 1996) 
and also acts directly to inhibit viral replication (Leib et al., 1999). IFNa/p do not 
induce an antiviral response on their own, but they activate a number of 
interferon-stimulated genes (ISG), that can also be stimulated directly by viral 
infections, and together function to inhibit viral replication and spread (Collins et 
al., 2004). The complementary viral RNA that forms dsRNA can activate the 
cytoplasmic protein IRF3 (IFN regulatory factor 3) that in turn translocates to the
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nucleus to activate the IFNp gene. This is then secreted and binds to the receptors 
of the same cells as well as to the neighbouring cells leading to activation of the 
IFN signalling pathway. Through the action of kinase (eg Jakl) and proteins (eg 
Stat2), this leads to the formation of an IFN stimulated growth factor 3 complex 
(ISGF3) that activates IFN stimulated response elements (IREs). Viral replication 
is then inhibited by an oligo-adenylate synthase (OAS) that activates RNAseL that 
in turn inhibits viral replication and activation of dsRNA-dependent protein kinase 
(PKR) that usually allows translation and thus viral replication.
As one of the most effective host antiviral responses, the virus has developed 
numerous mechanisms to overcome it, such as expression of ICP34.5 to target 
PKR (discussed later) or ICPO, which blocks ISG induction through a proteasome 
dependent mechanism not yet elucidated (Eidson et al., 2002).
The other major cytokine released following infection is TNFa, produced by 
activated macrophages. Like Typel IFNs, TNFa can inhibit viral infection and 
replication (Kodukula et al., 1999). Enhanced reactivation and more frequent 
primary acute corneal infection can be seen in trigeminal ganglia explants of 
TNFaa knockout mice implying that this cytokine plays an important role both 
during primary responses and during latency to avoid reactivation (Minagawa et 
al., 2004).
1.3.5.2 HSV-1 Immune evasion mechanisms
The efficiency of a vector for immunotherapy relies on the adequate stimulation 
of the immune system, usually obtained by appropriate stimulation of DC. 
Although it is important for the efficiency of gene delivery to understand but 
minimise the host response to the virus, in the construction of a vector targeted at 
stimulating an immune response, particular attention needs to be drawn to the 
mechanisms used by the virus to silence the numerous antiviral responses.
Herpesviruses all express genes that aid evasion of the immune response. Genes 
coding for proteins that cause false positive cell signalling such as the G protein 
coupled receptor, bcl2 anti-apoptotic protein analogue, and viral cyclin are
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common to most y herpesviruses. HSV-1 expresses ICP47, ICP34.5 and vhs 
amongst others, that act to block host responses.
The ability to infect and modulate the activity of DCs is a powerful method by 
which the virus escapes immune responses. HSV-1 infected DCs are poor 
stimulators of T cell responses (Pollara et al., 2003, Salio et al., 1999). HSV1 can 
infect DCs efficiently (Coffin et al., 1998b). Up to 90% of dendritic cells can be 
transduced at MOI as low as 1-5 (Kruse et al., 2000b, Salio et al., 1999), because 
of the presence of HVEM and nectin receptors on the surface of the cell. HSV-1 
preferentially infects immature cells (Salio et al., 1999) and although some 
replication has been reported from immature cells (Mikloska et al., 2001), the 
virus seems to infect DC non-productively, showing only IE and E transcripts 
production in mature DCs (Albers et al., 1989, Mikloska et al., 2001, Salio et al., 
1999). Immature cells undergo apoptosis soon after infection (Mikloska et al., 
2001) whereas mature cells can remain viable (Kruse et al., 2000b).
As an immune evasion mechanism, infection with wild type (Kruse et al., 2000b) 
or DISC (Salio et al., 1999) blocks cell maturation, and therefore antigen 
presentation. This is evident by the downregulation of expression of costimulatory 
markers (especially CD86) and antigen presentation molecules (both MHCI and 
MHCII) which is observed, as well as a decrease in the level of IL12 secretion 
upon stimulation of maturation, resolving in apoptotic cell death (Pollara et al.,
2003). Interestingly, despite the productive infection in immature DC, 
costimulatory molecules still undergo downregulation (Mikloska et al., 2001). 
This shows that HSV-1 infects DC and interferes with their activity, both with 
regard to maturation, and to antigen presentation to T cells. These effects are 
probably a result of a coordinated activity of a number of viral genes.
Both MHCI and MHCII loading mechanisms can be disrupted by infection 
through the action of ICP47 and gB respectively. ICP47 acts on a transporter 
associated with antigen processing (TAP) by inhibiting peptide transport into the 
ER lumen. Experiments carried out in mice have shown that deletion of the ICP47 
genes results in higher CD8+T responses and recognition of human DCs and
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decreased neurovirulence in mice (Goldsmith et al., 1998, Tigges et al., 1996). 
Interestingly, the action of ICP47 has been shown not to be very effective in 
mouse DC (Ahn et al., 1996). On the other hand, interference with MHCII 
presentation seems to take place as a result of reduced expression of the invariant 
chain for correct MHCII peptide loading. gB competes for binding of the invariant 
chain, thus forming complexes with DM and DR molecules that are prevented 
from reaching cell surface (Neumann et al., 2003).
The vhs protein plays a major role in the inhibition of the functions of DCs. 
Evidence that vhs has an immune evasion role and should be inactivated to obtain 
a vector able to induce a response came from the observation that vhs null viruses 
are more efficient at stimulating protective responses against HSV infection 
(Geiss et al., 2000, Walker et al., 1998, Walker & Leib, 1998). The ability of this 
protein to interfere with mRNA synthesis by various mechanisms (Sydiskis & 
Roizman, 1966) as discussed earlier (§1.3.2.2) is a major evasion mechanism, that 
results in multiple effects. Mainly, vhs impairs the ability of DCs to stimulate T 
cells and this takes place by various means (Kruse et al., 2000b, Salio et al., 
1999). Vhs acts in conjunction with ICP47 to downregulate expression of MHCI. 
Mutant viruses have shown that this protein is responsible for a decrease in MHCI 
presentation by decreasing the level of mRNA in the cell (Hinkley et al., 2000, 
Koppers-Lalic et al., 2001, Tigges et al., 1996). Similarly, MHCII presentation 
has also been shown to be impaired by the action of vhs (Trgovcich et al., 2002). 
Vhs is also involved in suppressing production of proinflammatory cytokines and 
chemokines including IL8, MIPla, ILip (Suzutani et al., 2000).
Vhs also plays a role in interfering with type I IFN responses. ICPO and vhs seem 
to act together to inhibit the host antiviral IFNaP response. ICPO appears to use its 
RING finger domain to block interferon regulatory factor 3 and 7 (IRF3, IRF7) 
mediated activation of IFN stimulated genes (Lin et al., 2004). ICPO also seems to 
downmodulate the expression of IFNy induced antiviral proteins by targeting them 
for destruction by proteasomes (Chee et al., 2003, Lin et al., 2004)
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Treatment of cells infected with a vhs- HSV-1 virus with IFN produces reduced 
levels of late genes as compared to cells infected with wild type virus (Chee & 
Roizman, 2004). On the other hand, cells lacking the IFNaP receptor can sustain 
normal replication by vhs- HSV-2, that although this may replicate well in vitro, 
they replicate poorly in vivo and have decreased virulence (Duerst & Morrison,
2004). This mechanism has been shown to involve vhs interfering with the PKR 
response induced by dsRNA. In fact, enhanced replication is obtained in the 
absence of PKR. Vhs also possibly interferes with the role of RNAseL (Khabar et 
al., 2000, Murphy et al., 2003). Recently, in HSV-1 studies, vhs has been shown 
to be involved in interference with the IFNaP response possibly by 
downregulating Jakl and Stat2. This would reduce IFN receptors on the cell 
surface (Jakl) and interfere with IFN signalling (Stat2). Together, these effects 
probably account for the reduced formation of complexes on interferon induced 
response elements (Chee & Roizman, 2004). Interestingly vhs from HSV1 had 
previously been shown to interferes only minimally with the response to IFNap in 
vitro (Mossman et al., 2000a) and in vivo (Leib et al., 1999). HSV1 and HSV2 
therefore seem to interact differently with IFN responses. Vhs from HSV2 has 
been suggested to be more effective than that from HSV1 and may act more 
efficiently to decrease the levels of IFNap (induced by viral infection) and of ISG 
transcripts (induced by receptor stimulation) (Duerst & Morrison, 2004).
In addition to the reduced MHCI and MHCII presentation and the interference 
with the type I IFN responses, HSV-1 infection also induces a decrease in the 
expression of CD83 on the cell surface (Kruse et al., 2000b, Salio et al., 1999). 
CD83 is completely degraded in lysosomal compartments (Kobelt et al., 2003) 
within lOhr of infection by blockage of mRNA transport from the nucleus, 
therefore resulting in reduced stimulatory capacity of the infected cells (Kruse et 
al., 2000a, Kruse et al., 2000b).
The viral protein ICP34.5 and the protein encoded by the US11 gene also function 
against the antiviral response. In infected cells, PKR phosphorylates the a  subunit 
of the eIF2a translation initiation factor, therefore blocking translation of viral 
proteins. ICP34.5 encodes a regulatory subunit that activates a cellular protein
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phosphatase (PP1) that dephosphorylates eIF2a (He et al., 1997, He et al., 1998). 
Similarly, the dsRNA binding protein expressed by US 11 can prevent eIF2a 
phosphorylation by inhibiting to an eIF2a kinase (Mohr, 2004).
Finally, glycoproteins expressed by the virus can interfere with the complement 
pathway. gC binds the C3 complement factor thus inhibiting its antiviral action 
(Lubinski et al., 1998), whereas gE and gl act by forming a complex that inhibits 
the classical complement cascade. IgG molecules can be produced and bind to 
viral gB, gC and gD (required for cell entry) via their Fab domain. Normally, this 
would trigger the classical complement pathway, leading to phagocytosis of the 
virus, but instead, the gE-gl complex can bind to the Fc domain of IgG (Dowler & 
Veltri, 1984) therefore blocking the immunoglobulin from activating the 
complement cascade.
Nonetheless, it has been suggested that despite downregulation and impairement 
of function of infected DCs, surrounding uninfected DCs are stimulated to mature 
by soluble factors released by the dying infected cells. This suggests that 
uninfected DCs can cross present antigens from infected DCs and undergoing 
maturation and possibly T cell activation (Pollara et al., 2003). Both Belz (Belz et 
al., 2004) and Allan (Allan et al., 2003) have shown that different types of DCs 
(those in the lung airway, or Langerhans cells in the skin epidermis) can be 
infected by HSV-1 but these may not be the cells involved in the presentation of 
antigen in the LN where a population of CD8a + cells is associated with antigen 
presentation of MHCI. Similarly, footpad injection of HSV-1 resulted in gB 
antigen presentation in the LN by a CD8a + DC subset (Smith et al., 2003). Taken 
together, these results imply that it is possible to target DCs with HSV-1 and 
achieve presentation in the LN, but the immune evasion mechanism acquired by 
this virus impair the function of DCs that therefore may present antigens via 
cross-presentation.
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1.3.5.3 Uses ofHSV-1 for immunotherapy
Potent immune responses can only be obtained by fully mature DC efficiently 
presenting the appropriate peptides and with a full set of costimulatory molecules. 
Therefore, to use HSV1 as a vector for immunotherapy, it is crucial to modify it 
so as to allow this level of cell maturation following infection. So far, because of 
the inhibiting properties of HSV-1 on dendritic cells, HSV-1 based amplicons 
(plasmid based vector packaged into an HSV-1 capsid) or replication incompetent 
viruses have been used to induce immune responses. Using an HSV-1 based 
amplicon expressing a tumour antigen it has been possible to show efficient 
transduction of dendritic cells and induction of antigen specific T cells after 
mouse injection of transduced DCs (Willis et al., 2001). In another study, ex vivo 
transduction of DC with an HSV-1 amplicon expressing marker genes could 
successfully express the genes and stimulate a reaction in MLR, but, interestingly, 
these cells in vivo could only stimulate antibody and no cellular responses to the 
genes (Nunez et al., 2004).
HSV has also been tested as a DISC. A DISC virus expressing mGMCSF showed 
a therapeutic effect inducing a strong CTL response against established murine 
colon carcinoma after either direct intratumoral injection of the vector, or, even 
better, after injection of infected DCs (Ali et al., 2002). Importantly, this study 
also showed that previous exposure to the virus did not affect the efficiency of 
vaccination.
Overall, taking into account the known function of specific HSV-1 genes that 
interfere with the immune system it is possible to construct vectors that should 
allow maximal expression of recombinant genes upon infection of DCs. 
Recombinant replication incompetent HSV have mainly been used to induce 
responses against viral antigens, mostly HSV (Da Costa et al., 1999b, McLean et 
al., 1994, Morrison & Knipe, 1996), but attenuated vectors have also proved 
capable of stimulating a response in rhesus monkeys against simian 
immunodeficiency virus (Murphy et al., 2000). Recently, a replication 
incompetent HSV-1 (ICP4', ICP22', ICP27", vhs‘) expressing the test antigen 
ovalbumin has also been used showing efficient stimulation of protective 
CD8+CTL responses against intracellular bacteria expressing the same antigen. A
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single immunisation dose could stimulate long term protective CD8+ responses 
while stimulating very low amounts of CD4+T cells and antibodies, with an 
efficiency stronger than DNA gene gun immunisation (Lauterbach et al., 2004), 
showing the advantage of using a viral vector and the potentials of using HSV-1 
viruses for immunotherapy purposes.
1.4 Hypothesis and Aims of this thesis:
The hypothesis behind this work is that HSV-1 can be modified and attenuated so 
as to allow it to infect dendritic cells without preventing them from undergoing 
maturation. It should then be possible to use this viral backbone to express foreign 
antigens such as malaria antigens, and use this recombinant virus to induce both 
IFNy release and antibody responses to the recombinant proteins and to the virus 
in vivo.
The aim of this thesis is to construct an HSV-1 based immunotherapeutic vector 
able to stimulate immune responses to malaria. The virus has to be able to 
transduce DCs efficiently, and allow them to undergo unaltered maturation, and 
trafficking to the lymph node so as to stimulate a maximal immune response to 
the delivered antigen, possibly by additional expression of immunostimulatory 
cytokines. Moreover, the vector should express multiple full-length genes and be 
able to stimulate both cellular and humoral responses to them. Finally, the 
constructed recombinant virus should stimulate an immune response both upon 
injection of ex-vivo transduced dendritic cells and upon direct injection of neat 
virus.
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Chapter 2
Materials and Methods
2.1 General reagents and suppliers
2.1.1 General Suppliers
General disposable plastic ware:
Greiner Ltd. (Stonehouse, Gloucester, UK).
Sterilin Ltd (Stone, Staffordshire, UK)
General analytical grade chemicals:
Merck Ltd (Poole, Dorset, UK)
Boehringer Mannheim (Lewes, East Sussex, UK)
Sigma chemical Company Ltd (Poole, Dorset, UK)
Tissue culture media, solutions and supplements for fibroblast and primary 
cultures:
Gibco-BRL Life Technologies Ltd., Renfrewshire, Scotland, UK. 
Tissue culture plastic ware:
Nunc (Roskilde, Denmark)
3MM chromatography paper:
Whatman International Ltd (Maidstone, Kent, UK)
Disposable filters 0.45pm and 0.2pm:
Gelman Life Scinences (Ann arbor, Michigan, USA)
Kodak X-OMAT imaging photographic film:
Sigma Chemical Company Ltd (Poole, Dorset, UK 
Restriction and modifying enzymes and buffers:
Promega Corporation (Madison, Wisconsin, USA)
Antibodies
DakoLtd. (High Wycombe, Bucks, UK)
Serotec
Insight Biotechnology Ltd.
2.1.2 Plasmids
pGemTeasy vector system I: Promega Corporation (Madison, Wisconsin, USA) 
was used according to manufacture instructions for the cloning of PyCS and 
PySSP2 genes
pBluescript: Stratagene Ltd, Cambridge, UK
pcDNA3: Invitrogen Corporation, Carlsbad, California, USA
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phrGFP-1: Stratagene Ltd, Cambridge, UK
pDsRedl-Nl: Clonetech, BD Biosciences, Franklin Lakes, NJ, USA
pCMVPyCS : This plasmid was obtained from Dr M.Tsuji (NewYork University
School of Medicine, NY). It contains the full length sequence of PyCS (amino
acids 1-356) without the terminal putative GPI-anchor sequence.
pBs43NP: This plasmid was present in the laboratory and expresses the full length
NP gene from H3N2 strain of influenza.
2.1.3 Genomic DNA
The genomic DNA of P. yoelii 17XNL (www.tigr.org) was a gift from 
Prof.A.Holder, (NIMR, London, UK)
2.1.4 Bacterial strains
The Escherichia Coli XL-1 Blue; this strain was used to carry out the cloning for 
all plasmids in this project.
Genotype: recAl end A l gyrl96 thi-1 hsdR17 supE44 relAl lac [F ’proAB Lacfi 
ZAM15, TnlO(Tet)r]
Source: Stratagene Ltd, Cambridge, UK
2.1.5 Antibodies
Antibody Application-
Dilution
Detection Dilution
Hamster anti-CD 1 lc+ biotin
conjugated
(BD Pharmingen)
FACS 1:50 Streptavidin-Red670
(Gibco)
1:100
Rat anti-mouse CD40 
(.Serotec)
FACS 1:50 Goat anti-rat 
PE conjugated 
(Serotec)
1:50
Rat anti-mouse CD 80 
(1Serotec)
FACS 1:50 Goat anti-rat 
PE conjugated 
(Serotec)
1:50
Rat anti-mouse CD86 
(Serotec)
FACS 1:50 Goat anti-rat 
PE conjugated
1:50
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{Serotec)
Rabbit anti-HSVl (.DAKO) FACS 1:50 Sheep anti-rabbit 
PE conjugated 
{Serotec)
1:50
Rabbit anti-HSV1 
HRP conjugated {DAKO)
Immunostaining
1:100
Swine anti-rabbit 
HRP conjugated 
{DAKO)
1:100
Mouse anti-human CD40 
{Insight)
FACS 1:50 Rabbit anti-mouse 
biotin conjugated 
{Serotec) 
Streptavidin-Red 
670
{Gibco)
1:100
1:250
Mouse anti-human CD86 
{Insight)
FACS 1:50 Rabbit anti-mouse 
biotin conjugated 
{Serotec) 
Streptavidin-Red 
670 {Gibco)
1:100
1:250
Mouse anti-human CD80 
PE conjugated {BD)
FACS 1:50
Mouse anti-human CD 19 
(Insight Biotechnology)
Depletion 
0.5|ig/106 cells
Mouse anti human CD3 
(Insight Biotechnology)
Depletion 
lpg/106 cells
Mouse anti-human CD2 
(Insight Biotechnology)
Depletion 
0.5pg/106 cells
Mouse anti-influenza A 
Nucleoprotein (NP) 
{Serotec)
Western blot 1:200 
ELISA 1:200
Rabbit anti-mouse 
HRP conjugated 
{DAKO)
1:1000
Anti-PyCS (9D3) ascite 
{Dr M. Tsuji 
New York University 
School o f Medicine, NY)
Western blot 1:300 
ELISA 1:300
Rabbit anti-mouse 
HRP conjugated 
{DAKO)
1:1000
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Anti-PySSP2 hybridoma Western blot 1:2 Rabbit anti-mouse 1:1000
Supernatant ELISA 1:2 HRP conjugated
{Dr A. Rodriguez {DAKO)
Dep. Medical and Molecular
Parasitology
New York University, NY)
Table 2.1: Antibodies used in this thesis together with the dilution used for each 
application and the detection antibody used.
2.1.6 Standard solutions and buffers
Luria Bertani media (LB): 1% (w/v) Bacto®-tryptone, 1% (w/v) NaCl, 0.5 % 
(w/v) Bacto®-yeast extract. This was then autoclaved at 120°C 20 minutes. 
Phosphate buffer solution (TBS): 137mM NaCl, 2.7mM KC1, 4.3mM disodium 
protophosphate dihydrate (Na2HP04.7H20), 1.4mM potassium hydrogen
orthophosphate (KH2PO4), pH7
TAE: 400mM Tris base, 200mM sodium acetate, 20mM EDTA pH8.3 
SSC: 150mMNaCl, 15mM sodium citrate
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2.2 Molecular Biology 
2.2.1 Propagation of bacteria
Liquid cultures of XL 1-Blue were grown in Luria Bertani media (LB) media 
containing either no antibiotic, lOOpg/ml ampicillin (Sigma), or tetracycline at a 
final concentration of lOpg/ml. Cultures were placed overnight in an orbital 
shaker (New Brunswick Sci Series 25) at 200rpm at 37°C. Stocks of ampicillin 
(Sigma) were made at lOOmg/ml (1000X) and stored at -20°C. Colonies of XL-1 
Blue were isolated by growing on LB plates containing 2% Bacto®-agar and 
ampicillin at lOOpg/ml or tetracyclin at 12.5pg/ml.
For long term storage of bacteria an overnight culture was diluted 1:100 into fresh 
LB media and incubated shaking at 200rpm 37°C for an hour after which an equal 
volume of 100% glycerol was added and the two solutions thoroughly mixed. The 
glycerol/bacteria solution was aliquoted into cyto-vials and frozen at -80°C.
2.2.2 Production of competent bacteria
This method of preparation of competent XL-1 Blue cells and transformation is 
based on the calcium chloride method described by Sambrook (Sambrook et al 
1989). A single bacteria colony was grown overnight in 10ml of LB without 
antibiotic. This culture was then diluted 1:100 in LB without antibiotic selection 
and grown for approximately 2hr until reaching OD580 of about 0.5 units. The 
cells were then pelleted in 50ml sterile tubes by centrifugation at 1496g 
(3200rpm) for lOminutes at room temperature. Supernatant was discarded and the 
cells resuspended in 10ml of ice cold lOOmM calcium chloride (CaCb) and left on 
ice for 2hr. The bacteria were then pelleted again by centrifugation at 1496g for 
lOmin at 4°C, the supernatant discarded and cells resuspended in 2ml ice cold 
lOOmM CaCh. These competent cells were kept on ice and used within 48hr.
2.2.3 Transformation of bacteria
Competent cells were transformed by addition of DNA to 1ml of cell and 
incubation on ice for 30min. These were then heat-shocked at 42°C for 90seconds 
and placed immediately on ice for a further 5minutes after which 4ml of LB 
without antibiotic selection were added and the mixture was placed in the orbital
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shaker at 200rpm 37°C for lhr. The cells were pelleted by centrifugation at 1496g 
(3200rpm) for lOmin at room temperature, the supernatant decanted and the pellet 
resuspended in lOOpl of LB. Cells were plated onto LB plates containing the 
appropriate antibiotic selection and these placed in an incubator 37°C overnight.
2.2.4 Small scale plasmid DNA extraction (mini-prep) from transformed 
bacteria
This “mini-prep” method of DNA extraction is based on the alkaline lysis method 
previously described by Bimboim (Bimboim & Doly, 1979). Individual colonies 
of transformed XL-1 Blue cells were used to inoculate 3ml of LB containing the 
appropriate antibiotic selection and placed overnight in the orbital shaker 
(200rpm, 37°C). 1.5ml of culture were then pelleted by centrifugation in a bench 
top centrifuge at 425g (2000rpm) for 2minutes, the supernatant was then removed 
by aspiration and the pellet resuspended in lOOpl of resuspension buffer (50mM 
Tris-HCl pH 7.5, lOmM EDTA pH8, 100pg/ml RNase-A). The cells were then 
lysed by addition of 200pl of lysis buffer (200mM NaOH, 1% (v/v) Triton X-100) 
and neutralised by addition of 150pl of neutralisation buffer (3M KOAc pH4.8). 
The cell lysate was vortexed and then centrifuged for 5minutes at 425g (2000rpm) 
and the pelleted precipitate was removed with a hypodermic needle bent at the tip, 
and discarded. 500pl of isopropanol were then added to the supernatant that was 
vortexed and centrifuged for 5minutes at 425g. After removal of the supernatant, 
the DNA pellet was washed with 500pl of 70% ethanol (EtOH) and the DNA 
pellet was then dried under vacuum and resuspended in 50pl of double-distilled 
water (dd^O ). Plasmid DNA was stored at -20°C.
2.2.5 Large scale plasmid DNA extraction from transformed bacteria
For extraction and precipitation of large scale plasmid DNA, a single transformed 
colony (or 100 pi of culture) was used to inoculate 400ml of LB containing the 
appropriate antibiotic selection. This was placed in an orbital shaker (200rpm, 
37°C) overnight. 100ml of this culture were centrifuges at 171 Og (3000rpm) for 
lOminutes and the supernatant discarded. Plasmid DNA was then extracted using 
the Marligen Midi-Prep Kit {Biosciences Inc) according to manufacturers
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instructions. The purified DNA was dried and resuspended in lOOpl of ddH20  and 
the average yield using this method was 1 OOpg.
2.2.6 Restriction enzyme digestions
Restriction digests were performed on plasmid DNA either for analysis or for 
isolation of DNA fragments. Analytical digests were performed in a total volume 
of 20pl containing 5pl of mini-prep DNA or lpl of midi-prep DNA. 10 units of 
enzyme were added together with the appropriate buffer as specified by the 
manufacturer. Digests were incubated 1-2 hours at the appropriate temperature. 
The digests were then run on a 1% agarose gel and the bands visualised on a UV 
transilluminator.
Restriction digests required for the isolation of DNA fragments were carried out 
in a total volume of 40pl containing 2-3 pg of midi-prep DNA and the appropriate 
buffer. Digests were incubated 2-16 hours at the appropriate temperature and then 
run on a 1% agarose gel. DNA bands were visualised on a UV transilluminator 
and the band corresponding to the required fragment carefully excised using a 
scalpel. The DNA was then extracted from the agarose using the GFX PCR DNA 
and Gel Band Purification Kit (Amersham Biosciences) following the instructions 
of the manufacturer. DNA was then eluted in a final volume of 50pl.
2.2.7 Blunting treatment
If compatible ends were not available to perform ligation of two fragments the 
digested DNA was purified and then the 3’ end overhangs were blunted using 
T4DNA polymerase (Promega). lpl of 25mM stock of dNTP (dATP; dCTP, 
dGTP, dTTP) and 15units of T4DNA polymerase were added to the DNA and 
incubated at 37°C for 20minutes. This reaction was then inactivated by heating at 
90°C for 5 minutes and cooled on ice before proceeding with additional 
manipulations.
2.2.8 Phosphatase treatment
When digesting DNA vector plasmids with enzymes that leave compatible or 
blunt ends, these were treated with calf intestinal alkaline phosphatase (CIAP) 
(Promega) to avoid religation of the two ends. The reaction was carried out in a
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total volume of lOOpl using 10 Units of CIAP with the appropriate buffer and the 
reaction was left at 37°C for 30 minutes. The DNA was then purified using the 
GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences).
2.2.9 Agarose gel electrophoresis
1% (w/v) agarose (.Invitrogen) gels were made using 1 x TAE (0.4M Tris, 0.2M 
sodium acetate, 20mM EDTA, pH8.3). Ethidium bromide was added to a final 
concentration of 0.5pg/ml. The gel was poured into a gel caster and left to set with 
a comb. 1Kb plus DNA ladder (.Invitrogen) was used as size marker and DNA 
samples mixed with 1 x loading buffer (1 x TAE, 50% v/v glycerol, 0.025% 
bromophenol blue) were loaded on the gel that was usually run at 60V to allow 
good separation of the bands. Bands were then visualised on a UV 
transilluminator.
2.2.10 Ligation reaction of DNA
lpl of purified vector and lpl of purified insert were run on a 1% agarose gel to 
empirically determine the amount present. Ligations were carried out in a total 
volume of 20pl, containing l-2pl of gel purified vector, 7-10pl of gel purified 
insert depending on the initial concentration of the fragments but usually 
obtaining a 1:3 vectoriinsert proportion. 1 x ligase buffer was added to the mix 
together with 1-3 units of T4 DNA ligase {Promega) in ddH^O. Reactions were 
carried out at room temperature for 2 hours and the enzyme then inactivated by 
incubation at 80°C 5 minutes. The ligation reaction was then transformed into 1ml 
competent XL-1 blue cells.
2.2.11 Polymerase chain reaction (PCR)
The specific PCR amplification of a target DNA sequence from P. yoelii genomic 
DNA was achieved using methodology essentially as described by Saiki et al 
(1985) and in www.tigr.org. Conditions used for the specific antigens are shown 
below. A working stock of P. yoelii 17XNL genomic DNA 7pg/ml (1:100 dilution 
of initial stock) was prepared in autoclaved ddELO. Samples for the PCR were 
prepared in a total volume of 50pl, using 5 pi of DNA, lpl of lOpM forward and 
reverse primers, lp l of lOpM dNTP mix (dATP, dCTP; dGTP, dTTP), 1 x pfu 
buffer and brought to volume with autoclaved ddELO. The pfu enzyme was added
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after the heat start as 2pl of pfu mix (5pi pfu, 2pi pfu buffer, in total 20pl). Pfu 
was the preferred enzyme used because of its proofreading activity. A negative 
control sample with ddFLO replacing DNA was included in each run to check for 
contamination.
To initially determine the ideal annealing temperature the samples were run in a 
thermocycler (Eppendorf Master Cycler Gradient) using a gradient of 
temperatures varying between 45-65°C (45°C, 50°C, 55°C, 60°C, 65°C). To 
obtain enough DNA to carry out the cloning, the fragments were amplified twice. 
5 pi of the PCR product were run on a 1% agarose gel to ensure correct 
amplification. The rest of the sample was then purified using a GFX PCR DNA 
and Gel Band Purification Kit (Amersham Biosciences) and resuspending in 25pi 
of ddFLO, the gene was then inserted into the pGemTeasy vector (Promega) as 
specified by manufacturer.
Primer name Primer sequence Location
PySSP FW 5’-GAGGGATCCGAAAAGACAGAAACA
TGAAGCTCTTA-3’
ATG of SSP2 gene
PySSP RV 5 ’ -G AGGGG AT C C AA AATT AGTT C C AGT 
CATTATCTTC-3’
Stop codon bp2996
NP int FW 5 ’ -G AA AGT GG AT G AGGG AACTC G-3 ’ bp350
NP int RV 5’-CCTCTCCAGAAGTTCCGATCAT-3’ bp671
T3 5’- ATT AAC CCT CAC TAA AG-3’ Sequencing primer
T7 5’- GAT ATC ACT CAG CAT AA-3’ Sequencing primer
Table 2.2: Primers sequences used to PCR amplification and their location in the 
gene
PCR cycles
Py SSP2 amplification: This is a ~2.5Kb gene therefore requiring a 5 minutes 
elongation time. The ideal annealing temperature for this set of primers was 60°C. 
The heat start cycle used was therefore: 94°C 6 minutes, 94°C 1 minute, annealing 
at 55°C for 2 minutes, and synthesis at 72°C for 5 minutes repeated a total of 35 
times.
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Amplification using NP internal primers: These primers were used with the cycle: 
95°C lmin, 95°C 30sec, 45°C 30sec, 72°C 2min repeated 30 times.
The amplified samples were then run on a 1% agarose gel.
2.2.12 Reverse transcription PCR (RT PCR)
All solutions used for this procedure were made using diethylpyrocarbonate 
(DEPC) treated water.
2.2.12.1 Isolation o f RNA
RNA was extracted from 5x106 infected cells using Tri reagent (Sigma). Cells 
were incubated with 1ml of Tri reagent for 5 minutes at room temperature after 
which 0.2ml of chloroform was added and the tube shaken vigorously for 15sec. 
The mix was then incubated at room temperature for lOminutes before being 
centrifuged at 12,000g for 15mins at 4°C. Following centrifugation the aqueous 
phase containing the RNA was transferred to a fresh tube and mixed with 0.5ml 
isopropanol, stored at room temperature 5-10 minutes and centrifuged at 12,000g 
for 8mins at 4°C to allow RNA precipitation. The pellet was washed with 75% 
ethanol and then air dried and resuspended in 20pl of DEPC treated H2O.
2.2.12.2 Synthesis o f cDNA
The RNA was then reverse transcribed using the OneStep RT-PCR kit (Quiagen) 
as described by the manufacturer and using the PCR cycle optimised for internal 
primers (§ 2.2.11). Internal primers were used because of the possibility of RNA 
degradation. As negative control, to ensure absence of genomic DNA 
contamination in the RNA samples, these were amplified using the same cycle but 
in a normal PCR reaction mix.
2.2.13 Quantification of DNA
Following plasmid DNA extraction this was quantified with a spectrophotometer. 
5 pi of DNA sample were diluted 200 fold into 1ml of ddEhO and the absorbance 
was read to A260. Absorbance of 1 at A260 corresponds to 50pg/ml, the reading 
was therefore multiplied by the dilution factor (x200) and by the conversion factor 
(x50) before being divided by a factor of 103 to obtain a measurement of DNA as 
pg/ml.
[DNA] = (A260 x 200 x 50)/1000 pg ml'1
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2.2.14 DNA sequencing
Plasmid DNA was purified using phenol/chloroform. DNA at a concentration of 
50ng/pl was sequenced by Department of Biochemistry, University of Cambridge, 
Cambridge, UK. The primers for each case were used at a concentration of 
lOpmol/pl.
2.2.15 Analysis of DNA by Southern blot
2.2.15.1 Southern blot
Southern blots (Southern, 1975) were performed on viral DNA to confirm the 
genome structures of newly constructed recombinant HSV-1 vectors. 10-30pl 
(depending on the density of the DNA preparation) of viral DNA were digested 
overnight with the appropriate enzyme and buffer in a total volume of 50pl. The 
enzyme was chosen in such way as to cut at both ends of the recombinant protein 
to obtain a band corresponding to the protein that could be easily identified. Viral 
DNA from a virus not containing the recombinant protein was also digested as a 
negative control, and 0.1 qg of plasmid DNA used to construct the recombinant 
virus was digested in a total volume of 20pl to be used as a positive control. The 
digestions were then loaded and run on a 1% agarose gel until bands were well 
separated.
The DNA was then visualised on a UV transilluminator and photographed against 
a fluorescent ruler. The gel was then left on the transilluminator for 2 minutes to 
degrade the DNA and was then placed into denaturing solution (1.5MnaCl, 0.5M 
NaOH) on a platform gently shaking at room temperature for exactly 45 minutes. 
The gel was then rinsed with water before being neutralised with neutralisation 
solution (1M Tris pH5.5, 2M NaCl) for at least 30 minutes on a shaking platform. 
The transfer was then assembled by placing the gel upside-down on a plastic 
support previously layered with 3MM chromatography Whatman paper (Whatman 
International Ltd) absorbing solution from a recipient containing 20 x SSC (1 x 
SSC: 150mM NaCl, 15mM sodium citrate). A piece of Hybond-N+ (.Amersham 
International pic) nylon membrane pre-soaked in neutralisation solution was then 
carefully placed on top of the gel to avoid air bubbles, and the position of the
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wells on the gel marked with a pencil. 10 more pieces of 3MM Whatman paper 
pre-soaked in 20 x SSC were placed on top of the nylon membrane and some dry 
paper towels were placed over them with a weight on top. DNA was allowed to 
transfer on the membrane overnight and the next day the membrane was carefully 
removed, washed in 6 x SSC and dried for 30 minutes at room temperature before 
crosslinking the DNA to the membrane using a UV Stratalinker 2400.
2.2.15.2 Radiolabelling o f DNA probe
The fragment of DNA (~300bp) to be used to identify the recombinant protein in 
the newly made viruses, was purified from the plasmid (§2.2.6). Labelling of the 
fragment was then carried out based on the random labelling reaction described by 
(Feinberg & Vogelstein, 1983) using the Ready-to-Go™ DNA labelling Beads (- 
dCTP) (Amersham Biosciences) as specified by the manufacturer. DNA was 
initially denatured (3 minutes 100°C) and added to the reaction mix bead 
(containing dATP, dGTP and dTTP as well as DNA polymerase) together with 
5jnCi of a  P-dCTP to reach a final volume of 50pl. The labelling reaction was 
then carried out at 37°C for at least 30 minutes before purifying the mix of 
unincorporated radioactivity by passing through a G50 Sephadex column 
{Amersham Bioscience). The purified probe was then made single stranded by 
heating at 100°C for 5 minutes and then immediately cooled on ice for 2 minutes. 
This probe was then added to the membrane.
2.2.15.3 Hybridisation o f the southern blot membrane
The membrane obtained from transfer of DNA (§ 2.2.15.1) were pre-hybridised 
for 1 hour at 65°C in 30ml of pre-hybridisation solution (5 x SSC, 5 x Denhardf s 
reagent {Sigma), 0.5% (v/v) SDS in ddFLO) to which lOOpg/ml of denatured 
(95°C 5minutes, ice 2 minutes) herring sperm DNA {Sigma) were added. After at 
least lhour of pre-hybridisation, 20ml of solution were removed and the 
radiolabelled probe (§ 2.2.15.2) was added and left to hybridise to the membrane 
overnight at 65°C.
Following hybridisation, the membrane was washed three times with solutions of 
decreasing stringency. An initial 5minutes wash with 2 x SSC, 0.5% SDS was
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followed by a 15minutes wash with 2 x SSC, 0.1% SDS and a final 30minutes 
wash with 0.1 x SSC, 0.1% SDS. The membrane was then wrapped in cling film, 
exposed to Kodak X-Omat AR x-ray film (Sigma) and developed after varying 
lengths of time.
2.2.16 Protein isolation and analysis
Resolving gel Buffer
1.5M (18.15g) Tris 
0.013M (0.4g) SDS 
in H20  (100ml) 
pH to 8.9 with HC1
Stacking gel Buffer
0.425M (5.1g) Tris 
0.013M (0.4g) SDS 
in H20  (100ml) 
pH to 6.7 with HC1
10 X Running Buffer
0.247M (30g) Tris 
1.918M (144g) Glycine 
0.0658M (19g) SDS 
Dissolved in H20  (1L)
Boiling mix
lml stacking buffer 
0.8ml 25% SDS 
0.5ml 2-mercaptoethanol 
bromophenol blue
2.2.16.1 Protein extraction
Monolayers of 106 BHK or Mam49 cells were washed twice with lml of HBSS 
and lysed adding lml of boiling mix and swirling using a bent pipette plastic tip. 
The samples were then immediately placed at -20°C until required. For extraction 
from dendritic cells, 106 cells were spun down (3 minutes 238g -1500rpm) and 
after removal of supernatant the pellet of cells was washed twice with lml of 
HBSS before being lysed by addition of lml of boiling mix. These were stored at 
-20°C until used.
Extraction of protein for samples to be tested for expression of influenza NP were 
carried out using the urea method that is usually used for transmembrane proteins 
that does not require boiling of the samples. The medium was removed from 106 
cells either monolayer or DCs in suspension (in this case by centrifuging the cells 
3minutes 238g and removing the supernatant) and cells washed in lml of HBSS 
by centrifuging for 3minutes at 425 g (2000rpm). The pellet was then resuspended 
in lOOpl of urea extraction buffer (48% (v/v) SDS, 2M Urea, 8% sucrose to which
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protease inhibitors (complete Mini-Roche) were added fresh immediately before 
use). The sample was passed 10 times through a 21 gauge needle (BD 
Microlance) and syringe to disrupt cellular membranes, and immediately frozen 
at -20°C until required.
2.2.16.2 SDS Polyacrylamide gel electrophoresis (SDS-PAGE)
Protein MW Range (kDa) 12-45 14-60 16-70 60-200
Acrylamide concentration 15% 12% 10% 5%
Table 2.3: Required acrylamide concentration of resolving gel according to the 
molecular weight of the protein.
Resolving gel (10%) Bis-Acrylamide (30:1.5)*
Resolving gel buffer
10% (w/v) APS
TEMED**
ddH20
10M Urea***
8ml
6ml
150pl (300pl in urea gels) 
15pi (30pl in urea gels)
1 lml (6ml in urea gels)
5 ml
Stacking gel (5%) Bis-Acrylamide (30:1.5) 
Stacking gel buffer 
10% (w/v) APS 
TEMED** 
ddH20
10M Urea***
2ml
3ml
150pl
15pl
7ml (4.5ml in urea gels) 
2.5ml
Table 2.4: Composition of resolving and stacking gel of SDS-PAGE gels 
*Bis:N,N’-Mehylene-bis-acrylamide
**NNNN-Tetraethylethalinediamine (Bio-Rad, Hemel Hempstead, Herts). This is 
added last as is responsible for polymerisation 
*** Only added in urea gels
22ml of resolving gel were poured between two glass plates separated by spacers 
and isopropanol was overlaid to ensure it is straight and to remove air bubbles. 
The density of the resolving gel (varying amount of acrylamide) was decided
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based on the size of the protein to be identified (table 2.3). For detection of NP 
(~60KDa) and PyCS (~60KDa) gels were made at 10%, whereas gels to detect 
PySSP2 (~140KDa) gels were 5%. This was left to set before removing the 
isopropanol, washing twice with dH20 and drying the excess with 3MM 
Whatman paper. The 5% stacking gel was then poured on top of the set resolving 
gel, an appropriate comb was inserted into it to allow formation of wells and was 
left to polymerise. Urea based gels were assembled in the same way but differing 
slightly in the composition of the buffers (table 2.4).
Upon complete polymerisation, the comb was carefully removed from the 
stacking gel and the total protein samples were separated into polypeptide units by 
SDS-polyacrylamide gel electrophoresis according to the method of (Laemmli, 
1970). Samples were prepared immediately before loading on the gel. Samples 
frozen in boiling mix were thawed and heated at 95°C for 5 minutes and then 
placed on ice for lOminutes before being loaded onto the gel (whole sample or 
50pl were loaded on the gel).
Samples extracted in urea extraction buffer were thawed and mixed with an equal 
amount of sample buffer (urea extraction buffer with 350mM 2-mercaptoethanol 
added and bromophenol-blue). This mixture was heated to 37°C for 10 minutes 
and the whole sample was loaded on a urea gel. A coloured molecular weight 
protein marker (Rainbow marker) {Amersham Biosciences) was also loaded on the 
gels (lOpl). SDS-polyacrylamide gels were prepared in a vertical gel 
electrophoresis separation system {Owl) and run in lx running buffer at 40mA/gel 
until good separation was obtained between the coloured molecular weight 
markers comprising the expected band.
2.2.16.3 Transfer o f protein to nitrocellulose by western blotting 
Proteins separated on SDS-PAGE gels were transferred onto nitrocellulose 
membranes (Hybond-C) {Amersham International Pic) using a wet-transfer 
method described by (Towbin et al., 1979).The gel, nitrocellulose membrane and 
six sheets of 3MM Whatman paper were soaked in transfer buffer (50mM Tris, 
380mM glycine, 0.1% (w/v) SDS and 20% (v/v) methanol). The gel and 
nitrocellulose membrane were then placed in between the filter paper in a Trans-
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Blot™Cell (BioRad) according to manufacturer’s instructions. Protein band 
transfer onto the membrane was carried out overnight at 4°C at 5V. Upon 
completion of transfer onto the nitrocellulose membrane this was stained for 
immunodetection of the protein.
2.2.16.4 Immunodetection o f proteins on nitrocellulose membrane 
The nitrocellulose membrane with the transferred protein bands were blocked by 
incubating in blocking solution (5% (w/v) skimmed milk, 0.1% (v/v) 
polyoxyethylene sorbitan monolaurate (Tween-20) made up in 1 x PBS) for at 
least lhour shaking at room temperature. The membrane was then incubated with 
primary antibody diluted in 2% (w/v) skimmed milk, 0.1% (v/v) Tween-20 in 1 x 
PBS for 2hours at room temperature with vigorous shaking. The antibody 
dilutions used are shown in table 2.1. Unbound antibody was then removed and 
the membrane rinsed with three 10 minutes washes with 1 x PBS 0.1%(v/v) 
Tween-20 at room temperature with constant shaking. The washed membrane was 
then incubated in the dark with the appropriate secondary anti-IgG horseradish 
peroxidase (HRP) conjugated secondary antibody diluted in 2% (w/v) skimmed 
milk made up in 1 x PBS 0.1% (v/v) Tween-20 shaking for lhour at room 
temperature. The unbound HRP antibody was then removed from the membrane 
by three washed for 10 minutes each with 1 x PBS 0.1% (v/v) Tween-20 at room 
temperature shaking. The bound HRP was visualised using the Enhanced 
Chemilluminescence system (ECL™) {Amersham International) according to the 
manufacturer’s instructions. Exposure times varied between 2 seconds and 20 
minutes, according to the strength of the signal.
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2.3 Tissue culture
Tissue culture manipulations were carried out under sterile conditions in a laminar 
flow safety cabinet class II (Heraeus) using standard aseptic techniques. Cells 
were maintained in incubators (Heraeus) at 37°C with 5%C02 in a humidified 
atmosphere. Primary cell preparations were obtained using separate cabinets and 
incubators from cell lines.
2.3.1 Heat inactivation of foetal calf serum (FCS)
FCS was heat inactivated by placing at 65°C for 45 minutes
2.3.2 Propagation of mammalian cell lines
BHK-21: Baby Syrian Hamster Kidney 21 clone 13 cells (ECACC number: 
85011433).
These cells were grown in full growth medium (FGM): Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% foetal calf serum (FCS) and 
lOOU/ml penicillin and streptomycin. The cells were passaged when reaching a 
80% confluency by washing with Hanks Balanced Salt Solution (HBSS) at room 
temperature and then incubated with thin layer of 10% (v/v) trypsin in versene 
until detachment of cells. This was stopped by addition of FGM and the cells split 
at a ratio of 1:20 with FGM into fresh flasks.
27/12/M:4 (Mam49) (Thomas et al., 1999): These are a BHK based cell line 
transfected with plasmids encoding ICP27, ICP4, and equine VP 16. These cells 
are grown in same medium as BHK cells but supplemented with 800pg/ml of 
Geneticin-G418 sulphate (Gibco) and 750pg/ml of Zeocin (CAYLA).
A20 cells: Balb/c cell lymphoma line (ATCC # TIB-208). These are B 
lymphocyte cells from reticulum cell sarcoma A20 cells were maintained in RPMI 
1640 supplemented with 2mM L-Glutamine, 10% heat inactivated FCS, lOOU/ml 
penicillin and streptomycin
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P815-1-1 cells: Mouse DBA/2 mastocytoma cell line (ECACC number: 
85011406). These cells were propagated in RPMI 1640 supplemented with 2mM 
Glutamine, lOOU/ml penicillin and streptomycin and 10% heat inactivated FCS. 
The cells were split when reaching -80% confluency by washing the cells with 
HBSS and pelleting by centrifugation followed by 1:10 replating.
2.3.3 Cell line storage
For long term storage, cells were taken in log phase. 0.5ml of cell suspension was 
mixed with 0.5ml of ice-cold freezing mixture (85%FCS, 20%
dimethylsulphoxide (DMSO)) and placed in 1.5ml cryovials. These were slowly 
cooled to -70°C for 24hr before being stored in liquid nitrogen. For recovery, 
cells from one vial were rapidly thawed, and transferred immediately to 10ml of 
fresh FGM specific for that cell type and incubated overnight. The FGM was 
replaced the next day with 10ml of fresh appropriate FGM.
2.3.4 Preparation of primary human dendritic cells from blood or buffy coat
This protocol follows the one described by Romani et al 1994 and Morse et al 
1997
100ml of peripheral blood mononuclear cells (PBMCs) were collected from 
healthy donors using syringes coated with heparin anticoagulant. The blood was 
added to 80ml of HBSS and this carefully layered onto 17ml of lymphosep 
{Fisher scientific) previously placed in 50ml tubes {Falcon). After centrifugation 
for 30minutes at room temperature 486g (1600 rpm) without break, the 
mononuclear cells in the interface was carefully removed using a Pasteur pipette 
and washed with HBSS (centrifuge 486g for lOminutes at room temperature). The 
cells were pulled together and washed twice with HBSS centrifuging for 5minutes 
at 372g (1400 rpm) at room temperature. The pellet was then lysed of red blood 
cells by addition of 10ml of red blood cell lysis buffer {Sigma) for 5 minutes. 
Cells were then washed twice more with HBSS and then resuspended in 18ml of 
complete medium (RPMI 1614 with 10% heat inactivated FCS, lOOIU/ml of 
penicillin/streptomycin). Cells were plated in six-well plates at 3ml/well and 
incubated 1.5 hours at 37°C, 5%C02. Non adherent cells were placed into a fresh 
tube and washed in HBSS centrifugating at 372g (1400rpm) for 5minutes and 
plated again. The adherent cells after both steps were replenished with fresh FGM
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supplemented with hGMCSF (.Insight Biotechnology) at O.lpg/ml and IL4 
{Insight Biotechnology) at a concentration of 0.05pg/ml.
On day 8 the cells were depleted of other cell types. Non adherent cells were 
harvested with gentle washing, and then pelleted at 4°C for 3mins at 321 g (1300 
rpm). The pellet was washed with ice cold HBSS and the supernatant discarded. 
The DC pellet was resuspended in 2ml of pre-chilled complete RPMI medium. 
The cells were then places on ice. For each million cells these were incubated with 
lpl of anti-CD19 (TCSN); 2pl anti-CD3(TCSN), and lpg/ml anti-CD2 {Insight 
Biotech). The mixture was placed on a rotating mixer in cold environment and 
incubated for 30min. Cells were then washed with ice cold HBSS and 
resuspended in 2ml of complete medium and then added to the dynabeads 
(dynabeads M450, Dynal) (lOpl of beads/million cells) previously prepared. 
Beads and cells were then incubated on a rotating mixer at 4°C for 30mins. DCs 
were then depleted by removing the supernatant after placing the suspension mix 
in contact with a magnet. The purified DC were then counted, resuspended at the 
required concentration with FGM and placed on ice for immediate use.
2.3.5 Preparation of mouse bone marrow dendritic cells
Bone marrow dendritic cells were derived from 4-6 weeks old female BALB/c 
mice and cultured following slightly modified protocol by Lutz et al (Lutz et al., 
1999). The cells from the mice tibiae and femur were flushed and washed twice 
with wash buffer (HBSS 2%FCS) by centrifuging 5minutes at 372g (1400 rpm) at 
room temperature. The red blood cells present in the pellet were then lysed by 
resuspending in 3ml red blood cell lysis buffer {Sigma) and incubating for no 
longer than 5 minutes at room temperature. The cells were then washed twice with 
wash buffer before being resuspended into lml of complete medium (Iscove’s 
modified Dulbecco Medium, 10% heat inactivated FCS, lOOU/ml penicillin and 
streptomycin, 50pM 2-mercaptoethanol [Gibco]). Cells were counted and 
resuspended at a concentration of 6 x 105 cells/ml in complete medium 
supplemented with lOng/ml mouse recombinant GMCSF (mGMCSF) 
{AutogenBioclear) to allow DC differentiation. The cells were plated on six-well 
plates and kept in humidified chamber 37°C 5%CC>2.
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On day 3 half the medium was replaced with fresh complete medium 
supplemented with mGMCSF taking care not to disrupt clumps of semi-adherent 
cells. The cells were then cultured for a further 4 days. On day 7 non adherent and 
slightly adherent cells were harvested and concentrated using lymphosep (.Harlan 
SeraLab). In 15ml polysterine screw cap tubes (Nunc) cells were overlayed onto 
3ml of lymphosep and spun at 486g (1600rpm) for 20min without break. The 
interfase containing the dendritic cells (DC) was then removed and washed twice 
with wash buffer. This step helps to obtain a cleaner population of cells (Lappin et 
al., 1999). Cells were resuspended in lml complete medium, counted and used 
immediately.
2.3.6 Preparation of splenocytes from mouse spleen
Cultures of fresh splenocytes from immunised mice were set up to be tested in an 
ELISPOT assay for presence of an antigen specific T cell response by the mice. 
Because the number of reactive cells may be relatively low and therefore causing 
detection problems, these cells can be amplified over non antigen targeted cells, 
by culturing them in presence of the specific peptide.
Mouse spleen were removed, disaggregated by using a syringe stuffer and passed 
through a 70pm nylon cell strainer (Falcon, BD biosciences) by flushing with 
10ml wash buffer (HBSS 10% heat inactivated FCS). A different strainer and 
syringe stuffer was used for each spleen. Cells were placed into a 50ml tube and 
spun at 32 lg (1300 rpm) 4°C 5 minutes. The pellet was then washed once with 
wash buffer and treated with 5ml of red blood cell lysis buffer (Sigma) for 5 
minutes. The reaction was stopped by addition of 10ml wash buffer and washing 
cells twice. The final pellet was resuspended in 2ml of complete medium (RPMI 
1614, 10% heat inactivated FCS, 50pM 2-mercaptoethanol, lOOU/ml penicillin 
and streptomycin) containing lOpM of the appropriate peptide for restimulation (§ 
2.3.13). Cells were counted, plated at a concentration of 2xl06 cells/ml in six-well 
plates and placed in a humidified chamber at 37°C 5%CC>2 for 7 days. On day 7 
splenocytes were harvested and washed twice with HBSS by centrifuging 
5minutes at 321 g (1300rpm) 4°C. The pellet was resuspended in 2ml of complete 
medium and cells were counted and used immediately.
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2.3.7 DNA transfection for transient expression
DNA was transfected into mammalian cell lines either to check a plasmid for gene 
expression or to obtain recombination for the construction of new viruses (§2.3.9)
DNA transfections were performed based on the calcium phosphate mediated 
method as previously described (Stow & Wilkie, 1976) and used supercoiled 
plasmid DNA.
Hebes trasfection buffer: 140mMNaCl, 5mMKCl, 0.7mMNa2HPO4, 5.5mMD- 
glucose, 20mMHepes, pH7.05 with NaOH. This was filter sterilised through a 
0.2pm filter and stored at 4°C.
Cells were grown to 80% confluency in six-well plates. Two tubes were set up: 
Tubel: 3lpl 2McaC12, lOpg plasmid DNA, 20pg herring sperm DNA 
(phenol/chloroform extracted).
Tube 2: 400pl Hebes transfection buffer
The contents of tube 1 were carefully mixed by gentle pipetting and then added to 
tube 2 drop-wise with constant mixing. The mixture was left at room temperature 
for 40minutes to allow DNA precipitation. The media was then removed from the 
monolayer of cells and the mixture of precipitated DNA was carefully added to 
the cells. These were incubated at 37°C 5%C02 for 30min gently shaking every 
lOmin to avoid drying out of the cells. Following this incubation lml of FGM was 
added to the cells and these placed back in the incubator 37°C 5%C02 for 4- 
6hours prior to DMSO shock. A 20% DMSO sterile solution was prepared in 
Hebes transfection buffer. After removal of the media from the cells, these were 
gently washed twice with lml of FGM and lml of 20% DMSO was added onto 
the cells for no longer than 90seconds. The DMSO solution was then removed and 
the cells washed twice with 2ml of FGM. A final 2ml of FGM was added to the 
cells and then incubated at 37°C 5%C02 for 48hr.
2.3.8 Virus infection of monolayer cells
The virus was diluted in a minimal final volume of SFM that would allow for 
overlay of the whole cell surface (eg. 500pl for a six-well). This was overlayed 
onto the monolayer from which the medium had previously been removed, and
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the cells incubated at 37°C, 5%C02 for lhour before overlaying with FGM 
supplemented with HMBS when required.
2.3.9 Construction of recombinant HSV-1 virus
2.3.9.1 Virus transfection
The principle by which construction of recombinant viruses are formed is 
illustrated in figure 2.1.To ensure maximal efficiency of viral transfection and 
infection, wells, flasks and plates of appropriate cells were prepared without 
selection present in the media.
Transfections to obtain a recombinant viruses were carried out similarly to 
plasmid transient transfections as described in section 2.3.7 except 10-30pg of 
purified viral DNA (§2.3.9.6) was added to tube 1. For construction of viruses 
with mutated VP 16 the media was supplemented with 3mM hexamethylene 
bisacetamide (HMBA) in order to induce immediate early gene transcription 
(McFarlane et al., 1992). Homologous recombination transfections were left for 3- 
5 days until complete cytopathic effect (CPE) was observed. The well was then 
harvested and freeze-thawed. The harvested cells were then titred out in a plaque 
assay (§2.3.9.2) and the efficiency of recombination determined by assaying for 
recombinants containing the required reporter gene.
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m FR HSV-1 genome
Plasmid encoding gene of interestFR o f i ntere^t
Homologous recombination between flanking regions
] o f  in terest FR Recombinant HSV-1
Excised non-essential HSV-1 gene
Figure 2.1: Homologous recombination
Schematic representation of the homologous recombination that needs to take place 
for the construction of recombinant HSV viruses. A plasmid containing the gene of 
interest (either a therapeutic gene or GFP) between the two viral flanking regions 
(FR) of the gene to be replaced in the HSV genome is transfected together with the 
viral DNA. Homologous recombination takes place between the flanking regions 
excising the viral gene and replacing it with the one from the plasmid. This forms the 
recombinant HSV virus that is then nurified.
2.3.9.2 Plague assay
BHK or Mam49 cells were grown to 80% confluency in six-well plates. A 1:10 
serial dilution of the virus preparation was prepared in DMEM without FCS 
(serum free media, SFM) to a volume of lOOpl. The lOOpl were added to 400pl of 
SFM placed on the cells, and these were incubated for lhr at 37°C, 5%C02. After 
this incubation 2ml of 1:2 (v/v) FGM: 1.6% (v/v) carboxymethyl cellulose (CMC) 
were added to each well. When using viruses with mutated VP 16, 3mM HMBA 
was also added as well. Cells were then incubated for 48hours at 37°C, 5%C02 
and the number of plaques in each well were counted in order to determine the 
virus titre in plaque forming units/ml.
2.3.9.3 Detection o f GFP expression
Cells expressing GFP could be directly visualised using an inverted fluorescent 
microscope at a wavelength of 520nm.
2.3.9.4 Purification o f  recombinant virus by plague assay
The harvested recombinant viral transfections were freeze-thawed to disrupt the 
cells allowing release of virus. The transfection was then plated in a plaque assay 
serial dilution. When using the plaque assay to purify a newly made recombinant 
virus, this also determined efficiency of infection by looking at the number of 
plaques expressing the recombinant protein under normal and UV light with the 
appropriate filter to visualise green, red, or white (without insert) plaques using an 
inverted fluorescent microscope {Nikon Eclipse TE200). Plaques expressing the 
reporter genes of interest were picked from the monolayer using a P20 Gilson 
micropipette (set at 18pl) and transferred to an eppendorf tube containing lOOpl 
of SFM. The plaque suspension was then freeze-thawed and plated out for further 
purification. The plaque purification process was repeated until the plaques 
formed were only those containing the recombinant gene and no parent virus. 
Each well was then harvested and used as stock to propagate the virus at a larger 
scale.
2.3.9.5 Production o fh ish  titre stock o f recombinant virus
lOOpl of the harvested purified plaques stock was used to infect an 80% confluent 
175cm2 flask of the appropriate cell line and medium without selection. Infection
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of flasks was carried out initially incubating the infecting virus in 5ml of SFM on 
the cells for lhr, after which 20ml of FGM with HMBA added when needed. This 
was incubated at 37°C, 5%C02 until achievement of complete CPE when the 
flask was harvested and frozen. This sub-master stock was titred and used to 
further propagate the virus into high titre stocks.
Ten 500cm2 tissue culture plates were seeded with the appropriate cell line in 
50ml of FGM not containing selection. At 90% confluency, cells were infected at 
an MOI of 0.05 (3xl06 pfu/ml) with the sub-master stock, in a total volume of 
50ml of fresh FGM without selection but supplemented with HMBA when 
necessary. The plates were then incubated at 37°C, 5%CC>2 for 2-4 days until 
complete CPE was observed. The whole plate was then frozen at -80°C and then 
thawed to release the virus from the cells. After thawing at room temperature, 
cellular debris was removed by centrifugation at 2330g (3500rpm) for 45 minutes 
at 4°C. The supernatant was then passed through a 5 pm filter, followed by a 
0.45pm filter and the viral particles were then pelleted by centrifugation at 
21,859.2g (12,000rpm) for 2 hours at 4°C. The supernatant was discarded and the 
pellet resuspended in 200pl of HBSS. The resuspended pellet was then sonicated 
for 5 times 10 seconds in a water bath sonicator and chilled on ice between 
sonications. The virus was then aliquoted and stored in liquid nitrogen. Virus titre 
was tested by plaque assay (§2.3.9.2).
2.3.9.6 Viral DNA extraction
In order to obtain viral DNA for Southern blot analysis, viral extractions were 
carried out from one well of a six-well plate infected, and at full CPE. 
Alternatively, when isolating DNA to be used in the construction of recombinant 
viruses, this was done from a 175cm2 flask of infected cells at complete CPE.
The medium was removed from the monolayer, the cells were washed gently with 
lml of HBSS (5ml in the case of 175cm2 flask) before adding 1ml (or 6ml for the 
175cm2 flask) of DNAzol {Helena Biosciences). This was swirled until the entire 
surface are was covered with solution. The lysate was added to a 15ml Falcon 
tube and overlaid with 3ml of absolute ethanol. This mixture was gently swirled to 
allow DNA precipitation initially as strings at the interface and subsequently as a
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lump. The DNA was removed with a pipette tip and washed in 3ml of 75% 
ethanol twice. DNA was finally placed into a 1.5ml tube and centrifuged 1 minute 
at 2653g (5,000 rpm) to remove the excess ethanol. The pellet was air dried at 
room temperature for 5 minutes and resuspended in 200pl (or 1 ml for the 175cm2 
flask) of 8mMNaOH freshly made. This DNA was then incubated at 4°C on a 
rotating platform overnight to allow good homogenisation, and then neutralised 
with 23pi (or 115pl of the 175cm2 flask extraction) of 0.1M HEPES. Viral DNA 
was then stored at -20°C.
2.3.10 Transduction of dendritic cells with HSV-1
The required number of cells (5xl06-106) was placed in a 15ml tube and 
centrifuged 372g (1400rpm) for 5 minutes at room temperature. The supernatant 
was decanted and the cells resuspended in lOOpl of serum free medium and high 
titre purified virus were added at MOI of 1 unless otherwise specified in the text. 
The cells were incubated for lhour at 37°C, 5%CC>2 after which complete medium 
was added supplemented with mGMCSF for mouse cells or hGMCSF and IL4 for 
human DCs to achieve concentration of 5xl05cells/ml and were plated in 24 well 
plates overnight at 37°C, 5%C02. The next day cells were harvested and used for 
FACS analysis.
When transducing mouse bone marrow dendritic cells for in-vivo injection, these 
were not incubated with medium containing cytokines because they were 
harvested 4 hours after infection. Cells were pelleted (5 minutes 427g -1500 rpm) 
and then washed twice with HBSS and counted before being resuspended in 
HBSS in an appropriate volume for injection.
For stimulation of maturation DCs were treated with lipopolysaccharide (LPS) 
(Sigma). LPS was added with the complete medium at a concentration of 
lOOng/ml for human cells and 5pg/ml for mouse bone marrow derived DC.
2.3.11 Trypan blue exclusion assay
Cell survival and most cell counting were made by trypan blue exclusion assay. 
With this test dead cells are identified because of they take up the blue dye. lOpl 
of cell preparation were mixed to an equal volume of 0.04% trypan blue solution
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and then loaded on a haemocytometer counting chamber. The live and dead cells 
were counted on a 4 x 4 square grid, this count was multiplied by a factor of 2xl04 
to obtain counts of cells/ml.
2.3.12 HSV-lGrowth curves
24-well plates with 80% confluent BHK or Mam49 cells (as specified by the text) 
were infected at MOI 0.01 and 0.001 with the virus (§ 2.3.8) in duplicate for each 
time point. These were harvested at 0, 2, 4, 8, 20, 24, 48 hours post infection. 
Cells were disrupted by freeze-thawing and virus yield was assessed by plaque 
assay (§ 2.3.9.2). All titrations and infections were carried out in duplicate.
105 human DCs were transfected at MOI of 1(§ 2.3.10) and frozen at 0, 10, 20, 24, 
36, 48, 72 and 96hours post-infection. After thawing of the samples to release the 
virus the yield was determined by titration of BHK cells. Similarly, 2 x 105 or 2 x
106 mouse bone marrow dendritic cells were transfected at MOI of 1 with the 
appropriate virus and samples were frozen at 0, 4, 8, 20, 24, and 48hr post 
infection. After thawing all samples were titered in duplicate to determine the 
yield of the virus by plaque assay.
2.3.13 Peptide pulsing of cells
Bone marrow derived dendritic cells
Cultured DCs were stimulated to mature overnight with LPS (§ 2.3.5). The mature 
DC were harvested and placed in a screw cap tube and after washing twice with 
serum free medium (Isocove’s Modified Dulbecco medium) by centrifugation at 
427g (1500rpm) 5 minutes the cell pellet was resuspended in lOOpl of serum free 
medium. The antigen diluted in the appropriate solvent (table 2.5) was added to 
the cells in the tube at a concentration 10pM considering as volume that in which 
the cells would have been plated (6 x 105 cells/ml). All peptides are nine-mer 
since this is the size of peptides that fit the MHCI binding cleft. DCs were pulsed 
for 45 minutes in a humidified chamber at 37°C, 5%CC>2 after which they were 
washed twice with HBSS before being resuspended in appropriate volume for in- 
vivo injection.
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Purified peptides were obtained from Invitrogen. When their polarity required the 
peptides to be dissolved in DMSO this was added in minimal amount to ensure 
minimal disruption of cells and the volume was made up with HBSS.
Protein Peptide sequence Amino acid position Solvent
NP TYQRTRALV 147-155 HBSS
CS SYVPSAEQI 280-288 DMSO
SSP2 KYIFVVLLL 8-16 DMSO
Table 2.5: Table indicating the sequence, position within the protein sequence 
and the appropriate solvent for the H2Kd CD8+ peptides used in this project.
A20 cells
A20 cells were pulsed with antigen peptides to act as antigen presenting cells in 
the set up of ELISPOT assays (§ 2.4.4). ELISPOTS were set up using lOOpl of 
A20 106/ml per well. Cells were pulsed at 20pM to account for the addition of one 
volume of responder cells therefore resulting in final pulsing at lOpM.
A20 cells from an 80cm2 flask in culture were harvested and spun down by 
centrifugation 5 minutes at 427g (1500 rpm). The cells were then washed twice 
with HBSS and the pelleted cells resuspended in 5ml of RPMI 1614 (serum free). 
These were counted and the number of required cells were spun down and 
resuspended in 200pl of RPMI 1614 to which enough peptide to achieve a 
concentration of 20pM in final volume was added. Cells were mixed well and the 
tube placed at 37°C, 5%C02 for 30minutes before adding the amount of serum 
free medium required to achieve a cell concentration of 106cells/ml.
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2.4 Immunological assays
2.4.1 Flow cytometry
Dendritic cells were analysed for expression of surface molecules by staining with 
fluorescent antibodies for flow cytometric quantitation.
2 x 105 previously counted DCs were placed in 96well round bottom plates and 
washed twice in 300pi FACS buffer (15mM EDTA, 30mM NaN3, 1% (w/v) 
bovine serum albumin (BSA), in 0.1M phosphate buffer PB), by centrifuging at 
427g (1500rpm) 3minutes at 4°C. The cells were initially fixed by incubation in 
lOOpl of 4% (w/v) paraformaldehyde for 20minutes on ice. For intracellular 
staining, after three washes with 300pl of FACS buffer at 427g (1500rpm) 
3minutes at 4°C, the cells were permeabilised with lOOpl of freshly prepared 
0.3% (w/v) saponin in 0.1MPBS for a further 45minutes on ice and then washed 
two times. The pelleted cells were resuspended in lOOpl of FACS block solution 
(0.1M PBS, 10%FCS) left on ice for lOminutes. Cells were then spun down 3 
minutes at 427g (1500rpm) 4°C to remove the blocking solution, and the pellet 
resuspended in lOOpl of antibody dilution (table 2.1) in block solution, this was 
left on ice for lhour. The cells were then pelleted by centrifugation 427g 
(1500rpm) for 3minutes at 4°C and the supernatant carefully removed. The pellet 
was then washed three more times with 300pl of FACS buffer spinning at 427g 
(1500rpm) for 3minutes at 4°C.
lOOpl of the secondary antibody, conjugated to a fluorochrome (or biotin 
conjugated for anti-CD 1 lc) was then added at the appropriate dilution (table 2.1) 
in blocking solution and incubated on ice in the dark for 30minutes then followed 
by three washed with FACS buffer. For mouse bone marrow dendritic cells anti- 
CDllc this was then followed by a staining with a third antibody conjugated to 
streptavidin and to a fluorochrome. Cells were washed three more times with 
300pl of FACS buffer by centrifugation at 427g (1500rpm) 4°C for 3 minutes and 
the pellet resuspended in 300pl of FACS buffer for analysis. The cells were 
transferred into Falcon FACS tubes (Becton Dickinson) and run on a 
FACScalibur (Beckton Dickinson). The right population was identified based on 
size and granularity and analysed for detection of specific fluorochromes.
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2.4.2 Mouse GMCSF Enzyme Linked Immunosorbent Assay (ELISA)
The supernatant from BHK, Mam49, or 106 DCs cells infected with viruses 
expressing mGMCSF or, as negative control, viruses not expressing mGMCSF, 
were collected and stored at -20°C.
50pl of sample or of standard were then tested for presence of mGMCSF using 
the Granulocyte-Macrophage Colony Stimulating Factor [(m)GM-CSF] mouse, 
Biotrak ELISA System (Amersham Biosciences) following the procedure 
suggested by the manufacturer. Briefly, samples were incubated at 37°C, 5%C02 
in plates pre-coated with anti-GMCSF antibody, the wells were then washed and 
incubated with anti-GMCSF antibody conjugated to HRP before washing again 
and developing the reaction with TMB substrate solution. The reaction was 
stopped using 0.18M sulphuric acid, and the plate read for chemiluniscence at 
450nm using a plate reader (OpsysMR-Dynex). Samples were always run in 
duplicates
Standard curves were then obtained using the values from the standard samples, 
and values extrapolated from this one.
2.4.3 Serum antibody Enzyme Linked Immunosorbent Assay (ELISA)
Coating agent Specification
Purified NP protein Influenza virus, type A (H3N2-Shangdon) 
Advanced ImmunoChemical
H2Kd B epitope PyCS (QGPGAP)3
H2Kd B epitope PySSP2 (NPNEPS)s
Table 2.6: Coating agent used for set up of ELISA for detection of antibodies in 
mouse serum
These ELISA assays were set up in 96-well Nunc-MaxiSorp plates. Each well was 
incubated overnight at 4°C with 50pl of the appropriate dilution (§ chapter 7) of
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peptide or protein in lx PBS (table 2.6). Excess coating reagent was removed by 
washing the wells three times with 200pl of ELISA wash (0.05%(v/v) Tween-20 
in 1 x PBS) and these were then blocked with lOOpl of ELISA block (3% (w/v) 
Milk, 0.05%(v/v) Tween-20 in 1 x PBS) for lhour at room temperature shaking. 
The block was removed and the wells washed three times with 200pi of ELISA 
wash before adding 50pl of serial dilution of mouse serum (§ 2.5.6) in ELSIA 
block, or anti-protein antibody at the required concentration (Table 2.1) as 
positive control. These were left shaking at room temperature for 2hours and then 
removed and the wells washed three times with 200pl of ELISA wash. The 
secondary antibody anti-mouse HRP conjugated (DAKO) diluted 1:1000 in 
ELISA wash was then added at lOOpl per well and incubated shaking in the dark 
at room temperature for lhour. Wells were again washed three times with 200pl 
of ELISA wash and then developed in the dark with lOOpl of TBS substrate/well 
at room temperature for 30minutes and the reaction stopped with lOOpl of 0.18M 
sulphuric acid. Plates were read at 450nm in a plate reader (OpsysMR-Dynex).
2.4.4 Mouse IFNy Enzyme-linked immunospot (ELISPOT) assay
2.4.4.1 ELISPOT Assay
IFNy ELISPOTS were set up to determine the presence of specifically activated 
primary/memory T cells in immunised mice. The Mouse IFN-y ELISPOT set (.BD 
Biosciences) was used according to manufacturer instructions.
Splenocytes that had been restimulated in vitro with the appropriate peptide (§ 
2.3.6) were harvested and placed in 50ml Falcon tubes. The cells were washed 
twice with HBSS by centrifuging at 32lg 5minutes at 4°C, resuspended in full 
growth medium and counted. Splenocytes were the concentrated at 106 cells/ml in 
FGM. Stimulator A20 cells were pulsed with the appropriate peptide (§ 2.3.13) 
and resuspended at a final concentration of 106 cells/ml. The ELISPOT assay was 
then assembled in plates (either from the kit, or Millipore MultiScreen Assay 
System 96 well plates 45pm- Millipore) previously blocked for lhour with 200pl 
of FGM. Three wells per sample were used. One well contained lOOpl 
corresponding to 105 splenocytes/well and two wells contained lOOpl of 5 x 10 
splenocytes/ well. Splenocytes were incubated with either lOOpl of FGM, lOOpl
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of 106 cells/ml non pulsed A20 cells, or lOOpl of 106 cells/ml peptide pulsed A20 
cells. As positive control, splenocytes were also incubated lOOpl of FGM 
containing 200ng/ml Phorbol 12-myristate 13-acetate (PMA), 20pM Ionomycin. 
Plates were left at 37°C, 5%C02 24hr and then developed according to 
manufacturers instructions. Briefly, wells were washed three times with 
350pl/well of ddH20 followed by two washes with 350pl/well of 0.05% (v/v) 
Tween-20 in PBS. 60pl/well of detection anti-IFNy antibody were added diluted 
appropriately in dilution buffer (10% (v/v) FCS in PBS) and incubated at room 
temperature for 2 hours or longer at 4°C. The detection antibody was then 
discarded and the wells washed three times with 350pl/well of 0.05% (v/v) 
Tween-20 in PBS before adding 60pl/well of avidin-HRP antibody appropriately 
diluted in dilution buffer. This was incubated for lhour at room temperature. After 
four washes with 200pl of 0.05% (v/v) Tween-20 in PBS, and two washes with 
200pl/well of PBS, lOOpl of substrate were added to each well. The substrate was 
prepared as 333pl of lOmg/ml AEC (3-amino-9-ethyl-carbazole) in DMF (N,N- 
Dimethylfomamide) to 10ml 0.1M Acetate filtered through 0.45pm filter 5pi of 
H20 2 were added per 10ml of substrate. The substrate was left for a maximum of 
lhour depending on the speed of spots development and the reaction was stopped 
by washing extensively with water. The plate was then air dried and spots counted 
on an ELISPOT reader {AID) using AID3.2 programme.
2.4.4.2 Analysis o f ELISPOT data
• Values obtained from the AID3.2 counting were checked manually for each 
well.
• The number of spots obtained from each well was calculated as spots/106 
splenocytes and averaged.
• Triplicates from incubation of different amounts of splenocytes were then 
averaged to obtain one value.
• The average number of spots obtained from each mouse from the incubation 
of the splenocytes with non pulsed A20 cells was subtracted to that obtained 
from stimulation with peptide pulsed A20.
• Final values per group of immunised mice and standard deviation was 
obtained by average of triplicate mice receiving the same immunisation.
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2.4.5 51Cr release assay
2.4.5.1 Restimulation o f splenocytes
51Cr release assay was performed on splenocytes from immunised mice. These 
splenocytes were restimulated in vitro in a slightly different manner from § 2.3.6. 
Splenocytes for 51Cr release assay were incubated together with irradiated 
splenocytes from non immunised mice, these have act as presenters of the peptide. 
Spleen cells from one non immunised mouse were prepared (§ 2.3.6) and 
resuspended in 10% (v/v) FCS in 1 x PBS in a 50ml Falcon tube. This was placed 
on ice within an X-ray machine and irradiated to 1500-3000 rad. Cells were then 
washed once with 10% (v/v) FCS in 1 x PBS, resuspended FGM and counted with 
trypan blue assay (§ 2.3.11). Irradiated cells were resuspended in FGM at 1-5 x 
105 cells /ml. The responders splenocytes from immunised mice were resuspended 
at 2-3 x 106 cells/ml and 9ml placed in a 25cm2 tissue culture flask to which 1ml 
of irradiated cells were added together with lOpM of appropriate peptide. The 
flasks were incubated upright at 37°C, 5%C02 for 5 days.
2.4.5.2 Preparation o f responder splenocytes
Cytotoxicity of the cells was measured by incubating restimulated spleen cells 
with antigen presenting cells pulsed with 51Cr. Restimulated splenocytes were 
collected, washed twice with FGM by spinning at 32lg (1300rpm) 5 minutes, 
counted and resuspended at 9 x 106cells/ml in FGM.
2.4.5.3 Pulsing o f  target cells
Target P815 cells were used at 104 cells/well and effector Target ratios started at 
90:1
Effector cells were resuspended in the appropriate volume. Two groups of target 
cells were formed, one to be pulsed with peptide atlOpM and one to be left 
unpulsed. The required number of targets were suspended in 200pl RPMI with/out 
peptide together with lOOpCi of 51Cr and incubated at 37°C, 5%C02 for lhour. 
Following this incubation, cells were washed three times in 20ml of warm RPMI 
and resuspended in RPMI 5%(v/v) FCS at a concentration of 105/ml.
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2.4.5.4 Assembly o f5ICr release assay
The test was assembled in 96-well round bottomed plates. The number of target 
cells was kept constant whereas responders were tested in serial dilutions. lOOpl 
of targets were incubated with lOOpl of responders in 1:3 serial dilutions. As 
positive control to measure the maximum 5lCr release from the target cells, these 
were incubated with lOOpl of 2.5% (v/v) Triton X-100. Test was carried out both 
for targets that had been pulsed with peptide and those that had not, and each 
sample was tested in triplicate.
The plate containing the assembled assay was spun down 2 minutes 32lg (1300 
rpm) at room temperature to pellet the cells and then placed for 4 hours at 37°C, 
5%CC>2. Following this incubation the plate was spun again 3 minutes 321 g (1300 
rpm) at room temperature and 25pi of the supernatant was transferred in 96 well 
sample counting plates (Wallac) and mixed with 175pi of SuperMix (Wallac). 
The plate was then sealed and mixed gently before being counted in a gamma 
scintillator counter {Microbile Trilux).
Percentage of killing was calculated as
(c.p.m. in presence of responders -  spontaneous 51Cr release)
  — — ___ —..     , X. 1 UU
(Total 51Cr release - spontaneous 51Cr release)
2.4.6 Neutralisation assay
This was carried out to determine the presence of anti-HSVl antibodies in the 
serum of immunised mice. The principle of this assay relies on the fact that if 
there are antibodies against the virus present in the serum, upon incubation with 
neat virus this will be neutralised, therefore resulting in the inability of the virus to 
infect monolayers of cells and form plaques.
5pl of serum from immunised mice (§ 2.5.6) were added to 45pl of serum free 
medium (DMEM) and these mixed in 96 well plates with 50pl of 200pfu/ml of 
17+47'NP/vhsVP 16', or 17+47'GMCSFNP/vhsVP16‘ in SFM. The mixture was 
left at 37°C, 5%C02 for 45 minutes before adding 200pl of SFM to each sample
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and plating it in duplicate on monolayer cells for plaque assay (§ 2.3.9.2). The 
titres obtained from the duplicates were averaged. A positive control was always 
added to the samples consisting of incubation of virus without serum from 
immunised mice, this also gave a reading of the initial titre of the virus against 
which the other samples could be compared for possible reduction.
2.4.7 Tissue processing and immunostaining
1 Opm sections of lymph nodes snap frozen in Oct embedding medium (Cell Path) 
were cut on a cryostat (.Leica) and placed on slides (§ 2.5.3)
Sections were dried and fixed in 4% paraformaldehyde (made in 1 x PBS) for 20 
minutes at room temperature. Paraformaldehyde was then removed and the 
sections washed twice in 1 x PBS before being permeabilised with 20pg/ml 
proteinase K in 1 x PBS at room temperature for 20minutes. Following this 
permeabilisation the sections were blocked for 20 minutes at room temperature 
with blocking solution (1% (v/v) FCS, lOmM Triton X-100, lOmM NaCl. The 
blocking solution was then discarded and the anti-HSVl antibody HRP 
conjugated (DAKO) was added diluted 1:100 in blocking buffer. This was left on 
the sections overnight at 4°C and then removed by washing the sections twice 
with abundant blocking buffer. The secondary antibody swine anti-rabbit HRP 
diluted 1 TOO in blocking buffer was then added on the section for lhour and then 
washed with three washes with blocking buffer. Antibody stain was developed 
with 3,3 N-Diaminobenzidine (DAB) (Sigma). DAB was made up at 1 mg/ml in 
H20 and then further diluted 1:2 in 1 x PBS. 12pl of H2O2 were added per 50ml of 
solution and placed on the slides until staining appeared. The reaction was 
stopped by washing with 1 x PBS.
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2.5 Animal procedures
All animal procedures were carried out according to Home Office regulations 
after having obtained Home Office approval an animal handling licence.
BALB/c female mice were used through out this project. 3-4 weeks old mice were 
used to obtain the bone marrow whereas 6-8 weeks old mice were used for 
immunisation purpose. All immunisation procedures were carried out on mice 
sedated under 5% Halothane
2.5.1 Injections in the footpad
6-8-week-old female BALB/c were inoculated via left footpad injection using an 
insulin needle. 106 pfu of neat virus or cells in HBSS were injected in a maximal 
volume of 25 pi.
2.5.2 Injections in flank
Female BALB/c mice received subcutaneous inoculations in the left flank. These 
were carried out using varying volumes of immunogen but usually not exceeding 
30pl.
2.5.3 Lymph nodes extraction
Mice were sacrificed and popliteal and inguinal lymph nodes were removed from 
the inoculated sides and when necessary from the controlateral side as well. These 
were placed in Oct and immediately snap frozen on dry ice and placed at -80°C 
until processed.
2.5.4 Spleen removal
At the appropriate time after immunisation the mice were sacrificed and the 
spleens removed. These were placed in HBSS and processed within the hour.
2.5.5 Blood collection by cardiac puncture
Mice were sedated using Halothane and blood was then collected by cardiac 
puncture mainly from the left ventricle, while the hart was still pumping, using an 
insulin syringe. The blood was collected in 1.5 ml tubes for extraction of serum.
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2.5.6 Extraction of serum
Serum was extracted from blood collected by cardiac puncture by centrifuging the 
blood for at least 50minutes at room temperature at 20798.5g (14000rpm). Upon 
this treatment the cells precipitate leaving a supernatant of serum. Serum was 
collected from each sample in a fresh 1.5ml tube and stored at -20°C until used. If 
planning to do more than one experiment or to repeat an experiment, aliquots 
were prepared and stored at -20°C until used.
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Chapter 3
Identification of an HSV-1 vector for 
transduction of dendritic cells
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3.1 Introduction
Herpes simplex virus 1 (HSV-1) has so far been used as a vector mainly for gene 
delivery to the nervous system. However, as it also naturally infects DC with high 
efficiency (Coffin et al., 1998, Kruse et ah, 2000, Mikloska et ah, 2001, Salio et 
ah, 1999), and with minimal replication, it can also be considered for use as a 
vector to deliver genes to DCs for the stimulation of specific immune responses. 
A successful viral vector should present properties such as efficient and specific 
infection of the target cell type, as well as limited toxicity and sufficient levels of 
expression of the delivered gene. In addition, with respect to DCs, it is important 
that the ability of DCs to stimulate an immune response is not compromised. DCs 
can naturally present antigens and stimulate an immune response against infecting 
viruses, including inactivated non replicative viruses (Banchereau et ah, 2000, 
Curran et ah, 2000). However, this is only possible if the infected cell maintains 
its capacity to mature and upregulate costimulatory molecules (eg. CD40, CD80, 
CD86) that are necessary for the interaction of DCs with T cells and for the 
migration of DC to lymph nodes.
Many viruses are able to infect DCs, often as an immune evasion mechanism. 
HSV (Salio et ah, 1999), like Sindbis virus (SIN) (Gardner et ah, 2000), and 
influenza virus (Engelmayer et ah, 1999), preferably infect immature DCs. 
However, unlike SIN and influenza, which stimulate cell maturation, HSV 
infection of immature DCs has been demonstrated to prevent cell activation 
(Kruse et ah, 2000, Salio et ah, 1999). HSV1 infected DCs also fail to produce a 
number of cytokines in response to activating stimuli, thus reducing their ability 
to stimulate T cell proliferation. Thus, in order for HSV-1 to be considered as a 
gene delivery vector for DCs, the virus must be modified appropriately such that 
DCs retain the ability to undergo their natural maturation process.
HSV1 expresses various genes to evade the immune system. For example, US 12 
encodes a protein (ICP47) which blocks the MHCI loading pathway. ICP47 is a 
cytosolic protein that binds via its N-terminus to the cytosolic peptide-binding 
domain of the human transporter associated protein (TAP) complex (Ahn et ah, 
1996, Tomazin et ah, 1996, Tomazin et ah, 1998) which normally translocates
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peptides across the ER membrane. Interference with peptide transport (a 
mechanism also used by CMV and EBV) results in empty MHCI molecules being 
retained within the ER and therefore an impaired presentation of peptides by 
MHCI. Interestingly, the effect of ICP47 has only been detected in human DC 
infection and not in mice (Tomazin et al., 1998). In addition, HSV-1 expresses 
glycoprotein C and gE/gl, which respectively block complement activation and 
bind IgG. Although all these factors are important in preventing DCs from 
triggering an immune response, none of these is responsible for the inhibition of 
DC maturation caused by infection of DCs with HSV.
The work presented in this thesis focuses on the role of the virus host shutoff 
(vhs) protein. Vhs is a 58kDa protein encoded by the UL41 open reading frame 
(Kwong et al., 1988). This enters the cell upon infection and non specifically 
degrades cellular and viral mRNAs, mainly to benefit the translation of viral 
mRNAs, which are produced in high abundance. It has previously been observed 
that potent anti-HSV immune responses are stimulated by vhs deleted HSV (Geiss 
et al., 2000, Keadle et al., 2002). In this thesis, the role that vhs plays in human 
and mouse DC maturation is investigated using both vhs+ and vhs" replication 
competent and attenuated HSV-1.
The toxicity of viral vectors is often reduced by preventing replication. HSV-1 
replication takes place accompanied by a cascade of gene expression. The 
immediate early (IE) genes (ICP0, ICP4, ICP22, ICP27, ICP47) are expressed 
first, followed by early (E) genes and finally late (L) genes. ICP4 and ICP27 are 
absolutely required for viral replication (DeLuca et al., 1985, Sacks et al., 1985) 
and deletion of either of these produces a replication incompetent virus. 
Replication incompetent HSV-1 has previously been used and shown to be 
effective for gene delivery to neurones (Coffin et al., 1996, Lilley et al., 2001). 
These are also now being investigated for DC transduction. The so called 1764 
viruses (Coffin et al., 1996) used in this thesis have y34.5 (the neurovirulence 
factor) deleted, and the in i814 mutation in VP 16 (viral transactivator) which 
inserts an in-frame linker sequence (Ace et al., 1989) to prevent its transactivation
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properties. ICP4, ICP27, ICP47 and vhs are additional deletions used in some of 
the viruses.
Less attenuated viruses in which ICP27 and ICP4 were not deleted were also used 
in the work presented. Viruses which have a VP 16 mutated are still replication 
competent. VP 16 is a structural HSV protein released into the cell upon infection. 
It then enters the nucleus with the viral genome and together with cellular factors 
transactivates the promoters of the HSV immediate early genes (Herr, 1998). As 
the protein is an essential structural component of the virion and can not be 
deleted, mutations are used which only affect its transactivating properties. The 
VP 16 mutation used here is either the V422 mutation (Lam et al., 1996, Smiley & 
Duncan, 1997), or the in i814 (Ace et al., 1989). The V422 mutation consists of 
the truncation of the C-terminal acidic activation domain by a chain termination 
mutation following codon 422. This mutation removes the majority of the C- 
terminal acidic transcriptional activation domain impairing viral replication. 
Previous studies have shown that the V422 mutation greatly reduces IE genes 
expression (Lilley et al., 2001, Mossman & Smiley, 1999, Smiley & Duncan, 
1997).
The aim of this chapter is to take advantage of the ability of HSV 1 to infect DCs 
and to develop a virus that is minimally toxic to the cells and which will allow 
infected DCs to mature and stimulate an immune response. An HSV1 vector with 
these properties might then be used for immunotherapy for a number of diseases.
All the experiments presented in this chapter were repeated at least three times 
although representative FACS profiles from only one experiment are presented.
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Viruses used in this chapter
This diagram indicates the progression of virus construction 
Specific deletions and inactivations o f each backbone are specified
X indicates inactivity of the gene either by deletion or inactivation 
* indicates the direction o f gene expression
17+
Wild type HSV strain.
ICP34.5 vhs UL43 VP 16 ICP27 ICP34.5 ICP4 ICP47 ICP4
17+CMVGFP/UL43
UL43 gene inactivation by insertion of a CMVGFP cassette.
ICP34.5 vhs UL43 VP 16 ICP27 ICP34.5 ICP4 ICP47 ICP4
17+pR20.5/UL43
UL43 gene inactivated by insertion of the pR20.5 cassette 
(Thomas, Lilley et al. 1999) The LAP2 region is kept because it 
allows better expression of both promoters in neuronal cells
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
GFPCMVRSV LAP2 pR20.5 cassetteLacZ
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17-‘-pR20.5/vhs
vhs gene disrupted by insertion of the pR20.5 cassette
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
r s v  L a p 'T T m v H M M ILacZ
17+vhs~CMVGFP/UL43 
vhs gene deleted
UL43 gene disrupted by insertion of a CMVGFP cassette 
ICP47 gene deleted
ICP4 ICP47 ICP4ICP34.5 vhs UL43 VP16 ICP27 ICP34.5
( M V  I fe j& IP
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17+vhs-IRESGF? V P16
vhs gene deleted
VP16 gene with V422 mutation and insertion of IRES GrP cassette 
ICP47 gene deleted
ICP34.5 vhs UL43 VP16 1CP27 ICP34.5 R T 4  K P 4  7 R P 4
IRES
1.74~vhs~47'CM¥  GFP/U S5 VP 16"
vhs and ICP47 genes deleted 
VP 16 with V422 mutation
US5 inactivated by insertion o f a CMVGFP cassette 
ICP47 gene deleted
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 US5 ICP47ICP4
XIX
CMV
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1764 27-4-
ICP4, ICP27 and ICP34.5 genes deleted 
in 1814 mutation of VP 16
ICK34.5 vhs UL43 VP16 1CP27 ICP34.5 ICpt" US5 ICP47 I^P4
X X X X X X
1764 27'4'vhs'
ICP4, ICP27, ICP34.5 and vhs genes deleted 
ini814 mutation of VP 16
10^4.5 vhs UL43 VP 16 ICP27 I?P34.5 10^4 US5 ICP47 I(?P4
IX X X X X X XI
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3.2 Infection of human DC with replication competent HSV-1
3.2.1 Efficiency of infection of DC with 17+ and 17+pR20.5/UL43
The first requirement for a viral vector is to infect target cells, efficiently while 
avoiding toxicity. HSV 1 has previously been shown to infect DCs efficiently 
(Coffin et al., 1998, Kruse et al., 2000, Mikloska et al., 2001, Salio et al., 1999). 
Here, wild type 17+ and a 17+ viruses expressing the marker gene GFP inserted in 
the non-essential gene UL43 (Thomas et al., 1999) were tested for infection of 
human DCs. Two different GFP expressing viruses were used: one in which GFP 
driven by CMV is inserted into the UL43 gene, and the second one in which the 
GFP gene is expressed from the pR20.5 cassette inserted into UL43. The 
percentage of infected cells at MOI 1 was then determined by FACS, looking at 
the percentage of anti-HSV stained cells as well as at the percentage of GFP 
fluorescent cells where possible (17+ CMVGFPAJL43 and 17+pR20.5/UL43). It 
appeared that wild type HSV-1 is able to infect up to -80% of human DCs at an 
MOI of 1 (figure3.1) and that this percentage is not affected by the presence of a 
marker gene. In addition, it was noticed that, staining for anti-HSV gives slightly 
higher numbers of infected cells than is evident by measuring GFP fluorescence.
Infection of human DCs with 17+ at an MOI 1 is non productive (figure 3.2). 
Although some infectious viral particles appeared to be produced between 20hr 
and 24hr post infection, the total amount of viral particles revealed never reaches 
the initial input levels and continuously decreases after 24hr post-infection.
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Figure 3.1: Infection of DC with HSV-1
Percentage of infected cells as determined by FACS analysis of anti-HSV 
stained cells and by GFP expression. Infected cells (green lines) are 
compared to non infected cells (black lines)
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Figure 3.2: Growth characteristics of HSV-1 in DC
Growth curve of HSV-1 strain 17+ in human DCs infected at an MOI of 1.
The yield was determined by titration on BHK cells at the indicated time 
points.
Ohr value corresponds to the amount of virus used to infect the cells, this was 
obtained by titration of the virus put on the cells. This is not the titre obtained 
from the supernatant immediately after putting on the cells.
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3.2.2 Efficiency of infection of DC with 17+pR20.5/vhs
HSV-1 infection is known to interfere with DC maturation (Kruse et al., 2000, 
Salio et al., 1999). In order to determine the possibility that vhs may play a role in 
blocking DC maturation, 17+ viruses differing only for the presence or absence of 
functional vhs were tested. Inactivating vhs by insertion of a pR20.5 expression 
cassette still gave -80% infection, implying that removing vhs had no effect on 
the ability of the virus to infect DC (figureS.3). As previously noticed, looking at 
GFP fluorescence, three populations were found, two of which can be considered 
positive, and taking both of them into account (as previously suggested as being 
the most accurate method), 76% of cells resulted infected. This result relates well 
with the -80% previously found for wild type virus infection.
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Figure 3.3: Infection of DC with vhs-HSV
Percentage of cells infected with 17+pR20.5/vhs at MOI1 according to GFP 
fluorescence (green). Negative control is non infected cells (black).
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3.2.3 Effect of 17+pR20.5/vhs on DC maturation
The role that vhs plays on DC maturation was investigated by comparing the level 
of expression of cell surface markers (CD40, CD80, CD86) on cells that had been 
infected with 17+ or 17+pR20.5/vhs at an MOI 1 and then stimulated with LPS.
As expected, infection with 17+ prevented DC maturation (figure 3.4 and 3.5). 
Infection of DC with 17+ resulted in similar marker expression levels as mock 
infected cells, indicating that the cells remained immature. Infection with 17+ 
pR20.5/vhs, on the other hand, clearly improved the ability of the cells to undergo 
maturation (figure 3.4 and 3.6). The profiles in this case showed a second 
population corresponding to mature cells. CD40 was upregulated to a greater 
extent. However, interestingly, CD86 showed two clear populations representing 
both the level of expression on immature and mature cells, indicating that 
although some maturation was occurring, inhibition had not been completely 
overcome. These experiments using wild type viruses with or without vhs clearly 
demonstrated that vhs alone plays a major role in the prevention of DC 
maturation. This work has subsequently been published in (Samady et al., 2003).
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Figure 3.4: Effects of vhs on DC maturation
Histograms represent the level of expression of costimulatory molecules on 
human DC after 24hr infection at MOI1 with the specified viruses and LPS 
stimulation.
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Figure 3.5: Inhibition of Dc maturation by HSV
Inhibitory effect of 17+ infection (green) on the level ot expression of 
costimulatory molecules on human DC compared to the expression levels on 
non infected immature cells (black) and on non infected LPS mature cells 
(pink).
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Figure 3.6: Effects of 17+pR20.5/vhs on DC maturation
Marker expression on human DCs stimulated to mature after infection at 
MOI1 with 17+pR20.5/vhs (green), and comparison with the expression 
on immature cells (black) and on LPS matured cells (pink).
CD40 CD80 CD86
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3.3 Infection of human DC with replication incompetent HSV-1
3.3.1 Efficiency of infection of DC with 1764 27-4- and 1764 27-4-vhs-
Replication incompetent viruses have previously been shown in our laboratory to 
have a beneficial effect on cell viability (Samady et al., 2003) as compared to 
replication competent viruses. The effect of removing vhs from viruses of this 
type was therefore investigated further. Two 1764 replication incompetent viruses 
both lacking the immediate early genes ICP27, ICP4, as well as ICP34.5 and with 
the in i814 mutation in VP 16 but differing for the presence of the vhs gene were 
compared.
Although, as previously found with 17+ viruses, removal of vhs did not affect the 
efficiency of infection (figure 3.7), making the virus replication incompetent 
reduced its infectivity from -80% (17+pR20.5/UL43) to -57% (replication 
incompetent viruses), as determined by anti-HSV stain FACS analysis. The level 
of infection, though reduced, was still quite high as compared to other vector 
systems for DCs. It was therefore important to examine whether removing vhs 
from these vectors also had the beneficial effect previously seen using wild type 
HSV.
3.3.2 Effect of 1764 27-4- and 1764 27-4-vhs- on DC maturation
DCs were infected with the replication incompetent viruses with or without vhs, 
and the effect of vhs on cell surface maturation markers expression was assessed 
after LPS stimulation (figure 3.8-3.10). Here the CD40, CD80 and CD86 profiles 
from DC infected with the 1764 vhs+ virus (figure 3.9) more closely overlap those 
from non infected immature cells than those from mature cells. Thus, simply 
making the virus the replication incompetent virus does not prevent the block that 
HSV-1 causes to DC maturation.
Removing vhs from an already disabled virus, on the other hand, (figure 3.8 and 
3.10) largely prevents the virus from interfering with the DCs normal maturation 
process. CD40 and CD86 in particular, showed complete overlap of the peaks 
from infected cells with those of mock infected LPS matured cells.
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These results demonstrate that vhs is a key factor in preventing DC maturation 
upon infection with either replication competent or replication incompetent 
HSV1.
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Figure 3.7: Infection of DC with replication incompetent HSV
Effect of removing vhs from replication incompetent viruses on the 
efficiency of infection. Percentage of infection was determined by FACS 
analysis of anti-HSV stained cells. Ceils infected with the specified virus 
at an MOI of 1 for 24hr and stained for anti-HSV (green line) are 
compared to equally treated non infected cells (black line).
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Figure 3.8: Effect of removing vhs from replication incompetent 
viruses
The level of expression of maturation markers on infected human DC. 
Cells were infected at MOI1 with the specified viruses and stimulated 
with LPS 24hr.
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Figure 3.9: Effects of vhs+ replication competent viruses on DC 
maturation
Level of expression of maturation markers on human DC after infection 
with 1764 27-4- and LPS stimulation 24hr (green), compared to the level 
of expression on immature mock infected cells (black) and on LPS 
matured mock infected cells (pink).
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Figure 3.10: Effects of vhs- replication incompetent viruses on DC 
maturation
Level of expression of maturation markers on human DC after infection 
with 1764 27-4- vhs- and LPS stimulation 24hr (green), compared to the 
level of expression on immature mock infected cells (black) and on LPS 
matured mock infected cells (pink).
CD40
O*-------------
CD80 CD86
1SR
3.4 Optimisation of HSV-1 vectors for the transduction of mouse bone
marrow derived dendritic cells (BMDO
3.4.1 Infection of mouse BMDC with 17+vhs'47'
To be able to conduct in vivo immunity studies in mice using HSV-1 vectors, as 
for human DC, it was important to identify a virus able to infect mouse bone 
marrow DCs efficiently without disrupting their ability to mature and to induce an 
immune response. The bone marrow contains precursors to a number of cell types, 
and different cells and DC subtypes develop depending on the cytokines present 
in the medium. BMDC cells cultured under GMCSF stimulation, lead to 
production of C D llc+ myeloid DCs able to induce IFN-y mediated immune 
responses. In order to identify the minimally deleted virus needed, differently 
deleted replication competent viruses were tested for the efficiency of infection 
and toxicity in immature mouse BMDC.
The studies conducted on human DCs demonstrated that disruption of the vhs 
gene is an important factor in allowing maturation of infected cells. Equally, 
removing vhs did not make a difference to the ability of the virus to infect mouse 
BMDC (figure 3.11). As ICP47 impairs MHCI peptide loading, 17+vhs‘47'might 
provide an ideal virus backbone to stimulate immune responses. To allow easy 
detection of infection, GFP driven by a CMV promoter was inserted in UL43 
(17+vhs'47‘CMVGFP/UL43). Deletion of vhs has previously been shown not to 
change the virus ability to infect DCs. Similarly, removing the US 12 (ICP47) 
gene should not influence infection but should increase antigen presentation on 
MHCI molecules.
Cells were infected with 17+ pR20.5/vhs or with 17+vhs‘47' and the percentage of 
infected cells was then determined by FACS (percentage of green fluorescent 
cells) (figure 3.11). Around 55% of cells became infected when ICP47 was 
present and — 60% when the gene was removed. ICP47 deletion therefore does not 
appear to compromise the ability of the virus to infect DCs. In addition, these 
results suggested that the virus infects mouse DC with lower efficiency than 
human DCs where —80% of cells were usually found to be infected.
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The specificity of the cell type infected was tested using 17+vhs' 47’. This resulted 
in -60% of the cells within the preparation being infected (GFP+), practically all 
of which (56%) expressed CD1 lc+(figure 3.11). The CD1 lc' infected cells (5.5%) 
were thought to probably still be in the precursor stage. Non infected cells (-22%) 
can be accounted for by the fact that the method of culture did not include any 
depletion or enrichment stage, and these cells are therefore probably other types of 
monocytes. If only C D llc+ cells are taken into account (making the population 
comparable to that obtained for human DCs), -79% of cells were infected. It can 
therefore be concluded that the virus infects mouse DCs as efficiently as human 
DCs but that the lower percentages obtained were probably only due to 
differences in the purity of the initial population. As 17+vhs'47‘ virus infected well 
and specifically, this was therefore characterised further in mouse BMDC 
infection.
3.4.2 Characterisation of 17+vhs-47- infection of BMDC
The 17+vhs-47- virus was found to efficiently infect BMDCs to an MOI as low as 
0.2. Although the percentage of infected cells remained similar within the MOI 
range 0.2-1 (figure 3.12), the GFP intensity increased constantly, indicating the 
rise in the number of viral particles producing GFP per cell. This further 
demonstrated good infectivity for DCs. Because in the construction of a gene 
delivery vector strong expression of the recombinant gene is important, an MOI1 
was used for subsequent experiments.
HSV-1 is not known to replicate within DC and both 17+ and 17+vhs 47 , though 
being replication competent, were found to infect non productively (Figure 3.13 
a,b). In addition, cells infected with the 17+vhs'47' virus maintained relatively 
high viability (75%) 24hr post-infection as measured by the trypan blue exclusion 
assay (Figure 3.13c). 17+vhs-47- therefore appeared to provide a promising vector 
for use with mouse BMDC.
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Figure 3.11: Effect of removing vhs and/or ICP47 on the ability of 
HSV-1 to infect BMDC.
Histograms showing the percentage of BMDC expressing GFP after 
infection at an MOI of 1 with 17+virus containing GFP (17+GFP/UL43), 
virus containing ICP47 but with vhs deleted (17+ pR20.5/vhs) or virus 
where ICP47 and vhs have been removed (17+ vhs' 47 GFP/UL43). The 
marker indicates the level of fluorescence under which cells are 
considered non fluorescent, this was set according to the profile of non 
infected cells.
Dot plot of C D llc  stained 17+vhs'47 GFP/UL43 infected BMDCs at 
MOI1, specific percentages indicate non C D llc  infected cells and 
infected CD1 lc+
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Figure 3.12: Efficiency of infection of 17+vhs"47*CM VGFP/UL43 at 
different MOIs
Values presented are the average o f two or three samples.
(a) Percentage of BMDCs expressing GFP after infection at different 
MOIs with 17+vhs'47'GFP/UL43 for 24hr.
(b) Difference in GFP intensity expression upon BMDC infection at 
different MOI.
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Figure 3.13: Assessment of the ability of HSV-1 vectors to replicate 
within mouse dendritic ceils.
Growth curves of 17+ (a) and of 17'Kvhs-47-CMVGFP/UL43 (b) in 
BMDCs infected at an MOI of 1 compared to growth of the same viruses 
on Mam49 on which the virus is usually grown. The yield was 
determined by titration on Mam49 cells at the indicated time points. 
Toxicity of 17+vhs-47-GFP/UL43 on BMDC (c) measured by trypan blue 
exclusion assay, the value shown is the average of three counts of the 
same sample.
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3.4.3 The effect of 17 and 17+vhs 47 infection on DC maturation
17 vhs 47 was shown to efficiently infect BMDCs without apparent toxicity. 
However, it was also important to determine whether the deletions to this virus 
were sufficient to allow DC maturation. Initially, the effect of the virus alone was 
investigated. DCs were infected at MOI 1 with 17+GFP/UL43 or 1T  vhs' 47' and 
the levels of surface markers CD40, CD80 and CD86 expression on the infected 
cells were compared to those of non infected immature or LPS stimulated cells 
(Figure 3.14). In LPS matured cells CD40 seemed to be the most highly 
upregulated marker (-60% of cells), although 30% and 40% of cells also showed 
upregulation of CD80 and CD86 respectively. Looking at the immature cells, it 
appeared that there was between 5-8% of mature cells already present in the 
population, probably due to cell manipulation.
Infection of BMDCs with 17+ GFP/UL43 or 17+vhs-47- did not induce the cells to 
mature as the markers profiles largely overlaid those of the immature cells (figure 
3.15), and as considered by the percentages of cells expressing high levels of 
CD40, CD80 and CD86 (Figure 3.14). -10% of cells appeared to be mature after 
17+GFP/UL43 infection, this being very similar to the percentage obtained from 
immature cells (see above), and showing that wild type virus infection does not 
appear to induce cell maturation. Similarly, removing vhs and ICP47 form the 
virus backbone did not change the effect of the virus on DC maturation, 
percentages and profiles ware again similar to the ones obtained after 
17+GFP/UL43 infection (Figure 3.14 and 3.16). These results were not entirely 
surprising since, in vivo too, it is not only antigen uptake or cell infection itself 
that induces cell maturation. The environment created around the infected cell is 
usually responsible for initiating maturation, which reaches completion upon 
arrival of the cell in the LN. The ability of infected cells to undergo maturation 
and effects of the deletions were therefore investigated after LPS stimulation.
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Figure 3.14: Effect of virus infection and deletion of vhs on BMDC 
surface marker expression.
Percentages refer to the number of cells that have upregulated markers 
with same or similar intensity to mature cells.
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Figure 3.15: Effect of 17+GFP/UL43 infection of BMDC on the level 
of expression of m aturation m arkers
Level of expression of maturation markers on BMDC after infection 
with wild type 17+GFP/UL43 (green), compared to the level of 
expression on immature mock infected cells (black) and on LPS 
matured mock infected cells (pink).
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Figure 3.16: Effect of 17+vhs"47" infection of BMDC on the level of 
expression of m aturation m arkers
Level of expression of maturation markers on BMDC after infection 
with 17+vhs"47' (green), compared to the level of expression on 
immature mock infected cells (black) and on LPS matured mock 
infected cells (pink).
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3.4.3 Effect of 17+ and 17+vhs'47‘ infection on the ability of DC to mature 
upon LPS stimulation
To investigate the possibility that the inhibitory effect of HSV-1 could be 
overcome by the 17+vhs-ICP47- mutant, and to parallel as much as possible the in 
vivo situation, cells were infected and then induced to mature with LPS before 
measuring the level of expression of maturation markers expression. This 
treatment should give an indication of the role that vhs plays in DC maturation, 
and mimic the situation of direct virus injection in that, upon injection, the virus 
should target the immature DCs present around the site, this, plus the surrounding 
environment should then trigger cell maturation and travelling to the LN, with 
induction of an immune response.
Immature DCs were infected at MOI1 with 17+GFP/UL43, 17+vhs'47‘ or mock 
infected, and then induced to mature by culturing in presence of LPS. Cell 
maturation was again assessed by FACS analysis, comparing the level of 
expression of surface markers CD40, CD80 and CD86 of infected cells with non 
infected cells.
As for human DCs, infection of BMDCs with 17+GFP/UL43 virus prevented the 
cells from undergoing maturation, showing FACS profiles and percentages of 
mature cells (Figure 3.17 and 3.18) practically identical to those of immature cells 
(-6%). Removing vhs and ICP47 from the virus, interestingly, improved the 
response of the infected cells to LPS (figure 3.17 and 3.19) showing both CD40 
and CD86 upregulation in —20% of the population. Not much upregulation was 
noticed in this experiment for CD80, though an improvement could still be seen. 
These percentages clearly showed an improvement compared to wild type virus 
infection and similarly, the profiles resembled more those of mature rather than 
immature cells (Figure 3.19). In addition it can be seen (figure 3.20) that the cells 
that show marker upregulation are not only those which are not infected, but most 
of the infected cells are able to mature.
Overall, as previously found for human cells, removing vhs seemed to have a 
beneficial effect on the ability of infected DC to undergo maturation, although
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complete identity of profiles of matured infected and non infected cells was not 
yet achieved suggesting further virus attenuation might be required.
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Figure 3.17:LeveI of expression of costimulatory molecules on 
infected BMDC stimulated with LPS
Expression of costimuiatory molecules on BMDC infected at MOI1 with 
the specified viruses and stimulated to mature with LPS The effect of 
removing vhs can be specified looking at the percentages which indicate 
the amount of mature cells present in the population after the different 
treatments.
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Figure 3.18:Effect of 17+GFP/UL43 infection on BMDC maturation
Effect of wild type 17+GFP/UL43 infection on BMDC ability to undergo 
maturation upon LPS stimulation. Level of markers expression on BMDC 
infected at MOI1 and LPS stimulated (green) compared to level of 
maturation markers expression on immature cells (black) and on mature 
cells (pink).
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Figure 3.19: Effect of 17+vhs'47‘ infection on BMDC maturation
Level of costimulatory molecules expression on BMDC infected at 
MOI1 with 17+vhs‘47~ and stimulated with LPS (green) compared to 
immature cells (black) and to mature cell (pink) levels.
172
CD80 CD86
LPS
00
Q
CJ
ooo
Q
O
17+vhs-47-GFP/UL43 
+ LPS
CM C
O '
: 65°/ /0
mw
l  j  m iiii  1 111'lVI 1 1 l l l l  1 1 1 11 IB
O
o
75°/ )
m m  1T in w  'm i iB  i t i  \ 11J
1 0 ' in1 irr in' 
FL1-H
10 1 0 ' 10' 104 10' 
FL1-H
10
• .2 0 %
m m
CM O t cm O  1
JcL
HTflmnMh-n 7,0//°
1 0 ’ 10"  10 
FL1-H
10 10- 
FL1-H
GFB.
Figure 3.20: Expression of CD80 and CD86 in 
infected cells.
Dot plots showing simulateous expression of GFP 
(FL1) and CD80 and CD86 markers (FL2) on non 
infected mature mouse BMDC (LPS) or BMDS 
infected with 17+vhs-47-GFP/UL43 and 
sitmulated to mature with LPS.
3.5 Infection of mouse BMDC with 17+vhs~47~VP16~
3.5.1 Infection of BMDC with 17+vhs‘47‘ VP16"
In human DC it was found that better cell maturation was achieved after infection 
with replication incompetent viruses. Therefore, further attenuated backbone, 
though replication competent was tested on mouse BMDCs. This virus was 
mutated for VP 16 as well as vhs and ICP47. The mutation in VP 16 present was 
the V422 mutation (Lam et al., 1996, Smiley & Duncan, 1997), different from the 
mutation present in 1764 viruses previously used as the transactivation domain is 
completely removed rather than only disrupted (Ace et al., 1989)(§3.1).
The virus used was 17+vhs'47' IRESGFP/VP16" in which GFP following an IRES 
sequence is inserted within the mutated VP 16 gene. Infection of DCs with this 
virus made detection of infected cells very difficult since GFP was only very 
weakly expressed in DCs. Expression of GFP from this site was also weak in 
complementing cell lines (Mam49) (figure 3.21). Failure to detect green 
fluorescence, made it necessary to attempt to detect the level of infection by 
antibody staining for HSV, however, unlike for human cells, non-specific binding 
of the anti-HSV antibody prevented this. Thus, finally, a virus of the same 
backbone but with GFP expressed from a CMV promoter inserted in the US 5 
gene (encoding for the viral glycoprotein gJ) was used. 17+vhs'47* 
CMVGFP/US5VP16‘ had increased, though still relatively faint fluorescence 
(figure 3.22), suggesting that mutation of VP 16 may affect gene expression, 
although a virus with GFP expression from UL43 as for the previous viruses was 
not constructed to allow a definitive conclusion to be drawn.
Using 17+vhs‘47‘GFP/US5VP 16* it was possible to detect infected cells both by 
fluorescence (Figure 3.22a) and by FACS (figure 3.22b). Infection with 17 vhs 
47‘VP16‘ led to -80% infected cells, indicating that unlike in human cells where 
the 1764 viruses had reduced infectivity, the additional VP 16 mutation does not 
influence BMDC infectivity in mice. Indeed, as previously —60% of the total 
population of cells were infected, it appears that the attenuated vector infects 
mouse BMDC better than 17+vhs~47*, possibly due to reduced toxicity. Similarly 
to 17+vhs*47" virus, this virus did not replicate in DCs (Figure 3.23a). Confirming
174
Figure 3.21: Weak GFP expression from 17+vhs'47'VP16" infected 
Mam49 cells
40X magnification of plaque formed following 17+vhs'47‘VP 16' virus 
infection of Mam49 cells.
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Figure 3.22: Infection of BMDC with 17+vhs 47 CMVGFP/US5 
VP16
(a): 40X BMDC infected MOI 1 with 17+vhs-47-CMVGFP/US5 VP 16 \  
The two images represent the same field photographed under white light 
and fluorescent light to show simulateneously (i) total cells and (ii) 
infected cells expressing GFP. Comparison of (i) and (ii) indicates 
efficiency of virus infection.
(b): FACS data of BMDC infected at MOI 1 with 17+vhs'47' 
CMVGFP/US5 VP 16". Histograms show the percentage of CD1 lc+ cells 
in the population and the percentage of green, infected cells; the dot plot 
incorporates the two histograms indicating specificity of infection for 
CD1 lc+ cells.
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the assumption that the VP 16 mutated virus might be less toxic to BMDC (figure 
3.23b), up to -90% of cells remained viable until 48hr post infection with 17+vhs‘ 
47 VP16 as determined by trypan blue exclusion assay, compared to the —75% 
obtained 24hr after 17+vhs"47’ infection (see fig 3.13). Overall, similarly to the 
situation with human DC infected with replication incompetent viruses (Samady 
et al., 2003), impairing viral replication by mutating the VP 16 gene, resulted in a 
vector which retained good infectivity, but with reduced toxicity.
VP16- virus growth curves in different cell types
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Figure 3.23: Characteristics of 17+vhs'47 IRESGFP/VP 16 infection of 
BMDC
(a) Growth curve of 17+vhs'471RESGFP/VP16' in BMDC (blue) infected 
at an MOI of 1, compared to the growth curve in Mam49 (pink). Yield was 
determined at the time points indicated by titration on Mam49 cells.
(b) Toxicity of 17+vhs"47'IRESGFP/VP16' in BMDC as determined by 
trypan blue assay, values used are the average of three counts of same 
sample.
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3.5.2 Effect of 17+vhs"47"VP16' on DC maturation
17+vhs’47‘VP16’ vims infected BMDC efficiently, did not replicate, and seemed 
minimally toxic. The effect of vims infection on cell maturation was therefore 
also investigated. For the following experiments, the 17+vhs’47TRESGFP/VP16' 
vims was used. Immature BMDC were infected at MOI1 and the expression 
profiles of the cell surface maturation markers were assessed by FACS 24hr post­
infection. Interestingly, and differently from what previously found with other 
backbones, infection alone was able to stimulate a certain degree of maturation 
(figure 3.24 and 3.25). Percentages of upregulated markers (figure 3.24) as well as 
the markers profiles (Figure 3.25) clearly showed a greater similarity to the 
mature cells rather than the immature ones. It therefore appeared that 17+vhs'47’ 
VP 16’ can infect DCs without inhibiting activation, as is the case for wild type 
HSV. This suggested that upon LPS stimulation, the cells might be able to 
become fully matured.
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Figure 3.24: Effect of with lTV hs^V Plh" infection on BMDC 
maturation
Level of expression o f maturation markers on BMDC after infection 
at MOI1 with 17+vhs~47VP 16' as compared to treatment with LPS.
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Figure 3.25: Effect of 17+vhs~47VP16 infection on BMDC 
maturation m arkers
Level of maturation markers expression on BMDC after 17+vhs 47~VP16' 
infection (green), compared to the level of expression on immature 
uninfected cells (black) and on LPS mature uninfected cells (pink).
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3.5.3 Effect of 17+vhs'47‘VP16‘ infection on DC maturation with LPS 
stimulation
As for the other backbones, the effect of the vhs- virus with the additional VP 16 
mutation was assessed on the ability of infected DC to mature upon LPS 
stimulation. Immature BMDCs were infected at MOI1 with 17+vhs'47'VP16* and 
then cultured in presence of LPS, before measuring the level of CD40, CD80 and 
CD86 on the cell surface. The percentages of cells expressing high levels of 
maturation markers (Figure 3.26) were similar to those previously obtained upon 
virus only infection (-35% for CD40, 11% for CD80, 28% for CD86). Overlaying 
the profiles of mature cells with those of infected matured cells for each marker 
(Figure 3.27) demonstrated a very similar profile, indicating undisrupted DC 
function by this measure.
The 17+vhs'47'VP 16‘ virus gave good infectivity without interfering with DC 
maturation and therefore is a good candidate for use for delivery of antigens to 
DC for immunotherapeutic studies. In the in vivo situation it might be expected 
that injection of infected DCs or this virus should allow the cells to mature and 
travel back to the LN, unlike the previous viruses. This would be expected to 
trigger an immune response to both the virus and the products of the genes carried 
by it.
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Figure 3.26: Level of maturation marker expression on BMDC infected with 
17+vhs"47VP16at MOI1 and stimulated with LPS.
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Figure 3.27: Effect of 17+vhs‘47 VP16‘ infection on maturation
Level of costimulatory molecules expression on the surface of BMDC 
infected with 17+vhs'47'VP16' (green) and stimulated to mature, 
compared to the levels found on untreated BMDC (black), or uninfected 
LPS mature BMCD (pink)
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3.6 Discussion
This chapter aimed at further investigating previous results using human DCs and, 
based on these, to define an optimal HSV-1 vector for gene delivery to mouse 
BMDC. For DCs to be used as vectors to stimulate an immune response, they 
must present antigens and undergo maturation with upregulation of surface 
markers. This allows DCs to travel to lymph nodes and interact with T cells. 
Here, vhs has been identified as a factor playing a major role in preventing both 
human and mouse DC maturation upon HSV-1 infection. The use of replication 
incompetent (for human DCs) or VP 16- (for mouse BMDC) backbones has been 
found to be necessary to completely overcome the HSV-1 mediated maturation 
block.
HSV-1 seems to have naturally evolved to infect DC as an immune evasion 
mechanism and indeed highly efficient infection was obtained both in human and 
mouse DC, using either wild type or attenuated vectors. As previously reported, 
HSV-1 was shown to infect both human and mouse DCs non productively. 
Although there is a small amount of viral particles produced ~24hr post infection 
of human DC which is in agreement with other studies (Albers et al., 1989, Kruse 
et al., 2000, Mikloska et al., 2001, Pollara et al., 2003, Sarmiento & Kleinerman,
1990), there is an overall steady decrease in virus titre. The mechanism of
immune evasion by infection of DCs is not unique to HSV1, but different viruses 
behave differently within these cells. Similarly to HSV1, vaccinia virus
(Engelmayer et al., 1999), as well as influenza virus (Lopez et al., 2000) have
been shown to abortively infect DCs, whereas Dengue virus (Ho et al., 2001, 
Libraty et al., 2001) and measles virus(Bhardwaj, 1997), can replicate within 
them. In addition, as an immune evasion mechanism, infection with measles virus 
(Grosjean et al., 1997) as well as vaccinia virus (Engelmayer et al., 1999) impairs 
the cells ability to mature, whereas infection with Dengue virus (Libraty et al.,
2001) or influenza virus (Celia et al., 1999) do not prevent maturation.
It is still not clear what effect wild type HSV1 infection has on human DC. 
Controversial studies have reported both no effect on costimulatory molecules 
(Salio et al., 1999), cell maturation (Pollara et al., 2003), or even decreased
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surface markers expression (Mikloska et al., 2001) upon infection, with 
differences occurring within an infected culture between the cells that do get 
infected and those that do not. Previous results from our laboratory (Samady et 
al., 2003) suggested that no effect is seen on infected human DC surface markers 
expression, and mouse DCs have now been shown to behave similarly. This 
supports the findings that contrarily to type I IFN producing DC (CD1 lc+CDl lb' 
B220+), myeloid BMDC (C D llc+ C D llb+ B220') do not respond to infection 
(Gilliet et al., 2002).
The response of the cell to virus infection and the ability of the cell to undergo 
maturation upon stimulation need to be considered separately. Although there is 
controversy over the first point, it is accepted (Pollara et al., 2003, Salio et al.,
1999) that HSV infected DCs are prevented from undergoing maturation upon 
LPS stimulus, and infected mouse DC have now been shown to respond similarly. 
Interestingly, the impairment is not limited to the maturation process, but can also 
affect the T cell stimulatory capacity of already mature DC, (Kruse et al., 2000, 
Pollara et al., 2003, Salio et al., 1999).
The exact mechanism by which HSV 1 prevents infected DCs from maturing upon 
LPS stimulation is still not understood, but it affects both cytokine release and 
surface molecule (MHC and maturation markers) upregulation. ICP47 and vhs are 
known to be involved in interfering with MHCI and MHCII presentation 
respectively. Considering that ICP47 does not interfere with mouse cell antigen 
presentation (Hill et al., 1995, Tomazin et al., 1996), the effect of removing this 
gene was only investigated from the infectivity point of view, and the slight 
improvement in maturation seen in BMDC upon infection with a 17+47-vhs- virus 
can therefore probably be attributed to the removal of vhs.
Vhs has been identified as a key mediator in blocking DC maturation as removing 
vhs from wild type virus improved both human and mouse cells ability to respond 
to LPS stimulation and making the virus replication incompetent had no beneficial 
effect unless vhs was also deleted. This finding is not surprising considering the 
known functions of vhs and the role it plays in anti-HSV immune responses. Vhs 
has been categorised as an RNase or as a required subunit of an RNase complex
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(Elgadi et al., 1999, Everly et al., 2002, Krikorian & Read, 1991, Sorenson et al., 
1991, Zelus et al., 1996) and it specifically degrades mRNAs (Krikorian & Read, 
1991, Kwong & Frenkel, 1987, Oroskar & Read, 1989, Zelus et al., 1996) 
probably by targeting translation initiation factors such as eIF4 (Feng et al., 2001). 
Vhs initially degrades both host cell mRNAs preventing peptide presentation and 
viral mRNAs favouring transition to expression of viral genes from later phases. 
Vhs activity is later blocked by binding to VP 16 thus allowing undisturbed viral 
mRNA transcription and translation, and viral replication (Lam et al., 1996, 
Smibert et al., 1994, Weinheimer et al., 1992).
Vhs, in addition to ICP47, has been shown to interfere with MHCI presentation, 
but by inhibiting de-novo protein synthesis (Hill et al., 1994, Tigges et al., 1996). 
It also seems to be responsible for downregulation of MHCII chain presentation in 
glioblastoma cell by preventing MHCII chain formation (Trgovcich et al., 2002). 
Taken together these results agree with the findings that vhs may be responsible 
for preventing costimulatory molecules upregulation and suggest that this would 
be due to inhibition of maturation marker synthesis.
Because of the ability of vhs to interfere with peptide presentation, vhs' viruses 
have mainly been studied as candidates for therapeutic or prophylactic vaccines 
against HSV1. Removing vhs from a replication incompetent (ICP8-) virus 
allowed stronger humoral and cellular responses against HSV1 comeal infection 
in a prophylactic vaccine (Geiss et al., 2000). Similarly, Keadle et al (Keadle et 
al., 2002) have found that removing vhs from either ICP8- viruses or wild type 
vims used as therapeutic vaccine, induced a stronger antibody response. 
Removing vhs therefore allows stimulation of a better immune response, in 
agreement with the fact that vhs- viruses interfere less with DC activity.
Vhs, therefore, plays a significant role in HSV-1 immune evasion, which seems to 
include prevention of maturation of infected DC. From our results it appears that 
vhs is not the only factor interfering with DC maturation, and the use of 
replication incompetent viruses seem to be necessary to completely overcome the 
maturation block in human cells, indicating that one of the IE genes may also 
takes part in the inhibition process. As replication incompetent vhs- HSV-1
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vectors are non pathogenic, and can not reactivate from latency (Smith et al.,
2000), these vectors appear good candidates for use in immunotherapy. 
Interestingly, in BMDC, the V422 mutation of the VP 16 activation domain gave 
similar beneficial effects as for replication incompetent viruses in human DC. 
Less disabled viruses were not tested on human DC.
VP 16, like vhs, is present in the tegument of the virus and is injected into the cell 
upon infection. VP 16 is a viral transactivator, responsible for the formation of the 
initiation complex that triggers IE gene expression for lytic viral infection 
(Batterson & Roizman, 1983). Inactivation of VP 16 is expected to attenuate the 
virus enough to render it safe and to reduce further replication, without having to 
delete additional immediate early genes. ICPO can usually take over IE genes 
activation upon VP 16 inactivation (Mossman & Smiley, 1999), but the vhs'VP16‘ 
virus was still unable to replicate in BMDCs, accounting for a significantly 
attenuated virus.
BMDC infection with a vhs'VP16’ backbone was less toxic to the cells, which, 
together with the other beneficial effects of this virus, are not due to reduced 
infectivity. Expression of recombinant genes from the VP 16 locus was found not 
to be very efficient, but inactivation of the transactivation domain did not seem to 
affect the virus ability to infect DCs or to express recombinant genes inserted in 
other positions. The fact that the vhs'VP16' virus could induce^ maturation of the 
cell even without LPS stimulation, indicates that the virus evasion mechanisms 
can be overcome by removing vhs and mutating VP 16 since the cell is now able 
to identify the presence of the virus and respond to it. Confirming this, no 
inhibitory effects were seen upon LPS stimulation.
The vhs'VP 16‘ backbone has therefore been shown to provide an attenuated 
vector, unable to replicate in BMDC, with reduced ability to express lytic genes, 
although capable of expressing recombinant genes, and allowing infected DC to 
undergo maturation upon stimulation. The aim of this chapter was to determine 
the appropriate backbone for use as a vector able to stimulate immune responses 
to delivered antigen encoding genes. Applying the data obtained from human DC 
to mouse BMDC indicated that the virus behaves similarly in both sets of cells,
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and 17+vhs’47’VP16‘ has been identified as a candidate vector for immunotherapy 
studies in mice. Upon in-vivo injection, the virus should efficiently target and 
infect local immature DC without disrupting their ability to undergo maturation, 
allowing them to travel back to the draining lymph nodes to initiate an immune 
response. Similarly, injection of infected DCs should be able to undergo the same 
process. This will be tested in later chapters.
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Chapter 4
Ability of HSV-1 to migrate to the
lymph node
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4.1 Introduction
Dendritic cells are unique in their ability to stimulate naive T cells. DC-T cell 
interaction is necessary to initiate an immune response and this specific function 
of DCs has made them key targets for vaccine development. T cell priming takes 
place in secondary lymphoid organs (lymph nodes and spleen) and because DCs 
are found scattered around the body in an immature form, their ability to migrate 
from their site of residence or from the site of infection to the lymph nodes or 
spleen is essential (Banchereau & Steinman, 1998). For migration to take place, 
the DC needs to be activated and to mature. Activation is a reversible state that is 
induced immediately following antigen uptake or stimulation and does not involve 
phenotypic changes in the cell. Maturation, on the other hand, follows activation 
and drives the cell into an irreversible state with upregulated costimulatory and 
migratory molecules.
In vivo, upon stimulus or infection, the immature DCs present take up the 
antigens or apoptotic cells containing the antigen by a process known as cross­
presentation (Carbone et al., 1998) (Albert et al., 1998a, Albert et al., 1998b). 
After antigen uptake, the activated DCs loose their ability to respond to stimuli in 
favour of developing a costimulatory and migratory capacity. Maturation and 
migration of DCs are processes that take place concomitantly, allowing the cells 
to reach the LN in a fully mature state capable of both presenting the specific 
antigen and of activating the na'ive T cells present. In addition to upregulation of 
costimulatory molecules (CD40, CD80, CD86), that allow the interaction with 
and activation of T cells, the maturation-migration process requires a shift of 
expression of CC chemokine receptors on the surface of the dendritic cell to allow 
migration to the LN (Sozzani et al., 2000). Immature DCs express CC receptors 
(such as CCR5) that bind inflammatory chemokines produced at the sites of 
infection (MIPla in the case of CCR 5). However, upon maturation the 
expression of these CC receptors is downregulated in favour of CC receptors that 
bind chemokines constitutively expressed in the lymphatics and LN. The most 
highly expressed of these is CCR7 that binds both the CC ligand CCL19 
expressed by stromal cells and DCs in the lymph node paracortex, and CCL21 
expressed by endothelial cells in the lymphatics and in high endothelial venules.
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Release of these and other chemokines drive the DCs that express the appropriate 
receptors to move into the lymphatics and then into the LN (Dieu et al., 1998, 
Sozzani et al., 1998, Sozzani et al., 2000).
The LN is where an immune response is initially mounted. Lymph nodes are 
found at major intersections of the lymphatic system. They contain lymphocytes, 
macrophages and dendritic cells packed in organised sectors (figure 4.1). The LN 
is surrounded by a capsule from which trabiculae (connective tissue) penetrate and 
partition the node. There are three main layers that form the lymph node: the 
cortex, paracortex, and medulla, each containing different cell types. The cortex 
mainly contains B cells, macrophages and follicular dendritic cells arranged into 
follicles. These are either primary follicles, mainly containing B lymphocytes, or 
secondary follicles, consisting of aggregates of lymphocytes and containing a 
germinal centre (activated lymphocytes: plasma cells and memory B cells). T 
lymphocytes are mainly found in the paracortex, located beneath the cortex, 
together with interdigitating DCs that have migrated from peripheral tissue and 
some macrophages. Finally, the most central part of the LN, the medulla, contains 
lymphoid lineage cells, mainly antibody secreting plasma cells and macrophages.
The incoming antigen loaded mature DCs enter the LN through the capsule via 
the afferent lymphatic vessels that releases the lymph in the subcapsular sinus 
separating the capsule from the cortex. While passing through sinuses located in 
the cortex and paracortex, the lymph is filtered and depleted of any antigens, 
including antigen presenting cells, by a mesh of macrophages and dendritic cells 
present in these zones. Incoming DCs stop in the paracortex near high endothelial 
venules (HEVs) (Bajenoff et al., 2003, Mempel et al., 2004) where they become 
interdigitating DCs ready to scan the incoming Th cells and to interact with the Th 
cells present in the same area (Mempel et al., 2004). Once the cells have reached 
the lymph node, interaction and priming of T cells takes place in three phases 
(Mempel et al., 2004). Initially, short lived encounters of T cells and DC activate 
the T cells. The second phase sees stable interactions between the two cells and T 
cell cytokine release leading to the third phase of T cell proliferation and high cell 
mobility. The lymph depleted of antigen presenting cells further crosses the LN 
through the medulla, which contains mainly plasma cells, and finally leaves the
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node enriched with lymphocytes, via the efferent lymphatic vessels in the hilus of 
the node.
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Figure 4.1: Structure of the lymph node
Diagram of a lymph node showing the main layers; the cortex, 
paracortex, medulla and the type of cells found within them. A connective 
tissue capsule surrounds the node.Afferent lymphatic venules pierce the 
capsule and release the lymph in the subcapsular sinus. The lymph then 
migrates through the node via the medullary sinuses and leaves via the 
efferent lymphatic vessel in the hilum. Trabiculas partition the node 
unevenly. The cortex contains mainly B cells arranged into primary 
follicles containing B cells, macrophages and follicular dendritic cells, or 
secondary follicles, containing a germinal centres.The paracortex area is 
mainly populated by T lymphocytes but also contains interdigitating 
dendritic cells. The medulla is composed of sparse lymphoid cells mainly 
plasma cells secreting antibodies.
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The possibility of specifically targeting dermal DCs for vaccine purposes and 
their ability to migrate to the LN has already been shown using fluorescent dyes 
applied to the skin (Masurier et al., 1998, van Wilsem et al., 1994), gene gun 
immunisation (Larregina et al., 2001) or virus infection (Esslinger et al., 2003, 
Oberholzer et al., 2002). In addition, injection of DCs labelled ex-vivo with either 
dye (Bajenoff et al., 2003, Hermans et al., 2000, Labeur et al., 1999, Lappin et al., 
1999), Indium-111 (Eggert et al., 1999) or by infection with a non-engineered or 
GFP expressing virus (Barratt-Boyes et al., 2000, Esslinger et al., 2003, Gardner 
et al., 2000, Masurier et al., 1998) has shown that after subcutaneous (s.c.), 
intradermal (i.d), as well as intramuscolar (i.m.) injections cells accumulate in the 
T cell area of the draining LN, whereas intravenous injection (i.v) resulted in 
localisation to the spleen (Lappin et al., 1999).
An ideal viral vaccine should therefore be able to infect local DCs upon injection, 
allowing them to become activated and mature inducing upregulation of 
costimulatory and migratory molecules. The antigen loaded cells should then, 
therefore, travel to the draining LN to activate naive T cells by presentation of 
both viral and recombinant antigens. HSV-1 antigens have already been identified 
in draining LN after footpad injection (Mueller et al., 2002), but these were found 
to have been transported following virus replication at site of infection. Although 
most routes of injection result in DCs presenting antigens in the LN, the strength 
of the immune response induced varies and the subcutaneous has been found to be 
among the routes achieving the strongest responses (Eggert et al., 1999).
Tracking of DCs infected with HSV-1 ex-vivo has not been possible so far 
because of the effect of the virus on cell maturation, but following HSV-1 
subcutaneous footpad (f.p) injection, viral antigens have been found in the 
popliteal LN (Mueller et al., 2002). This has not always been correlated to the 
presence of virus (Jones et al., 2000, Mueller et al., 2002), instead, as expected, 
HSV-1 infection prevented maturation of DCs, and thus migration did not occur. 
The presence of antigen was therefore attributed to uptake by cross-presentation. 
Contrary to infection with HSV-1, infection of DCs with influenza or Sendai virus 
do not interfere with DC maturation (Hamilton-Easton & Eichelberger, 1995, 
Usherwood et al., 1999) and has been shown to allow infected DCs to migrate to
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the LN. Therefore, having demonstrated that 17+vhs"47'VP16' infection allows 
DC maturation, migration of both ex-vivo and in-vivo infected DCs should be 
possible. This was tested in the following experiments.
Virus used:
17+vhs~47~CMVGFP/US 5 VP16~ 
vhs and ICP47 genes deleted 
VP 16 with V422 mutation 
US5 inactivated by insertion of CMVGFP
ICP34. vhs UL43 VP 16 ICP27 ICP34.5 ICP4 US5 ICP47 ICP4
CMV
X indicates a deleted or inactivated gene 
—► indicates the direction in which the gene is expressed
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4.2 Identification of DCs in the LN
4.2.1 Identification of ex-vivo infected DCs in the draining LN
The most practical way of following infected cells is to use a virus expressing a 
marker gene. 5x10s immature bone marrow DCs were infected for 4hr at MOI=l 
with 17+vhs'47'CMVGFP/US5 VP 16", and then injected s.c. into mouse footpads. 
Taking into account previous studies (Barratt-Boyes et al., 2000, Nair et al., 2003) 
and anticipating that infected cells would be activated, and ready to respond to 
local stimuli, cells were not otherwise matured prior to injection. To ensure that 
cells were well infected and remained fluorescent for the duration of the 
experiment, a sample was kept in culture in vitro and GFP expression was 
checked before removal of the popliteal LN 24hr after injection. Many studies 
have looked at the timing of cells homing to the LN after injection, and although 
6hr post-injection antigen presenting cells are already found in the LN (Bajenoff 
et al., 2003), maximal cell numbers have been detected between 24-48hr post­
injection (Binder et al., 2000, Hermans et al., 2000, Lappin et al., 1999, Masurier 
et al., 1998, Oberholzer et al., 2002).
It was not possible to identify GFP fluorescent cells in whole LN or in LN 
sections, in both cases partly because of autofluorescence problems. There is a 
possibility that by the time the injected cells reach the LN, GFP has been 
processed by the cell and can therefore not be detected. To overcome this problem 
it was decided to track migration by loading the infected cells with a red 
fluorescent dye (CMTMR). However, unfortunately, still no fluorescent cells 
could be detected. Finally, LN sections were stained using an anti-HSVl Ab. 
Considering that infected DCs were extensively washed before injection, no free 
virus should be present, and therefore any stain observed should represent injected 
cells that have migrated.
Mice were injected in the footpad with 5x10s immature DC or 5x10 DC infected 
at MOI1 with 17+vhs"47"GFP/US5 VP16", and draining popliteal lymph nodes 
removed 24hr later. As it can be seen from figure 4.2, it was possible to detect 
HSV-1 antigen positive cells in what appeared to be the T cell area of the LN after 
injection of infected DC but not non-infected DCs. This implied that infected
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immature DCs were able to induce and respond to maturation and migration 
stimuli upon injection. Direct comparison of infected and non infected DC 
injections should be sufficient to prove specificity of the stain. However, it 
appeared from additional controls (not shown) that when infected DCs were 
injected the DAB stain developed even when no antibody was added, albeit to a 
lesser extent.
Figure 4.2: Detection of HSV-1 infected DCs in the LN
10pm cryoseetions of LN from mice injected in the footpad with 5xl05 
non-infected DC (a) or 5xl05 DC infected MOI1 with 17+vhs'47' 
GFP/US5 VP 16' (b). LN were removed 24hr post-injection and stained 
with anti-HSV antibody detected with DAB staining.
This last observation indicated that the presence of virally infected cells caused a 
non-specific reaction with DAB. To further study this phenomenon, DCs and 
BHK cells were infected with 17+vhs~47"GFP/US5 VP 16 in vitro and DAB stain 
was then added to test for possible reaction of the virus with DAB (Figure 4.3). 
However, no reaction could be seen from either infected or non infected cells, 
suggesting that the staining seen in the LN is not due to the virus itself but 
possibly to some other factor found in the LN environment, maybe related to the 
activation of T cells.
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Figure 4.3: HSV-1 infected DCs and BHK cells with DAB stain added to 
them
Schematic representation of principle of DAB staining
20X photo of dendritic cells and BHK cells infected with 17+vhs'47' 
GFP/US5 VP 16\ These cells had no primary or secondary antibody added 
to them, only the DAB stain was added to check for unspecific development 
of this stain due to presence of virus.
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4.2.2 Identification of infected cells in draining LN after virus injection
Having shown that DCs infected with 17+vhs’47'VP16' viruses maintain their 
ability to migrate to the LN, and having defined a potential (although not totally 
specific) method of identifying infected DCs in LN, migration of in-vivo infected 
DCs was investigated. Because following footpad injection of HSV-1 viral DNA 
has been found in LN as soon as 2hr post-infection (Mueller et al., 2002), it was 
decided to look at migration at both 6hr and 24hr post-injection. Mice were either 
left un-injected or were administered with 5xl05 pfu of 17+vhs'47'GFP/US5 
VP 16' in the footpad and draining lymph nodes removed after 6hr and 24hr. 
Figure 4.4 shows that HSV1 is only detected in sections from infected mice, and, 
as expected, more cells are found in the LN 24hr after infection. It is possible to 
clearly see the localisation of the infected cells to the paracortex of the LN 
especially 6hr post-infection. Sections were not counterstained with haematoxylin 
and eosin but the B cell follicles are clearly distinguishable in the 6hr sections. By 
24hr more cells are present, and spread across the LN, also reaching the medulla 
where more naive T cells can be found. Similarly to the previous results from DC 
injection, sections from LN of immunised mice, but not from unimmunised mice, 
reacted to DAB staining in absence of antibody (not shown). As before, the 
injected virus that reaches the LN, probably having infected DCs at the site of 
injection, seems to stimulate peroxidase activities in the LN. Comparing the two 
methods of injection it appears that neat virus inoculation results in a higher 
amount of virus present in the LN, although the two have not been quantified.
These results demonstrated the presence of viral antigens in the LN, which in the 
case of infected DC injection could only be due to trafficking of infected DCs. 
However, it had not been possible to specifically correlate the presence of virus 
with the arrival of infected DCs. To demonstrate actual trafficking of DCs, and to 
quantify any differences in the efficiency of the two immunisation methods, 
FACS analysis on LN cells was carried out to determine the numbers of DCs 
present.
199
ifuLMayyaBp
d B m
V  .' h
. i ' t
negative control
Figure 4.4: DAB staining of LN after footpad inoculation of mice with 
17+vhs 47 GFP/US5 VP16
10pm cryosections of draining lymph nodes from mice injected in the 
footpad with 5x105 pfu 17+vhs'47'GFP/US5 VP 16* or non immunised 
(control). LN were removed 6hr or 24hr post-injection and sections were 
stained with anti-HSV antibody developed with DAB.
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4.2.3 Detection of DC trafficking by determination of the cellular composition 
of the LN.
In these experiments the proportion of C D llc+ cells within the draining LN was 
assessed. An increase in the percentage of C D llc+ cells in the LN following DC 
or virus injection would indicate migration of infected and activated DCs from the 
site of infection to the LN. Other studies have looked at differences in the LN cell 
population, mainly identifying incoming fluorescently labelled cells (Labeur et al., 
1999, Lappin et al., 1999, Masurier et al., 1998, van Wilsem et al., 1994). 
However, in this study it was decided not to use fluorescent dyes because it would 
not be possible to track cells infected directly in vivo. In addition, considering 
previous FACS data, GFP expression from the 17+vhs'47'VP16' backbone may be 
too weak to be detected.
Groups of 9 mice each were injected s.c. in one footpad with either DC (DC only), 
DC infected with 17+vhs‘47'GFP/US5 VP 16' at MOI 1 (DCV), neat virus (V only) 
or non immunised (n.i.). The draining popliteal LN from the nine mice were 
removed 24hr post injection and pooled together, crushed and stained for anti- 
C D llc  for FACS analysis. As shown in figure 4.5a, it appears from all three 
experiments performed that resident CD1 lc+ cells usually account for ~2% of the 
total LN cell population. In two out of three experiments, a -50% increase in the 
C D llc+ population was noticed 24hr after injection of immature DCs (becoming 
-3% C D llc+ cells), and surprisingly, since viral infection is expected to be 
activate the DCs, this increase was not higher after injection of infected DCs. 
Interestingly, however, upon immunisation with neat virus the percentage of 
C D llc+ cells in the LN increased remarkably compared to the non immunised, 
DC, and DCV mice, reaching 7% of the total population.
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Figure 4.5(a): Detection of C D llc+ ceils in LN following
immunisation of mice
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Figure 4.5 (a) continued
FACS dot plots from three replicate independent experiments showing the 
percentage of CD1 lc+ cells found in the total population of draining LN of 
mice injected with nothing (non immunised), 5x1 CP immature DC (DC 
only), 5xl05 immature DCs infected with 17+vhs'47'GFP/US5 VP 16' 
(DCV), or with 5x10s pfu of 17+vhs'47'GFP/US5 VP16" (virus only). The 
percentages of cells stained with the anti-CD l lc+ antibody are compared 
to the percentages of positive cells obtained by addition of secondary 
antibody only.
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These differences in cell population are shown more clearly in figure 4.5b, where 
the average of the three independent experiments is presented. As suggested from 
the staining of LN sections, injection of neat virus resulted in higher accumulation 
of DCs than injection of infected cells, although this method did not show that the 
incoming cells are infected. In order to understand whether the difference between 
the two groups was due to inappropriate in-vivo maturation of the injected cells, 
the percentage of CD1 lc+ cells detected in the LN after immature and mature DC 
injection was determined. As it can be seen from the FACS data (figure 4.6), 
injection of immature DCs increased the CD1 lc+ LN population by -50-100%, as 
in the previous experiment, but if DCs were matured with LPS prior to injection, a 
-  200% increase in CD1 lc+ cells was found in the LN.
The immunohistochemistry and FACS results taken together show that viral 
antigens can reach the LN and there is an increase in the CD1 lc+ population in the 
LN after injection of in vivo or ex-vivo infected DCs and that this is higher after 
neat virus injection than when injecting infected or mature DCs.
204
%CD11c+ cells in LN
________________  virus only
DC only ~ DC V
non immunised
-
r  r r r T . E _ _ T r n
T
□ Red 670
□ CD11c
A verage %CD11c+
QO
A 
\
1- I - i r
Non
im m unised
DC only DCV Virus only
Figure 4.5 (b): Detection of DC in LN after inoculation of mice
Graphic representation of data shown in figure 4.5 (a) percentage of 
CD1 lc+ cells present in the draining LN of mice. Values obtained by 
addition o f  secondary antibody only (Red670) are compared to the 
percentages obtained by staining with anti-CD l lc + antibody. Values 
for the three independent experiments are shown, (b) Average of 
C D llc+ values obtained from the three independent experiments. 
Percentages obtained from staining with secondary antibody only 
were subtracted to the percentages obtained after C D llc+ stain. 
Error bars represent the standard deviations.
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Figure 4.6: Detection of DCs in LN with or without activation of DCs 
prior to footpad inoculation
Comparison of the percentage o f CD1 lc+ cells present in the draining LN 
in non injected mice, and after injection of 5xl05 immature or mature DC 
in the footpad. Lymph nodes pooled from 9 mice either non-immunised, or 
immunised with immature DC or LPS matured DC were removed 24hr 
post-injection and the percentage of total CD1 lc+ cells present in the node 
(C D llc+) was determined and compared (as negative control) to the 
percentage of cells resulting positive by addition of only secondary 
antibody (secondary only).
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4.3 Discussion
In vivo, dendritic cells are found in the immature state and are stimulated to 
undergo maturation upon antigen uptake. This modifies the pattern of cell surface 
receptors by promoting expression of molecules that allow cell migration to the 
draining LN and interaction with T cells. The 17+vhs‘47'VP16' backbone has been 
shown to allow infected DCs to undergo maturation when stimulated to do so, it 
was therefore important to determine whether infected cells also retained their 
ability to migrate to LN and initiate a response against recombinant antigens 
carried by the virus. Injection of infected DCs and neat virus resulted in viral 
antigen being found in the LN, this being higher after virus injection, and 
similarly injection of infected cells induced lower CD1 lc+ draining in the LN than 
neat virus.
Injected DCs have previously easily been tracked using fluorescent dyes (Bajenoff 
et al., 2003, Barratt-Boyes et al., 1997, Hermans et al., 2000, Lappin et al., 1999, 
Masurier et al., 1998), GFP expressing viruses (Esslinger et al., 2003, Gardner et 
al., 2000), or by labelling with Indium-11 l(Eggert et al., 1999), all resulting in 
identification of the injected cells in the T cell area of the draining LN. Direct 
tracking of injected virus using GFP expressing HSV1 infected DCs has not been 
possible in this study due to the low level of GFP expressed from the particular 
backbone used. Although it is clear that activated T cells appear in the draining 
LN shortly after infection (Coles et al., 2002, Mueller et al., 2002), whether the 
antigens reach the LN from infected cells or by cross presentation at the periphery 
has been controversial. Early reports suggested that following i.d. injection, some 
infectious virus could be recovered in the draining LN and this was accompanied 
by an increase in the LN DC population (Sprecher & Becker, 1989), implying that 
the virally infected cells do undergo migration. Similarly, a study has recently 
shown that viral DNA can be detected in draining LN as soon as 2hr after s.c. 
footpad injection of HSV1, but this decreased with time, while antigen 
presentation increased, indicating that both infected DCs and DCs that have taken 
up viral antigens from infected cells migrate to the LN (Mueller et al., 2002). On 
the other hand, Jones et al (Jones et al., 2000) could not detect infectious viral 
particles or viral DNA in the LN at various times following f.p. infection, or flank
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scarification (Mueller et al., 2002). Even in these last two reports, a CTL response 
could always be seen, suggesting cross presentation at the site of infection. In this 
chapter, migration of infected DCs to the LN was detected by staining for HSV 1, 
which can only detect the presence of viral antigens but not track infected DC. 
However, the detection of staining after injection of infected cells, where no free 
virus should be present, suggests that infected DCs can migrate to LN.
The results presented here are in line with those of Jones et al (Jones et al., 2000) 
as, unlike in other studies, DCs have been infected with a virus that does not 
prevent maturation, thus allowing cell migration. It would have been appropriate 
to include an additional control using wild type virus to prove that travelling of 
infected cells is possible only when the appropriate deletions to allow DC 
maturation are present in the backbone. With this control it would have been 
possible to conclude that migration of HSV-1 infected DCs is possible only if 
maturation of the cell is not prevented, in which case cross presentation takes 
place at the site of infection. This can be further seen using viruses that do not 
disrupt the ability of DCs to mature, such as influenza and Sendai virus, which 
have both been shown to infect DC inducing their migration (Hamilton-Easton & 
Eichelberger, 1995, Usherwood et al., 1999).
The fact that sections reacted to DAB (even in absence of primary antibody), only 
in the presence of virus following either infected cells or neat virus injection, is an 
indication of the arrival of viral antigen in the LN. Having proved that the virus 
itself does not react with DAB, a reaction must be stimulated by the virus in the 
LN. The in-vivo or ex-vivo infected DCs that reach the LN stimulate T cells 
resulting in IFNy release. IFNy has been shown to be sufficient to activate primary 
macrophages in a Myd88 dependent way (Shi et al., 2003), resulting in 
macrophage gene expression and NF-kB activation with production of reactive 
oxygen intermediates (ROIs) (Shi et al., 2003). These could develop DAB 
staining. Alternatively, considering that infected cells start reaching the LN within 
6hr of injection (Bajenoff et al., 2003, Mueller et al., 2002, Olasz et al., 2002), 
there could be some minimal viral replication taking place in the LN in the mature 
DCs resulting in macrophages being activated and producing ROIs from 
mitochondrial oxydative stress (Mogensen et al., 2003). Although non productive
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infection of DCs by 17+vhs47VP16 has already been shown, macrophage 
activation only requires HSV1 IE and/or E genes (Mogensen et al., 2003), which 
can still be produced by infected mature DCs (Kruse et al., 2000) in the LN, 
although full viral replication and packaging of infectious particles does not take 
place.
Despite the unexpected DAB staining, is possible to conclude from these results 
that DCs infected with the 17+vhs"47’VP16' backbone are able to migrate to the 
LN, as well as the suggestion of the initiation of an immune response by the 
activation of T cells.
The identification of migrated cells within a LN focuses on a very restricted 
number of cells. In fact, DCs as shown here and by others (Barratt-Boyes et al., 
2000, Binder et al., 2000) account for ~2% or less of a LN population. A general 
increase in LN cellularity (Binder et al., 2000, Mori et al., 2001, Mueller et al.,
2002) is an indication of the stimulation of an immune response. Following 
infection, both migrating antigen presenting DCs (Binder et al., 2000, Gardner et 
al., 2000, Lappin et al., 1999, Mori et al., 2001) and naive T cells (Mempel et al., 
2004, Mori et al., 2001) drain to the local LN. The number of antigen presenting 
cells that reach the LN is a very important factor in the determination of the type 
of response induced: a large number of cells result in a sustained stimulation 
through single or successive DC-T cell interactions, whereas low numbers of 
poorly stimulatory DCs will induce abortive T cell proliferation and tolerance 
(Lanzavecchia & Sallusto, 2001). Following s.c. injection of DCs, the number of 
injected cells that are found in the draining LN has always been quite low, 
accounting for 0.1%-10% of the initially injected cells (Barratt-Boyes et al., 2000, 
Hermans et al., 2000, Labeur et al., 1999, Lappin et al., 1999, Olasz et al., 2002). 
Such low efficiency of injected DC migration partly depends on the route of 
administration. S.c. injection results in a high proportion of cells remaining at the 
site of injection (Eggert et al., 1999, Labeur et al., 1999, Lappin et al., 1999, Olasz 
et al., 2002), but, despite this, when compared to other routes, s.c. inoculation has 
been identified (Bedrosian et al., 2003, Lambert et al., 2001, Onaitis et al., 2002) 
to be able to induce one of the strongest CTL responses (Eggert et al., 1999, 
Lappin et al., 1999, Mullins et al., 2003), with only intranodular injection giving a
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better response. The increase seen here in the CD1 lc+ population are higher than 
previously reported, considering that no DC enrichment step was used, and that 
the increase is noticeable over the whole CD llc+ population. Sufficient DCs 
would therefore be expected to be present in the LN to stimulate CTL responses 
rather than inducing tolerance.
To further confirm that the increase in the C D llc+ LN population was due to 
draining of skin derived DCs, it would have been appropriate to identify which of 
the five different types of C D llc+ cells present in the LN (Henri et al., 2001) 
accounted for the increase by staining for additional markers such as CD lib , 
B220, and CD8oc.
Both staining of LN sections and FACS data showed that neat virus injection 
resulted in higher accumulation of DCs in the draining LN than infected DC 
injection. The most important factor in DC trafficking is the maturation state of 
the cells. Ex-vivo maturation of the DCs prior to injection should not be 
necessary (Barratt-Boyes et al., 2000, Nair et al., 2003), and results from the 
previous chapter had shown that after infection with 17+vhs'47'VP16" most of the 
cells were still immature. It was assumed that ex-vivo infected cells would be in 
an activated state, having taken up a foreign antigen, and that upon injection they 
would undergo self-maturation (Barratt-Boyes et al., 2000, Nair et al., 2003) such 
that they would react as well as in-vivo infected cells to local stimuli, resulting in 
similar trafficking to the LN. Although a certain degree of maturation did take 
place upon injection, accounting for an increase in the LN C D llc+ population, 
similarly to that found in other studies (Labeur et al., 1999, Lambert et al., 2001, 
Mackey et al., 1998), this migration was not as strong as seen after injection of 
mature cells.
The level of maturation of the ex-vivo infected cells therefore seems to explain the 
reduced flow of C D llc+ cells to the LN compared to neat virus injection. 
Migration of mature infected cells was not investigated, but considering that 
infection did not confer any increase in the trafficking of immature DC, both 
infected and uninfected DCs might benefit form a maturation step prior to
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injection. Ex-vivo manipulated cells therefore retain their ability to migrate 
efficiently, but injection induced maturation does not result in the cells maturing 
completely, resulting in reduced trafficking to the LN compared to in-vivo 
infected cells. Comparison of ex-vivo and in-vivo infection methods has 
previously reached the same conclusion (Esslinger et al., 2003), thus indicating 
that ex-vivo infected cells do not respond as well as in-vivo infected cells to local 
stimuli encountered upon injection.
The previous points demonstrate that the methods used for the injection of DCs 
gives considerable variability in the results, making this route of administration 
not as efficient or reproducible as neat virus injection. Factors such as the 
efficiency of infection, the extent to which manipulation affects the maturation 
status of the injected cells, as well as DC in vitro culturing conditions and 
purification methods, may all be important variables that influence the efficiency 
of trafficking and reproducibility of the assay.
The data in this chapter suggests that the 17+vhs'47’VP16' viral backbone can 
infect DCs without disrupting their ability to migrate to the LN and thus initiate an 
immune response. In addition it can be speculated, by comparing the efficiencies 
of migration, that neat virus injection might result in a stronger immune response 
than through the use of ex-vivo infected DC.
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Chapter 5
Ability of HSV-1 to induce CD8* CTL 
immune responses
212
5.1 Introduction
Immune responses are stimulated in the lymph nodes (LN) by arrival of antigen 
loaded dendritic cells (DC). Here, the mature DCs form clusters (Bajenoff et al., 
2003, Ingulli et al., 1997) and prime naive T cells that soon migrate to the spleen, 
where their proliferation takes place (Coles et al., 2002, Mueller et al., 2002). The 
previous chapter has shown an increase in LN DC cellularity following injection 
of ex-vivo infected DCs, or virus, suggesting that both techniques may lead to the 
induction of an immune response. The stimulation of CTL responses against a 
recombinant antigen has been shown to be possible following arrival in the LN of 
either peptide pulsed DCs (Eggert et al., 1999, Hermans et al., 2000), plasmid 
loaded DC (Lisziewicz et al., 2001), or DCs infected in vivo with replicons 
(Gardner et al., 2000). Similarly, ex-vivo virally infected DCs as well as those 
targeted in vivo by recombinant viruses such as lentivirus (Esslinger et al., 2003) 
or adenovirus (Nakamura et al., 2002) have been shown, following arrival in the 
LN, to stimulate antigen specific responses. When using viral vectors, in addition 
to the response against the recombinant protein, anti-viral responses are usually 
also stimulated. In particular, footpad injection of (Coles et al., 2002) or 
scarification (Mueller et al., 2002) with HSV1 have been shown to stimulate anti- 
HSV responses in the LN initiated by CD8a cells (Smith et al., 2003). In the 
construction of a viral vector, both types of immune responses need to be 
considered to ensure a balance and to avoid the anti-viral response overriding the 
specific targeted one.
Each pathogen has an immunodominant antigen, as well as immunodominant 
peptides within it (different for CD4, CD8, or B cells), towards which immune 
responses are mainly targeted. Vaccine therapies using DCs have focussed on the 
specific presentation of these immunodominant peptides for stimulation of 
specific responses. However, the use of the full length antigen to load DCs may be 
advantageous. Identification of CTL epitopes is very laborious though necessary, 
for each HLA allele if peptides are to be used. Expressing full-length genes in 
DCs allows the HLA profile of the patient to be ignored. Moreover, some 
individuals are tolerant to the immunodominant epitope, therefore subdominant 
epitopes should preferably also be identified (Cibotti et al., 1992). However, using
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the full-length gene, multiple epitopes (including secondary ones) are naturally 
presented. By this means MHCII epitopes are presented in addition to MHCI, 
stimulating both CD8+ CTL cells and CD4+ Th cells (Hamel et al., 2002, Wan et 
al., 1999), which may therefore result in an increased response. Taking into 
account the data presented in previous chapters, the 17+vhs'47‘VP16‘ backbone 
appears to be the most appropriate vector for DC based therapy.
Replication deficient HSV1 viruses have already been studied for the induction of 
CTL responses to recombinant antigens (Brockman & Knipe, 2002), or to 
bacterial infection (L.monocytogenes expressing OVA) (Lauterbach et al., 2004), 
and have even been shown to confer partial protection to Simian 
immunodeficiency virus when encoding both Env and Nef genes (Murphy et al., 
2000). Additionally, HSV-1 has been used as an amplicon vector where injection 
of ex-vivo infected DCs has been shown to be efficient in inducing an immune 
response to prostate cancer (Willis et al., 2001). Alternatively, in vivo injection of 
an HSV1 amplicon carrying the HIV gpl20 gene has also resulted in successful 
stimulation of a specific CTL response (Hocknell et al., 2002). Together, this data 
indicates the potential for HSV-1 vectors to stimulate an immune response either 
by direct injection or by injection of infected DCs.
In this chapter, influenza nucleoprotein (NP) is used as a test gene to evaluate the 
ability of the 17+vhs'47'VP16‘ backbone to induce an immune response in mice 
following subcutaneous footpad injection of ex-vivo or in vivo targeted DCs. As 
previously shown in this work, as well as by others (Larsson et al., 2000), 
injection of mature cells results in a greater degree of migration to the LN but, to 
avoid excessive manipulation of the cells, as well as possible non specific 
responses caused by LPS, the cells used for ex-vivo infection were not subject to 
maturation. However, as a positive control, the cells pulsed with the NP peptide 
were previously matured with LPS to ensure maximal presentation. This chapter 
will therefore focus on the possibility of inducing an anti-NP CTL response in 
comparison to the responses after immunisation with either naive mature DCs, 
mature peptide pulsed DCs, DCs infected with 17+47"NP/vhsVP16 at MOI=l, or 
by injection of 17+47*NP/vhsVP16‘ directly.
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Different cytokines may be used in conjunction with a vector to increase (eg. 
GMCSF) or inhibit (eg. IL-10) immune responses. When compared, to other 
cytokines, GMCSF has generally been demonstrated to be the strongest enhancer 
(Weiss et al., 1998). GMCSF is a 23kDa, 127aa glycoprotein produced by many 
cells in the body that enhances the maturation of DC cell precursors. GMCSF 
promotes upregulation of co-stimulatory molecules and MHC presentation on 
APC (Morrissey et al., 1987, Wang et al., 2000) and also stimulates cell migration 
to the LN by enhancing expression of CC chemokine receptor 7 on DCs 
(Nakamura et al., 2002). An increased cellularity both in the spleen and in the LN 
seen after continuous or discontinuous injection of GMCSF has been shown to be 
due to recruitment of cells of the myeloid lineage, produced by the bone marrow 
(Basak et al., 2002, Miller et al., 2002), but with different stimulatory properties 
to the usually matured myeloid cells (Miller et al., 2002). For example these cells 
release less IFNy but much higher levels of IL6.
Many studies have focussed on the advantages of using GMCSF to recruit DCs 
for tumour therapies. In particular, the use of HSV1 vectors expressing cytokines 
(IL2 or GMCSF) has been exploited to enhance the killing of tumour cells by 
virus replication (Liu et al., 2003, Loudon et al., 2003, Parkinson et al., 2003). 
The ability of this cytokine to enhance a response to various infections such as 
chlamydia (Lu et al., 2002), or plasmodium yoelii (Weiss et al., 1998) has also 
been demonstrated.
Incorporation of GMCSF into a vaccine vector therefore aims to enhance the 
activation of antigen presenting cells and antigen presentation to T cells. Many 
studies have delivered adjuvant cytokines as a plasmid or recombinant protein. 
However, expression from a virus has several advantages including a longer time 
of presence and lower cost. In addition, co-localisation of the antigen and the 
enhancer is important, as proved by experiments with BCG vaccine (Lu et al., 
2002, Wang et al., 2002), and since HSV1 can easily co-express multiple proteins, 
this chapter will assess the effect of co-expressing GMCSF and NP on the CTL 
response induced.
215
Viruses used in this chapter
This diagram indicates the progression of virus construction 
Specific deletions and inactivations of each backbone are specified
X indicates inactivity of the gene either by deletion or inactivation 
—> indicates the direction of gene expression
17+vhsTRESGFP/VP 16
vhs and ICP47 genes deleted
VP 16 gene with V422 mutation and insertion of IRES GFP cassette
ICP34.5 vhs UL43 VP 16 ICP27 ICP34.5 ICP4 ICP47 ICP4
X
17+vhs~NP/47VP 16~ 
vhs gene deleted
ICP47gene inactivated by insertion of the CMVNP cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
CMV
17+47'NP/vhs VP 16'
ICP47 gene deleted
vhs gene inactivated by insertion of the CMV-NP cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
----------------------------------------- X
CMV
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17+47~mGMC SF -NP/vhs VP 16~
ICP47 gene deleted
vhs gene inactivated by insertion mutation of the mGMCSF-NP cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
nGMCSfl RSV NPCMV
►
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5.2 Ability of the 17+vhs~NP/47 VP16~ virus to stimulate an immune response
5.2.1 Construction of 17+vhs'NP/47 VP16'
The 17+vhs’47’VP 16' backbone seemed, from the previous results, to be the most 
appropriate immunotherapeutic vector for DC based therapy. In order to 
determine its ability to stimulate an immune response, it was necessary to 
construct a virus with this backbone but expressing an immunostimulatory 
antigen: influenza nucleoprotein (NP) from H3N2 strain. To ensure disruption of 
the ICP47 gene, the NP gene was inserted at this position although insertion into 
vhs would have been equally appropriate. The only possible difference would 
have been on the efficiency of expression of NP from the different sites.
The NP gene was initially excised from pBs43NP with EcoRI and EcoRV, a 
plasmid already present in the laboratory based on pBluescript (pBs) and 
containing the HSV1 UL43 flanking regions. NP was then inserted into the 
pcDNA3 plasmid between the EcoRI and EcoRV sites (following the CMV 
promoter) forming pcDNA3NP (figure 5.1). The CMVNPpolyA fragment was 
purified from pcDNA3NP by digestion with Nrul and BbSl and inserted at the 
Hindlll site (blunted and dephosphorylated) of pBs47 (a pBluescript based 
plasmid containing the HSV1 ICP47 flanking regions), forming pCMVNP/47 
(figure 5.1). After checking the integrity of the NP gene by sequencing, the 
pCMVNP/47 plasmid was transfected into BHK cells together with 17+vhs 
CMVGFP/47 VP 16' viral DNA (already present in the laboratory) to allow 
recombination at the ICP47 locus and formation of the 17+vhs"NP/47 VP 16'virus. 
White plaques were purified.
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Figure 5.1: Construction of pCMVNP/47
Cloning strategy for the construction of the plasmid encoding the NP gene 
driven by the CMV promoter between the ICP47 flanking regions of 
HSV1.
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Three pure white plaques (17+vhs'NP/47 VP 16’) were obtained and tested by 
Southern blot to ensure presence of the NP gene (figure 5.2). The viral DNAs 
from the purified plaques and from the 17+vhs’471RESGFP/VP16* virus (negative 
control) as well as the pCMVNP/47 plasmid (positive control) were digested with 
BamHI, which cuts twice within the NP gene and at either sides (figure 5.2). The 
blot was probed with an NP fragment comprising the majority of the gene 
linearised with Hindlll from pcDNA3.
As it can be seen from figure 5.2, all three plaques showed the expected ~1.3Kb, 
291 bp and 216bp bands, confirming the presence of the NP gene. Plaque 2 was 
grown as larger stock for subsequent experiments.
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Figure 5.2: Anti-NP Southern Blot
(a) Diagram of the cassette inserted into the viral DNA showing the 
BamHI sites and the fragments expected.
(b) Southern blot of viral DNA from three pure plaques of 17+vhs'NP/47 
VP16* digested with BamHI and probed with NP fragment excised from 
pcDNA3NP using Hindlll. The negative control is 17+vhs47- 
ERESGFP/VP16' DNA. The positive control is the pCMVNP/47 plasmid 
digested with BamHI (260bp).
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Having confirmed the presence of the NP gene in the virus, expression of the 
protein was investigated by Western blot and compared to expression from 17+47' 
NP/vhsVP16 in which the NP gene is inserted in the vhs locus (prepared by 
others in the laboratory). Samples were extracted using the urea method (§ 2.2.16) 
and electrophoresed on a 10% urea SDS PAGE gel given that the expected size of 
NP is ~60kDa. As shown in figure 5.3, a clearly positive band was successfully 
obtained in the lysates of cells infected with either of the viruses containing NP, 
regardless of the insertion position. The band appeared at a size slightly lower 
than expected but this is not surprising considering the denaturing conditions. 
Interestingly, expression from the vhs site appeared to be slightly better than from 
ICP47 although quantification/equalisation of samples was not carried out. 
Despite this, judging from the background bands, the two samples appear to have 
been loaded in similar amounts. Because of this comparison, and because in 
mouse cells it is essential to inactivate vhs whereas ICP47 does not have much 
activity (Ahn et al., 1996), it was decided to use the 17+47"NP/vhsVP16' virus for 
further experiments.
17+47'vhs* 17+ 47'NP/vhs 17+vhs'NP/47
IRESGFP/VP16* VP 16" VP16'
50kDa
NP "
30 kDa
Figure 5.3: Anti-NP Western blot comparing vhs and ICP47 as 
insertion sites
10% Urea SDS PAGE gel stained for influenza NP.Cells were infected 
with virus not containing NP (17+47vhs'IRESGFP/VP16 ) or with NP 
inserted in either vhs (17+ 47'NP/vhs VP 16), or inserted in ICP47 
(17+vhsTSlP/47 VP 16).
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5.2.2 IFNy response induced by 17+47'NP/vhsVP16' at 1 month post­
immunisation.
5.2.2.1 IFNy response to NP
To obtain the strongest immune response, it is important to optimise the route and 
dose of immunisation. Initially it was decided to look at the immune response 
induced by 5x10s pfu or cells one month after immunisation since this was the 
dose used in the previous migration experiments. Two (figure 5.4 a) or three 
(figure 5.4 b) mice per group were immunised in one footpad with either 17+47* 
NP/vhsVP16' (V), DCs infected at MOI1 with 17+47'NP/vhsVP16‘ (DCV), 
mature DCs loaded with NP CD8+peptide (DCNP), or, as negative control, mice 
received non pulsed mature DCs (DC) or nothing. Based on the literature 
(Gardner et al., 2000, Hocknell et al., 2002, Wang et al., 2002), spleens were 
removed one month after immunisation and the cells were cultured in vitro for 7 
days in medium containing 10pM NP peptide. The IFNy response produced by 
immunisation was then measured with an IFNy ELISPOT assay. No immune 
response could be detected from this experiment (not shown), it was therefore 
decided to repeat the experiment but increasing the dose of immunogen, thus 
using 106 cells or pfu and immunising both in footpad and flank. As for the 
previous experiment, spleens were removed one month after immunisation and 
cells restimulated 7 days in vitro with NP peptide before setting up the ELISPOT. 
In the assay, T cells were incubated either with naive stimulators (A20) or with 
stimulator cells presenting the NP peptide (A20NP). To prove antigen specific 
response, the responder T cells should only be activated by A20NP, resulting in 
IFNy release from the T cells.
To ensure that the T cells are indeed able to release IFNy, and therefore confirm 
any negative results, responders from each group were also incubated with PMA 
and ionomycin and all showed strong IFNy release. As it can be seen from figure 
5.4, T cells from mice that had received peptide loaded DC, virus infected DCs or 
neat virus, all stimulated an NP specific response. Immunisation with peptide 
loaded DCs was the general positive control of this experiment and, as expected, 
it gave a strong response. Similarly, as expected, non immunised mice did not 
respond to presentation of the NP peptide. It can also be seen that there is large
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variability between the members of a same group, especially when DCs are used 
for the immunisation. Nevertheless, the results obtained from non immunised 
mice should be compared to mice immunised with neat virus, and responses from 
injection of naive DC compared to those obtained with infected DC. Interestingly, 
some activity, although lower, was also seen from spleen cells of mice immunised 
with non-pulsed DCs. This response can not be attributed to in-vitro priming since 
it does not take place on cells from non-immunised mice but, rather, initial 
activation of T cells may result in vivo due to some factor present in the DC 
culture medium. In vitro restimulation then possibly primes these already active 
cells against NP. Despite this, it can still be concluded that there is an NP specific 
response stimulated both by immunisation with infected DCs and neat virus, and 
that using infected DCs gives a stronger response than immunisation with neat 
virus.
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Figure 5.4: Anti-NP IFNy ELISPOT 1 month after immunisation
IFN-y ELISPOT measuring specific responses to NP from mice that had 
been immunised for 1 month in both footpad and flank with nothing (non 
immunised), non infected mature DC (DC), NP pulsed mature DC (DC 
NP), DC infected at MOI1 with 17+47'NP/vhsVP16‘ (DCV), or with 
virus alone (V). IFN y release is measured in response to presentation of 
the NP peptide by A20 cells (A20NP), and background IFNy release 
levels are obtained by incubation with non pulsed A20. The values 
shown are the average from two mice per group and the error bars are the 
standard deviation from triplicate values from each sample.
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5.2.2.2 IFNy response to HSV-1
In addition to looking at the response to the antigen carried by the virus, the 
response to the virus itself was also investigated one month after immunisation. 
On the day of spleen removal, an IFNy ELISPOT using HSV infected DCs as 
stimulators were set up with the fresh splenocytes. DC were used rather than A20 
cells since these are the cells that present the virus in vivo and, also, it is not 
known how well A20 cells are infected by HSV1 or how their presentation 
mechanism is affected by it.
As expected, following injection of virus or virally infected cells, a relatively 
strong IFNy response was observed (figure 5.5). As also noticed previously, there 
seemed to be a specific response induced by cells of mice immunised with DC 
only or peptide pulsed DC, again suggesting non specific activation induced by 
the injection of DC. The fact that naive DCs can activate T cells is supported by 
the fact that in this experiment there is some IFNy release also from cells of non 
immunised mice when incubated with infected DC. These results show overall 
that although the background is high, there is a strong anti-HSV IFNy response 
induced both by injection of infected DCs or neat virus, with no significant 
difference between the two.
Unfortunately, although the response to HSV was reproducible in repeated 
experiments, this was not the case for the anti-NP response. In the hope to 
increase the anti-NP response to a level that would probably give more 
reproducible results, it was decided to add a 1 week boost to the immunisation 
regime.
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Figure 5.5: Anti-HSVl IFNy ELISPOT 1 month after immunisation
IFN-y ELISPOT measuring specific antiviral response from mice 
immunised from 1 month in both footpad and flank with nothing (non 
immunised), 106 non infected mature DC (DC), NP pulsed mature DC 
(DC NP), DC infected at MOI1 with 17+47-NP/vhsVP16' (DCV), or with 
virus alone (V). Viral antigens are presented by DCs infected with 
17+47'NP/vhsVP 16" that act as stimulators, and background IFNy release 
levels are measured by incubation with non infected DC. The values 
shown are the average response from two mice per group and are from 
one experiment representative of two. The error bars are the standard 
deviation from triplicate values from each sample.
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5.2.3 Effect of boosting on IFNy responses
5.2.3.1 IFNy response to NP measured by ELISPOT
An IFNy response has been shown to be induced over tolerance using repetitive 
cell stimulation and a high dose of antigen (Feunou et al., 2003, Huang & Yang, 
2004, Lang & Nemazee, 2000). It was therefore thought that a more reliable anti- 
NP IFNy response might be achieved after immunisation followed by boosting. 
Two mice per group were immunised both in the footpad and flank with either 
nothing, mature DC, mature DC loaded with NP peptide, DC infected with 17+47' 
NP/vhsVP16', or neat virus, the mice then received a boost of the same 
immunogen one month later. Spleens were removed one week after the second 
injection and the cells were restimulated in vitro for 7 days in the presence of NP 
peptide before setting up an IFNy ELISPOT assay to determine the presence of 
anti-NP IFNy secreting cells. As predicted, introducing a boosting immunisation 
improved the reproducibility of the results. Figure 5.6 shows the results obtained 
from one experiment, representative of two, and shows the average number of 
spots obtained from three mice per group. As before, the very few spots appearing 
in wells from spleen cells of non immunised mice suggest that the response seen 
upon neat virus injection is dependent on NP expression. In addition, the response 
also appeared to be NP specific since very few cells reacted to A20 cells alone. 
Interestingly, the intensity of the response obtained following immunisation with 
neat virus was similar to that obtained without boosting (-1200 spots), implying 
that boosting does not have an amplifying effect. Immunisations involving DCs 
still presented background problems, and infected DCs seemed to give similar 
number of IFNy producing cells as the group immunised with naive DCs. As 
previously suggested, T cells from mice immunised with DCs only are probably 
already activated (possibly by the FCS) and undergo further activation upon 
incubation with antigen presenting cells (A20NP). Non specific activity of T cells 
after DC injection seems to be higher following boost than after single 
immunisation, but the response stimulated by infected DCs, disappointingly, did 
not appear to be higher than background, suggesting abolition of the antigen 
response by boosting.
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The results presented, therefore, allow the conclusion that immunisation with neat 
virus can successfully stimulate an NP specific CD8+ IFNy response and that this 
can be obtained more reliably if a boosting step is added. Boosting of infected 
cells, on the other hand, abolished the response, suggesting that expression of a 
high amount of NP is beneficial but should be achieved by means other than 
boosting.
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Figure 5.6: Anti-NP IFNy ELISPOT 1 month + 1 week boost after 
immunisation
IFNy ELISPOT to measure response to NP from mice immunised for 1 
month and boosted for a week with nothing (non immunised), 106 mature 
non infected DC (DC), 106 mature NP pulsed DC (DCNP), 106 DC 
infected at MOI 1 with 17+47TNP/vhsVP16' (DCV), or with the virus only 
(V). The values shown are from one experiment representative of two and 
are the average response from three mice per group. Responder T cells 
were incubated with NP peptide pulsed A20 cells (A20NP), or naive A20 
cells (A20).
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5.2.3.2 CTL response to NP measured by 51 Cr release assay
In addition to the IFNy ELISPOT assay for the determination of the anti-NP
51
response, a Cr release assay was carried out to assess cytotoxicity of the 
activated T cells (figure 5.7). The splenocytes from three immunised mice that 
received a boost one month after the initial immunisation were restimulated in 
vitro for 7 days in presence of NP peptide and irradiated spleen cells (§ 2.4.5), and 
were used to set up the assay at various effector .‘target ratios. T cells were 
incubated either with 51Cr loaded P815 cells alone or with 51Cr loaded P815 
presenting the NP peptide. Figure 5.7 shows the average value obtained from the 
three mice per group. Figure 5.7a indicates that there is a relatively high degree of 
lysis of P815 cells including when these are not presenting the NP peptide. This 
suggests that the T cells are non specifically activated, and are therefore able to 
lyse cells regardless of peptide presentation. Interestingly, the results obtained 
from incubation with NP pulsed P815 cells (figure 5.7b) showed a clear 
distinction between the reaction from immunised mice and the negative controls 
(DC only and non immunised) which would suggest specific lysis even though 
this is not actually the case. Mice immunised with peptide loaded DCs or infected 
cells do not present a stronger reaction than that seen with nai've P815, therefore 
indicating that the activity seen is not specific to the NP peptide but due to non­
specific activation of the cells. The results obtained from mice immunised with 
neat virus, on the other hand, show an increased reactivity upon incubation with 
peptide presenting P815, thus showing that these cells can specifically recognise 
and lyse cells presenting the NP peptide.
Overall, as for the ELISPOT results, no specific anti-NP reaction could be seen 
after immunisation with infected DCs, but despite the strong over-activation of the 
splenocytes, it was still possible to identify an NP specific response from cells of 
mice immunised with neat virus. In conclusion, it is possible to say that the T 
cells, of boosted mice are highly active, able to lyse A20 cells non-specifically, 
and only those from mice immunised with neat virus are able to lyse cells at a 
higher level than background. This was also noticed in the ELISPOT assay, 
showing specificity of response.
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Figure 5.7: 51Cr release assay anti-NP at 1 month + 1 weeks 
boosting
51Cr release assay after immunisation for 1 month + 1 week boosting 
with nothing (non immunised), 106 mature non infected DC (DC 
only), mature DC that have taken up NP peptide (DCNP), DC 
infected at MOI 1 with 17+47‘NP/vhsVP 16' (DC Virus), or with 106 
pfu of 17+47'NP/vhsVP16' only (V only). The values shown are the 
average of data from three mice. T cells were incubated with naive 
P815 cells (a) or peptide pulsed P815 cells (b).
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5.2.3.3 IFNy response to HSV1
As for the previous experiment, in addition to the anti-NP response, the antiviral 
IFNy response was measured after o n e  month and one week boosting
immunisation. Non restimulated splenocytes were incubated with HSV1 infected 
DCs or uninfected DCs in an IFNy ELISPO T. The responses seen following a 1 
week boost (figure 5.8) were higher than those recorded after 1 month
immunisation (figure 5.5). Comparing th e  results obtained from non immunised
mice with the ones from mice im m unised with neat virus a strong anti-viral
response is seen. Similarly, despite the h ig h  background from peptide loaded DC 
as previously observed, a strong antiviral response can also be seen following 
immunisation with infected DCs. The h ig h  background makes it difficult to 
compare whether a stronger response is obtained after immunisation with infected 
DCs or neat virus, although the strong anti-HSV response from DCV might 
explain die lack of reaction from this group in the anti-NP ELISPOT.
OveraH these results show that imm unisation with neat virus clearly induces 
strong anti-NP and anti-viral IFNy responses, whereas immunisation strategies 
that involve injection of DCs result in h ig h  background readings in the ELISPOT 
assay. ' lowever, it is still possible to conclude that stimulation of anti-NP and 
anti-FI >V IFNy responses may be occurring using the method tested.
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Figure 5.8: Anti-HSVl IFNy ELISPOT after 1 month + 1 week 
boost immunisation
IFNy ELISPOT to measure the antiviral response from mice 
immunised for 1 month and boosted for a week with nothing (non 
immunised), 106 mature non infected DC (DC), 106 mature NP pulsed 
DC (DCNP), 106 DC infected at MOI 1 with 17+47'NP/vhsVP16' 
(DCV), or with the virus only (V). The values shown are from one 
experiment representative of two independent ones, and are the average 
response from two mice per group. The antiviral response is given by 
incubation of T cells with DCs infected with 17+47NP/vhs VP 16', 
whereas negative controls are the values obtained using non infected 
DCs as stimulators.
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5.3 Effect of co-expressing GMCSF on the ability to stimulate an immune 
response
5.3.1 Construction of the 17+47 RSVGFP-CMVRFP/vhs VP16 ' virus
HSV-1 allows the expression of multiple genes. As a tool for construction of 
viruses expressing two genes (GMCSF and NP), a further virus encoding two 
marker genes was constructed. It was decided to express both genes from the 
same location in the virus backbone, using a double expressing cassette containing 
an RSV as well as a CMV promoter back to back (figure 5.9). The pvhsDC 
plasmid (already available in the laboratory) is based on pBluescript and contains 
the double expressing cassette between the vhs flanking regions, this is to allow 
insertion of the recombinant genes at this location of the viral genome. GFP and 
RFP were therefore cloned into this plasmid. GFP was purified from the hrGFP 
plasmid digesting with Notl and Xhol and was subsequently blunted before being 
inserted at the Pmel blunt site of pvhsDC, under the RSV promoter, forming 
pvhsDCGFP. RFP was purified from the pDsRedNl plasmid via BamHl and 
Notl digestion and then blunted before cloning it into pvhsDCGFP following the 
CMV promoter, at the Apal site, forming pvhsDCGFP-RFP (figure 5.9). This 
plasmid was transfected with the viral DNA from 17+vhs 47 VP 16 to achieve 
insertion at the vhs site, and plaques that resulted both green and red were 
purified. The purified plaques clearly appeared to express both genes under 
fluorescence (figure 5.10), showing that both genes had been successfully 
incorporated.
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Figure 5.9: Construction of pvhsDC GFP-RFP
Cloning strategy for the insertion of the GFP and RFP genes, into the 
double expression plasmid containing the vhs flanking regions
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Figure 5.10: 17+47 GFP-RFP/vhs VP16 plaque expressing both GFP 
and RFP genes
Plaque from BHK cells infected with 17+47' GFP-RFP/vhs VP16 .The 
same plaque was photographed under the light microscope (a), showing 
the infected rounded cells, and using different fluorescence filters to show 
expression of both GFP (b) and RFP (c) in the infected cells.
5.3.2 Construction of the 17+47 mGMCSF-NP/vhs VP16' virus
Taking into account previous reports (Bukreyev et al., 2002, Lu et al., 2002, 
Rodriguez et al., 1999, Wang et al., 2002, Weiss et al., 1998), it seemed possible 
that immune responses produced by the 17+47’NP/vhsVP16‘ virus would be 
increased by co-expressing murine GMCSF (mGMCSF). A virus with the same 
structure as the 17+47’RFP-GFP/vhsVP16" was therefore constructed expressing 
mGMCSF from the RSV promoter and NP under the CMV promoter (figure
5.11). Both genes were cloned into pvhs DC, initially GMCSF was purified from 
pGemTeasyGMCSF (provided by other members of the laboratory) with Notl and 
blunted before being inserted at the Pmel site of pvhsDC to form 
pvhsDCGMCSF. As a second step NP was isolated from pcDNA3NP (§ Figure 
5.1) by initially linearising the plasmid with Kpnl followed by blunting and then 
digestion with A pal. The purified NP gene was inserted between the Pmll and the 
Apal sites of pvhsDCGMCSF forming the pvhsDCGMCSF-NP plasmid (figure
5.11).
To make the 17+47'GMCSF-NP/vhsVP16‘ virus, pvhsDCGMCSF-NP was 
transfected into BHK cells with the viral DNA of 17+47'RFP-GFP/vhsVP 16’ to 
allow for recombination at the vhs site. Because it is possible for recombination to 
take place between one flanking region and the linker sequence between the two 
promoters, to ensure that both genes would be incorporated in the virus it was 
important to check that the purified plaques were neither green nor red.
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Figure 5.11: Construction of pvhsDC GMCSF-NP
Cloning strategy for the construction of the plasmid expressing both 
GMCSF and NP from the double expressing cassette inserted between 
the vhs flanking regions. In the first step of cloning GMCSF was 
inserted following the RSV promoter and subsequently NP was 
inserted at a position following the CMV promoter.
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Four pure plaques were obtained and tested both for NP and for mGMCSF 
expression. Cell lysate samples from the purified plaques, run on a 10% urea SDS 
PAGE gel and western blot, all showed expression of NP (figure 5.12). As 
expected, a band was also obtained from the cells infected with the virus 
expressing only NP (17+47“NP/vhs VP 16') whereas no band appeared from the 
cells infected with the RFP-GFP expressing virus.
The supernatants from the cells infected with the pure plaques as well as that from 
cells infected with the RFP-GFP virus (negative control) were tested by ELISA 
for presence of GMCSF. It appeared (figure 5.13) that infection with either of the 
four 17+47'GMCSF-NP/vhsVP16‘ pure plaques produced significant amounts of 
GMCSF, whereas this was not the case from infection with the RFP-GFP virus. 
The SHS PAGE gel results together with the ELISA results indicated that the 
virus was properly constructed, able to express both the NP and the GMCSF 
genes in non complementing cell lines.
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Figure 5.12: Anti-NP Western blot of extracts from 17+47'GMCSF- 
NP/vhs VP16 infected BHKs
10% urea SDS PAGE gel western blotter and tested for NP expression in 
cell lysates of BHKs cells infected with four different pure plaques of 
17+47'GMCSF-NP/vhsVP16' (1-4), with 17+47NP/vhsVP16' as positive 
control or with 17+47'RFP-GFP/vhsVP16* as negative control.
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Figure 5.13: Production of GMCSF in BHKs from 17+47'GMCSF- 
NP/vhs VP16" plaques
ELISA measuring GMCSF present in supernatant of BHKs cells 
infected with different plaques of 17+47GMCSF-NP/vhsVP16'. 
Negative control is the supernatant from cells infected with 17+47 RFP- 
GFP/vhsVP16‘ which does not express GMCSF.
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5.3.3 Characterisation of 17+47 GMCSF-NP/vhsVP16‘ infection of DC
The 17+47’GMCSF-NP/vhsVP16’ virus has the same backbone as the 17+47‘ 
NP/vhs VP 16’ and 17+vhs’47"CMVGFP/US5 VP 16' both previously shown to be 
able to efficiently infect and deliver genes to DCs. Similarly, the newly 
constructed virus was expected to be able to infect and express both genes 
efficiently in DCs. Unfortunately, it was not possible to detect NP by Western blot 
starting from 106 DCs infected at MOI=l with 17+47'GMCSF-NP/vhsVP16’ 
(figure 5.14). In case this was because the amount of protein was not sufficient to 
be detected by western blot, RT-PCR was used. NP RNA expression from 
infected DCs was the1 confirmed (figure 5.15). RNA isolated from 106 non­
infected DC or 106 DCs infected at MOI1 with 17+47'GMCSF-NP/vhsVP16' was 
reverse transcribed, and PCR for NP was carried out on these samples (RT PCR) 
using primers internal to the gene (§ 2.2.11), amplifying a 320 bp fragment 
(bp350-bp671). To ensure that any amplified band was not due to genomic DNA 
contamination, the PCR was also carried out on the same amount of non reverse 
transcribed RNA samples (RNA PCR). In the PCR carried out on cDNA 
templates, the 320bp fragment could only be amplified from the plasmid positive 
control and the sample from infected DCs, showing expression of the gene from 
infected cells. The non-reverse transcribed RNA sample of infected DCs (RNA 
PCR-DCGMNP sample) did not generate product confirming the sample to be 
free of genomic DNA contamination.
Unfortunately it was not possible to detect mGMCSF in the supernatant from DCs 
infected with 17+47’GMCSF-NP/vhsVP16\ This was probably because, 
considering that RSV is not as strong a promoter as CMV, only small amounts are 
produced. Despite this, there is no reason to believe that only one of the two genes 
would be expressed in DCs.
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Figure 5.14: Western blot to detect NP expression in DC infected 
with 17+47 GMCSF-NP/vhs VP16*
Anti-NP 10% urea SDS PAGE gel on samples prepared from 106 non 
infected DC (DC only, negative control) and 106 DC infected at MOI of 
1 with 17+47 GMCSF-NP/vhs VP16' (DC GMCSF-NP), western blotted 
and probed with an antibody against NP.
RT PCR RNA PCR
H20 plasmid DC DC GMNP H20 plasmid DC DC GMNP
Figure 5.15: Detection of NP expression in DC by RT PCR
RT PCR: PCR carried on cDNA reverse transcribed from RNA of 
uninfected DC (DC) and from DCs infected MOI1 with 17+47GMCSF- 
NP/vhs VP 16- (DC GMNP).
RNA PCR: these are negative controls, the PCR was carried out on total 
RNA isolated from the DC samples without reverse transcription.
Both PCRs were also carried out on a water negative control (H20), and 
on the pcDNA3NP plasmid that contains the NP gene, as positive 
control. The primers amplify a 320bp fragment (bp350-bp671).
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5.3.4 Effect of GMCSF on the induction of anti-NP IFNy responses
Following reports published by other groups (Matsui et al., 2002, Nakamura et al., 
2002, Wan et al., 1999), it was decided that to assess primary responses, it would 
be appropriate to look at IFNy responses two weeks after the initial immunisation 
(rather lhan one month). Three mice per group were immunised both in the flank 
and the footpad with either nothing (non immunised), 106 mature DC (DC only), 
106mature DCs pulsed with NP peptide (DC NP), 106 DC infected at MOI 1 with 
17+47'NP/vhsVP 16' (DCV), 106 DC infected at MOI1 with 17+47'GMCSF- 
NP/vhsVP16' (DCVGM), 106 plu of 17+47NfP/vhsVP16‘ (V) or 106 pfu of 17+47' 
GMCSF-NP/vhsVP16' (VGM) and spleens were removed 2 weeks post­
immunisation. Splenocytes were restimulated in vitro for 7 days in the presence of 
NP peptide and were then used to set up an IFNy ELISPOT with, as stimulator, 
either A20 cells only or A20 cells pulsed with lOpM NP.
This immunisation, as with previous experiments, resulted (figure 5.16) in very 
high background levels from mice receiving mature DCs, which does not allow 
definite conclusions to be drawn as to the effect of immunisation with infected 
DCs. There is a strong response induced by immunisation with peptide pulsed DC 
that appears considerably above background, and immunising with DCs infected 
with the GMCSF expressing virus (DCVGM) results in all three mice giving a 
response lower than DCNP, but higher than the background (DC only). This is not 
the case for cells from mice receiving cells infected with virus not expressing 
GMCSF where no response above background is seen. From the analysis of these 
results it therefore appears that GMCSF confers an advantage to the injection of 
infected cells.
In order to try to compare the different groups more accurately, the values 
resulting from incubation of cells with A20 only (very similar for all groups) has 
been subtracted from the value obtained from incubation of the cells with A20NP, 
to give a net value (figure 5.16b). Comparison of the net values clearly show that 
immunisation with DCs infected with GMCSF containing virus is more efficient 
than when GMCSF is not present, but unfortunately because of the high
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background is not possible to compare injection of DCs with injection of neat 
virus.
Virus injection gave a specific response not seen in non immunised mice, but 
addition of GMCSF did not appear to confer an advantage to the strength of the 
response (figure 5.16b). Looking at the overall results showing the average 
response obtained from the three mice (figure 5.17), the conclusion that 
expression of GMCSF confers an advantage to the injection of infected DCs but 
not to neat virus injection can be drawn.
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Figure 5.16: Effect of GMCSF on anti-NP immune responses
Specific immune responses to NP from individual mice as determined 
by IFNy ELISPOT after two weeks immunisation in footpad and flank 
with nothing (non immunised), mature DC (DC only), mature DC 
pulsed with NP peptide (DC NP), DC infected at MOI of 1 with 17+47‘ 
NP/vhsVP16' (DCVNP), or infected at MOI of 1 with 17+47'GMCSF- 
NP/vhsVP16' (DCVGMNP), 106 pfu of 17+47'NP/vhs VP 16“ or 106 pfu 
of 17+47"GMCSF-NP/vhsVP 16‘. (a) specific response to A20 cells only 
(A20) and to A20 cells presenting peptide (A20NP). (b) net response: 
number of spots from incubation with A20NP - number of spots from 
incubation with A20 only (A20NP-A20).
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Figure 5.17: Effect of GMCSF on the average immune response to 
NP
Immune response to NP calculated as the average number of spots from 
net values obtained from three mice per group. Error bars represent the 
standard deviation.
Mice were immunised 2 weeks in the footpad and in the flank with either 
nothing (non imm.), 106 LPS mature DC (DC only), 106 mature DC 
loaded with NP peptide (DCNP), 106 DCs infected at MOI1 with 17+47* 
NP/vhsVP16' (DCV), 106 DCs infected at MOI1 with 17+47GMCSF- 
NP/vhsVP16- (DCVGM), 106 pfu of 17+47 NP/vhsVP16- (V), or 106 pfu 
of 17+47GMCSF-NP/vhsVP16- (VGM)
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To ensure that the immune response seen following virus injection was actually 
due to expression of NP and not to activation of the cells from injection of virus 
(as is the case for DCs), the response from mice immunised with the neat GMCSF 
NP virus was compared to that induced by a virus not containing the NP gene 
(17 vhs 4 7 IRESGFP/VP16). It appeared that the response seen was specifically 
due to expression of the NP gene since only minimal response was mounted 
following injection of 17+vhs'47'IRESGFP/VP16' (figure 5.18). In this 
independent experiment, the values obtained from immunisation with the GMCSF 
NP virus were in the same range as the one obtained previously (400-1300 spots 
per 106 spleen cells), indicating the reproducibility of the result.
The 17+47‘GMCSF-NP/vhsVP16' virus is therefore able to stimulate an IFNy 
response against the recombinant protein, as can be seen from the neat virus 
injection groups. However, addition of GMCSF does not seem to confer an 
advantage by improving this response. On the other hand, co-expression of 
GMCSF may have a beneficial effect in improving the response stimulated 
following the injection of infected DCs.
C onfirm ation of th e  spec ific ity  of th e  re s p o n s e s  se e n :
co m p ariso n  of v iru s e s  w ith/out NP
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Figure 5.18: Specificity of immune responses following injection of 
neat virus
Anti-NP IFN y response from mice immunised with viruses expressing 
or not expressing the NP gene. Three mice were immunised 2 weeks 
with either 106 pfu of 17+vhs'471RESGFP/VP16 * or with 106 pfu of 
17+47‘GMC S F -NP/vhs VP 16\
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5.4 Discussion
The main focus of this study was to determine whether an immune response could 
be induced to a recombinant antigen carried by an HSV-1 vector, and whether this 
would be stimulated after either injection of infected cells or neat virus. These 
results have shown that a 17+vhs 47 VP 16' HSV 1 virus expressing NP can induce 
an IFNy response to it. Replication incompetent HSV-1 viruses have previously 
been used as vectors to stimulate an immune response (§5.1). The results 
presented here show that this may also be possible by injection of transduced 
DCs. 1 he mechanism by which the response is stimulated has not been 
investigated. IFNy ELISPOT assays do not specify the type of cells involved: 
CD4+ Th cells, NK cells as well as IFNy secreting cells can release IFNy. Previous 
studies using HSV1 have shown that the response induced did not involve CD4+T 
cells (Lauterbach et al., 2004), while CTL and B cell responses to the antigen 
carried have been shown to be stimulated (Brockman & Knipe, 2002, Willis et al.,
2001). Similarly, here, the MCr release assay indicated that CTL cells play a part 
in the response. Nonetheless, considering that the full length antigen was 
expressed, it is possible that the release of IFNy seen is due not only to activation 
of CDS+T cells but also of CD4+T cells.
From the previous chapter, more cells seemed to be draining to the LN following 
virus rather than infected DC injection (figure 4.7), suggesting that the former 
method would result in a greater immune response. Interestingly, after a single 
immunisation, injection of infected DCs resulted in a stronger anti-NP response 
than vi us injection. Because studies with HSV-1 have only looked at injection of 
virus and not of infected DCs, the results presented here need to be compared to 
findings obtained using different vector systems. Matsui et al (Matsui et al., 2002) 
and Wan et al (Wan et al., 1999) compared the two methods using adenoviruses 
expressing the HCV core gene or gplOO respectively. This showed that in both 
cases infected DCs were more efficient at stimulating an IFNy responses in 
accordance with our HSV-1 results. On the other hand, third generation 
lentivi ruses result in a more efficient induction of an IFNy response after neat 
virus i jection as compared to lentivirus infected DCs (Esslinger et al., 2003). It 
appears, therefore, that the type of virus determines the most efficient method of
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immunisation. In this study HSV-1 appeared to behave similarly to adenoviruses. 
Interestingly, whereas in adenovirus studies, administration of two immunising 
doses of either cells or virus did not change the advantage of injecting infected 
DCs over virus (Brossart et al., 1997), with HSV1, a second dose, according to the 
ELISPOT data, abrogated the response induced by the infected cells, whereas that 
from virus injection remained unchanged. In a boosting regime, immunisation 
with neat virus therefore seems to be more advantageous.
The absence of an immune response to NP following a second injection of 
infected DCs and the lack of improvement in IFNy stimulation when using neat 
virus is paralleled and may be due to the strong antiviral response after primary 
and secondary immunisation. This has already been detected in other studies using 
various vectors such as toxoplasma gondii, in which case even primary responses 
to plasmodium yoelii circumsporozoite protein (PyCS) were prevented by strong 
anti-vector immunity (Charest et al., 2000). Similarly, repetitive injection of 
vaccinia or influenza virus expressing the PyCS protein have been shown not to 
increase the number of activated cells compared to single immunisation (Murata 
et al., 1996). To avoid this, the secondary responses should be induced by 
different priming and boosting vectors, which often should be administered in a 
specific order (Murata et al., 1996).
A response to the virus following the first DCV or V injection is expected, 
footpad injection of HSV1 stimulates an anti-viral IFNy dependent response, 
primed by CD11 c+CD8a+CD45RA‘dendritic cells (Smith et al., 2003), very 
shortly after injection (Mueller et al., 2003), and is targeted mainly to the gB 
antigen (Mueller et al., 2003, Wallace et al., 1999). This IFNy response, on one 
hand, has been shown to be an essential factor for clearance of the HSV1 from 
cutaneous sites of infections, and a single footpad immunisation with attenuated 
HSV1 has previously resulted in a response strong enough to be protective against 
subsequent viral challenges (Brehm et al., 1999). On the other hand, other studies 
have shown that IFNy is not required for virus clearance (Milligan & Bernstein, 
1997) or for protection (Bouley et al., 1995, Ghiasi et al., 2000). These 
controversial studies imply that the antiviral response induced from the first
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inoculation may be strong enough to fully clear in some cases, or partially in 
others, the incoming virus form the second injection. To clarify this point, 
Brokman and Knipe (Brockman & Knipe, 2002) have investigated the effect of 
previous immunisations to HSV1 on the efficiency of an incoming recombinant 
HSV1 to stimulate an IFNy and antibody responses both to the virus and to the 
recombinant antigen. No adverse effect was reported in this case from previous 
immunisation and, similarly, when using an HSV amplicon encoding HIVgpl20, 
previous immunisation resulted in only a slight reduction of response (Hocknell et 
al., 2002).
Taken together, these reports imply that although a strong antiviral response is 
induced by footpad injection of virus, this should not, or only minimally, 
influence subsequent administrations of virus. The results presented here are in 
agreement with this model since, as in the experiments referred to, despite the 
strong antiviral response, administration of two doses of neat virus did not alter 
the anti-NP response (which was not increased either). Nonetheless, the anti- 
HSV1 response induced by infected DCs has not previously been investigated but 
here has resulted in a stronger immune response when using virus alone. Probably 
there is a certain threshold above which there is complete clearance of the 
subsequent incoming infected cells and abrogation of IFNy response to NP. This 
model is supported by the fact that immunisation with peptide pulsed DCs, to 
which no other response is mounted from the primary infection, gives a similar 
response independent of boosting
Overall, although it is possible to stimulate an anti-NP response by DCV and virus 
injection, a second injection did not confer any advantage to virus injection but 
rather inhibited the response from infected cells. Moreover, although following a 
single immunisation infected DCs induced a stronger anti-NP response than virus 
injection, from a vaccine prospective, immunising with neat virus is more reliable 
at ensuring a response in case of previous exposure to the virus.
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well as in studies using vaccinia virus expressing HIV Env (Rodriguez et al., 
1999). Additional injection of recombinant adenovirus expressing GMCSF upon 
BCG vaccination (Wang et al., 2002) or in conjunction with live attenuated 
vaccines such as clamydia (Lu et al., 2002) have shown an increase and 
prolongation of the immune response in the first case, and even to induce 
protection in the second case when compared to vaccination without GMCSF. 
Similarly, co-injection of a plasmid expressing mGMCSF with one expressing the 
CS protein of P. yoelii, significantly improved protection (Weiss et al., 1998). 
Incorporation of GMCSF directly as part of the live attenuated parainfluenza 3 
vaccine has also been shown to be beneficial in non human primate (Bukreyev et 
al., 2002).
All these studies showed an increase in CD4, CD8, or INFy responses, together 
with antibody production, showing that GMCSF has an effect on the stimulation 
of both cellular and antibody responses. Interestingly, although transient 
expression of GMCSF can potentially promote CD8 and CD4 T cell responses 
and increase the number of IFNy releasing cells, the level of cytotoxic CTL 
response is not usually affected (Weiss et al., 1998). In addition, GMCSF has 
been found not to change the type of response usually stimulated, but rather to 
amplify ongoing responses (Morrissey et al., 1987, Wang et al., 2000).
Surprisingly, no significant difference could be seen in the experiments reported 
here by the addition of GMCSF when injecting neat virus. However, on the other 
hand, co-expression of GMCSF in infected cells induced a response stronger than 
was seen following injection of cells infected with the virus not expressing 
GMCSF.
The fact that a stronger response is obtained from DCV than from virus even in 
experiments where no GMCSF is involved, implies that ex-vivo infected DCs 
produce and present a larger amount of protein (both NP and GMCSF). The fact 
that no improvement is seen in neat virus injection by the addition of GMCSF 
may therefore be due to the insufficient amount of GMCSF produced and 
released. The amount of GMCSF needed to stimulate an increase in the response
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is not very high, a serum level of 8-10ng/ml is enough to have a beneficial effect 
(Miller et al., 2002). In fact, overexpression of GMCSF in vivo (55ng/ml) by an 
adenovirus vector has actually resulted in fatal toxicity in nearly 50% of mice 
within two weeks (Miller et al., 2002). In addition, studies by Peretz (Peretz et al.,
2002) and Basak (Basak et al., 2002) have shown that repeated or continuous 
injections of GMCSF do not further increase the number of DCs found in the 
spleen than are found following the first injection and this reaches a plateau 
following administration of lOpg/day for 7 days.
In the experiments presented here, GMCSF could not be detected in the 
supernatant of 106 infected DCs, but despite this, infected DCs might still produce 
sufficient GMCSF to have a beneficial effect. On the other hand, virus injection 
does not target as many cells as ex-vivo infection, and therefore, although the 
amount of antigen delivered and presented is enough to stimulate a response, the 
amount of GMCSF produced may not be high enough to allow it to have an effect.
Taken together these results show that ex-vivo infected DCs present and express 
antigen more efficiently than neat virus injection. This has the adverse effect of 
inducing a very strong antiviral response which does not allow boosting, but 
contrarily to virus injection, has the advantage of producing enough GMCSF to 
enhance the response following a single immunisation. When using viral vectors 
for immunotherapy, a balance between the response to the virus and to the 
recombinant protein is essential: injection of neat virus seems to achieve this goal 
since previous exposure to the virus does not affect the efficiency of the incoming 
vector. In addition, co-expression of GMCSF is recommended for virus injection 
even if it does not enhance the response, since this appears to increase the 
reproducibility of the results. An improvement in the anti-NP response after 
immunisation with the GMCSF expressing virus could probably be achieved by 
additional expression of a DC-targeting molecule such as CD40 ligand.
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Chapter 6
HSV-1 vectors applied to malaria 
immunotherapy
6.1 Introduction
The 17+47"NP/vhs VP 16‘ virus has been demonstrated to be able to stimulate IFNy 
responses to the test antigen NP. It was therefore decided to investigate the ability 
of this backbone to induce an immune response to malaria antigens. Malaria 
infection comprises both intracellular and extracellular stages. Upon biting, the 
anopheles injects sporozoites that rapidly migrate to the liver and infect the 
hepatocytes. Within the hepatocytes, the sporozoites replicate producing 
merozoites that are released from the liver cells and in turn infect and replicate in 
red blood cells: the successive cycles of infection of red blood cells are 
responsible for the onset of the symptoms of malaria. Targeting the pre- 
erythrocytic stage of the disease would block the initial infection of hepatocytes 
and successive formation of merozoites. Mice (Weiss et al., 1988) and humans 
(Malik et al., 1991) immunised with irradiated sporozoites are in fact able to 
inhibit parasite development in the liver (Khusmith et al., 1991), and show strong 
CD8+T and CD4+T cell response mainly against the circumsporozoite protein 
(CS) and sporozoite surface protein 2 (SSP2), also known as thrombospondin- 
related anonymous protein (TRAP), thus making CS and SSP2, two main 
candidates for inclusion in malaria vaccines.
Of the numerous strains of malaria, Plasmodium yoelii, one of the strains of 
murine malaria, has been extensively studied, where protective immune 
mechanisms against the pre-erythrocytic stages have been well characterised 
(Nardin & Nussenzweig, 1993). Genes from plasmodium yoelii were therefore 
used for the work in this chapter. CS is the most abundant protein on the surface 
of the sporozoites, and allows the sporozoites to bind to hepatocytes. CS is also 
involved in the formation of sporozoites in the plasmodium oocysts, and in the 
binding of sporozoites both to the plasmodium salivary glands, and to ribosomes 
in the host, thus inhibiting protein synthesis. Taking into account these functions, 
inducing an immune response against CS may result in significant protection 
against sporozoite invasion.
CS is a transmembrane protein with a conserved structure throughout the different 
strains of plasmodium. PyCS from plasmodium yoelii (PyCS) is 367 amino acids
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in length, with a molecular weight of ~60kDa with an amino terminal signal 
sequence and an anchor sequence at the carboxy tenninal. Following the signal 
sequence, a stretch of aminoacids (pre-region I repeats) precede region I, which, 
together with region II, are conserved throughout the plasmodium species. The 
repeat domain of the protein is comprised between region I and region II and is 
slightly unusual in the p. yoelii protein, having two groups of repeats, the first set 
of 6 amino acids and repeated 15 times and the second set composed of 4 amino 
acids repeated 8 times (Lai et al., 1987). Finally, between the tetramer repeats and 
region II resides is the CD8+CTL immunodominant domain SYVPSAEQI (aa280- 
288), the main target of cellular immune responses.
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Figure 6.1: Schematic diagram of PyCS
Immunisation with a recombinant adenovirus expressing the full length PyCS 
(AdPyCS) has been shown to induce CD8+CTL cells as well as CD4+T cell and 
antibody responses, and to be sufficient to confer protection against challenge, 
(Rodrigues et al., 1997).
The second immunodominant protein of the pre-erythrocytic stage is sporozoites 
surface protein 2 (SSP2). Studies have shown SSP2 to be essential for the gliding 
motion of the sporozoite and for cell invasion (Menard, 2000), making the SSP2 
gene an equally promising target for vaccines. PySSP2 is 826 amino acids in 
length, 140kDa protein, with the immunodominant CD8+T cell peptide 
(KYIFWLLL) between amino acid 8-16 (Hetttihewa, 2003). Similarly to PyCS, 
PySSP2 contains a middle sequence of 6 amino acids tandemly repeated and 
flanked by non-repetitive sequences (Rogers et al., 1992).
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Figure 6.2: Schematic diagram of PySSP2
Individuals who are naturally exposed to plasmodium falciparum  have been 
shown to generate immune responses to SSP2 (Flanagan et al., 2003), and 
immunisation with cells expressing SSP2 resulted in CD8+T cell dependent 
protection in 33-67% of immunised mice upon sporozoite challenge (Khusmith et 
al., 1991). Similarly, passive transfer of CD8+ T cell clones raised against PySSP2 
could induce immunity against sporozoite challenge (Khusmith et al., 1994) by 
eliminating infected hepatocytes (Khusmith et al., 1991, Khusmith et al., 1994), 
and injection of irradiated sporozoites could induce both CTL (Khusmith et al., 
1991) and antibody responses (Charoenvit et al., 1987) in mice. These observation 
make CTL responses to SSP2 a promising target of pre-erythrocytic vaccines, and 
suggest that the use of full length genes would be appropriate since both CD4+ 
and antibody responses would be expected to be induced too.
Considering the immunogenicity of both CS and SSP2, and the ability of the 
17+47'vhs'VP16' vector to induce CD8+CTL responses, the work in this chapter 
aimed at using this viral backbone to express the PyCS or PySSP2 genes and to 
stimulate a CD8+CTL response to both proteins. In addition, the possible 
advantage of coexpressing GMCSF from the virus suggested by the previous 
chapter will be further investigated.
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Viruses used in this chapter
This diagram indicates the progression of virus construction 
Specific deletions and inactivations of each backbone are specified
X indicates inactivity of the gene either by deletion or inactivation 
—► indicates the direction of gene expression
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VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
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ICP34.5 vhs UL43VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
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6.2 Use of 17+vhs 47 VP16~ backbone to stimulate an immune response to 
Plasmodium yoelii sporozoite surface protein 2 (PySSP2)
6.2.1 Construction of 17+47~GFP-SSP2/vhs VP16'
The level of expression of recombinant genes from cassettes inserted in the HSV1 
genome has been shown to depend on the promoters used and on whether a 
double or single promoter expression cassette is used (Palmer et al., 2000). The 
work presented so far in this thesis has mainly used cassettes expressing a single 
gene, except in the construction of 17+47"GMCSF-NP/vhsVP16\ The effect of 
expressing GMCSF from the virus has therefore been studied comparing two 
viruses differing in the type of cassette inserted. In this chapter, two identical 
viruses containing double expressing cassettes one of which expresses GFP and 
one mouse GMCSF (mGMCSF) in addition to the recombinant PySSP2 were 
constructed and compared for their ability to induce immune responses.
The PySSP2 gene was amplified by PCR from the genome of 17XNL 
Plasmodium yoelii using primers containing a BamHI site (§ 2.2.11). The 2.5Kb 
gene was cloned into the pGemTEasy vector forming pGemTeasyPySSP2, and 
sequenced. To construct a plasmid expressing both GFP and SSP2, hrGFP was 
purified from phrGFP by digestion with Notl and Xhol, it was then blunted, and 
inserted into pvhsDC at the Pmel site following the RSV promoter, thus forming 
pvhsDCGFP. To insert PySSP2 into the pvhsDCGFP plasmid, the PySSP2 gene 
was purified from pGemTEasyPySSP2 using Notl, and was blunted before 
cloning into the blunted Apal site of pvhsDCGFP to obtain pvhsDCGFP-SSP2 in 
which hrGFP is driven by the RSV promoter and PySSP2 by the CMV promoter 
(figure 6.3).
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Figure 6.3t Construction of pvhsDCGFP-SSP2 plasmid
Cloning strategy for the construction of the plasmid encoding both the 
GFP and PySSP2 genes.
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The pvhsDCGFP-SSP2 plasmid was transfected into BHK cells together with 
17+vhs 47 VP 16* viral DNA and recombinant green fluorescent plaques purified. 
Southern blotting was used (figure 6.4a) to confirm the presence of the PySSP2 
gene. Here, viral DNA was digested with BamHl with sites at either sides of the 
inserted 2.5Kb PySSP2 gene which was identified using a 560bp probe internal to 
SSP2 (bp760-bpl320 obtained by SspI digestion of pGemTEasyPySSP2) (figure 
6.4a lane7). Expression of PySSP2 from six purified plaques was subsequently 
checked by running a 5% SDS PAGE gel (figure 6.4b) followed by western 
blotting which showed strong expression from all plaques, with a band appearing 
at ~160kDa, corresponding to PySSP2, the theoretical molecular weight of which 
is ~140kDa. This band was not present in the sample of cells infected with 17+47" 
RFP-GFP/vhsVP16". Plaque 1 was used for further experiments.
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Figure 6.4: Detection of recombinant SSP2
(a) Southern blot of 17+47GFP-SSP2/vhsVP16\ Viral DNAs and plasmid 
control (pGemTEasyPyS SP2) were digested with BamHI and probed with 
560bp fragment from pGemTEasyPySSP2 cut with Sspl.
(b) Western blot of lysates of BHK cells infected with 17+47GFP- 
SSP2/vhsVP16‘ plaques (1-6), or with 17+47 RFP-GFP/vhsVP16* (-ve 
control) using a polyclonal anti-SSP2 antibody (§2.1.5, 2.2.16).
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6.2.2 Construction of 17+47 GMCSF-SSP2/vhsVP16
To construct a plasmid containing both the mGMCSF and PySSP2 genes driven 
by the RSV and CMV promoters respectively, PySSP2 was excised from 
pGemTEasyPySSP2 with Notl, blunted and cloned into the Pml I site of 
pvhsDCGMCSF plasmid (§ 5.3.2, figure 5.11), to form pvhsDCGMCSF-SPP2 
(figure 6.5).
The pvhsDCGMCSF SPP2 plasmid was transfected into BHK cells together with 
17+47'RFP-GFP/vhs VP 16' viral DNA. Plaques that were neither green nor red 
fluorescent were purified, and two pure plaques characterised by Southern blot for 
the presence of the PySSP2 gene. Viral DNAs, including that from 17+47'RFP- 
GFP/vhsVP16" as a negative control, were digested with BamHI, and the blot 
probed with a 630bp fragment released by Sspl digestion of pGemTEasyPySSP2 
(figure 6.6a, lanes 6,7). Expression of PySSP2 was confirmed by western blot 
where a ~160kDa protein was detected (figure 6.6b lanes 1,2).
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Figure 6.5: Construction of pvhsDCGMCSF-SSP2
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Figure 6.6: Detection of recombinant PySSP2
(a) Southern blotting of 17+47~GMCSF-SSP2/vhsVP16‘ DNA (lane6-7). 
Viral DNAs and plasmids were digested with BamHI and probed with 
560bp fragment from pGemTeasySSP2 digested with Sspl.
(b)Westem blotting using lysates of BHK cells infected with two different 
plaques of 17+47 GMCSF-SSP2/vhsVP16' (lane 1-2) or with 17+47RFP- 
GFP/vhsVP16* as negative control (lane 3) probed with an anti-SSP2 
antibody (§materials and methods).
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Expression of mGMCSF gene by 17+47‘GMCSF-SSP/vhsVP 16' was tested by 
ELISA on the supernatant of BHK cells infected with either this virus or, as 
negative control, with the 17+47'GFP-RFP/vhsVP16' virus (figure 6.7). This 
confirmed the expression of GMCSF from the appropriate virus. Plaque 2 was 
grown to large stocks for future experiments.
mGMCSF p ro d u ced  by 17+47 GMCSF-SSP2/vhsVP16'
p laques
too
P la q u e  n u m b e r
Figure 6.7: Production of mGMCSF from 17+47~GMCSF-SSP2/vhsVP16’
ELISA for mGMCSF using supernatants from BHK cells infected for 24hr with 
either 17+47 GMCSF-SSP2/vhsVP 16 \ or 17+47'RFP-GFP/vhsVP16'. The values 
shown are the average of each sample tested in duplicate.
6.2.3 Expression of PySSP2 in infected dendritic cells
Although the ability of the HSV-1 17+vhs'47"VP16' backbone to infect and 
express genes in dendritic cells had already been demonstrated for GFP and NP 
(§3.5, 5.2.), expression of mGMCSF and PySSP2 was tested in infected DCs 
using Western blot. It was possible to detect SSP2 expression after infection with 
either 17+47'GFP-SSP/vhsVP16' or 17+47'GMCSF-SSP/vhsVP16‘ and not in 
uninfected DC (figure 6.8a).
Expression of mGMCSF from DCs infected with 17+47'GMCSF-SSP2/vhsVP16" 
was assessed by ELISA (figure 6.8b), and similar to the results from the virus 
expressing mGMCSF and NP (§5.3.3), only very low levels of mGMCSF could 
be detected in the supernatant of 106 infected DCs.
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Figure 6.8: Expression of SSP2 and mGMCSF from infected DCs
(a) Anti-SSP2 western blot using 106 DC either non-infected (DC only), 
or infected with 17+47-GFP-SSP2/vhsVP16\ or 17+47'GMCSF- 
SSP2/vhsVP 16' at MOI= 1.
(b) mGMCSF ELISA using supernatants of DCs uninfected (DC only), or 
infected with 17+47'GFP-SSP2/vhsVP16' (DCGFPSSP2), or 17+47‘ 
GMCSF-SSP2/vhsVP 16' (DCGMSSP2) at MOI=l. OD values are 
presented rather than quantitative values since these were lower than the 
standard curve minimum.
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6.2.3 Ability of viruses containing the full length PySSP2 gene to induce an 
IFNy immune response and the effect of mGMCSF on the response
Despite the fact that previous experiments with ex-vivo manipulated DCs had 
resulted in high levels of background in the ELISPOT assay (§5.2.2, 5.2.3), it was 
decided to investigate both ex-vivo infected DCs and in vivo targeted DCs as 
possible routes of immunisation especially taking into account that DCs have been 
suggested to be functionally inhibited by plasmodium infection (Ocana-Morgner 
et al.. 2003, Urban et al., 1999). Groups of three mice were immunised in the 
flank and footpad with 106 mature DCs loaded with the CD8+CTL SSP2 peptide 
(KYIFVVLLL) (DCSSP), 106 DCs infected with the GFP-SSP2 virus 
(DCVGFPSSP) or with the GMCSF-SSP2 virus (DCVGMSSP), or 106 pfu of 
either viruses alone (VGFP and VGMSSP). Non-immunised mice and mice that 
received 106 mature DCs (DC only) were used as negative control. Considering 
that studies looking at malaria responses have shown that the response obtained 
two weeks post immunisation is stronger than at one month (Rodrigues et al., 
1997, Tsuji et al., 1998), as for the monitoring of NP responses, a 2 week time 
point was used for this experiment. Spleens were removed 13-14 days following 
immunisation, and the cells were restimulated in vitro for 7 days in medium 
containing the KYIFVVLLL peptide. An IFNy ELISPOT was then set up using 
either peptide loaded A20 cells or naive A20 cells as stimulators. The average 
number of spots obtained from the incubation with naive A20 cells was subtracted 
from the average response obtained from incubation with peptide presenting cells, 
and the values obtained for each mouse and per group are presented in figure 6.9. 
Unfortunately, one sample from the DCVGMSSP group was lost during 
manipulation.
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Figure 6.9: Anti-SSP2 IFNy ELISPOT and effect of GMCSF 
expression
IFNy response to SSP2 as measured by IFNy ELISPOT assessing the effect 
of co-expressing GMCSF. Mice were immunised 2 weeks in footpad and 
flank with: nothing (non immunised), 106 LPS matured DC (DC only), 106 
mature DC pulsed with SSP2 peptide (DCSSP), 106 DC infected at MOI of 
1 with 17+47'GFP-SSP2/vhsVP16'(DCVGFPSSP), or infected at MOI 1 
with 17+47'GMCSF-SSP/vhsVP 16" (DCVGMSSP), direct injection of 106 
pfu of 17+47'GFP-SSP2/vhsVP 16" virus (VGFPSSP), or direct injection of 
106 pfu of 17+47‘GMCSF-SSP2/vhsVP 16' (VGMSSP). The values shown 
are for each mouse (a) or the average of three mice per group (b), the error 
bars represent the standard deviation.
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The first encouraging result was the convincing SSP2 specific IFNy response 
obtained from immunised mice. In this case, unlike with NP, no non specific 
response was seen in mice immunised with DC only (figure 6.9) or with a virus 
not expressing SSP2 (figure 6.10). This observation suggests that the non specific 
response previously obtained from incubation with the NP peptide was probably 
not only due to the DC medium, but rather to the NP peptide itself. The NP 
peptide may be more immunogenic than the SSP2 peptide, and therefore may be 
able to prime the T cells from mice immunised with DC only, which are already 
slightly activated by the injection of the cells. Following this hypothesis, no 
priming is observed in non-immunised mice in either the NP or SSP2 experiments 
as these T cells were not initially activated by an injection and the NP or SSP2 
peptides therefore do not prime these naive cells. The stronger efficacy of the NP 
peptide would also explain why the response seen in experiments using NP is 
around lOx higher than the one observed for SSP2.
The large variability within each group meant it was not possible to determine 
clearly whether immunisation with DCs or neat virus was more efficient. 
Flowever, looking at the average responses to the GFP-SSP2 virus, ex-vivo 
infection of DCs seemed to raise a stronger response. On the other hand, when 
using the GMCSF-SSP2 virus, mice receiving neat virus appeared to respond 
slightly better.
In order to further define the effect of co-expressing GMCSF, groups receiving 
the same immunisation (DCs or virus) were compared. Surprisingly, and 
contrarily to that observed for NP (§5.3.4), co-expression of GMCSF from the ex- 
vivo infected DCs, did not result in an increased immune response, but rather a 
lower but more reproducible response was obtained. On the other hand, upon 
injection of neat viruses, expression of GMCSF resulted in the suggestion of a 
slight advantage provided by GMCSF.
Due to the high variability within groups, the suggestion that the addition of 
GMCSF conferred an advantage when neat virus was injected was investigated 
further using larger groups of 10 mice each. The larger sample group clearly
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induce a stronger response than a virus only expressing SSP2 but rather, as for 
immunisation with infected DCs, GMCSF produces a decrease in the number of 
responding cells but gives more reproducible results, which is an important factor 
in vaccine development.
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Figure 6.10: Specificity of response after virus injection
IFNy ELISPOT measuring the anti-SSP2 response by individual mice after 
2 weeks immunisation with 106pfu of 17+vhs'47TRESGFP/VP16' 
(IRESGFP) or 17+47~GMCSF-SSP2/vhsVP16' (GMCSF-SSP).
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Figure 6.11: Effect of co-expression of GMCSF on anti-SSP2 immune 
response
Anti-SSP2 IFNy ELISPOT using 10 mice per group following 
immunisation in the footpad and flank either non immunised, or 
immunised with 106 pfu of 17+47'GFP-SSP2/vhsVP16' (GFP-SSP2), or 
17+47~GMCSF-SSP2/vhsVP 16' (GMCSFSSP2). The immune response 
for each mouse is shown in (a) and the average response per group is 
shown in (b) with error bars representing the standard deviation.
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6.3 Use of 17 vhs 47 VP16 backbone to stimulate an immune response to 
Plasmodium voelii circumsporozoite surface protein (PyCS)
6.3.1 Construction of 17+47'GMCSF-CS/vhsVP16'
For the construction of 17+47’GMCSF-CS/vhsVP16* the nearly full length PyCS 
gene, missing the anchor sequence, was inserted into the pvhsDCGMCSF 
plasmid. PyCS was initially excised from pCMVPyCS (obtained from Dr Tsuji, 
NY) using BamHl and inserted into the BamHl site of pvhsDCGMCSF to form 
pvhsDCGMCSF-CS (figure 6.12) and placing CS under CMV promoter control. 
The inserted CS was then sequenced.
vhsDCGMCSF-CS was used for transfection into BHK cells with the 17+47'RFP- 
GFP/vhsVP16’ viral DNA to obtain recombinant, non-marker gene expressing 
plaques which were plaque purified, and six pure plaques were tested for presence 
of PyCS by Southern blot. The membrane was probed with a 764bp fragment 
(bpl92-bp956 of PyCS) excised with Hindlll from pCMVPyCS. A 1.1Kb 
fragment corresponding to the full length PyCS was identified following digestion 
of viral DNA with BamHl. BamHl cuts either side of PyCS in pvhsDCGMCSF- 
CS. (figure 6.13a). No band was present using 17+47’RFP-GFP/vhs VP 16' DNA 
(lane 3).
Expression of both PyCS and mGMCSF from the virus were confirmed by 
Wastem blot and ELISA respectively. Interestingly, two bands appeared on the 
Western blot around the expected size for PyCS (~60kDa) (figure 6.13b). Because 
the bands are so close, and at the right size, dimerisation or possibility of the 
protein being split into two have to be dismissed. Instead, the fact that malaria 
proteins are very unstable during refolding upon expression (Hetttihewa, 2003) 
and that problems in the purification of full length CS have previously been 
reported (Stratmann et al., 1997) suggest that the smaller band is possibly a 
degraded form of PyCS.
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Figure 6.12: Construction of pvhsDCGMCSF-CS
Cloning strategy for the construction of the plasmid containing the double 
expression cassette between the vhs flanking regions and expressing 
mGMCSF from the RSV promoter and PyCS under the CMV promoter. 
PyCS was inserted at the BamHl locus of the plasmid already containing 
mGMCSF.
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Figure 6.13:
Presence and expression of PyCS using 17+47‘GMCSF-CS/vhsVP16' 
infected BHKs
(a) Southern blot. Viral DNAs and plasmids were digested with BamHl 
and the membrane was probed with the 860bp CS fragment from Hind II 
digested pCMVPyCS.
(b) anti-CS (60kDa) Western blot using BHK cells infected with 17+47‘ 
GMCSF-CS/vhsVP 16’ (1-6) or 17+47-RFP-GFP/vhsVP16- (negative 
control).
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AH plaques of 17 47 GMCSF-CS/vhsVP16' were also tested for their ability to 
express mGMCSF in non complementing cell lines (BHKs). The supernatants of 
infected BHKs were assayed for presence of mGMCSF and all the pure GMCSF- 
CS plaques were shown to produce mGMCSF, whereas the supernatant of BHK 
cells infected with 17+47”RFP-GFP/vhsVP 16 did not (figure 6.14).
mGMCSF produced by 17+47GMCSF-CS/vhs VP16‘ plaques
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Figure 6.14: mGMCSF expression from 17+4TGMCSF-CS/vhs\rP16‘
mGMCSF ELISA using supernatant from BHK cells infected for 24hr with 17+47' 
GMCSF-CS/vhsVP 16' or 17+47"RFP-GFP/vhs VP 16'. The values shown are the 
average of the value obtained from each sample run in duplicate
776
As before, expression in infected DCs was also tested. An SDS PAGE gel was run 
on lysates of 106 infected DCs and then western blotted to try to identify 
expression of PyCS. Unfortunately, a strong band corresponding to the size of 
PyCS also appeared in non-infected DCs (figure 6.15a), indicating cross reactivity 
of the antibody, thus making it impossible to specifically detect PyCS in DCs.
Production of mGMCSF from infected DCs was assessed using the supernatant 
from 106 DCs infected at various MOI (figure 6.15b). mGMCSF levels were very 
low, as before, and it was not possible to definitely concluded that mGMCSF was 
expressed in the DCs.
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Figure 6.15: Expression of PyCS and mGMCSF in infected DCs
(a) Western blot on 106 non infected dendritic cells (DC only), 106 DC infected 24hr 
with 17+47'GMCSF-CS/vhs VP16’ at an MOI of 1 (DC GMCS 1), at an MOI of 10 
(DC GMCS 10), or at an MOI of 20 (DC GMCS 20) and stained for CS.
(b) mGMCSF ELISA on the supernatant of the infected DCs. OD values are presented 
rather than quantitative values since these were lower than the standard curve limit.
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6.3.2 Ability of 17+47 GMCSF-CS/vhsVP16’ to induce an IFNy response
Immunisation with the 17+47 vhs'VP16’ backbone expressing different proteins 
had so far always stimulated a specific IFNy immune response. As for the other 
proteins, the strength of anti-CS response was measured after immunisation of 
three mice per group with ex-vivo infected DC (DCV), direct virus injection 
(VCS), and, as a positive control, injection of DCs pulsed with the CS 
SYVPSAEQI CD8+ CTL peptide (DCCS). The negative controls received mature 
DC (DC only) or were not immunised. Mice were immunised both in the footpad 
and in the flank, and spleens were removed 14-15 days later and restimulated with 
peptide in vitro for 7 days. The IFNy response was measured in an ELISPOT 
assay in which the spleen cells were stimulated with either A20 cells or A20 cells 
presenting the PyCS peptide. The values shown in figure 6.16 represent the net 
value obtained after subtracting the response from incubation with A20 cells to 
the response from incubation with A20 presenting the CS peptide.
Similarly to the anti-SSP2 experiment, no response was obtained from non 
immunised mice or mice immunised with mature DC only. Surprisingly, no 
response was obtained from two out of three mice that received neat 17+47' 
GMCSF-CS/vhs VP 16' virus, or peptide pulsed mature DCs. Two out of three 
mice responded to injection of infected DCs indicating that delivery of the protein 
may be more efficient by this method. The results shown are those obtained from 
one experiment, but a repeat gave similar results. Considering that co-expression 
of mGMCSF might give more reproducible results than if mGMCSF was not 
included, the responses obtained using the 17+47'GMCSF-CS/vhsVP16 virus 
were ^disappointing, but do show that the virus can induce a cellular response 
against PyCS. Due to time restrictions it was not possible to optimise this 
response further, but considering the results from the PySSP2 experiments, it 
might have been appropriate to use larger groups of mice.
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Figure 6.16: Anti-CS IFNy response to 17+47'GMCSF-CS/vhsVP16'
Anti-CS IFNy ELISPOT on spleen cells from mice immunised for 2 
weeks with nothing (non imm), 106 mature DC (DC only), 106 DC pulsed 
with CS peptide (DCCS), 106 DC infected at MOI1 with 17+47'GMCSF- 
CS/vhsVP16'(DCVCS), or with 106 pfu of the virus (VCS). The response 
from individual mice is shown.
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6.4 Discussion
The results presented in this chapter have shown that it is possible to stimulate a 
cellular response to the sporozoite surface proteins CS and SSP2 of Plasmodium 
yoelii by immunising with dendritic cells infected with 17+47'GMCSF- 
CS/vhsVP 16 or with 17+47 SSP2/vhsVP 16 or by using neat virus.
The ability to stimulate a cellular immune response against malaria proteins may 
be very important for vaccine development. It is now accepted that CD8+T cells 
responses are fundamental for protection against malaria, although initial studies 
found that the sera of mice or humans immunised with irradiated sporozoites 
could precipitate the surface coat of sporozoites, suggesting that the main 
response against sporozoites was antibody based (Oliveira-Ferreira & Daniel- 
Ribeiro, 2001). Subsequently, in vivo depletion of CD8+ CTL or CD4+T cells also 
showed reduced protection against sporozoite challenge (Rodrigues et al., 1993), 
whereas B cell deficient mice were shown to still be able to mount an immune 
response after sporozoite immunisation (Tsuji & Zavala, 2003). Additionally, 
transfer of cloned T cells raised against sporozoite surface proteins could give 
protection in mice, (Khusmith et al., 1991, Rodrigues et al., 1991, Romero et al., 
1989) and treatment with anti-IFNy antibodies in mice previously immunised with 
irradiated sporozoites abolished protection (Oliveira-Ferreira & Daniel-Ribeiro, 
2001, Schofield et al., 1987). Thus CD8+ CTL cells, rather than antibodies, are the 
critical effector cells for protection at the pre-erythrocytic stage of malaria.
A single immunisation with the 17+vhs‘47'VP16‘ backbone expressing PySSP2 
either as neat virus or as ex-vivo infected DCs successfully showed induction of 
IFNy responses. Fortunately, no background problem was noticed in these 
experiments, allowing the comparison of the two methods of immunisation, and 
suggesting that the previous background problems were due to the peptide used. 
Interestingly, no significant difference in the strength of the response against 
PySSP2 could be seen between immunisation with infected DCs or neat virus, 
indicating a high efficiency of virus infection in vivo. Similar to the experiments 
presented here, previous studies have used DCs infected with recombinant 
retrovirus expressing PySSP2 to successfully induce a CTL response (Hetttihewa,
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2003). Injection of neat vims expressing SSP2, has so far only been reported from 
MVA used as boost following DNA immunisation in mice (Schneider et al., 1998) 
and non human primates (Schneider et al., 2001) where protection was achieved. 
CTL responses to SSP2 have otherwise been induced by injection of synthetic 
peptides (Wang et al., 1996) or by injection of mastocytoma cells (P815) 
transformed with the SSP2 gene (Khusmith et al., 1991). The ability to stimulate a 
IFNy response to SSP2 using the HSV1 viruses may be effective at inducing 
protection, as injection of CD8+T cell clones raised against SSP2 could induce 
protection in Balb/c mice (Khusmith et al., 1994).
The mechanism of action of the anti-SSP2 response has not been investigated 
here, although the response to SSP2 after peptide (Wang et al., 1996) or infected 
DC injection (Hetttihewa, 2003), has been shown to involve both CTL and CD4T 
cells, and to take place in an IFNy dependent mechanism. Clearance of the 
infected liver cells is believed to be CD8+CTL, IFNy dependent (Bruna-Romero et 
al., 2001, Bruna-Romero & Rodriguez, 2001, Gilbert et al., 2002, Hetttihewa, 
2003, Li et al., 1993, Wang et al., 1996), although IFNy independent mechanisms 
have also been suggested (Rodrigues et al., 2000).
It is thought that infected hepatocytes present sporozoite peptides on their surface, 
these are recognised and presented to CD8+ CTL cells which are activated and 
release IFNy that induce the liver cells to eliminate the intracellular parasite by 
mechanisms possibly involving nitric oxide (Doolan et al., 1996). Alternatively, 
killing of the hepatocytes may take place in an IFNy independent, but perforin, 
TNFa or Fas dependent way (Rodrigues et al., 2000). Sporozoite injection seems 
to trigger the IFNy dependent pathway whereas recombinant adenovirus 
immunisation may rely on the alternative mechanism (Rodrigues et al., 2000). The 
type of response induced may be dependent on the immunising vector, HSV1, in 
fact, despite being a virus like adenovirus, it seems to produce results suggesting 
of the IFNy dependent pathway.
Enhancers have often been used in experimental malaria vaccines, and GMCSF in 
particular has been shown to impair resistance to blood stage malaria (Riopel et
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al., 2001). Vaccines expressing GMCSF have also been tested on non-human 
primates (Kumar et al., 2002) and in human clinical trials for safety (Hoffman & 
Doolan, 2000). GMCSF can increase the protective effect of a plasmid encoding 
PyCS (Weiss et al., 1998) or PbCS (Singh & Singh, 2001) when co-administered 
as a second plasmid, and to increase both cellular (CTL and IFNy release) and 
antibody responses when included in the priming dose of a PyCSDNA-Poxvirus 
prime-boost immunisation (Sedegah et al., 2000). The effect that GMCSF has 
when expressed from HSV1, does not appear to enhance the response, but rather 
makes it more reproducible. Also, no significant difference was seen between 
injection of infected DCs or neat virus. As previously suggested in the studies 
looking at anti-NP responses, the lack of effect of GMCSF expression could be 
due to the low levels produced. Although as little as 3pg are enough to have an 
effect (Weiss et al., 1998), GMCSF may not be produced in sufficient amounts by 
the vectors constructed to enhance the response, although the amount present 
might be enough to ensure a minimal but constant recruitment of DCs and T cells.
Considering the high immunogenicity of PyCS and the additional expression of 
GMCSF from the vector, as well as the fact that good responses had been 
obtained for NP and SSP2, the highly variable responses seen from 17+47' 
GMCSF-CS/vhsVP16' was surprising. PyCS is a strong immunogen, the main 
target of the immune response upon injection of irradiated sporozoites. Many 
studies have used this protein either by delivering the full length gene (Rodrigues 
et al., 1997, Rodrigues et al., 1998, Rodrigues et al., 1994) or specific epitopes 
(Franke et al., 1997, Franke et al., 2000, Gonzalez-Aseguinolaza et al., 2003, 
Murata et al., 1996, Rodrigues et al., 1994, Tsuji et al., 1998), to successfully 
stimulate a response, though not necessarily protection. DCs infected with 
adenovirus expressing full length PyCS (AdPyCS) have been shown to stimulate 
both CD4+ and CD8+ T cells resulting in inhibition of liver stage parasite (Bruna- 
Romero & Rodriguez, 2001), and a single immunisation of Balb/c mice with 
adenovirus expressing PyCS (AdPyCS) can induce a protective response, 
involving both CD8+ and CD4+ cells (Rodrigues et al., 1997).
The strength of response to CS obtained from HSV-1 appears about ten fold lower 
than the number of activated T cells obtained with adenovirus, but of the same
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magnitude as the response obtained by immunisation with sporozoites (Rodrigues 
et al., 1998), suggesting that the response seen with HSV1 expressing a single 
malaria protein might not be strong enough to be protective, but might be 
effective if multiple antigens were used simultaneously. Immunisation with single 
malaria antigens has in fact rarely been protective despite stimulation of both the 
cellular and humoral branches of the immune system, Kushmit et al (Khusmith et 
al., 1991) have shown that responses to both CS and SSP2 are necessary to 
achieve protection. Alternatively, protection against P. yoelii has been achieved 
with a prime boost regime using adenovirus and vaccinia virus expressing full 
length PyCS (Bruna-Romero et al., 2001) or using influenza and vaccinia virus 
expressing CS peptides and full length gene respectively to induce protection 
against P. yoelii (Li et al., 1993) or P. berghei (Gilbert et al., 2002).
Overall, confirming the results initially obtained with the influenza NP test 
antigen, the results from this chapter have shown that 17+47’vhs"VP 16' can be 
used as a backbone to stimulate cellular responses to malaria antigens. It has been 
possible to induce SSP2 and CS IFNy specific responses and to show the 
beneficial effect of the co-expression of GMCSF in obtaining more reproducible 
results. The magnitude of response obtained is similar to the one reported by 
immunisation with sporozoites, therefore a virus co-expressing SSP2, CS and 
GMCSF might be a good candidate to achieve protection. Alternatively, a prime- 
boost regime using two different vectors expressing the same protein could be 
tested. In conclusion, the 17+vhs'47'VP16' has been proved to be capable of 
stimulating cellular immune responses to malaria antigens both by injection of 
infected DCs and by injection of neat virus.
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Chapter 7
Ability of HSV-1 vectors to induce 
antibody responses
7.1 Introduction
Dendritic cells have been investigated mainly for the stimulation of CTL 
responses. The experiments presented in this thesis so far, have demonstrated that 
the HSV-1 17 vhs 47 VP 16 backbone expressing influenza NP, plasmodium 
yoelii CS or SSP2 from the vhs locus, are able to induce an IFNy response both to 
the virus and to the delivered protein after subcutaneous immunisation with either 
neat virus or ex-vivo infected DCs.
Having constructed the recombinant viruses using the full length genes, it is 
probable that in addition to cellular responses, a humoral response could be 
induced too. Expression of full length genes allows presentation of peptides both 
on MHCI and MHCII molecules. Therefore any epitope, including CD4+T cells 
and B cell epitopes can be presented. Although DCs are known for their unique 
ability to prime naive T cells, they can also activate B cells directly (Banchereau 
et al., 2000, Kikuchi et al., 2000), or indirectly via CD4T cells. Immunisation with 
DCs infected with recombinant HSV1 vectors therefore offer the possibility of 
stimulating both humoral and cellular immune responses.
In the construction of a vaccine vector, and for malaria in particular where both 
intracellular and extracellular stages are present, the possibility of stimulating 
both arms of the immune system would provide a significant advantage. 
Especially when using HSV1, in which multiple genes can be inserted inducing 
both types of response, multiple stages of an infection can be targeted. With 
regard to malaria, antibodies should be able to block hepatocyte infection by 
sporozoites, thus avoiding merozoite release by infected liver cells. Similarly, 
antibodies targeted to merozoites would inhibit red blood cell infection and the 
onset of clinical malaria.
Although cellular responses seem to play the dominant role in combating malaria 
infection, antibodies have also been shown to be important. Initial observations 
showed that mice immunised with irradiated sporozoites produced, in addition to 
CTL responses, anti-sporozoites antibodies (Charoenvit et al., 1987, Rodrigues et 
al., 1998), in particular against PySSP2 (Charoenvit et al., 1987) and PyCS. Also,
285
passive transfer of monoclonal antibodies against the CS protein could protect 
mice against malaria (Charoenvit et al., 1991b), and passive transfer of sera from 
immune African individuals to Thai children resulted in protection (Sabchareon et 
al., 1991). Recent studies have also highlighted the importance of antibody 
responses to multiple malaria antigens using oral immunisation of mice and 
showing that protection was dependent on the induction of antibody responses 
(Wang et al., 2003). Finally, strong evidence of the importance of antibody 
responses in malaria therapy has been provided by a recent vaccine clinical trial 
(RTS,S/AS02) which uses the carboxy terminal of the CS protein fused to the 
hepB surface antigen (HbsAg) expressed together with unfused HbsAg in yeast as 
the immunogen (Stoute et al., 1997). This was administered with an adjuvant 
(AS02) and showed protection (Kester et al., 2001) correlated with strong 
antibody and cellular immune responses(Bojang et al., 2001, Lalvani et al., 1999).
Viral vectors have the ability to induce both cellular and humoral responses, but 
protection may not necessarily require both of these (Rodrigues et al., 1997). 
Adenovirus expressing PyCS (AdPyCS) has been shown to be able to induce 
antibody responses to the protein in addition to stimulation of a strong cellular 
response (Rodrigues et al., 1998). Similarly, both CTL and antibodies to CS have 
been reported after immunisation with recombinant vaccinia or pseudo-rabies 
virus expressing CS (Khusmith et al., 1991), although protection was not 
achieved.
The CS protein binds to hepatocytes (Frevert et al., 1993), and there is evidence 
that in addition to CD8+T cells, antibodies to the central repeat region of P. yoelii 
CS, which contain the immunodominant B cell epitope mediates protection 
against malaria (Charoenvit et al., 1991b, Marussig et al., 1997). Antibodies 
against the repeat region are able to immobilise sporozoites (Stewart et al., 1986), 
and neutralise their infectivity (Gantt et al., 2000). It was therefore thought that it 
would be beneficial to stimulate antibody responses to this protein. Studies have 
shown that the inclusion of MHCII CD4+T cells epitopes is necessary to induce 
high levels of antibodies against the repeat region of CS (Tsuji & Zavala, 2003), 
and expression and presentation of both T and B epitopes from the same protein 
should facilitate natural boosting (Bharadwaj et al., 1998). Having included full
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length antigens within the vectors constructed in this thesis, it would be likely that 
in addition to the induction of an IFNy response, antibody responses might also be 
induced.
For SSP2, which is known to play a central role in cell invasion, point mutations 
in the metal ion-dependent adhesion site greatly impair the ability of sporozoites 
to invade hepatocytes (Michishita et al., 1993), suggesting that again, antibodies 
against this protein might be beneficial. Although in some cases, a certain degree 
of inhibition of hepatocyte invasion has been achieved (Charoenvit et al., 1997, 
Rogers et al., 1992), antibodies against SSP2 have been suggested to be of low 
effectiveness against sporozoite invasion (Gantt et al., 2000). Passive 
immunisation experiments using high concentrations of antibodies against SSP2 
repeats very rarely showed protection against sporozoite challenge (Charoenvit et 
al., 1987, Rogers et al., 1992, Wang et al., 1996), and no protection was achieved 
either when high titres of anti-SSP2 antibodies against undetermined epitopes 
were induced (Khusmith et al., 1991). Nonetheless, being able to stimulate 
antibody responses to various antigens may well be important. This has been 
shown in monkeys, where beneficial antibody responses were stimulated to both 
the preerythrocytic and erythrocytic stages of malaria (Rogers et al., 2002) by 
immunisation with DNA and poxvirus expressing proteins from different stages of 
the malaria life cycle together with GMCSF.
The inclusion of GMCSF in a malaria vaccine has previously been shown to 
improve the level of protection induced by a plasmid vaccine by increasing both 
CD4 and CD8 responses and also enhancing the level of antibody produced 
against PyCS (Weiss et al., 1998). Also, the addition of GMCSF has been shown 
to increase the antibody responses induced by expression of full length PyCS gene 
(Weiss et al., 1998). As a vaccine able to combine both immune effector 
mechanisms is more likely to be efficient in protecting against infection, it was 
therefore decided to investigate the ability of vectors constructed to induce 
antibody responses to the delivered proteins, and to the virus, and to assess the 
effect of co-expressing GMCSF.
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Viruses used in this chapter
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Specific deletions and inactivations of each backbone are specified
X indicates inactivity of the gene either by deletion or inactivation 
—^  indicates the direction of gene expression
17+47-NP/vhsVP16- 
ICP47 gene deleted
vhs gene inactivated by insertion of the CMV-NP cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP 16 ICP27 ICP34.5 ICP4 ICP47 ICP4
X X 1
CMV
17+47 mGMCSF -NP/vhs VP 16~
ICP47 gene deleted
vhs gene inactivated by insertion mutation of the mGMCSF-NP cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP 16 ICP27 ICP34.5 ICP4 ICP47 ICP4
ImGMCSFl RSV
M-----
CMV
288
!7 +47- RS VGFP-CM VSSP2/vhs VP 1 &
ICP47gene deleted
vhs gene inactivated by insertion of the RSVGFP-CMVPySSP2 
cassette
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47 ICP4
CMV V': S S F 2  0fcSVGFP-CMVPySSP2 cassette
17+47- RSVGMCSF-CMVSSP2/vhsVP16- 
ICP47gene deleted
vhs gene inactivated by insertion of the RSVGMCSF-CMVPySSP2 
cassette
VP 16 gene with V422 mutation
ICP34 5 vhs UL43VP16 ICP27 ICP34.5 ICP4 ICP47ICP4
X
lhGMCSf RSV I CMV 1 SSP2 RSVOMCSF-CMVPvSSP2 cassette
\T 4 T  RS VGMCSF-CMVCS/vhs VP 16~
ICP47gene deleted
vhs gene inactivated by insertion of the RSVGMCSF-CMVPyCS cassette 
VP 16 gene with V422 mutation
ICP34.5 vhs UL43 VP16 ICP27 ICP34.5 ICP4 ICP47ICP4
foGMCSff RSV CMV
><r~
RSVGMCSF-CMVPyCS cassette
290
7.2 Antibody response to NP after immunisation with 17+47~NP/vhs VP16~ or
17+47 GMCSFNP/vhs VP16'.
The results in this thesis have shown that it is possible to induce an IFNy response 
to both the delivered antigen and to the virus vector two weeks after immunisation 
when using the 17+vhs"47"VP16‘ backbone. Depending on the pathology of 
interest and on the antigen, it may be beneficial to also induce a humoral response. 
It was therefore decided to determine the antibody responses induced by 
immunisation with 17+47'NP/vhs VP 16' and with 17+47'GMCSFNP/vhs VP16'.
7.2.1.Optimisation of the anti- NP antibody ELISA
The anti-NP antibody ELISA assay was optimised using different concentrations 
of purified NP protein to coat microtitre plates to identify the amount of NP 
allowing maximal sensitivity without non specific secondary antibody binding. A 
range of 1000ng-5ng of purified protein was tested both with and without the 
primary antibody to check for non-specific binding of secondary antibody (figure 
7.1). When coating with 40ng of NP, maximal OD was achieved with minimal 
secondary antibody binding (figure 7.1). This concentration was therefore used to 
coat plates to carry out assays on serum samples.
7.2.2 Detection of anti-NP antibodies in serum samples
The mice used for this experiment were those used for the experiment comparing 
the effect of GMCSF expression (§ 5.3.4). The groups of mice were non 
immunised, or received mature DC (DC only), mature DC loaded withNP peptide 
(DC NP), DC infected with 17+47“NP/vhs VP 16' (DCV), DC infected with 
GMCSF-NP virus (DCGM), neat NP virus (V), or neat GMCSF-NP virus (VGM). 
Serum from mice two weeks post-immunisation was tested for presence of anti- 
NP antibodies at the dilution (1:10) at which the OD value from non immunised 
mice and mice immunised with mature DC only was in the same range as the 
negative control (no serum) (figure 7.2). No difference could be seen between the 
groups (figure 7.2), implying that there was no anti-NP antibody response 
generated. The possible reasons for this will be discussed later.
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Anti-NP ELISA optimisation
n g  p e p t i d e with primary antibody no primary antibody
Figure 7.1: Anti-NP antibody ELISA optimisation
The ELISA test was optimised for the coating protein using a range 
(5ng-lpg) of purified NP and using a constant amount of commercial 
primary anti-NP antibody and secondary antibody (blue line, with 
primary controls).
The different amounts of protein were also tested for non specific 
binding of secondary antibody by carrying out the test omitting the 
primary antibody (pink line, secondary antibody only).
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Figure 7.2: Anti-NP antibody response
ELISA test showing the production of anti-NP antibodies in the serum 
of mice 2 weeks after immunisation with nothing (non immunised), 
mature DC (LPS DC), mature DC pulsed with NP peptide (DC NP), DC 
infected at MOI of 1 with 17+47-CMV-NP/vhsVP16 ‘ (DCVNP), or with 
17+47-GMCSF-NP/vhs VP 16 ' (DCVGMNP), or with 106pfu of neat 
17+47'CMV-NP/vhsVP 16 ' (VNP) or neat 17+47 ‘ GMCSF-NP/vhs 
VP16 " (VGMNP). The positive control is the value obtained by using 
commercial anti-NP antibody instead of serum and the negative control 
is the value obtained by using medium instead of serum.
Various dilutions o f the serum were tested (a) and the dilution where the 
value o f the negative control was similar to the non immunised mice 
(0.1 pi o f serum) was used for comparison of the groups (b).
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7.3 Antibody response to PvSSP2 after immunisation with 17+47 GFP- 
SSP2/vhs VP16 or 17+47 GMCSF-SSP2/vhs VP16
7.3.1 Optimisation of the anti-SSP2 antibody ELISA
The protective antibody domain of PySSP2 in Balb/c mice has still not been 
identified. Various peptides from the different domains of the protein have been 
tested (Gantt et al., 2000, Wang et al., 1996) but it has been shown, contrarily to 
what was expected, that the immunodominant domain is not in the extracellular 
repeat domain, nor in the A domain or in the N terminus of the protein (Gantt et 
al., 2000). Despite the fact that monoclonal antibodies against different peptides 
of the SSP2 repeats do not inhibit in vivo infectivity of P. yoelii sporozoites in 
Balb/c mice (Gantt et al., 2000, Wang et al., 1996), the (NPNEPS) 3 peptide was 
used in the experiments presented here for the detection of anti-SSP2 antibodies. 
Antibodies against this peptide alone are not protective in Balb/c though they are 
effective in A/J mice at protecting (Wang et al., 1996). However, using this 
peptide should show if antibodies against the PySSP2 protein are produced. 
Positive results from this test would encourage investigation of antibody 
production against whole sporozoites by IFA. ELISA plates were coated with the 
PySSP2 B cell peptide (NPNEPS)3 at concentrations varying between 750ng and 
lOng. To optimise the assay, the anti-SSP2 hybridoma supernatant antibody 
(F3B5, gift from Dr A.Rodriguez) was used as the primary antibody and the 
different peptide concentrations were tested both with and without this. The 
background staining of secondary antibody is very low even at high peptide 
concentrations. The optimal coating dilution was therefore determined with regard 
to the detection sensitivity. When using 50ng of peptide, the OD starts to drop 
slightly (figure 7.3). It was therefore decided to use 60ng of peptide per well 
which gave optimal results with minimal secondary antibody binding.
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Anti-SSP2 ELISA optimisation
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Figure 7.3: Anti-SSP2 antibody ELISA optimisation
The ELISA test was optimised for the coating peptide using a range 
(10ng-750ng) of SSP2 (NPNEPS)3 peptide and using a constant 
amount of primary' anti-SSP2 antibody and secondary' antibody (blue 
line, anti-SPP2).
The different amounts of coating peptide were also tested for non 
specific binding of secondary antibody by carrying out the test omitting 
the primary antibody (pink line, no primary Ab).
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7.3.2 Detection of anti-SSP2 Ab in serum samples of mice two weeks after 
immunisation
The antibody response induced by immunisation with the different viruses was 
investigated by performing a sandwich ELISA assay on serum samples of 
immunised mice. The sera from the same mice that had previously been tested for 
IFNy responses (§6.2.3) were analysed for the presence of anti-SSP2 antibodies. 
Three mice per group had been immunised with either nothing, LPS mature DC, 
mature DC that had taken up the CD8+CTL SSP2 peptide, DCs infected with 
17+47' GFP-SSP2/vhs VP 16', DCs infected with 17+47'GMCSF-SSP2/vhs VP16', 
neat 17+47' GFP-SSP2/vhs VP 16', or neat 17+47'GMCSF-SSP2/vhs VP16'. The 
serum was removed together with the spleen from each mouse two weeks after 
immunisation and tested for presence of anti-SSP2 antibodies (figure 7.4).
Similarly to the experiment carried out for the NP expressing viruses, different 
dilutions of serum were tested (figure 7.4a). The signal obtained was very low at 
all concentrations used. When testing 1 pi of serum, the values obtained from non 
immunised mice and mice immunised with mature DC were similar to the 
negative control (no serum). These were therefore considered further (figure 
7.4b), but unfortunately no difference could be seen between the different groups 
(figure 7.4b). As for the IFNy response, the effect of GMCSF on the production of 
anti-SSP2 antibodies was investigated using slightly larger groups for 
immunisation with neat virus (figure 7.5). Contrarily to the IFNy responses, no 
difference could be attributed to GMCSF, suggesting that no antibody response is 
produced after two weeks immunisation with the 17+47 GFP-SSP2/vhs VP 16 or 
17+47’GMCSF-SSP2/vhs VP 16' viruses, as was the case for NP. Strangely two 
high responses appeared at 0.01 pi and 0.001 pi of the vGMSSP2 sample, this can 
probably be attributed to handling of the sample during dilution of the samples.
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Figure 7.4: Anti-SSP2 antibody responses
ELISA test to detect anti-SSP2 antibodies in the serum of mice 2 weeks 
after immunisation with nothing (non imm), mature DC (DC only), 
mature DC pulsed with SSP2 peptide (DC SSP pep), DC infected at MOI 
of 1 with 17+47'GFP-SSP/vhsVP 16 ' (DCVGFPSSP), or 17+47 - GMCSF- 
SSP/vhs VP 16 - (DCVGMSSP), or with 106pfu of neat 17+47'GFP- 
SSP/vhsVP16 - (VGFPSSP) or neat 17+47 ' GMCSF-SSP/vhs VP 16 ' 
(VGMSSP). The negative control is the value obtained by using medium 
instead of serum.
Various amounts of the serum were tested (a) and that in which the 
negative control was similar to the non immunised mice (0.1 pi of serum) 
was used for comparison of the groups (b).
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Large scale study of V only injection: anti-SSP Ab produced by immunisation
Anti-SSP Ab produced by V only injection
Figure 7.5: The effect of GMCSF on antibody responses to SSP2
Anti-SSP2 ELISA using serum from non immunised mice (yellow) or 
mice immunised 2 weeks previously with 106pfu of 17+47'GFP- 
SSP/vhsVP16 - (VGFPSSP) or 17+47 - GMCSF-SSP/vhs VP 16 “ 
(VGMSSP). (a) Various amounts were tested and compared to the 
negative control (media alone), (b) The amount of serum at which non 
immunised mice give values similar to the negative control (lpl) was 
used to compare the different groups.
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7.4 Antibody response to PyCS after immunisation with 17+47 GMCSF-
CS/vhs VP16"
7.4.1 Optimisation of the anti-CS ELISA assay
Passive transfer of monoclonal antibodies against PyCS protect animals against 
malaria, (Ak et ak, 1993). It was therefore important to determine if the viruses 
constructed would induce a humoral response against this protein. As for the 
previous assays, the presence of anti-CS antibodies in the sera of immunised mice 
was determined by sandwich ELISA. Plates were coated with the B cell 
immunodominant peptide of PyCS (QGPGAP)2. The B cell epitope of PyCS has 
been mapped to the repeat region of the protein. The (QGPGAP)2 peptide has 
been extensively studied and used for immunisation or in ELISA for identification 
of antibodies in the serum (Charoenvit et al., 1991b). Being able to determine the 
presence of antibodies against this peptide may provide an insight into protective 
immunity (Charoenvit et al., 1991b), as immunisation of Balb/c mice with a 
multiple antigen peptide containing a T epitope and three QGPGAP repeats as a B 
cell epitope has previously shown protection against challenge with sporozoites. 
Here the level of anti-repeat antibodies correlated with anti-parasite antibodies 
and protection. Protection did not depend upon CD4 or CD8 cells (Marussig et al.,
1997). In addition, passive transfer of antibodies against the (QGPGAP)2 region 
were shown to induce protection, therefore indicating that this region is an 
important target of antibodies (Ak et al., 1993).
To optimise the anti-CS ELISA assay, microtitre plates were coated with various 
dilutions of the peptide to determine the optimum coating concentration that 
would allow maximal antibody detection with minimal non specific binding of 
secondary antibody. Peptide concentrations were tested in a range from l-1000ng 
(figure 7.6). Similarly, the 9D3 anti-CS antibody raised against this peptide and 
used in the assay (gift from Dr Tsuji) was tested at varying dilutions.
It appeared that the maximal level of detection that could be obtained was 
relatively low, only reaching OD 1.3. Using higher concentrations of antibody did 
not improve detection of the peptide but resulted in even higher background when 
no peptide was present. It was decided to use the antibody at 1.50 since the
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purpose of the experiment was as a positive control to ensure the functionality of 
the assay, regardless of background staining, and lower concentrations of 
antibodies strongly decreased the level of detection without considerably 
decreasing the background. Coating of the wells using 750ng/well gave very low 
signal when no antibody was added, but a strong signal in presence of antibody 
and was used for the assay as described below.
-anti-C S  1:50
-  m - anti-CS 1:100
anti-CS 1:500
-anti-C S  1:1000
—* - -n o  primary Ab
Anti-CS ELISA optimisation
o  o  o  m  o  m  10
10 o  in  cm t -
CM t -
ng CS peptide
Figure 7.6: Anti-CS antibody ELISA optimisation
The ELISA test was optimised for the coating peptide using a range (lng-lpg) of 
CS (QGPGAP)3 peptide and for the primary' antibody 9D3 using a range of 
dilutions (1:50-1:1000) but using constant amounts of secondary antibody.
The different amounts of coating peptide were also tested tor non specific 
binding of secondary' antibody by carrying out the test omitting the primary 
antibody (purple line, no primary Ab).
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7.4.2 Measurement of anti-CS antibody level in serum two weeks after 
immunisation
Sera were collected from mice two weeks after immunisation with either nothing, 
mature DC, mature DCs loaded with the CS CD8+ CTL peptide, DC infected ex- 
vivo with 17+47’GMCSF-CS/vhs VP16\ or with 17+47'GMCSF-CS/vhs VP 16" 
directly. Serial dilutions of the sera were tested for presence of anti-CS antibodies 
(figure 7.7). However, as before, none of the groups showed detectable antibody 
levels looking at 1:10 dilution (figure 7.7). Considering that no response could be 
obtained from immunisation with the viruses expressing NP or SSP2 either, the 
inability to detect antibody production in this experiment is unlikely to be due to 
the low maximal detection level of the assay, but possibly due to the 
immunisation regime.
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Figure 7.7: anti-CS antibody response
ELISA test showing the production of anti-CS antibodies in the serum 
of mice 2 weeks after immunisation with nothing (non imm), mature 
DC (LPS DC), mature DC pulsed with CS peptide (DC CSpep), DC 
infected at MOI of 1 with 17+47GMCSF-CS/vhsVP16 ' (DCV), or 
with 106pfu of neat 17+47'GMCSF-CS/vhsVP16 * (VGMCS). The 
positive control is the value obtained by using anti-CS antibody instead 
of serum and the negative control is the value obtained by using 
medium instead of serum.
Various amounts of the serum were tested (a) and the amount at which 
values from of the negative control and the non immunised mice were 
similar (0.1 pi) was used for comparison of the groups (b).
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7.5 Antibody responses to HSV-1
Previous results have shown (§ 5.2.2.2, 5.2.3.3) that following neat virus injection 
as well as following injection of infected DCs, there is stimulation of strong IFNy 
response against the virus backbone. Although no antibody response to NP, SSP2, 
or CS could be detected, it was of interest to investigate whether antibodies 
against the virus could be detected two weeks after immunisation.
The same serum samples that had been used to look at anti-NP antibody responses 
were used in an HSV1 neutralisation assay. The assay consists (figure 7.8) of the 
incubation of serum samples with a known amount virus (17+47'NP/vhsVP16') 
and this was then plated on cells that allow virus growth and the titre of the virus 
then counted. All samples were titered in duplicate. If antibodies against the virus 
were present in the serum, these should neutralise the free virus resulting in a 
decrease in titre. Alternatively, if immunisation had not produced antibodies 
against the virus the titre of the input virus should remain unchanged.
In this experiment, effective neutralisation of virus was seen, but only after 
immunisation with neat virus and not following immunisation with infected DCs 
(figure 7.9). In addition, although the differences were small, the neutralisation 
appeared to be slightly enhanced in mice immunised with the virus expressing 
GMCSF.
These results therefore show that antibodies are being produced against the virus, 
although the detected antibody levels were not increased. That antibodies did not 
appear to also have developed against the delivered protein is perhaps not entirely 
surprising as the antibody response against all viral epitopes of all viral structural 
proteins are effectively being tested here, whereas antibodies against only one 
epitope were investigated for the responses to NP, SSP2 or CS. Since the anti- 
HSV response is only obtained following neat virus injection, it seems possible 
that there is predominant infection of cells other than DCs.
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Figure 7.8: Schematic representation of neutralisation assay
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Figure 7.9: Anti-HSV antibody response
HSV-1 neutralisation assay using serum samples from mice immunised 
2 weeks previously with nothing (non immunised), mature DC (DC 
only), mature DC pulsed with NP peptide (DC NPpeptide), DC 
infected at MOI of 1 with 17+47 CMV-NP/vhsVP16 ' (DCVNP), 17+47 
* GMCSF-NP/vhs VP 16' (DCVGMNP) or with 106pfu of neat 17+47' 
CMV-NP/vhsVP 16 ' (VNP) or neat 17+47 ' GMCSF-NP/vhs VP 16' 
(VGMNP). Serum was incubated with 17+47 CMV-NP/vhsVP16 ' and 
then plated on BHK cells for plaque formation. The groups are 
compared to the sample in which no serum was added (no serum/input 
virus) confirming the initial amount of input virus. The responses from 
individual mice (a) or the average of the groups (b) are shown.
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7.6 Effect of boosting for two weeks on the induction of antibody responses
7.6.1 Effect of boosting on the induction of the antibody response to NP
The previous results suggested that two weeks were not enough to induce an 
antibody response against the recombinant protein carried by the virus although a 
humoral response could be stimulated against the virus itself. Considering that the 
onset ot an antibody response is much amplified by a boosting dose (diagram 7.1), 
it was thought that undertaking a prime-boost regime would be beneficial.
 ^ Secondary response
Ab production
Primary response
Time
BoostImmunisation
Diagram 7.1 Representation o f  the dynam ics o f  an antibody response.
The effect of boosting was only investigated on the serum form mice immunised 
with neat virus. 106 pfu of 17+47'GMCSFNP/vhs VP 16' were injected in the flank 
and footpad of mice, using three mice per group. Non immunised mice were kept 
as controls. Two weeks after the first immunisation, mice received an identical 
boost immunisation and were then sacrificed two weeks later. All three mice that 
had received the virus showed a convincing antibody response (figure 7.10). 
Boosting therefore gave an advantage for the induction of a humoral response 
against the recombinant protein carried by the virus.
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7.6.2 Effect of boosting on the induction of the antibody response to PySSP2 
Using the 17+47'GFP-SSP2/vhs VP 16' and the 17+47'GMCSF-SSP2/vhs VP 16' 
viruses, it was possible to look both at the effect of boosting on the stimulation of 
anti-SSP2 Ab responses and at the effect of GMCSF on the induction of this type 
of response. Three mice per group received flank and footpad injections of 106 pfu 
of either viruses and two weeks after the first injection a second dose was 
administered for an additional two weeks before collecting the sera.
Serial dilutions of the serum from each immunised or non immunised mouse were 
tested for presence of anti-SSP2 Ab where it appeared that both mice immunised 
with 17+47’GFP-SSP2/vhs VP 16" or 17+47'GMCSF-SSP2/vhs VP16’ were able to 
produce anti-SSP2 antibodies. The values obtained from non immunised mice 
were slightly higher than the negative control (no serum) but even when the 
dilution at which these controls gave similar values (0.1 pi) it was possible to see a 
clear positive result in immunised mice.
Comparing the two viruses used is possible to conclude that expression of 
GMCSF does not induce stronger antibody responses in this case.
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Figure 7.10: Anti-NP antibody response after 2 weeks boosting
Presence of anti-NP antibody in the serum of mice receiving a boosting 
injection two weeks after the primary immunisation with nothing (non 
immunised) or with 106pfu of 17+47'GMCSF-NP/vhs VP 16 
(GMCSFNP). Serum was removed two weeks following the boost and 
various amounts were tested (a). The negative control is the value 
obtained by the addition of medium instead of serum and the positive 
control is the value obtained using the commercial anti-NP antibody 
instead of the serum sample. A comparison of the groups (b) was made at 
the amount of serum where non immunised mice give similar values to 
the negative control.
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Figure 7.11: Anti-SSP antibody production after boosting: effect of 
GMCSF
Anti-SSP2 ELISA on serum samples from non immunised mice 
(yellow), or mice receiving a boost two weeks after immunisation with 
106pfu of 17+47*GFP-SSP/vhsVP16 " (GFPSSP, blue) or neat 17+47 ' 
GMCSF-SSP/vhs VP 16 ' (GMCSFSSP, pink). Serum was collected two 
weeks after boosting and tested at various dilutions and compared to the 
values obtained from using medium (negative, red) or F3B5anti-SSP2 
(positive, green) instead of serum samples (a). The groups were 
compared more specifically at the serum dilution where non immunised 
mice give similar results to negative control (0.1 pi) (b). The ellect ol 
GMCSF can be seen comparing the results from virus not containing the 
cytokine (blue) with those from immunisation with GMCSF virus 
(pink).
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7.6.3 Effect of boosting on the induction of the antibody response to PyCS
Three mice per group were immunised with 106 pfu 17+47'GMCSF-CS/vhs VP16* 
in one flank and footpad and boosted two weeks later with the same virus for a 
further 14 days before collection of serum.
Testing of serial dilutions of the sera (figure 7.12) showed a strong anti-CS 
antibody response following this immunisation regime.
Anti-CS Ab production after boosting
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Figure 7.12: Anti-CS antibodies produced after boosting
Anti-CS ELISA on serum sample of non immunised mice (yellow) or 
mice receiving a primary immunisation with 17 47 GMCSF- 
CS/vhsVP16 ' (GMCSFCS, blue) and a boost with the same virus two 
weeks later. Serum was removed 14 days following the boost, tested at 
various dilutions for anti-CS antibodies and compared to values obtained 
using medium (negative, red) or 93D anti-CS antibody (positive, green) 
instead of serum. The effect of the virus can be seen at every dilution 
comparing yellow and blue results and more specifically when using 1 pi 
of serum where non immunised mice have similar values to the negative
control.
3 10
7.6.4 Effect of boosting on the stimulation of the antibody response to HSV1
As for the recombinant protein, the response to HS V1 was expected to be stronger 
after boosting the immunisation. The serum samples from three mice immunised 
with 17 47 GMCSFNP/vhs VP 16, or non immunised, were tested in a 
neutralisation assay using 17+47 GMCSFNP/vhs VP 16' as input virus. As 
expected, virus was neutralised after boosting (figure 7.13), although, as no serial 
dilution of the serum was performed, the strength of the response can not be 
compared.
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Figure 7.13: Anti-HSVl antibodies after boosting
Neutralisation assay on serum samples from non immunised mice 
(blue) or mice receiving a first immunisation with 17+47~GMCSF- 
NP/vhsVP16 ' (GMCSFNP) and a boost with the same virus two weeks 
later. Serum was removed 14 days following the boost and incubated 
with neat 17+4 7  GMCSF-NP/vhsVP16 ' before plating on BHK cells 
for plaque assay. The serum samples can be compared to the number of 
plaques obtained by incubating the virus with medium instead of virus 
(yellow), this value corresponds to the amount of input virus.
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virus
Anti-HSV Ab production after boosting
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7.7 Discussion
The results presented in this chapter have shown that in addition to cellular 
responses, HSV1 vectors can induce an antibody response both to the recombinant 
protein and to the virus.
It was surprising to see that antibodies against NP, CS, or SSP2 could only be 
detected after boosting. Previous studies have shown an antibody response to NP 
three weeks after single immunisation with a highly attenuated modified vaccinia 
Ankara (MVA) (Sutter et al., 1994) and that an immunisation with a replication- 
defective recombinant adenovirus expressing the PyCS protein induced, in 
addition to CD8 responses, high titres of anti-sporozoite antibodies (Rodrigues et 
al., 1997). Similarly, influenza virus expressing only the B cell epitope of PyCS or 
both the B and CD8 epitopes could stimulate antibody production after a single 
immunisation (Rodrigues et al., 1994) as did immunisation with a non linear 
peptide expressing the B cell epitope of PySSP2 (Wang et al., 1996). The results 
therefore suggest that HSV1 is not as efficient as the other viruses in stimulating a 
humoral response or alternatively that two weeks is an insufficient time for such 
responses to be efficiently stimulated. There is, however, an anti-HSV response, 
present two weeks after a single immunisation detectable in a neutralisation assay. 
That there is an anti-delivered protein antibody response present at two weeks is 
supported by the fact that the other studies mentioned mostly relied on 
immunofluorescence assays (IFA) to identify antibodies, using sporozoites or 
recombinant protein, which has been shown to be more sensitive than the ELISA 
test presented here using peptides (Sedegah et al., 2002). Another reason for the 
lack of response after the first immunisation might be the insufficient amount of 
protein expressed which could also explain the lack of enhancing effect from 
GMCSF expression. Experiments using recombinant adenovirus expressing PyCS 
showed that the response seen 12 days post-injection was dose related (Rodrigues 
et al., 1997), it is therefore possible that using a higher dose of HSV vector would 
result in detection of antibodies after the first immunisation.
A second injection was expected to increase the antibody response (diagram 7.1), 
and this turned out to be the case as robust antibody responses against the
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recombinant proteins could then be detected. Being able to detect anti-NP, CS, or 
SSP2 antibodies after boosting is a sign that the strong neutralising response to the 
virus does not prevent the response to the recombinant proteins and suggests that 
the inability to detect antibodies after the primary immunisation is likely to be due 
to low levels of response rather than its absence. A 3-15 fold increase in the 
antibody response to NP has previously been reported after boosting a 
recombinant MVA immunisation (Sutter et al., 1994). Also, maximal responses 
have previously been obtained two weeks after boosting with vaccinia virus or 
MVA expressing PyCS (Gonzalez-Aseguinolaza et al., 2003). Less work has been 
performed using SSP2, but an increase in antibody responses have been detected 
in chimpanzees following three DNA immunisations and a boost of MVA 
expressing the same full length protein (Schneider et al., 2001). It could be that 
the initial low levels of antibodies produced against the recombinant proteins may 
give protection, but increasing this response as following boosting would be 
expected to be beneficial.
It would have been interesting to determine the isotype of antibodies produced 
both to HSV1 and to the proteins to confirm a Thl type response. The fact that 
IFNy is released as a cellular response to this immunisation is an indication of a 
Thl mechanism, which seems to be appropriate to protect against malaria 
challenge (Wang et al., 1996). Anti-viral antibodies are only detected after neat 
virus injection and not after immunisation with infected DCs. This suggests that 
activation of B cells takes places via a CD4T cell mechanism rather than by direct 
contact of DC with B cells. Also, it indicates that the virus may infect other cell 
types that present viral antigens and activate B cells in a type 1 mechanism.
The advantages of being able to stimulate antibodies against PyCS or PySSP2 in 
particular, is still not clear. Passive transfer of anti-PyCS antibodies in Balb/c 
(Charoenvit et al., 1991b), and immunisation with adenoviruses expressing full 
length PyCS (Rodrigues et al., 1997) could induce both CTL and antibody 
responses upon s.c. immunisation and have led to protection, but numerous other 
studies have shown that induction of antibody responses in addition to CTL 
responses to malaria proteins is very often not necessary for protection (Khusmith
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et al., 1991, Wang et al., 1996). It has been suggested that the reason that anti- 
SSP2 antibodies are not protective is that the protein is only released in close 
proximity of the cell to be infected, in which case antibodies only have a minimal 
opportunity to bind (Gantt et al., 2000). Nonetheless, having demonstrated 
production of antibodies is encouraging because the data presented here, 
especially tor PyCS, reflects production of antibodies specific for the epitope that 
is known to be important for protection. When using full length genes, antibodies 
may in fact be raised against loci of the protein that do not play a role in 
protection, as demonstrated in a PyCS vaccine study carried out in monkeys 
(Charoenvit et al., 1991a). Expression of the B cell epitope of PyCS alone can 
confer a certain level of inhibition of the plasmodial liver stages (Rodrigues et al., 
1994), and, in addition, the presence of both B and CTL epitopes of PyCS does 
not compromise the strength of responses of either, thus supporting the use of a 
full length gene and presentation of multiple antigens.
Being able to induce the highest possible antibody response may well be an 
advantage in the construction of a vaccine in order to achieve protection (Sedegah 
et al., 2000), and co-expression of GMCSF may help in doing this. The additional 
expression of GMCSF has previously been demonstrated to increase not only 
CTL responses but also antibody responses in mice immunised with plasmids 
encoding P. yoelii proteins and boosted with a recombinant poxvirus expressing 
the same protein (Hoffman & Doolan, 2000). Similarly, the level of antibodies has 
also been shown to be increased by GMCSF expression in monkeys by a live 
attenuated parainfluenza virus vaccine (Bukreyev et al., 2002). Addition of 
GMCSF in a plasmid based vaccine against PyCS has also been shown to increase 
the amount of antibody produced possibly in a CD4 T cells dependent fashion 
(Weiss et al., 1998). Despite the encouraging literature, in the previous chapter 
GMCSF co-expression from HSV-1 did not prove to have an enhancing effect on 
IFNy responses. Therefore, not surprisingly, no advantage was seen of the 
expression of this cytokine in the antibody response against the recombinant 
proteins. From the data presented here, expression of GMCSF seems to have an 
effect mostly on the antiviral response after single immunisation, where the virus 
seems to be neutralised to a higher extent when GMCSF is expressed.
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Contrary to a hepatitis B vaccine study where the addition of GMCSF led to 
antibody production after a single immunisation (Tarr et al., 1996), here GMCSF 
did not influence the level of response after boosting either. The reason for the 
effect of GMCSF may be due to the amount of protein produced and antigen 
presented and to the strength of the initial response, which seemed to be higher for 
the virus than the recombinant protein. The response obtained by boosting may be 
possibly enhanced further by increasing the time between the priming and the 
boosting (Bruna-Romero et al., 2001, Gonzalez-Aseguinolaza et al., 2003) and 
this might even produce enough antigen and cytokine to allow for GMCSF to 
have an effect.
Overall, the results obtained in this study, show specific induction of both 
branches of the immune system, with potential for malaria protection studies 
(Rodrigues et al., 1997). Despite the fact that antibodies to CS and SSP2 in 
particular have never been shown to be essential for protection, partially protected 
individuals in endemic areas show a response largely mediated by antibodies 
directed against blood stage antigens (Rogers et al., 2002). Therefore, having been 
able to show that it is possible to use this particular viral backbone to stimulate 
antibody responses is important, since it could be used to express other antigens, 
towards which an antibody response may be more important to give protection. 
MSP1 would be an appropriate antigen to include in such vaccine since antibodies 
against the C terminal of this protein have been associated with resistance to 
clinical malaria (Egan et al., 1996). Monoclonal antibodies against this protein are 
present in immune individuals and may account for the inhibition of invasion 
(Weiss et al., 1998) as well as inhibiting parasite growth in vitro (Egan et al., 
1996). Alternatively, apical membrane antigen 1 (AMA1) would also be a good 
candidate considering that antibodies against this protein can inhibit erythrocyte 
invasion by merozoites (Plodder et al., 2001). Finally, MSP3 or glutamine-rich 
protein (GLURP) may be two more candidate proteins from the blood stage of the 
disease that would be appropriate to include in a vaccine able to stimulate 
antibodies since they can induce antibodies able to inhibit the growth of the 
parasite (Hodder et al., 2001, Oeuvray et al., 2000). Erythrocyte membrane 
protein 1 (EMP1) would also be an ideal candidate for such vaccine given its role 
in cyto-adherence of erythrocyte to endothelial cells, but the very high
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in cyto-adherence of erythrocyte to endothelial cells, but the very high 
polymorphism of this protein and the presence of a large number of copies of this 
gene within each parasite might render antibodies against this protein ineffective 
(Richie & Saul, 2002).
Having identified that a boosting regime using neat virus is possibly the most 
suitable immunisation regime, it would have been appropriate to investigate the 
IFNy response induced under these conditions. Extrapolating the results obtained 
by immunisation of one month followed by boost, it is possible to suggest that an 
improved cellular response might have been obtained too.
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Chapter 8
General Discussion
HSV naturally infects dendritic cells (Coffin et al., 1998, Kruse et al., 2000, 
Mikloska et al., 2Q01, Salio et al., 1999) probably as an immune evasion 
mechanism since it prevents the cell from undergoing maturation (Kruse et al., 
2000, Salio et al., 1999) and thus from presenting viral antigens to the immune 
system. HSV also expresses genes that disrupt the antigen presentation 
mechanism. This thesis has shown that HSV-1 with the virus host shutoff (vhs), 
and ICP47 proteins removed, and with the V422 mutation (Lam et al., 1996, 
Smiley & Duncan, 1997)in the VP 16 gene can efficiently infect both human and 
mouse dendritic cells without compromising their ability to undergo maturation, 
allowing stimulation of immune responses in vivo.
The vhs protein had previously been shown to play a role in inhibiting maturation 
of HSV1 infected human dendritic cells (Samady et al., 2003). In this thesis it has 
been shown to have a similar function in mouse dendritic cells. Although 
removing only vhs from the viral backbone allowed for an improvement in the 
ability of the infected cells to mature, further attenuation of the virus by including 
the V422 transactivation terminating mutation in the C-terminal activation domain 
of the VP 16 gene is necessary to allow complete maturation of the infected DCs. 
The ICP47 gene was also deleted so as to maximise antigen presentation. It was 
concluded that the 17+vhs'47'VP 16' backbone had the required characteristics for 
use as a vector for immunotherapy.
Injection of 17+vhs'47'VP16‘ based viruses, or of dendritic cells infected with 
these viruses into the footpad of mice resulted in the trafficking of viral antigens 
to the draining lymph nodes, which also showed an increased CD1 lc cellularity. 
Immune responses are usually initiated in the lymph nodes where dendritic cells 
loaded with antigen drain from the infected site, and present peptides to naive T 
cells within the node. Identification of the production of peroxidase in the LN was 
an indication of antigen arrival and presentation, and thus the probable initiation 
of an immune response. An increase of DC cellularity in the LN is also an 
indication of an ongoing immune response. This observation therefore implied 
that ex-vivo or in-vivo infected DCs retain their ability to mature and migrate in 
vivo, and to possibly induce an immune response. Injection of neat virus appeared 
to stimulate the highest level of CD1 lc cell accumulation.
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Viruses with the 17 vhs 47 VP 16 backbone expressing influenza NP or 
plasmodium yoelii SSP2 or CS protein from the vhs site were constructed and 
used to investigate the possibility of using this vector to stimulate an immune 
response. Two weeks after subcutaneous immunisation in both flank and footpad, 
a CTL response to both the virus and recombinant protein could be detected, 
identified by IFNy release from splenocytes. It appeared that splenocytes are 
activated by immunisation with non-transduced dendritic cells and that the NP 
peptide, but not the SSP2 or CS peptides are sufficient to prime these T cells in 
vitro. Despite these technical difficulties, the results obtained from the 
immunisation with the viruses expressing SSP2 or CS indicated the ability of this 
vector to induce a CTL response two weeks after immunisation with infected DCs 
or with neat virus.
In contrast to the results obtained from cell migration, immunisation with ex-vivo 
infected cells appeared to in general be slightly more efficient at generating a CTL 
response than using neat virus, although these differences were not significant. 
Injection of viral vectors is expected to induce a response both to the virus and to 
the delivered protein, and it is fundamental that a balance between the two occurs 
such that one does not block the other. Injection of infected DCs, but not of neat 
virus, one month after immunisation, was shown to stimulate an anti-viral 
response that was possibly too strong to allow a boosting regime, although this 
was necessary to ensure good antibody production to the delivered protein. The 
detection of a response to the protein after single (2 weeks) or repeated (1 month 
and 2 weeks) immunisation with neat virus is an indication that the anti-viral 
response does not mask the response directed against the delivered protein, 
showing that a balance has been achieved in the construction of the vectors.
Co-expression of cytokines, and of GMCSF in particular, has often been 
identified as a valuable means of enhancing the immune response (Weiss et al., 
1998). In the case of GMCSF this is by stimulating DC recruitment. Contrary to 
the positive effect that GMCSF has when expressed from plasmid (Weiss et al.,
1998) or adenovirus (Wang et al., 2002), coexpression of GMCSF from HSV-1
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resulted in an increase in the level of response in only one case: injection of DCs 
infected with virus encoding NP. The effect of GMCSF on the ability of a viral 
vector to induce an immune response would not be expected to be determined by 
the particular recombinant protein expressed. Since GMCSF did not show any 
enhancing effect from injection of DCs infected with viruses expressing PySSP2, 
or from immunisation with neat virus expressing NP or PySSP2, it was concluded 
that, in general, GMCSF has no effect on the strength of the response induced 
when expressed from the HSV vectors. Despite the inability of GMCSF to 
enhance the immune response in this case, GMCSF was still shown to have a 
beneficial effect by improving reproducibility of the response induced when 
injecting neat virus, regardless of the antigen expressed. The amount of GMCSF 
released by the ex-vivo or in-vivo infected cells is important (Miller et al., 2002). 
Possibly, in these experiments, inefficient GMCSF was released to stimulate an 
increase in the response, although sufficient amounts were present to ensure a 
minimal but constant flow of DC recruitment, possibly accounting for the' 
reproducible response.
Malaria is a multistage pathology that comprises both intracellular and 
extracellular phases. Vaccines in development are using vectors that express 
antigens (full length or peptides) from various stages of the disease (Ockenhouse 
et al., 1998, Shi et al., 1999, Tine et al., 1996), indicating that both cellular and 
humoral responses are thought to be important. Ideally, a vaccine vector should be 
able to stimulate both branches of the immune system allowing application to a 
variety of pathologies independent of the type of protective response required. 
The 17+vhs*47‘VP16" based HSV1 vectors expressing GMCSF together with NP, 
PySSP2 or PyCS, were shown to stimulate production of antibodies against the 
vector and the recombinant proteins. Interestingly, virus neutralising antibodies 
are only detected after neat virus injection and not after immunisation with 
infected DCs indicating that the virus, in vivo, probably infects different cell types 
(eg. macrophages) that trigger a mechanism that is more efficient than ex-vivo 
infected DCs at stimulating antibody responses.
That a boosting regime was necessary to detect antibodies against the recombinant 
proteins implied that a single immunisation only produced relatively low levels of
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antibody. A boosting regime, however, resulted in a strong antibody response 
against the recombinant proteins that was not masked by the response against 
HSV.
Overall, this study has shown that immunisation with neat 17+vhs'47‘VP16' based 
viruses expressing GMCSF together with a delivered protein can stimulate a Thl 
type response inducing production of CTL (IFNy release) and antibodies against 
the delivered protein, in this case from malaria. A prime-boost regime appears to 
allow a better humoral response, and may also be appropriate for a maximal 
cellular response, although cellular responses following two weeks priming and 
two weeks boosting need to be determined. The finding that injection of neat virus 
is as efficient as immunisation with infected DCs provides a potential advantage 
in vaccine development as this reduces the complexity of the treatment.
The results are promising seen that experiments aimed at achieving protection 
against malaria challenge might similarly be performed in mice. However, more 
work should be undertaken using the HSV-1 vector, particularly investigating its 
ability to induce similar levels of immune responses when expressing multiple 
malaria proteins together. LSA1 is a good candidate since expressed by liver stage 
parasites and studies on naturally exposed populations have revealed a connection 
between protection and immune responses against this protein (Kurtis et al., 
2001). MSP1 is another antigen of interest since responses, in particular 
antibodies against it would block entry into RBC. The use of multiple antigens is 
now recognised as one of the best strategies in malaria vaccine development, 
particularly due to the high antigenic polymorphism of malaria protein and as it 
has already been shown that this does not induce inhibiting competition between 
antigens (Saul et al., 1999). Ring infected erythrocyte surface antigen (RESA) and 
apical membrane antigen are two more antigens that should be included in a 
multiantigen vaccine.
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Glossary
Hi: microliter
aa: amino acid
AAV : Adeno associated virus
Ab: Antibody
ADCC: antibody dependent cellular cytotoxicity
AdPyCS: Adenivirus expressing PyCS
AEC: 3-amino-9-ethyl-carbazole
Ag: Antigen
AMA: Apical membrane antigen
APC : Antigen presenting cell
APL : Altered peptide ligand
ARE: AU-rich elements
BHK: Baby hamster kidney cells
BM : Bone marrow
BMDC: Bone marrow dendritic cell
bp: Base pair
BSA: Bovine serum albumin
CAR: Coxsackievirus and adenovirus receptor
OCR: CC receptor molecule
CD: Cluster determinant
CEA: Carcinoembryonic antigen
CIAP: Calf intestinal alkaline phosphatase
CLP : Common lymphoid precursor
CMP : Common myeloid precursor
CMV: Cytomegalovirus
CNS: Central nervous system
CPE: complete cytopathic effect
CS : Circumsporozoite surface protein
CTL: Cytotoxic T lymphocyte
DAB: B iaminobenzidine
DC : Dendritic cell
DEPC: Diethylpyrocarbonate
DISC: Disabled infectious single cycle
DMED: Dulbecco’s Modified Eagle medium
DMF: N,N-dimethylformamide
DMSO: Demethylsulphoxide
DNA: Deoxyribonucleic acid
DRG: Dorsal root ganglia
E: Early genes
EBV: Epstein-Barr virus
ELISA: Enzyme liked immunosorbent assay
ELISPOT: Enzyme linked immunospot assay
EMP: Erythrocyte membrane protein
FACS: Fluorescence activated cell sorting
FCS: Foetal calf serum
f.p: Footpad
FP: Fowlpox
g: gram
GFP: Green fluorescent protein
GLURP: Glutamine-rich protein
GMCSF: Granulocyte monocyte colony stimulating factor
HbsAg: Hepatitis B surface antigen
HBSS: Hank’s balanced salt solution
HCF: Host cell factor
HEV: High endothelial venules
HHV: Human herpes virus
HIV: Human immunodeficiency virus
HMBA: Hexamethylene bisacetamide
HRI3: Horse radish peroxidase
HSV: Herpes simplex virus
HVEM: Herpes virus entry mediator
ICP: Infectious cell protein
i.d.: intradermal
IE: Immediate early
IFA : immunofluorescence assay
IFN: Interferon
Ig: Immunoglobulin
IL : Interleukin
i.m.: intramuscular
IRE: Interferon response element
IRES: Internal ribosome entry site
IRF: Interferon regulatory factor
ISG: Interferon stimulated gene
ITR: I nverted terminal repeat
i.v: Intravenous
Kb: Kilobase
kDa: KiloDalton
L: Late genes
LAT: Latency associated transcripts
LB: Luria Bertani
LCMV: Lymphocytic choriomeningitic virus
LN : Lymph node
LPS : Lypopolysaccharide
LSA: Liver stage antigen
LTR : Long terminal repeat
M: Molar
MAC: Membrane attack complex
MAP: Multiple antigen peptide
MDC: Macrophage derived chemokine
ME: Multiple epitope
mGMCSF: mouse GMCSF 
MHC: Major histocompatibility complex
MIP: Macrophage inflammatory protein
ml: millilitre
MLV: Murine leukaemia virus
MMLV: Moloney murine leukaemia virus
MOI: Multiplicity of infection
MSP: Merozoite surface protein
MVA: Modified vaccinia Ankara
NK: Natural killer
NP: Nucleoprotein
NYVAC: New York vaccinia strain
OAS: Oligo-adenylate synthase
OD: Optical density
PAGE: Polyacrylamide gel electrophoresis
PAMP: Pathogen-associated molecular patterns
Pb: Plasmodium berghei
PBMC: Peripheral blood mononunlear cells
PBS: Phosphate buffer solution
PCR: Polymerase chain reaction
PfEMPl Plasmodium falciparum erythrocyte membrane protein 1
PM A: Phorbol 12-myristate 13-acetate
PML: Premyelocytic leukaemia
PP: Protein phosphatase
Py: Plasmodium yoelii
PyHep: Plasmodium yoelii hepatocyte erythrocyte protein
RBC: Red blood cell
RESA: Ring infected erythrocyte surface antigen
RFP: Red fluorescent protein
RNA: Ribonucleic acid
ROP. Reactive oxygen intermediate
RSV: Rous sarcoma virus
RT PCR: Reverse transcription polymerase chain reaction
s.c: Subsutaneous
SDS: Sodium dodecyl sulphate
SERA: Serine repeat antigen
SFM: Serum free medium
SIN: Sindbis virus
SIV: Simian immunodeficiency virus
SSP2: Sporozoite surface protein 2
STAT: Signal transducer and activator
TAP: Transport associated protein
TARC: Thymus and activation regulated chemokine
TGF: Tumour growth factor
Th: T helper cell
TLR: Toll like receptor
TNF: Tumour necrosis factor
TRAP: Thromobospondin associated protein
Treg: Regulatory T cell
Ty-VLP: Ty-virus like particle
UL: Unique long
US: Unique short
Vhs: Virion host shutoff protein
VIC: VP 16 induced complex
VLP: Virus like protein
VP16: Virion protein 16
VZV: Varicella zoster virus
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